<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     tm2024737-1_10k.htm     <description>      FORM 10-K      <text>       <title>       </title>       <p style="margin: 0pt">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         UNITED STATES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         SECURITIES AND EXCHANGE COMMISSION        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         WASHINGTON, D.C. 20549        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        FORM 10-K       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Wingdings">         x        </font>        ANNUALREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        SECURITIES EXCHANGE ACTOF 1934       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        FOR THE FISCAL YEAR ENDED JUNE 30, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         NANOVIRICIDES, INC.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Name of Business Issuer in Its Charter)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 49%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NEVADA           </font>          </td>          <td style="width: 2%; text-align: center">          </td>          <td style="width: 49%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            76-0674577           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (State or other jurisdiction of incorporation or            <br/>            organization)           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (I.R.S. Employer Identification No.)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        1 CONTROLS DRIVE, SHELTON, CONNECTICUT,06484       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Address of principal executive offices)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        203-937-6137       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        (Issuer’s telephone number, includingarea code)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OFTHE ACT: NONE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OFTHE ACT:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 49%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            COMMON STOCK, PAR VALUE $0.001 PER SHARE           </font>          </td>          <td style="width: 2%; text-align: center">          </td>          <td style="width: 49%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NYSE AMERICAN           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Title of Class)           </font>          </td>          <td style="text-align: center">          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Name of exchange on which registered)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark if the registrantis a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by a check mark if the registrantis not required to file reports pursuant to Section 13 or Section 15(d) of the Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registrant(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 duringthe preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Yes        </font>        <font style="font-family: Wingdings">         x        </font>        No        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registranthas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Yes        </font>        <font style="font-family: Wingdings">         x        </font>        No        <font style="font-family: Wingdings">         ¨        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Indicateby check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not becontained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by referencein Part III of this Form 10-K or any amendment to this Form 10-K.        </font>        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the Companyis a larger accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 25%; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large accelerated filer           </font>          </td>          <td style="vertical-align: top; width: 20%; padding-right: 0.8pt; text-align: center">           <font style="font-family: Wingdings">            ¨           </font>          </td>          <td style="width: 10%">          </td>          <td style="vertical-align: bottom; width: 30%; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accelerated filer           </font>          </td>          <td style="vertical-align: bottom; width: 15%; padding-right: 0.8pt">           <font style="font-family: Wingdings">            ¨           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; padding-right: 0.8pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated filer           </font>          </td>          <td style="vertical-align: top; padding-right: 0.8pt; text-align: center">           <font style="font-family: Wingdings">            x           </font>          </td>          <td>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller reporting company           </font>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt">           <font style="font-family: Wingdings">            x           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top; padding-right: 0.8pt">          </td>          <td style="vertical-align: top; padding-right: 0.8pt; text-align: center">          </td>          <td>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth company           </font>          </td>          <td style="vertical-align: bottom; padding-right: 0.8pt">           <font style="font-family: Wingdings">            ¨           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         <font style="font-family: Wingdings">          ¨         </font>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Indicate by check mark whether the registrantis a shell company (as defined in Rule 12b-2 of the Exchange Act.).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         Yes        </font>        <font style="font-family: Wingdings">         ¨        </font>        No        <font style="font-family: Wingdings">         x        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of October 14, 2020, there wereapproximately 10,654,000 shares of common stock of the registrant issued and outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate market value of thevoting stock held on December 31, 2019 by non-affiliates of the registrant was approximately $8,246,000 based on theclosing price of $2.51 per share, as reported on the NYSE American on December 31, 2019, the last business day of theregistrant’s most recently completed fiscal second quarter (calculated by excluding all shares held by executiveofficers, directors and holders known to the registrant of five percent or more of the voting power of the registrant’scommon stock, without conceding that such persons are “affiliates” of the registrant for purposes of the federalsecurities laws).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         TABLE OF CONTENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; width: 0.75in; text-align: justify">           <a href="#b_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              PART I             </b>            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; width: 0.5in; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#b_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#b_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Business            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#b_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             3            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1A            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Risk Factors            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             52            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    1B            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Unresolved Staff    Comments            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             74            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    2.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Properties            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             74            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    3.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Legal Proceedings            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             74            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    4.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Mine Safety Disclosures            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             74            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <b>              PART II             </b>            </font>           </a>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    5.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Market for the Registrant’s    Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             75            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    6.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Selected Financial    Data            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             80            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    7.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Management’s    Discussion and Analysis of Plan of Operation and Results of Operations            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             81            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    7A            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Quantitative and    Qualitative Disclosures About Market Risk            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             91            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    8.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Financial Statements    and Supplementary Data            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             91            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Changes in and Disagreements    with Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             91            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9A.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Controls and Procedures            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             91            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    9B.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Other Information            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             92            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PART III            </b>           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    10.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Directors, Executive    Officers, Promoters and Corporate Governance.            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             93            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    11.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Executive Compensation            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             96            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    12.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Security Ownership    of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             98            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    13.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certain Relationships    and Related Transactions and Director Independence            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             101            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    14.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Principal Accountant    Fees and Services            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             103            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             PART IV            </b>           </font>          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">           <a href="#c_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    15.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Exhibits, Financial    Statement Schedules            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             104            </font>           </a>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top; text-align: justify">           <a href="#c_022">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Item    16.            </font>           </a>          </td>          <td style="vertical-align: top">           <a href="#c_022">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Form 10-K Summary            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_022">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             105            </font>           </a>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: top; text-align: justify">          </td>          <td style="vertical-align: top">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>         </tr>         <tr style="background-color: White">          <td colspan="2" style="vertical-align: top">           <a href="#c_023">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             SIGNATURES            </font>           </a>          </td>          <td style="vertical-align: bottom; text-align: right">           <a href="#c_023">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             106            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          2          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          <a name="b_003">          </a>          PART I         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         SPECIAL NOTE ON FORWARD-LOOKING STATEMENTS        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The information in this report containsforward-looking statements. All statements other than statements of historical fact made in this report are forward looking. Inparticular, the statements herein regarding industry prospects and future results of operations or financial position are forward-lookingstatements. These forward-looking statements can be identified by the use of words such as “believes,” “estimates,” “could,” “possibly,” “probably,” anticipates,” “projects,” “expects,” “may,” “will,” or “should,” “designed to,” “designed for,” or othervariations or similar words. No assurances can be given that the future results anticipated by the forward-looking statements willbe achieved. Forward-looking statements reflect management’s current expectations and are inherently uncertain. Our actualresults may differ significantly from management’s expectations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Although these forward-looking statementsreflect the good faith judgment of our management, such statements can only be based upon facts and factors currently known tous. Forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. As a result,our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors,including those set forth below under the caption “Risk Factors.” For these statements, we claim the protection ofthe safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You should notunduly rely on these forward-looking statements, which speak only as of the date on which they were made. They give our expectationsregarding the future but are not guarantees. We undertake no obligation to update publicly or revise any forward-looking statements,whether as a result of new information, future events or otherwise, unless required by law.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="b_004">          </a>          ITEM 1: BUSINESS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Organization and Nature of Business         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides, Inc. (the “Company,” “we,” or “us”) was incorporated in Nevada on April 1, 2005. Our corporate offices are located at 1Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137. Our Website is located at        <u>         http://www.Nanoviricides.com        </u>        .We do not incorporate by reference into this Annual Report the information on or accessible through our website, and you shouldnot consider it part of this Annual Report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On September 25, 2013, the Company’scommon stock began trading on the New York Stock Exchange American under the symbol, “NNVC”.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are a development stage company withseveral drugs in various stages of pre-clinical development, including late stage IND-enabling non-clinical studies. We have nocustomers, products or revenues to date, and may never achieve revenues or profitable operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides is one of a few biopharmacompanies that has its own cGMP-compliant manufacturing facility. The Company intends to produce its drugs for clinical trialsin this facility. The Company has the capability to produce sufficient drugs for about 1,000 patients in a single batch of production,depending upon dosage. This production capacity is anticipated to be sufficient for first-in-human use in the current SARS-CoV-2pandemic for our anti-coronavirus drug in development, as well as for the anticipated clinical trials of NV-HHV-101 skin creamfor the treatment of shingles. NV-HHV-101 has completed IND-enabling studies and an IND is in preparation (see below).The Company has developed several anti-coronavirus drug candidates. Of these, the Company recently nominated one for further safety-toxicologystudies, with other candidates continuing development as further advanced future candidates or as back-up candidates. This strategyof developing multiple candidates for a given indication is a normal risk-minimization strategy that the Company employs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 3; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          3          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The Nanoviricide Platform Technology in Brief         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company develops its class of drugs,that we call nanoviricides®, using a platform technology. This approach enables rapid development of new drugs against a numberof different viruses. A nanoviricide is a “biomimetic” - it is designed to “look like” the cell surfaceto the virus. The nanoviricide® technology enables direct attacks at multiple points on a virus particle. It is believed thatsuch attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particleat only a maximum of two attachment points per antibody. In addition, the nanoviricide technology also simultaneously enables attackingthe rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) withinthe core of the nanoviricide. The nanoviricide        <sup>         ®        </sup>        technology is the only technology in the world, to the best of ourknowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously(b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        The Company’s technology relies on copying the human cell-surfacereceptor to which the virus binds, and making small chemicals that are called “ligands” that will bind to the virusin the same fashion as the cognate receptor. These ligands are chemically attached to a nanomicelle, to create a nanoviricide®.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        It is anticipated that when a virus comesin contact with the nanoviricide, not only would it land on the nanoviricide surface, binding to the copious number of ligandspresented there, but it would also get entrapped because the nanomicelle polymer would turn around and fuse with the virus lipidenvelop, harnessing a well known biophysical phenomenon called “lipid-lipid mixing”. In a sense, a nanoviricide drugacts against viruses like a “venus-fly-trap” flower does against insects. Unlike antibodies that tag the virus andrequire the human immune system to take over and complete the task of dismantling the virus, a nanoviricide is a nanomachine thatis designed to not only binds to the virus but also complete the task of rendering the virus particle ineffective.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our lead program in this fiscal year hasbeen NV-HHV-101 skin cream for the treatment of shingles rash. In addition, we began working on developing a treatment for SARS-CoV-2virus infection that causes COVID-19 spectrum of diseases, since about January 2020, and accelerated this program since March 2020,in response to the epidemic that has now become a long-lasting global pandemic. We continued to work on the Shingles NV-HHV-101drug project as the primary project, and the Coronavirus project as a secondary project throughout the reported fiscal year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Fiscal Year 2019-2020 in Review         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Lead Drug Program: NV-HHV-101 SkinCream for the Treatment of Shingles Rash         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NV-HHV-101 is our lead drug candidate inthe HerpeCide™ program. It has advanced as a skin cream through pre-clinical development stages and at present it is at theIND application stage, with the design of clinical protocols, clinical site selection, and preparing for clinical trials, in process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On Aug 5, 2019 we reported that NV-HHV-101has been found to be safe and well tolerated at all dosage levels in the clinical observation portion of the GLP Safety/Toxicologystudy of NV- HHV-101 as a dermal treatment. The in-life stage of the first part of the GLP Safety/Toxicology studies was completed.Both the non-GLP and GLP Safety/Toxicology studies were conducted by BASi, Evansville, IN, a Contract Research Organizationthat is specialized in IND-enabling safety/toxicology studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 9, 2019, we further reportedthe current status of NV-HHV-101 in a press release, as discussed at the Annual Shareholders’ Meeting held on December 7,2019. The in-life animal studies portions of the required GLP safety/toxicology studies were already completed then and resultingblood samples were sent by the contract research organization, BASi, to other laboratories for different analyses.The Company had also sent the NV-HHV-101 drug product for other required testing to different laboratories. Most of the studieswere already completed by the external collaborators and the Company was then awaiting draft reports from the completed studiesto guide the IND application drafting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 4; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          4          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has received reports from variousexternal laboratories and has integrated them into appropriate sections of the IND application for NV-HHV-101. The Company hasalso substantially completed the Chemistry, Manufacture, and Controls section of the IND filing as of date of this Annual Report.Thereafter, having successfully completed the pre-clinical IND-enabling drug development studies, the Company began discussionswith clinical sites and retained consultants for the design of the clinical program for NV-HHV-101, which needs to be includedin an IND. Thus the IND application is substantially complete, except for the clinical trial design that was still being performedwith the help of consultants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        However, the COVID-19 epidemic expanded across the US, and alsoglobally, since March 2020, and did not show signs of abating rapidly. It became apparent that this epidemic would have a significantimpact on any new clinical trials for other viruses such as for our shingles treatment development. The impact would be in termsof  the ability to recruit and retain patients, as well as in the design of the clinical trial in presence of COVID-19 relatedcontingencies, and most importantly, in the interpretation of the resulting datasets. The Company therefore determined that itwas better to wait for resolution of the COVID-19 epidemic prior to entering into NV-HHV-101 clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our NV-HHV-101 drug is thus in the INDstage and we intend to file the IND soon after the COVID-19 epidemic situation resolves. Assuming an IND application is approvedby the US FDA, we will then be able to commence clinical trials in this program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Importantly, NV-HHV-101 has shown broad-spectrumactivity against HSV-1 (cause of “cold sores”), HSV-2 (cause of “genital ulcers”), and VZV (the varicella-zostervirus, that causes chickenpox in children and immune-compromised humans, and shingles in adults). Our other HerpeCide program candidatesin progress at present are based on NV-HHV-101, thereby maximizing return on investments and shareholder value.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The market size for the treatment of shingles is estimated atapproximately one billion dollars by various estimates. These estimates take into account the Shingrix® vaccine as well asexisting vaccines. About 500,000 to 1 million cases of shingles occur every year in the USA alone.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The market size for our immediate targetdrugs in the HerpeCide™ program is variously estimated at billions to tens of billions of dollars. The Company believes thatits dermal topical cream for the treatment of shingles rash will be its first drug heading into clinical trials in the HerpeCideprogram. The Company believes that additional topical treatment candidates in the HerpeCide™ program, namely, HSV-1 "coldsores" treatment, and HSV-2 "genital ulcers" treatment are expected to follow the shingles candidate into IND-enablingdevelopment and then into human clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, our newly engaged programfor development of a broad-spectrum anti-coronavirus drug treatment has progressed well and we have fully engaged into this programas of this writing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Our New Coronavirus Drug DevelopmentProgram         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since  January 2020, theCompany began working on developing a treatment for the SARS-CoV-2 virus (then known as 2019-nCoV virus) infection thatcauses COVID-19 spectrum of diseases. Our efforts were at that time boot-strapped upon existing work being performed for ourShingles treatment drug candidate and earlier work that we had performed on developing drug candidates for MERS-Coronavirusin 2014, and for SARS-Coronavirus in 2012. Although we had designed and made drug candidates for MERS-CoV, these candidateswere not tested as the global efforts quickly shifted to the Ebola epidemic in the 2014-2015 timeframe. For the SARS-CoV-2drug development program, we had a good head start because the structure of the first SARS-CoV and its interaction with thehuman receptor ACE2 had been solved. SARS-CoV-2 uses the same receptor, ACE2, as does SARS-CoV, and another coronavirus,namely h-CoV-NL63. Also it was found that SARS-CoV antibodies were cross-reacting with SARS-CoV-2.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have achieved several milestones inour newly instituted drug development program against SARS-CoV-2 since beginning these efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 5; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          5          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Very quickly, in January 2020, wedeveloped anti-viral ligands capable of binding to the SARS-CoV spike protein (i.e. S1 antigen) at the same site where this viralspike protein binds to the human ACE2 cellular receptor protein as a doorway to enter and infect the cell. We perform design ofsuch anti-viral ligands using molecular modeling tools. We continued to evolve these developments further as the program progressed.We already had some of the lead chemicals or their fragments for these newly designed ligands in our existing chemicals and ligandslibrary. We used the same polymer backbone as used for NV-HHV-101 to speed up the development, and attached the different testanti-coronavirus ligands to the polymer backbone using covalent chemical linkages, resulting in new anti-coronavirus nanoviricidestest compounds.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Viral mutations lead to viruses escapingdrugs such as antibodies and small chemicals in the field. In spite of mutations, the virus binds to the same site on the samecellular receptor in the same fashion. We develop small chemical ligands that are designed to bind to the virus protein at thesame binding area, mimicking the cellular receptor. Thus, even if the virus mutates, the nanoviricide drugs so designed would continueto work, provided they mimic the cellular receptor adequately and successfully.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company also developed anti-coronavirusassays for testing these compounds in our own BSL2 certified Virology laboratory very quickly. These cell culture assays employknown less threatful, circulating human coronaviruses. Of these, coronavirus hCoV-NL63 uses the same ACE2 receptor, but causesa milder disease with similar pathological manifestations, as do SARS-CoV-1 and -2. HCoV-NL63 is known to cause severe lower respiratorytract infections in young children leading to hospitalization. The symptoms are generally less severe than SARS-CoV-2 but are similar.In most cases, hCoV-NL63 causes relatively mild disease, often associated with croup, bronchiolitis, and lower respiratory tractdisease in children, and is considered to cause some of the common colds in adults. Thus, the clinical manifestation of hCoV-NL63infection in pediatric patients is similar to that of SARS-CoV-2, although much less severe. SARS-CoV-2 causes clinically similarmilder forms of disease in most patients, but moderate to severe disease requiring hospitalizations in about 15-20% of infectedpersons. These similarities imply that hCoV-NL63 should be a reasonable model virus for antiviral cell culture and animal studiesin BSL2 environment in the course of antiviral drug development for SARS-CoV-2. Thus NL63 serves as a good surrogate for SARS-CoV-2drug development. Another coronavirus we are testing against, namely hCoV-229E, uses a different but somewhat related receptor(in terms of biophysics). Investigating against both of these strains would allow us to examine which of the test candidates havemore broad-spectrum effectiveness against coronaviruses. However, there can be no assurance that successful results against theseforms of coronaviruses will lead to similar results against SARS-CoV-2. There can be no assurance that even successful resultsagainst SARS-CoV-2 itself will lead to successful clinical trials or a successful pharmaceutical product. This is true of everydrug development effort against SARS-CoV-2. The effectiveness of a drug against SARS-CoV-2 will need to be evaluated in human clinicaltrials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We confirmed in a press release on January 30,2020, that we had begun working on developing a broad-spectrum anti-coronavirus drug for the treatment of SARS-CoV-2 and othercoronaviruses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 16, 2020, we reported ina press release that we had completed synthesis of certain test candidates that we had designed, and that we had completed developmentof anti-Coronavirus assays for testing such novel candidates, in our own laboratories.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 12, 2020, in a pressrelease, we reported that we had successfully developed drug candidates that demonstrated very high anti-viral effectivenessin cell culture studies against multiple human coronaviruses. Two of the tested nanoviricides drug candidates were highlyeffective in cell culture assays against multiple coronaviruses that infect humans. In particular, they were several-foldmore effective than favipravir (aka T-705), against the tested viruses. Favirpravir is a broad-spectrum nucleoside-likeanalog drug that is in clinical testing against SARS-CoV-2, originally developed by Fujifilm. We tested these drug candidatesfor anti-viral effectiveness against two distinctly different, unrelated coronaviruses that cause human disease, namelyhCoV-NL63, and hCoV-229E. The assays evaluated the reduction caused by the drug candidate in cell death upon viral infection,formally known as cytopathic effects (CPE) assays.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 6; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          6          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We found that the same two nanoviricidesdrug candidates were highly effective against hCoV-NL63, the coronavirus that uses the same cellular receptor as SARS-CoV-2, aswell as another coronavirus, namely hCoV-229E, that causes seasonal common colds in humans. HCoV-229E uses the APN (Aminopeptidase-N)membrane protein on human cells as its receptor to enter cells, different from the ACE2 receptor used by hCoV-NL63 and SARS-CoV-2.ACE2 and APN may be considered to belong to a common superfamily of enzyme membrane proteins in terms of biophysics. The variousreceptors used by different coronaviruses all appear to fall in the broad family of membrane-associated serine proteases. As afamily, they share several structural features. Their substrate specificities are dictated by specific amino acid residues andtheir positions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe the fact that these nanoviricidesanti-coronavirus drug candidates are highly effective against two distinctly different coronaviruses that use different cellularreceptors is very significant. Specifically, it provides substantial confidence and scientific rationale that even if the SARS-CoV-2coronavirus mutates, the nanoviricides can be expected to continue to remain effective. In contrast, it is generally thought thatSARS-CoV-2 may be able to escape antibodies being developed as drugs. Antibodies are known to become ineffective upon viral mutations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that broad-spectrum anti-coronavirusdrugs such as its nanoviricides drug candidates would be expected to provide the ideal solution for combatting COVID-19, providedthat the candidates show effectiveness in human clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 20, 2020, we reported in apress release that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model was observed forour test drug candidates in development against SARS-CoV-2 to treat COVID-19 spectrum of diseases. In this lethal, direct-lung-infectionmodel, animals in all groups infected with hCoV-NL63 developed lung disease which later led to multi-organ failures, a clinicalpathology resembling that of the SARS-CoV-2. Reduction in loss of body weight at day 7 was used as the primary indicator of drugeffectiveness. Rats were infected directly into lungs with lethal amounts of hCoV-NL63 virus particles and then different groupswere treated separately with five different nanoviricides test drug candidates, remdesivir as a positive control, and the vehicleas a negative control. The treatment was intravenous by tail-vein injection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Animals treated with the five differentnanoviricides showed significantly reduced body weight loss. The body weight loss was only 3.9% for the best nanoviricide candidate,ranging to 11.2% for the potentially least effective one, as compared to 20% in the vehicle-treated control group, in female animals(n=5 in each group). Male animals treated with the same nanoviricides also showed significantly reduced body weight loss. The bodyweight loss in male animals was 8.0% for the best nanoviricide candidate and ranged up to 10.9% for the potentially least effectiveone, as compared to 25% in the vehicle-treated control group (n=5 in each group). In comparison, remdesivir treatment led to abody weight loss of 15.2% in females and 18.6% in males in this study. Remdesivir is known to be rapidly metabolized in nativeanimal models, and its effectiveness was evaluated in specially constructed serum esterase negative mice in published literature.Importantly, this study demonstrated that our drug candidates were highly effective in a native animal model of lethal coronaviruslung infection, which may be considered more stringent than the clinical condition in human patients. Smaller numbers mean lessloss in body weight compared to starting body weight in the group, and indicate greater drug effectiveness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The striking difference in weight lossbetween the two sexes in this animal model was remarkable. It has been widely reported that men are more likely to suffer severeinfection and fatalities from SARS-CoV-2 than women in the current pandemic. This feature was replicated in our animal model studyindicating that biological sex differences are the driver of the differences in the severity of infection by the coronavirusesthat utilize the ACE2 receptor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The strong effectiveness of nanoviricidetest drug candidates in this model is consistent with the effectiveness observed in cell culture studies against infection of bothhCoV-NL63, which was used in this study, and hCoV-229E, another circulating coronavirus that uses a distinctly different receptor,namely APN.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Thus this study corroborated the cell-cultureeffectiveness and provided confidence that these nanoviricides drug candidates may be expected to result in a clinical candidateto be pursued in human clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subsequent to the reporting period, onJuly 8, 2020, we reported in a press release that excellent safety and tolerability of the drug candidates in development against SARS-CoV-2 to treat COVID-19 spectrum of diseases was observed in an animal model. Three different drug candidatesat three different dosage levels (low, medium, and high) and vehicle control were administered to separate groups of mice intravenouslyin this non-GLP Safety-Tolerability study. Sixteen mice in each group (8 males, 8 females), were administered one of the threedrug candidates at one of the three dose levels, and additionally, one group was administered vehicle control, for seven days bydaily tail-vein intravenous infusion in this blinded study with additional evaluations on 8th day. This non-GLP safety/tolerabilitystudy was conducted under GLP-like conditions by AR BioSystems, Inc., Tampa, FL.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 7; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          7          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There were no clinical signs ofimmune or allergic reactions such as itching, biting, twitching, rough coat, etc. Further, there were no observablechanges in any organs including large intestine or colon on post mortem in gross histology. The only reportable changesobserved were, in the high dosage groups of two of the three drug candidates tested, associated with the non-absorption ofwater, in the colon. This is consistent with the clinical observation of loosened stools in the same groups. In clinicalusage, the drug candidates are not anticipated to be administered in such high levels. The objective of this study was todiscover the dosage level at which such an effect may occur. Loose or very loose stools at very high dosages in such a studyis an expected and acceptable side effect of the polyethylene glycol (PEG) moiety, which we believe forms the backbone of thenanoviricides drug candidates. PEG is used prior to colonoscopy in humans to promote loose stools and internalcleaning of the intestines, by causing non-absorption of water.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Clinical observations and gross post-mortemstudies showed that the tested drug candidates were safe and well tolerated, thereby clearing the path for further developmenttowards a treatment for SARS-CoV-2 infection that has caused the current COVID-19 pandemic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On the basis of these studies, we havedeveloped a strategy for drug development with the goal of creating the most effective medicine to obtain regulatory approval foremergency use in the COVID-19 pandemic in the shortest timeline feasible, after having achieved proof of concept of broad-spectrumanti-coronavirus effectiveness of test candidates. To this end, we have worked to harness the full power of the nanoviricide platform,which (1) enables attacking the virus particle blocking infection by itself as described above, as well as (2) enablesprotection and delivery of other payload drug(s) that can interfere with the replication of the virus inside cells.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A curative treatment for a virus suchas SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) the ability of the virus to infecthost cells, and simultaneously, (ii) the ability of the virus to multiply inside the host cells. The nanoviricide®platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect newcells. At the same time, a nanoviricide is also capable of carrying payload in its “belly” (inside the micelle)that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload frommetabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatmentagainst SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have previously stated that we are currently working on developingthe “first generation” nanoviricides nanomedicines that block the re-infection cycle of the virus towards drug approvals,as in the case of NV-HHV-101. We had also stated that in a second generation later on we planned on harnessing the full power ofthe nanoviricides nanomedicine platform towards creating second generation drugs that also encapsulated payload to additionallyblock the replication cycle of the virus, thereby effectively creating cures against viruses that do not integrate into human cellsor form latent reservoirs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We accelerated the development of asecond generation nanoviricide against COVID-19 given that a well known drug that affects the replication cycle is alreadyavailable and is the only direct-acting antiviral currently authorized in the USA, albeit for emergency use, namelyremdesivir. While highly effective in cell cultures, the clinical effectiveness of remdesivir is known to be limited by therapid metabolism it undergoes in the bloodstream upon infusion. We believe that by encapsulating remdesivir into ournanoviricide, it may undergo limited metabolism thereby improving its effectiveness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On September 16, 2020, we announced that we had nominateda clinical drug candidate, identified as NV-CoV-1-R for further development. The candidate is made up of a nanoviricide that wehave found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated insidethe core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infectedcells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally,remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled byNV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level canbe attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness ofNV-CoV-1-R.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 8; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          8          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Remdesivir is a well-known antiviral drug(developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries.NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness.It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside formwhich is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapidmetabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may leadto increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction inthe required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act asan adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also continue to work on additionalvariants of drug candidates that we have found to be effective against coronaviruses in cell culture studies, with and withoutencapsulated payload drugs. We thus guard against the risk of unknown effects in the drug development process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Thus we believe we have made significantprogress in developing novel drug candidates against SARS-CoV-2 under the severe time pressure of the pandemic. We plan on GLPSafety/Pharmacology studies, a pre-IND filing with the US FDA for guidance, and thereafter an IND application for our clinicaldrug candidate against COVID-19. We are working on these activities as rapidly as possible. We believe that we are developing highlyeffective drug candidates against coronaviruses that we anticipate should be able to enter and succeed in human clinical trials.However, we cannot provide timelines because of extreme dependence on external collaborators for these activities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Financings         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, we had cash and cash equivalents ofapproximately $13.7 million and prepaid expenses of approximately $.3 million. In addition, the Company had approximately $9.5million in property and equipment, net  of accumulated depreciation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 16, 2019, the Company enteredinto an Open End Mortgage Note (the “Note”) with Dr. Anil Diwan, the Company’s founder, Chairman, President andCEO to loan the Company up to $2,000,000 in two tranches of $1,000,000 (the “Loan”). The Note bears interest at a rateof 12% per annum and is secured by a mortgage granted against the Company’s headquarters. Dr. Anil Diwan received 10,000shares of the Company’s Series A preferred stock as a loan origination fee. As of June 30, 2020, the Company has drawn down$1.1 million on this loan. On April 30, 2020, the Company and Dr. Diwan have mutually agreed to extend the maturity date of theNote, at the Company’s option, to May 15, 2021, with the rest of the terms remaining the same.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 17, 2019, the Company enteredinto a Deferred Expense Exchange Agreement with TheraCour Pharma, Inc. (“TheraCour”), whereby the Company and TheraCouragreed to exchange 100,000 shares of Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred developmentfees owed to TheraCour. The Company recognized a loss on the exchange of $142,669 during the year ended June 30, 2020. Dr. Diwanis principal shareholder of TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 9; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          9          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These two transactions together provideda much needed cash infusion of up to $2.3 million to the Company at a critical time. There were no agents or brokers in these transactionsand no commissions or agency fees were paid other than legal and regulatory fees. Dr. Diwan, being a party with interest,recused himself from, and was not present at, the discussions and negotiations of the independent members of Company’s Boardof Directors on both of these transactions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 24, 2020, the Company announcedin a press release that it had completed an underwritten public offering (the “Offering”) with gross proceeds of $8,625,000before deducting underwriting discounts and other estimated offering expenses. The Offering included 2,500,000 shares of the Company’scommon stock, and 375,000 additional shares from the exercise of the underwriter’s option to purchase to cover over-allotmentsat the public offering price of $3.00 per share. No warrants were issued in this Offering. The net proceeds to the Company afterdeducting offering costs was $7,457,575.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        On May 26, 2020, the Company announced it had raised $10,220,000in gross proceeds from the sale of 1,400,000, shares of common stock, at a price of $7.30 per share, in a previously announcedregistered direct offering (the  “May Offering”). No warrants were issued in this May Offering. The net proceedsto the Company were $9,219,400 after deducting placement agent fees and other costs. The May Offering closed on May 22, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With these financings and continued controlof expenditures, the Company ended the current fiscal year with approximately $13.7 million in cash and cash equivalents, and $9.5million in property and equipment net of accumulated depreciation. As of June 30, 2020 the Company had a mortgage note payable-relatedparty of approximately $1.1 million and a loan payable of approximately $60,000 that will mature on December 15, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 10; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          10          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On July 8, 2020, subsequent to the date of the reporting period,the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Kingswood Capital Markets, aDivision of Benchmark Investments, Inc. (“Kingswood”). The offering was consummated on July 10, 2020, whereby the Companysold 1,369,863 shares of Common Stock and a fully exercised Underwriters’ over-allotment option of 205,479 additional sharesthe public offering price of $7.30 per share. No warrants were issued in this Offering. The net proceeds to the Company from theoffering was approximately $10.53 million after deducting underwriting discounts and commissions and other estimated offering expensespayable by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On July 31, 2020, the Company entered into an At Market IssuanceSales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and Kingswood Capital Markets, a division ofBenchmark Investments, Inc. (each a “Sales Agent” and collectively, the “Sales Agents”), pursuant to whichthe Company may offer and sell, from time to time, through or to the Sales Agents, shares of Common Stock (the “PlacementShares”), having an aggregate offering price of up to $50 million (the “ATM Offering”). Sales pursuant to theSales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannot provide any assurancesthat it will issue any Shares pursuant to the Sales Agreement. Actual sales will depend on a variety of factors to be determinedby the Company from time to time, including (among others) market conditions, the trading price of the Company’s Common Stock,capital needs and determinations by the Company of the appropriate sources of funding for the Company. The Company is not obligatedto make any sales of Common Stock under the Sales Agreement and the Company cannot provide any assurances that it will issue anyshares pursuant to the Sales Agreement. The Company will pay a commission rate of up to 3.5% of the gross sales price per sharesold and agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursements of its legalcounsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales Agents an amount not to exceed $2,500 per quarterduring the term of the Sales Agreement for legal fees to be incurred by the Sales Agents. The Company has also agreed pursuantto the Sales Agreement to provide each Sales Agent with customary indemnification and contribution rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        The Company thus believes that it isin a strong financial position now and can undertake the COVID-19 clinical program, and also, when opportune, reengage theNV-HHV-101 clinical program. The Company also believes that additional non-dilutive financing will be available under theCOVID-19 program upon advancing it further toward or  into human clinical trials. The Company also believes that due tothe pandemic, it will be possible to rapidly take our anti-coronavirus drug into human clinical trials under the COVID-19regulatory pathways of the US FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          CorporateEvents -         </b>        </font>        <b>         Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s drug development businessmodel was formed in May 2005 with a license to the patents and intellectual property held by TheraCour that enabled creationof drugs engineered specifically to combat viral diseases in humans. This exclusive license from TheraCour serves as a foundationfor our intellectual property. TheraCour is a privately owned company, controlled by Anil R. Diwan, PhD, principal developer ofthe polymeric-micelle based nanomedicines technologies. TheraCour licenses its intellectual property from AllExcel, Inc.,a company that is owned and controlled by Dr. Diwan. The Company has a worldwide exclusive license to this technology forseveral drugs with specific targeting mechanisms for the treatment of a number of human viral diseases including HSV-1, HSV-2,and VZV.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 4, 2019, the Company announcedin a press release that it has completed the process of licensing the VZV (shingles and chickenpox virus) field for drug developmentand commercialization from TheraCour. The Company executed this license agreement for VZV with TheraCour on November 1, 2019(the “Agreement”). Under this Agreement, NanoViricides has obtained a world-wide, exclusive, sub-licensable, licenseto use, promote, offer for sale, import, export, sell and distribute drugs that treat Varicella Zoster Virus infections, usingTheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materialsas well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performedby TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. NanoViricidesdid not pay any upfront licensing fee under the Agreement. The Company will pay a first milestone payment to TheraCour upon thegrant of approval of an Investigational New Drug application (IND), of 75,000 shares of the Company’s Series A preferredstock. A second milestone payment will be due upon completion of Phase I human clinical trials in the cash amount of $1.5 million.A third milestone payment will be payable to TheraCour upon completion of Phase II human clinical trials in the cash amount of$2.5 million, and a fourth milestone payment will be due upon completion of Phase III human clinical trials in the cash amountof $5 million. However, NanoViricides shall have no obligation to continue clinical trials beyond Phase I. Upon commercialization,NanoViricides will pay royalties of 15% of Net Sales to TheraCour, as defined in the Agreement. The Agreement contemplates thatthe parties will enter into a separate Manufacturing and Supply Agreement for the commercial manufacture and supply of the drugproducts if and when NanoViricides intends to engage into commercialization of the drugs. The Agreement provides that the Manufacturingand Supply agreement would be on customary and reasonable terms, on a cost-plus basis, using a market rate based on then-currentindustry standards, and include customary backup manufacturing rights. Dr. Diwan recused himself in the Board’s discussionson the VZV license agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 11; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          11          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 9, 2020, the Company reportedin a press release that it has signed a Memorandum of Understanding (“MoU”) with respect to anti-viral treatmentsfor coronavirus derived human infections (the “Field”) with TheraCour. The MoU specifically provides a limited, exclusivelicense to all research and development in the Field for further research and development purposes towards human clinical trials.Dr. Diwan recused himself in the Board’s discussions on the MoU, and recuses himself from the Company’s discussionsregarding the license agreements as well. McCarter &amp; English, LLP advised the NanoViricides Board of Directors and DuaneMorris,LLP advised TheraCour on this MoU. These law firms are expected to continue as attorneys for the parties for the negotiation ofthe license predicated in the MoU. The Board of the Company has since retained an independent consultant for the evaluation ofthe assets in order to develop the full license agreement. The Company intends to perform the regulatory filings and own all theregulatory licenses for the drugs it is currently developing. The Company will develop these drugs in part via subcontracts toTheraCour, the exclusive source for these nanomaterials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        The Company believes that it currently does not need a licensefor the use of remdesivir in developing the novel nanoviricide drug candidates that encapsulate remdesivir. The Company has undertakenencapsulation of remdesivir into certain of its drug candidates for the treatment of coronavirus because we believe that this encapsulationwould result in substantial patient benefits. However, the Company believes that our anti-coronavirus drug candidates have shownsignificant anti-coronavirus activity in cell culture and animal studies, and therefore are expected to be viable drugs againsthuman coronavirus infections by themselves, without encapsulating remdesivir. At present, the Company believes that to developthem as independent, we will need to also use the approved remdesivir treatment as standard of care in addition to the new nanoviricidedrug candidate in the human clinical trial treatment arm. It may be possible that encapsulation would improve the pharmacokineticsof remdesivir and thereby improve its effectiveness when in encapsulated form. These possibilities can only be evaluated in a humanclinical trial. We believe that any license for the use of remdesivir encapsulation in our novel drugs, if necessary, will be feasiblein the interests of resolving the pandemic. The Company would also be willing to collaborate with Gilead Sciences, Inc., the developerof remdesivir, for developing the encapsulated drug. There is currently no collaboration agreement with Gilead Sciences, Inc.,nor any assurance that such an agreement can be reached. The Company is currently developing its anti-coronavirus drugs independently,on its own.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 12; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          12          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Investor Outreach        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the reporting period and thereafter,the Company has made significant efforts in its investor outreach programs. The Company has retained Tradigital, Inc. as itsinvestor relations firm. In addition, the Company has presented at various investor conferences. The Company has also been interviewedon national and investor-oriented channels, unsolicited, due to our engagement in COVID-19 drug development efforts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 3, 2019, the Company reportedin a press release that Dr. Diwan, Company’s President, Chairman and CEO was interviewed by broadcast journalist ChristineCorrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with officesin New York, Sydney, Toronto, Frankfurt, and London.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On February 4, 2020, the Company reportedin a press release that Dr. Diwan was interviewed on the Kennedy show on Fox Business News (FBN), on January 23, 2020.The Company has licensed a copy of the video excerpt from FBN and it is available on the Company’s website (www.nanoviricides.com)under the heading “NanoViricides In the News”, by clicking on “Dr. Anil Diwan on Fox Business - 01/23/2020- By - Kennedy”.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On February 10, 2020, the Company reported in a press releasethat Dr.  Diwan was interviewed on the Stuart Varney show on Fox Business News (FBN), on January 28, 2020. The Companyhas licensed a copy of the video excerpt from FBN and it is available on the Company’s website (www.nanoviricides.com), homepage, under the heading “Dr. Anil Diwan on Fox Business - 01/28/2020”.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Dr. Diwan participated as a paneliston a virtual panel discussion entitled, “COVID-19: Current Pipeline and Innovations for Therapeutics and Vaccine”,organized by BioCT, an association of biotechnology and pharmaceutical businesses in Connecticut, on April 8, 2020. The panelwas moderated by Dr. Mostafa Analoui, Executive Director, Venture Development &amp; Technology Incubation Program (TIP),Office of the Vice President for Research, University of Connecticut, Storrs, CT. A transcript of the panel discussion is availableat https://www.youtube.com/watch?v=WpTP_wnEZKw&amp;feature=youtu.be.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 13, 2020, the Company reportedthat Dr. Diwan and key staff members at the Company’s Shelton, CT headquarters were interviewed by broadcast journalistChristine Corrado of Proactive Investors on March 27, 2020, remotely, from their New York office.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 22, 2020, Dr. Diwan, presenteda corporate update focused on the COVID-19 and shingles programs at the Planet Microcap Virtual Showcase 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 13; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          13          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 30, 2020, the Company reportedin a press release that it has been added to the Russell Microcap        <sup>         ®        </sup>        Index effective after the U.S. markets openedon Monday, June 29, 2020. Membership in the Russell Microcap        <sup>         ®        </sup>        Index, which remains in place for one year, meansautomatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexesprimarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managersand institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assetsare benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.Inclusion of NanoViricides in the Russell Microcap Index may be expected to increased participation in the NNVC stock positionsof investment managers and institutional investors that purchase, follow or employ this index.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Subsequent to the reporting period, Dr.Diwan, was invited to participate in the “B. Riley FBR Virtual Infectious Disease Summit – Therapeutics Day”on Tuesday, July 21, 2020. The Conference was organized by B. Riley FBR, Inc. (        <u>         https://brileyfbr.com/        </u>        ). Dr. Diwanparticipated in Panel #3 at 2020 at 2:10 p.m. ET, entitled “Taming the Severe Disease Presentations”.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        Dr. Diwan provided a further update on its programs atthe LD500 Virtual Conference on September 3        <sup>         rd        </sup>        , 2020, as reported by the Company in a press release issued on September4, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Thus we have made strong progress in drugdevelopment, despite engaging into a novel drug program against coronaviruses in response to the current pandemic, as well as financingand leadership building in the reported year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s primary focus has shiftedto bringing its broad-spectrum anti-coronavirus drug into human clinical trials as soon as possible, in response to the currentpandemic, as detailed above.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our other lead program, namely NV-HHV-101skin cream for treatment of shingles rash, is now in IND-ready stage, with clinical trial design and clinical trial selection asthe remaining steps prior to filing an IND. Shingles is caused by reactivation of VZV (Varicella-Zoster Virus), which causes chickenpoxin children. Several additional indications in the HerpeCide™ program, including skin creams for the treatment of “genitalulcers” (HSV-2), and for the treatment of “cold sores” (HSV-1”) are expected to follow the shingles candidateinto clinical development. In addition, the Company has drug candidates in development against severe influenzas (including birdflu), HIV, Dengue, Ebola/Marburg and other viruses at different preclinical stages. According to a 2014 market report preparedby Jain PharmaBiotech (“Jain”), entitled “Antiviral Thereapeutics, Technologies, Markets &amp; Companies,”the overall market size for our potential drugs is estimated to be between $40~65 Billion by 2023. This broad pipeline is enabledby our unique post-immunotherapeutic “bind-encapsulate-destroy” technology platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 14; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          14          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are a development-stage company withthe goal of commercializing special purpose nanomedicine for anti-viral drugs based on a novel, first-in-class mechanism. The Company'snovel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles, on the same sitesthat they use to bind to cells and dismantle them. Our unique biomimetic approach promises that a virus cannot escape our nanoviricidedrugs due to mutations, if the virus-binding ligands perform as designed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s drug candidates arelicensed from TheraCour, and are developed by TheraCour for the Company on thebasis of several patents, patent applications, provisional patent applications, and other proprietary intellectual property heldby TheraCour. Unlike usual pharma industry licenses that are specified for single chemical entities or for groups of similar chemicalentities, our licenses are specified for the vertical application field of use, thereby providing us with a large universe of diversedevelopment candidates under the same umbrella. The Company has exclusive licenses from TheraCour for drug candidates derived fromand based on TheraCour’s technologies for several viruses. In 2005, the Company obtained a license from TheraCour for thetreatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird FluVirus (INF), Herpes Simplex Virus (HSV-1 and HSV-2), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. Thereafter,on February 15, 2010, the Company entered into an Additional License Agreement with TheraCour granting the Company the exclusivelicenses for technologies developed by TheraCour for the additional virus types for Dengue viruses (DENV), Japanese Encephalitis(JEV), West Nile Virus (WNV), viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes Keratitis, and Ebola/Marburgviruses. While herpes simplex viruses were already specified as licensed previously, the term “ocular herpes keratitis”was added to this additional license agreement at the specific request of the Company for clarity only. In addition, the Companycompleted the process of licensing the VZV (shingles, chicken pox virus) field from TheraCour in November 2019. The Companyand TheraCour have executed a Memorandum of Understanding which already provides a limited development license to the Company forthe field of human coronavirus indications in June, 2020. The Company is in the process of conducting a valuation for the humancoronavirus indications. A definitive agreement to license the human coronavirus field is currently being negotiated by the parties.To date, TheraCour has not withheld any licenses for antiviral nanomedicines that NanoViricides has asked for, and we anticipatethat the human coronavirus field license will be executed shortly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company retains worldwide exclusiverights to commercially develop, commercialize, and market the licensed products. The Company pays TheraCour for the R&amp;D workasked to be performed by the Company to develop these drugs, their chemistries, formulations, and manufacturing processes, substantiallyat cost, with a certain fee as specified in the license agreements. The Company may perform initial developmental testing by itselfand through third parties, such as academic labs, government institutions, contract research organizations, for safety and effectiveness,among other tests. The Company may perform further IND-enabling advanced pre-clinical studies using third parties, such as contractresearch organizations, usually on clinical drug candidates. The Company expects to perform human clinical trials using contractresearch organizations with expertise in such clinical trials. The Company intends to sponsor the drugs for commercialization activitiesand obtain the rights of commerce under various regulatory authorities for its own use.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company focuses its research and clinicalprograms on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discoveryand clinical development programs and through an in-licensing strategy. To date, the Company has not commercialized any product.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s objectives are to createthe best possible anti-viral nanoviricides and then subject these compounds to rigorous laboratory and animal testing towards USFDA and international regulatory approvals. Our long-term research efforts are aimed at augmenting the nanoviricides that we currentlyhave in development with additional therapeutic agents to produce further improved anti-viral agents in the future. We believethat many viral infections that are at present untreatable or incurable would be curable using such an advanced approach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 15; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          15          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The Nanoviricide® Platform Technology         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides, Inc. is engaged inthe application of nanomedicine technologies to the complex issues of viral diseases. The nanoviricide® technology enablesdirect attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becomingineffective at infecting cells. Antibodies in contrast attack a virus particle at only a maximum of two attachment points per antibody.In addition, the nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virusby incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The nanoviricide technologyis the only technology in the world, to the best of our knowledge, that is capable of both (a) attacking extracellular virusthereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enablingcomplete control of a virus infection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our anti-viral therapeutics, that we call “nanoviricides®” are designed to look to the virus like the native host cell surface to which it binds. Since thesebinding sites for a given virus do not change despite mutations and other changes in the virus, we believe that our drug candidateswill be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus, provided the virus-bindingportion of the nanoviricide is engineered appropriately.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This powerful platform technology has enabledus to develop several drug candidates against a large number of different viruses that could be further improved into clinicaldrug candidates, thus building a very broad drug pipeline that may lead to exponential growth of the Company upon the approvalof our first drug candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        It is important to realize that the flexiblenanoviricides nanomedicines show substantial advantages over hard sphere nanoparticles in this antiviral drug application. Hardsphere nanomaterials such as dendritic materials (dendrimers), nanogold shells, silica, gold or titanium nanospheres, polymericparticles (such as PLA-PLGA, others), etc., were never designed to be capable of completely enveloping and neutralizing thevirus particle.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Nanoviricides are designed to work by bindingto and eliminating virus particles from the blood stream, just as antibodies do, only potentially much better. Treating a patientthat has a viral infection with a nanoviricide against that virus is expected to result in reduction in viremia. Reduction in viremiais an important goal in diseases caused by all viral infections. Nanoviricides are designed to accomplish this using a “Bind-Encapsulate-Destroy”strategy to eliminate the free virus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A nanoviricide is constructed by chemicallyattaching a ligand designed to bind to a virus particle, to a polymeric material that forms a flexible nanomicelle by self-assembly.If antibodies are known to affect a viral disease, it is possible to construct a nanoviricide against it, and there can be a generalexpectation of some success, depending upon the ligand chosen. We can choose a ligand from any of a number of chemical classes,including small chemicals, peptides, or antibody fragments or even whole antibodies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A nanoviricide is made by chemically covalentlylinking a “nanomicelle” - a globular polymeric micelle with pendant lipid chains inside, to one or more different smallchemical ligands designed to mimic the cellular receptor to which the virus binds. In addition, the nanoviricide can carry additionalactive pharmaceutical ingredients (APIs), which may be chosen to affect the intracellular virus life cycle. Thus, the nanoviricideplatforms enables construction of complete virus-killing nanomachines that block the virus from entering the cell as well as thatblock further production of the virus inside the cell.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 16; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          16          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Attacking the “Achilles Heel”of the Virus- Unchanging Ability of the Virus to Bind to Its Cognate Receptor on Cell        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We strive hard to develop virus-bindingsmall chemical ligands mimic the cognate cellular receptor of the virus, using rational design and molecular modeling strategiesand our internal, accumulated expertise. This is the receptor to which a virus binds to gain entry into the human cell. Some virusesuse more than one, different, receptors. The nanoviricide® platform technology allows use of different ligands on the samenanoviricide drug to be able to attack such difficult viruses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        It would be very difficult for a virusto become resistant to a nanoviricide that mimics the virus’ cellular receptor. This is because, no matter how much a virusmutates or changes, its binding to the cellular receptor does not change. If the virus does not bind to the nanoviricide efficiently,it would likely have lost its ability to bind to the cellular receptor efficiently as well, resulting in an attenuated versionwith limited pathogenicity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Beyond Antibodies or “Post-Immunotherapeutic”Approach: A Nanoviricide in Its Design is a Nanomachine Built to Destroy Viruses        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A nanoviricide exposes a very high densityof virus binding sites on its surface, in contrast to a human cell. Thus, a virus would be more likely to be captured by the nanoviricidethan to bind to a cell. Once bound to the virus, it is thought that the nanoviricide would wrap itself around the virus, and theinterior lipidic chains of the nanoviricide would merge into the lipid envelope of an enveloped virus, thus destabilizing the virus.This attack is expected to result in loss of the viral glycoproteins that it uses to bind to cell and to fuse with the cell membrane,thus rendering the virus particle non-infectious. In contrast, for an antibody to be successful as a drug, as many as ten to fifteenantibodies must bind to saturate the virus surface. The resulting antibody-virus complex then may be subject to the complementprotein system in the bloodstream, or it may bind to antibody-receptors on human immune cells. Thus the human immune system needsto be functional for an antibody to be effective as a “drug”. In a sense, antibodies only “flag” the virusparticle as foreign.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Almost any virus that causes pathologyin humans is able to do so because it has developed intelligent and complicated pathways for disabling the human immune systemat one or more points. This may be one of the reasons why many antiviral antibodies fail in the field use. Additionally, virusesreadily escape antibodies by mutations. Such viral escape from antibodies has been witnessed in almost every viral epidemic, beit HIV/AIDS, Influenza pandemic of 2009, or the Ebola epidemic of 2014-15. In contrast, a nanoviricide would complete thejob of making the virus particle non-infectious, without any help from the human immune system.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Broad-Spectrum Nanoviricide Drug Candidates        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A nanoviricide is generally “broad-spectrum”in the sense that it would be effective against all viruses that use the same cellular receptor, binding to the same site on thatcellular receptor.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Formulation is Inherent in the DesignAspect of a Nanoviricide        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since declaring our clinical candidate,namely NV-HHV-101 formulated as a skin cream for topical treatment of shingles rash, further development of this drug towards scale-up,formulation, and cGMP-like manufacture has already been accomplished in a relatively rapid manner. Formulation development fornovel drugs in normal pharmaceutical paradigm often takes years. However, in the nanoviricide approach, the nanomicelle polymericbackbone itself takes care of the formulation aspects. The nanomicelle is designed to optimize the drug for its intended routeof administration, be it injectable, skin cream, eye drops, or even oral. Thus, no specific or extensive formulation developmentis expected to be required after clinical candidate declaration.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Similarly, the development of drug candidatesto treat the SARS-CoV-2 infection has progressed rapidly, from discovery to pilot scale manufacture within months, because of thespecific advantages of our platform.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 17; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          17          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have previously manufactured multi-kilogramquantities of the final drug product for shingles cGLP Safety/Toxicology studies that are required for filing an IND.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Uniform Polymer Nature Enables NanomedicineManufacturing Quality Assurance        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A major problem in the field of nanomedicineshas been that most nanomedicines have been found to be notoriously difficult to manufacture in a consistent manner from batch tobatch. This is because of the complexity inherent in making large molecules, and the very nature of polymer and particle makingprocesses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The nanoviricide technology has been designedfrom the ground up to enable consistent manufacture and control. Thus, the nanoviricide backbone is a homopolymer of a single repeatingunit or monomer, and not a block copolymer. In addition, the nanoviricide polymer is designed to dynamically and naturally self-assembleinto micelles in a solution. Also, the virus-binding ligands are chemically attached to the polymer. The extent of attachment canbe assessed by analytical techniques that we have developed and continue to develop as needed. Further we use specialized techniquesin the polymer processing to minimize any contamination with endotoxins or other foreign particles. The final nanoviricide solutionscan be sterile filtered using standard membrane filtration processes. The resulting solutions can be concentrated in a non-contaminatingenvironment in our Process Scale-Up Lab or our cGMP-capable Manufacturing Facility.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Thus the nanoviricides platform has beendesigned from the ground up to enable simplifications in processes and analyses that need to be implemented in order to developrobust, reproducible, and scalable processes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our BSL-2 Certified Virology Lab         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have a BSL-2 (Biological Safety Level2) certification from the State of Connecticut for our Virology suite at the Shelton campus. This suite comprises three individualvirology workrooms, enabling us to work on several different viruses and strains at the same time. This facility is designed onlyfor cell culture studies on viruses, and no animal studies can be conducted at any of our own facilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are able to perform drug efficacy andsafety studies in cell cultures for multiple different viruses at the same time in this facility, in isolated lab rooms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have developed in-house cell culturescreening capability for developing drug candidates against human Coronaviruses, VZV, HSV-1 and HSV-2, as well as influenzas andHIV, among others. This capability has substantially strengthened our drug development programs. We believe that this internalscreening enables speedy evaluation of a much larger number of candidates than external collaborations allow. We believe this hassignificantly improved our ability to find highly effective ligands and performing structure-activity-relationship studies of thesame in a short time period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          cGMP Manufacturing Facility         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Manufacturing of drug products for sale,as well as for late stage clinical trials is required to be performed in FDA-registered cGMP manufacturing facilities. Manufactureof drugs for earlier stage clinical trials as well as for IND-enabling GLP Safety/Toxicology studies needs to be performed in ac-GMP-compliant manner.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe we are one of the very fewsmall pharmaceutical drug innovators that possess its own cGMP or cGMP-capable manufacturing facility. With our Shelton,Connecticut campus and pilot-scale cGMP-capable manufacturing facility, we believe we are in a position to advance our drugcandidates into clinical trials, produce the pre-clinical “tox package” batches, and the clinical drug substancebatches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 18; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          18          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that this facility will be capableof scaling to the quantity of product needed for initial market introduction and revenue generation from our first drug when approved.We have already performed production of kilogram-scale batches of drug substance and multi-kg scale batches of drug product atthis facility successfully. We believe this scale is sufficient for clinical trials, and, depending upon final dosage level, thisscale may be sufficient for initial market entry.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          State of the Company – DrugDevelopment Programs         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition to the rapid advancementin drug development against human coronaviruses in response to the current pandemic undertaken since January, 2020, asdescribed earlier, during a major part of the reported fiscal year ending June 30, 2020, we have focused our effortsprimarily on the HerpeCide program. We are developing drugs against three indications in this program in parallel at present,namely, HSV-1 “cold sores” (orolabial herpes and recurrent herpes labialis or RHL), HSV-2 “genitalulcers”, and VZV shingles. We are developing topical treatments (skin creams or lotions) for these three indications.All of the drug candidates in these three leading indications comprise common chemistry features and are based on the samefamily of ligands and polymers, enabling efficient parallel development. Our parallel development of these indicationsmaximizes return on investment and shareholder value. Of these, the shingles indication program is in the process of clinicaltrial design and clinical site selection, which will be a part of the IND application. The IND filing has been delayed due tothe potential impact of COVID-19 on upcoming human clinical trials, and we will complete this task to engage into clinicaltrials as soon as the pandemic wears down to the point that these clinical trials can be conducted without excessive impacton design, execution, and cost of the trials. We believe that the other two indications will advance to an IND stage in thevery near future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our HerpeCide™ program has maturedtowards multiple drug indications. Besides the three indications listed above, modifications of the same drug candidates are anticipatedto be developed into (iv) Eye Drops to treat ocular (i.e. external eye) Herpes Keratitis (HK) caused by HSV-1 or HSV-2, andpossibly (v) Intra-Ocular injections to treat viral Acute Retinal Necrosis (vARN) caused by herpes viruses, primarily VZV,shingles (varicella zoster virus) and HSV-2, a cause of blindness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, we believe that the shinglesdrug candidate may be eligible for the PHN indication as well. PHN clinical studies are long and expensive, and we plan to advancethe candidate for this indication only after its shingles indication clinical trials are completed. Further, the same drug candidateis expected to work against chickenpox in children. Chickenpox remains a sporadic epidemic disease despite vaccines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Expansion to additional indications islikely, as we perform further studies. It is likely that some of these drug candidates with variations may be able to address diseasescaused by the remaining human herpes viruses, namely EBV, HCMV, HHV-6A, HHV-6B, and HHV-7. Such expansions would enable maximizationof return on investment (ROI) and maximization of shareholder value.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Including the HerpeCide program explainedabove, we currently have nine different drug development programs, attesting to the strength of our platform technology. We havechosen to focus strategically on the anti-coronavirus program at present, and we believe that we have candidates that are worthyof human clinical trials. We are in the process of moving them into IND-enabling safety/toxicology studies at this time. We believethat these IND-enabling studies should be conducted rapidly due to the expedited nature of the anti-coronavirus programs at boththe CROs and at the US FDA. After this, we plan on taking the NV-HHV-101 skin cream clinical drug candidate for treatment of shinglesrash into human clinical trials, and further develop additional HerpeCide™ program indications and drug candidates that areexpected to result in a robust franchise with drug approvals against a number of different herpes virus indications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our drug development strategies may beinfluenced by considerations regarding the ability to engage into licensing or co-development relationships with other pharmaceuticalcompanies. Pharmaceutical drug development is an expensive and long duration proposition. Management’s plan is to developeach of our nanoviricides to the necessary stage(s) for potential collaborations. Our drug development strategies may be influencedby considerations regarding the ability to engage into collaborations with other pharmaceutical companies. Such licensing or co-developmentrelationships may entail upfront payments, milestones payments, cost sharing, and eventual revenue sharing, including royaltieson sales. There is no guarantee that we will be able to negotiate agreements that are financially beneficial to the Company. TheCompany intends to develop its drugs on its own if a suitable collaboration does not occur. As and when needed, management plansto continue to raise additional funds for our continuing drug development efforts from public markets. However, there can be noassurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 19; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          19          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe we are one of the very few smallpharmaceutical drug innovators that possess their own cGMP or cGMP-capable manufacturing facility. With our Shelton, Connecticutcampus and pilot-scale cGMP-capable manufacturing facility, we are in a position to advance our drug candidates into clinical trials,produce the pre-clinical “tox package” batches, and the clinical drug substance batches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s cGMP-capablepilot-scale manufacturing facility in Connecticut may enable initial market entry for some of our products upon approval,allowing the Company to grow into a stand-alone Pharma company, in addition to a potential licensing strategy for success.The Company thus continues to minimize risk to investors by improving the potential for success.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have continued to make significant progressin advancing our newly engaged anti-coronavirus drug program, and our HerpeCide program drug pipeline. Our drug development capabilitiesare substantially enhanced by the recent financings discussed earlier.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        All of these studies are dependent on externalcollaborators providing available time slots for us. Thus, there can be delays in achieving the milestones that are beyond theCompany's control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         The Human Coronavirus Treatment DrugProgram        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In a very short time, we have been ableto develop drug candidates worthy of human clinical trials to treat SARS-CoV-2 infection that causes COVID-19 spectrum of diseases.  We have nominated a clinical candidate subsequent to the reporting period, and are advancing this candidate as well as additionalcandidates into safety/toxicology studies in parallel to maximize the chances of success in the shortest period of time, as describedearlier.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our coronavirus drug treatment candidates were shown to be highlyactive against multiple coronaviruses in cell culture studies, and also highly active against a coronavirus that uses the sameACE2 cellular receptor as the SARS-CoV-2 (and SARS-CoV-1), namely, h-CoV-NL63, in animal studies. We are therefore confident thatthese candidates may result in a drug that can be used not only during the pandemic but also normally for the various circulatinghuman coronavirus diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Due to the severe nature of the pandemic,several companies are developing treatments and vaccines for COVID-19. Of these, only two at present are directly acting on thevirus itself, namely remdesivir (Gilead), and favipravir (Fujifilm). Remdesivir is currently approved for emergency use only inthe USA and other countries, and Favipravir is approved for emergency use in Japan and other countries, for COVID-19. Both of thesehave limited effects. They both act inside the cell by blocking the replication cycle of the virus. Several known antivirals (developedagainst other viruses) have been tested clinically both alone and in combinations, with limited effect if any. Several of suchclinical trials are on-going.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our nanoviricide that is designed to destroythe external virus so it does not go inside cells should be complimentary to the approach of blocking viral replication insidecells. Blocking both the external virus and the internal replication cycle at the same time could potentially result in a cure,if effective agents to do so can be developed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Additionally, several antibodies are indevelopment to neutralize the external virus. Antibodies are generally highly specific and the viruses are known to escape antibodytreatments readily. Convalescent plasma (plasma from recovered patients that contains neutralizing antibodies) is being attemptedas a treatment. Further, several repurposed drugs that do not attack the virus but effect the host have entered clinical trials,and many of them have shown limited or little benefit. Dexamethasone, a corticosteroid, has been shown to help hospitalized patientswith severe disease and reduce lethality, due to its effect on calming the human immune system attacking the lungs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        There continues to remain a need for an effective, broad-spectrumanti-coronavirus drug, in spite of all of these efforts. We believe the Company is uniquely positioned to respond to this needwith its novel technology.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 20; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          20          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         The Shingles Topical Treatment DrugProgram        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our most advanced drug candidate is a nanoviricideagainst VZV (varicella-zoster virus), the virus that causes debilitating shingles rash in adults and chickenpox in children. Itsfirst indication is expected to be as topical treatment of shingles rash. About 500,000 to 1 million episodes of herpes zoster(shingles) occur annually in the United States alone. In spite of the new Shingrix™ vaccine, the market size for a therapeuticfor shingles is estimated to be in excess of $1 billion dollars according to two consulting firms, namely BioEnsemble, LLC andNanoTech Plus LLC, in reports prepared for the Company. There is currently no approved drug against shingles, PHN or chickenpox,indicating an unmet medical need.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Broad-Spectrum HerpeCide™ DrugCandidates Enable Additional Indications        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The potential broad-spectrum nature ofour anti-HSV drug candidates is expected to enable several anti-herpesviral indications. Thus, HSV-1 primarily affects skin andmucous membranes causing “cold sores”. HSV-2 primarily affects skin and mucous membranes leading to genital herpes.HSV-1 infection of the eye causes herpes keratitis that can lead to blindness in some cases. In addition, human herpesvirus-3 (HHV-3),aka varicella-zoster virus (VZV) causes chickenpox in children and, when reactivated in adults, causes shingles. Shingles breakoutsare amenable to topical treatment, as are the HSV cold sores, genital lesions, and herpes keratitis of the eye.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Topical treatment is expected to resultin extremely high antiviral efficacy. This is because such treatment would provide higher concentrations of the antiviral at thesite where the virus is manifesting at its highest levels. Highly effective topical treatments in most of these scenarios remainunmet medical needs. Most of these indications do not have satisfactory treatments at present, if any. Further, the treatment ofherpes virus infections caused by acyclovir- and famciclovir- resistant mutants is currently an unmet medical need.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With additional indications in the diseasescaused by viruses in the herpes virus family, it is likely that our HerpeCide program could expand into a much broader productpipeline than currently anticipated. We anticipate that many of these new drugs would be variations on our current drug candidates.It is therefore expected that the incremental cost of drug development for such additional indications could be substantially smallerthan the cost of developing drugs against other viruses in our portfolio.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 21; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          21          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Progress in Identifying Clinical LeadDrug Candidates against the Four HerpeCide Program Indications        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Previously, in August 2015, we obtainedconfirmatory animal studies data on our then current lead anti-herpes virus drug candidate from TransPharm, LLC. The data confirmedthe results earlier obtained in Professor Ken Rosenthal’s Lab at the NorthEast Ohio Medical Center (NEOMED). In both studies,dermal topical treatment with our anti-HSV drug candidate led to 85~100% survival in mice lethally infected with the zosteriform,neurotropic, clinically derived and relevant strain, namely HSV-1 H129. In contrast, all of the untreated mice had severe clinicalmorbidity and none of the untreated mice survived. These studies established this drug candidate as a viable, effective potentialdrug. Professor Rosenthal has since retired from NEOMED and is now Professor of Biomedical Sciences at the College of Medicine,Roseman University of Health Sciences, Summerlin, NV.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have developed additional variationsof the ligand used in this older herpecide drug candidate using molecular modeling and rational design strategies. The new ligandsappear to have substantially improved effectiveness and with a similar level of safety as did the prior tested ligand. We are nowperforming studies on chemical covalent conjugates of these ligands with different “nanomicelle” polymer backbones.We are performing a set of studies to identify the lead clinical candidates for the different herpes virus indications based onthese new nanoviricides.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have found in preclinical studies thatthe nanoviricides drug candidates developed against herpes HSV-1 and HSV-2 are also effective against the shingles virus, namelythe Varicella Zoster Virus (VZV), also called HHV-3 (human herpesvirus-3) in cell culture studies in house. These data were presentedat the American Society of Virology 2017 annual meeting held in June 2017 at Madison, WI. Additional studies have continuedto demonstrate strong effectiveness as the development progresses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These results have enabled the identificationand declaration of a clinical drug candidate in the HerpeCide program. We have taken this candidate, namely NV-HHV-101, into IND-enablingstudies, towards human clinical trials. The first indication we intend for treatment with this drug is the topical treatment ofshingles rash.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s drug candidates inHerpeCide™ program are being developed for direct topical application on the affected areas to control the infections. Directtopical application enables delivery of the highest possible concentrations of the active substance directly at the site of infection.This allows for maximal clinical effectiveness, while at the same time minimizing side effects that are seen with systemic therapy(such as oral drugs or injectables).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This dermal drug development workload isexpected to be significantly shorter than the studies for ocular, injectable, or oral drugs. We anticipate filing an IND once thereport of these IND-enabling studies is available.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Topical treatment of herpes virus infectionsis important because herpes viruses become latent in neuronal cells or in ganglia and cause periodic localized breakouts that appearas skin rashes and lesions. Systemic drug treatment results in side effects because of the high systemic drug concentrations thatneed to be achieved and the large drug quantities that must be administered. Since the virus remains mostly localized in the areaof the rash and connected nerve apparatus, using high concentrations of drugs delivered in small quantities topically would allowmaximizing the effectiveness while minimizing side effects.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 22; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          22          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since these nanoviricides are designedto attack the virus directly, we believe that human clinical studies should reflect the success of the preclinical studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         HerpeCide Program Collaborations andProgram Update        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have engaged in several collaborationsto help us finalize clinical candidates and develop IND-enabling pre-clinical data in our various programs this year. Notably,we have continued collaborations with the CORL at the University of Wisconsin for HSV-1 and HSV-2, with focus on small animal modelsfor ocular and dermal diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, we have a continuing relationshipwith Bio-Analytical Systems, Inc. (“BASi”), Indiana, a CRO for GLP and non-GLP safety/toxicology (“ToxPackage”) studies. Further, we continue to engage Biologics Consulting Group (BCG), Virginia, for advice and help with regulatoryaffairs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also have a collaboration with the CampbellLab at the University of Pittsburgh for in vitro cell culture models of various ocular viruses including many adenovirus and herpesvirus strains, as well as animal models for ocular herpes keratitis (HK) and adenoviral epidemic keratoconjunctivitis (EKC).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, we have continued our agreementwith SUNY Upstate Medical University for the testing of the Company’s nanoviricides® drug candidates against varicellazoster virus (VZV), i.e. the shingles virus. This research is being performed in the laboratory of Dr. Jennifer Moffat.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Initially, Dr. Moffat conducted cellculture studies i.e.        <i>         in vitro        </i>        studies. Upon finding that the nanoviricides drug candidates were effective against VZV incell cultures, Dr. Moffat advanced the studies to the        <i>         ex vivo        </i>        human skin-patch organ culture (SOC) model studies stage,wherein our drug candidates are being evaluated against VZV infection of human skin patches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Dr. Moffat has extensive experiencein varicella zoster virus (VZV) infection and antiviral agent discovery. The goal of these studies is to help select a clinicaldrug development candidate for toxicology and safety evaluation intended for clinical trials for the treatment of shingles in humans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        VZV is restricted to human tissue and onlyinfects and replicates in human tissue. The        <i>         ex vivo        </i>        studies are continuing to evaluate the efficacy of the Company’snanoviricides to inhibit VZV in human skin organ cultures. Dr. Moffat has developed the human skin organ culture VZV infectionmodel for the evaluation of therapeutics. This model is a good representative model of natural VZV infection in humans as wellas an important model for evaluating antiviral activity, because it demonstrates behavior similar to the skin lesions caused byVZV in human patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Dr. Moffat is an internationally recognizedexpert on varicella zoster virus, and her research has focused on the pathogenesis and treatment of infection by this virus. TheNational Institute of Health has recognized this VZV model via a contract with Dr. Moffat’s lab for evaluating antiviralcompounds against VZV. Dr. Moffat is the director of two research core facilities at SUNY Upstate: the Center for HumanizedMouse Models and        <i>         In vivo        </i>        Imaging.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has established a direct relationshipwith the Moffat lab, without NIH as an intermediary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, the Company continues to performextensive antiviral cell culture studies against VZV, HSV-1 and HSV-2 using multiple cell lines and multiple strains of the viruses,in our BSL-2+ anti-viral cell culture laboratory in Shelton, CT.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 23; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          23          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Shingles and Associated Pain, PostherpeticNeuralgia (PHN)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Shingles is caused by re-activation ofthe chickenpox virus that most humans acquire in childhood. The chickenpox vaccine for children is a live, attenuated virus (LAV).The LAV is not as pathogenic as the wild-type virus. However, this means the virus is present in the vaccinated individual, butremains suppressed by the immune system. In both vaccinated and unvaccinated persons, re-activation occurs when the immune systemis suppressed which may be simply because of stress, advanced age, or some other immune modifying circumstances including immune-compromisedue to organ transplants or other diseases. Generally, humans in the age range of 50-60 are more prone to shingles, with next reactivationoccurring about 10~15 years later. There is a shingles vaccine approved for adults age 60 and above which is also available foradults younger than that.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Acyclovir-based oral drugs, such as valacyclovir(Valtrex®), are available as systemic therapy for shingles. Intravenous acyclovir is also employed for treatment of variousVZV indications. However, VZV is substantially less sensitive to (val)acyclovir than is HSV-1. Thus the oral drug generally doesnot result in optimal level of the active drug at the site of VZV viral production, and does not result in significant controlof the pathology. The antiviral drugs may be given for a period of 14 days or longer, with as much as 5g of dose per day, due topoor efficacy. In some indications, the treatment has been continued for a year or so. Thus, there is an unmet need for developinganti-VZV antivirals with high efficacy and safety.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Most adults with shingles recover in about15~30 days from the shingles rash. While the rash is unsightly, its stinging pain is often the debilitating pathology that leadsto lost workdays and other effects. Further, 65~70% of patients develop postherpetic neuralgia, or PHN, a stinging, debilitatingpain that lasts more than 30 days, and, in some patients, may last for years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        It is generally believed that PHN resultsfrom damage to the local nerve endings and nerve cells caused by the uncontrolled production of the shingles virus. However, VZVhas been found to be present in at least 75% of PHN cases in a study, indicating a role for antivirals in controlling PHN. We believethat an effective therapy, such as our nanoviricide against VZV, which blocks progression of the virus to infect new cells andthereby limits further production of virus, would minimize the damage to nerve endings and nerve cells caused by the virus. Webelieve that this would minimize the occurrence, severity, and time period of PHN, in addition to having significant effects onthe severity of shingles rash, lesions, and healing time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In light of this we have conducted an animalstudy regarding the effect of our nanoviricide drug candidates against shingles on neuropathic pain in a classical animal modelof pain (without VZV infection). On August 7, 2018, we reported that our anti-Shinglesdrug candidates were effective in ameliorating pain sensations in an animal model of abnormal pain. In this animal study, topicaltreatment with the nanoviricides® anti-VZV compounds significantly reduced the measures of abnormal pain sensations in a ratmodel of neuropathic pain. The study was conducted at AR Biosystems in Tampa FL. A characteristic excruciating pain is a debilitatingpathology of shingles presentation. Thus a direct pain-reducing effect of the Company’s anti-shingles drug candidates wouldbe very important in ameliorating the pathology of shingles, in addition to the already demonstrated significant antiviral effect.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that a skin cream would be thebest form of treatment to provide rapid control of the virus and shingles lesions patch expansion, since the shingles outbreakremains highly localized. A skin cream would afford much greater local exposure of drug to virus compared to a systemic oral orinjectable treatment.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        An effective therapy for patients withsevere shingles continues to be an unmet need.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         HSV-1, HSV-2, Ocular Herpes Keratitis        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that a skin cream for the controlof HSV-1 “cold sores” (herpes labialis, and recurrent herpes labialis or RHL) is another drug candidate that may beclose to entering human clinical trials. We have already achieved strong success in animal studies against HSV-1, as discussedabove.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 24; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          24          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that we will be able to successfullydevelop a drug candidate for Ocular Herpes Keratitis (HK) as well. It is caused by HSV-1 or HSV-2 infection of the external eye.We are developing this drug as topical eye drops or eye lotion, in order to achieve maximum local drug effect while minimizingsystemic exposure. We plan on testing these drug candidates against adenoviruses as well, to determine if the same drug would alsobe effective against epidemic keratoconjunctivitis (EKC, the severe “pink eye” disease). If the same drug works againstherpes virus and adenovirus infections of the eye, we expect this drug may cover almost 99% of all external eye viral pathologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We also believe that we will be able todevelop a drug against HSV-2 genital herpes. We plan on developing a skin cream for this indication, to maximize local effectiveness.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Viral Acute Retinal Necrosis (v-ARN)        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is also exploring additionalindications of its anti-herpes drug candidates that are expected to broaden the pipeline and require limited development work.In particular, certain eye diseases of the retina have been causatively linked to herpes viruses. For example, most cases of viralAcute Retinal Necrosis (ARN), a disease that leads to severe loss of vision and can lead to blindness, have been linked to VZVand HSV-2, with some also associated with HSV-1 or CMV infection of the eye. It is believed that, HSV-2 ARN in children and adolescentsmay result from undiagnosed and asymptomatic neonatal HSV-2 infection, which has reactivated several years later from latency ina cranial nerve and entered the retina. Currently, intravenous followed by oral acyclovir derivatives daily for several monthsto years and sometimes intravitreal (into the eye) foscarnet injections are therapeutically employed with limited effectiveness,establishing the potential of effective antiviral therapy to avoid blindness as well as multiple surgeries related to retinal detachment.A highly effective antiviral that can be injected into the eye infrequently and provides sustained antiviral therapeutic effectover a long period of time for ARN is an unmet medical need.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Neonatally acquired herpes virus infections,even when asymptomatic, are thought to have led to ARN as late as age 22. There are approximately 2,500 cases per year of diagnosedneonatal herpes virus infections in the USA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         cGMP Manufacture        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have already manufactured our lead drugcandidate, NV-HHV-101, in a cGMP-compliant manner at this facility for the IND-enabling GLP Safety/Toxicology study. The drug substance,or active pharmaceutical ingredient (API) was produced at approximately 1kg-scale. Drug products, i.e. different dose levels ofthe skin cream, were made at scales of 3-5kg batches.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have also manufactured our developmentaldrug candidates for the treatment of human coronaviruses at approximately 0.5kg scale already in our scale-up manufacturing facilityand in our cGMP-compliant manufacturing facility.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         The FluCide™ Program        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We intend to re-engage the FluCide programonce the HerpeCide drug candidates enter human clinical trials, resource permitting. Previously, we had achieved industry-leadingeffectiveness levels demonstrating as high as 1,000-fold viral load reduction in a lethal animal model of influenza infection withmultiple strains of influenza. We were developing an injectable drug candidate for treatment of severely ill patients, and an oraldrug candidate for the treatment of outpatients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         DengueCide™        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We intend to reengage the DengueCide programif and when non-dilutive funding such as research grants become available to us. At present we have not applied for any grantsfor this program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 25; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          25          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         HIVCide™        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We intend to re-engage the HIVCide programonce the HerpeCide drug candidates enter human clinical trials, resource permitting. Previously, the drug candidates in the HIVCide™program were found to have effectiveness equal to that of a triple drug HAART cocktail therapy in the standard humanized SCID-huThy/Liv mouse model. Moreover, the nanoviricides were long acting. Viral load suppression continued to hold for more than fourweeks after stopping HIVCide treatment. The Company believes that this strong effect and sustained effect together indicate thatHIVCide can be developed as a single agent that would provide “Functional Cure” from HIV/AIDS. The Company believesthat substantially all HIV virus can be cleared upon HIVCide treatment, except the integrated viral genome in latent cells. Thiswould enable discontinuation of treatment until HIV reemerges from the latent reservoir, which may be several months without anydrugs. Moreover, the Company believes that this therapy would also minimize the chances of HIV transmission. The Company is currentlyoptimizing the anti-HIV drug candidates. These drug candidates are effective against both the R5 and X4 subtypes of HIV-1 in cellcultures. The Company believes that these drug candidates are “broad-spectrum”, i.e. they are expected to be effectiveagainst most strains and mutants of HIV, and therefore escape of mutants from our drugs is expected to be minimal. Certain anti-HIVnanoviricides have already been demonstrated that appear to provide extended viral load suppression for as long as 30 days or moreeven after stopping the drug, in animal studies. Given the chronic nature of HIV/AIDS, such a drug that has long sustained effectis expected to provide significant benefits to the patient. We believe once a week dosing is possible. Anti-HIV drug developmentis both expensive and slow because of the nature of the animal studies that require SCID mice whose immune system is destroyedand then replaced by surgically implanting and growing human immune system tissues in the mouse body. Due to our limited resources,HIVCide development is further hampered.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         EKC        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is developing broad-spectrumeye drops that are expected to be effective against a majority of the viral infections of the external eye. Most of these viralinfections are from adenoviruses or from herpes viruses. The Company has shown excellent efficacy of its drug candidates againstEKC (adenoviral epidemic keratoconjunctivitis) in an animal model. If feasible, we are planning to merge the anti-EKC drug developmentprogram and the ocular Herpes Keratitis drug development program, to develop a single drug that is effective against both diseases,i.e. effective against both adenoviruses and herpes viruses. This work is in research stage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Other Drug Programs: Ebola, Rabies andothers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, the Company also has researchprograms against Rabies virus, Ebola and Marburg viruses, and others. We will not be undertaking socially important programs suchas the development of an anti-Zika virus drug candidate, or continuation of our efforts in developing anti-Ebola drug candidate,unless non-dilutive funding for such efforts becomes available. At present we have not applied for any grants for these programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To date, the Company does not have anycommercialized products. The Company continues to add to our existing portfolio of products through our internal discovery andclinical development programs and also seeks to do so through an in-licensing strategy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Thus, this year, we have further focusedour programs and prioritized them in order to advance our first drug candidate into the clinic in the fastest possible path.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Safety and Toxicology Studies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We expect that our drug candidate for COVID-19treatment should enter into formal GLP safety/toxicology studies required for filing an IND application in the near future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As part of the IND-enablingdevelopment of our topical skin cream for treatment of shingles rash, we have performed a substantial amount of safety andtoxicology studies. We performed non-GLP safety toxicology studies in a rat model with two of the development stagecandidates first. Both candidates were extremely well tolerated and no adverse events occurred. This, along with efficacystudies in the Human Skin Organ Culture model of Dr. Moffat, led us to identify a clinical candidate, namely,NV-HHV-101. We have performed IND-enabling non-GLP Safety Toxicology studies of this clinical candidate in multiple animalspecies. NV-HHV-101 was well tolerated at all dosages tested and none of the parameters tested were affected. Based uponthese results, a GLP Safety/Toxicology study of dermal treatment in mini-pigs has been commissioned. These safety results arein agreement with histopathological observations in the human skin organ culture model studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 26; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          26          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We previously performed initial safety-toxicologyscreening of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats, as an injectable drug. We reportedthat a good safety profile was observed for this drug candidate in rats at the end of January 2015. These results are in agreementwith the previously reported results of a non-GLP toxicology study in mice. These study results also support the Company’spositive findings in animal models of infection with different influenza A virus strains in which no safety or toxicology concernswere observed. The Company has previously reported that many of its FluCide candidates demonstrated extremely high anti-influenzaactivity in those models. These results are extremely important since they indicate that FluCide continues to look very promisingas one of the most advanced candidates in the Company’s drug development pipeline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that these safety/toxicologyresults are also applicable to other drug candidates as well in the sense that they have established the safety of the polymerbackbones that we have employed. The polymer is made up of PEG (polyethylene glycol) chains put together into a single polymerchain with ligands and pendant lipids substantially uniformly attached at the connector points. This enables the nanoviricide tobe substantially non-immunogenic. PEG chain attachment or PEGylation is a widely used technique for rendering antibodies and otherdrugs substantially non-immunogenic.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Successful preliminary safety study inan animal model has cleared the way for us to begin IND-enabling safety/toxicology study for our shingles treatment drug candidate,as described earlier.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Clinical and Regulatory Strategy        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have engaged a number of regulatoryconsultants with US FDA experience, to advise us on the regulatory pathways, and the studies required for the IND applicationsfor the various disease indications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are expeditiously working on takingone of our anti-coronavirus developmental candidates into human clinical trials for the treatment of the SARS-CoV-2 infection thatcauses COVID-19 spectrum of diseases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At present, our anti-VZV drug candidateis in IND writing stage, and is expected to enter human clinical trials once the COVID-19 impact on conducting such clinical trialsis abated.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The other HerpeCide™ program drugcandidates are expected to follow into clinical development, as the necessary additional safety and efficacy studies in cell cultureand animal models are performed. We depend upon external collaborators for animal safety and efficacy studies, limiting the speedof our drug development work. While we seek collaborators and providers that have animal models that may be predictive of efficacyin human clinical trials, pharmaceutical drug development relies on what is available and what is doable rather than this goldstandard. Newly implemented animal models require validation studies to establish how reproducibly they can discriminate betweenplacebo and drugs that are known to work in the clinic, when such drugs are available. In many cases, we have to rely upon researchlevel animal models that have not yet established such robustness. Nevertheless, we can continue to use such models to obtain preliminaryindications for drug candidate refinements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the efficacy we have observedof our anti-VZV drug candidates in the        <i>         ex vivo        </i>        Human Skin patch Organ Culture “SOC” model in the Moffat Labis a strong indicator that these drug candidates are worthy of clinical development. There is no well-established animal modelfor shingles at present. As such we assume that these datasets will be sufficient for filing an IND.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With the non-GLP Safety/Toxicology data,and our Chemistry, Manufacture and Controls (CMC) manufacturing dataset, we filed a pre-IND application with the US FDA for NV-HHV-101as a topical treatment for shingles rash.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 3, 2019, the Company reportedthat the US FDA (the Agency) has generally agreed in its pre-IND response that the plan of drug development presented by the Companyto the FDA is generally adequate at this time. The Company received the response on May 23, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 27; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          27          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Split-Segment; Name: a3 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In particular, the Agency agreed that theCompany’s strategy for drug substance and drug product acceptance criteria is adequate. The Agency further agreed that theIND-enabling non-clinical studies proposed by the Company are generally adequate. The US FDA also said that the proposed designof the IND-opening human clinical studies appears reasonable at this time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA made valuable suggestions in thepre-IND response. The additional non-clinical studies recommended by the Agency are generally consistent with the Company’splanned IND-enabling non-clinical studies. The Company has discussed the Agency’s comments and suggestions in detail withits regulatory consultants from Biologics Consulting Group, VA, and has continued the pre-clinical development program accordingly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that our existing cGMP-capablemanufacturing facilities are sufficient for the production of drug products for human clinical studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Large Market Sizes – The CompanyTargets an Overall Anti-Viral Drug Market Size that Exceeds $40B        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The current market size for drugs for the treatment of differentherpes simplex infections is estimated to be approximately $2-4 billion. The current market size for the treatment of shinglesis estimated to be approximately $500 million to $1 billion. We believe that when an effective topical treatment is introduced,the market size is likely to expand substantially, as it has for several drugs in the antivirals, oncology, and other areas.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The approximate market size for severecases of shingles may be approximately one billion dollars. Severe cases of shingles may lead to hospitalization in several thousandcases in the USA every year. In addition, shingles appearing on the face may reach the eye and may cause significant vision issues.The outpatient treatment market size for shingles at present is limited, because of the limited effectiveness of existing drugs.An effective drug could expand this market into billions of dollars globally. A new two-dose shingles vaccine called Shingrix®has recently been introduced. However, due to the severe side effects in a significant percentage of persons taking this vaccineat its first dose, compliance as well as market penetration may be limited. The supplies of this vaccine are limited at present.Shingles is not seen as a life-threatening or life-modifying disease, the use of vaccines is limited, and may continue to be limited,especially if an effective drug is developed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, the estimated market sizefor an effective anti-Influenza drug is expected to be in tens of billions of dollars. The current estimate of anti-influenza drugmarket size is approximately $4 billion. The current market size for anti-HIV treatments is in excess of $20 billion. Other drugsin our pipeline, taken together, are estimated to be several billion dollars in market sizes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our focus at present is on the coronavirusprogram, with second priority on the topical treatments for different herpes virus infections in the HerpeCide program, as listedelsewhere in this report. We plan on re-engaging our Influenza and HIV programs when sufficient funding and skilled human resourcesare available.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Our Campus in Shelton, CT        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The multi-kilogram production scaleof our cGMP-capable manufacturing facility would enable the potential for NanoViricides to become a fully integratedpharmaceutical company (“FIPCO"), organically growing by generating revenues from initial market entry, if ourfirst drug is approved for marketing by appropriate regulatory authorities. As an example, a similar transition from R&amp;Dto FIPCO at Alexion (stock symbol: ALXN) led to a significant upswing in the market value of that company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With the large R&amp;D labs, Analyticallabs, the Bio labs, the Process Scale-Up production facility, and the cGMP-capable manufacturing facility established at our Sheltoncampus, we are in a much stronger position than ever to move our drug development programs into the clinic rapidly. These capabilitieshave enabled the rapid progress of our first drug candidate from development cycles through clinical drug candidate declarationto IND-enabling non-GLP and GLP Safety/Toxicology studies over the past two years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 28; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          28          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Process Scale-Up Production Capability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Process Scale-up area is availableand operational at scales of 200g to 2kg per step for different chemical synthesis and processing steps as required. It comprisesreactors and process vessels on chassis or skids, ranging from 1L to 30L capacities, as needed. Many of the reactors or vesselshave been designed by us for specific tasks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         cGMP Production Capability        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our versatile, customizable cGMP-capablemanufacturing facility is designed to support the production of multiple kilograms-scale quantities of any of our nanoviricidesdrugs. In addition, it is designed to support the production of the drug in any formulation such as injectable, oral, skin cream,eye drops, lotions, etc. The production scale is designed so that clinical batches for Phase I, Phase II, and Phase III canbe made in this facility. The clean room suite contains areas suitable for the production of sterile injectable drug formulations,which require special considerations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the production scale issufficient for initial market entry of the current drugs in the HerpeCide program.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This cGMP-capable facility can handle multiplereactors on chassis of up to 75L capacities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        At present, we move operations to our cGMP-capable manufacturingfacility from the Process Scale-up facility as the operational steps are developed to the level needed for moving them into thecGMP facility. This requires the development of draft-level Standard Operating Procedures, training, and drill-through of operations.We now have a functional Quality Assurance and Quality Control Department.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Our BSL-2 Certified Virology Lab        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have established several different typesof assays for screening of candidates against VZV, HSV-1 and HSV-2 in our BSL-2+ Virology lab. We believe that having developedthe internal capabilities for cell culture testing of our ligands and nanoviricides against a variety of viruses has substantiallystrengthened our drug development programs. We believe that this internal screening enables speedy evaluation of a much largernumber of candidates than external collaborations allow. This has significantly improved our ability of finding highly effectiveligands and performing structure-activity-relationship studies of the same in a short time period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have the ability to work on multipletypes of viruses or multiple virus strains at the same time, as this facility comprises three independent virological rooms. Wealso have the capability for performing HIV screening assays based on cell culture in house now, once we re-engage that program.We also have the ability to perform limited anti-influenza drug screening assays in cell culture in house.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        It is now possible for us to implementseveral other cell culture-based assays for many different viruses. These capabilities are expected to enable rapid drug developmentonce we re-engage the drug development efforts in areas beyond the HerpeCide program again.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We do not have the facilities for performinganimal model studies for any of our programs. We depend upon external collaborators for such studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Manufacturing Requirements of Some ofOur Drug Candidates        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The anti-coronavirus batch drug candidatemanufacturing requirements are expected to be modest. We have sufficient capacity to support potential clinical trials from possiblya single batch of production, depending upon dosage requirements. We may have the ability to produce sufficient drug to producetens of thousands of patients, depending upon dosage requirements, at our current facility itself.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The HerpeCide program drug product batchrequirements are estimated to be fairly modest because of the topical nature of treatment. In consultation with BASi and BCG, wehad estimated a batch size of approximately 1kg drug substance to be sufficient for the “Tox Package” (i.e. safetyand toxicology) studies of our dermal topical shingles drug candidate. NV-HHV-101 drug substance manufactured at approximately1kg scale in a cGMP-compliant manner and formulated into drug products at different concentrations at scales of up to 5kg was manufacturedfor the GLP Safety/Toxicology studies in our facility. Performing the manufacture in house has saved us a significant amount ofmoney, possibly in tens of millions of dollars, as well as in time, possibly at least one year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 29; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          29          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are estimating that a ~500g batch willbe more than sufficient for initial Phase-I human clinical studies as well. Our current estimate for a Phase 2a human clinicalefficacy study is also in the range of a ~500g batch requirement. We already have the facilities for producing up to 1kg per batchor more.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As we move our drug candidates into clinicalstudies, we plan to perform further scale-up studies. In the current facility, we may be able to manufacture about 20kg to 50kgof cGMP API (active pharmaceutical ingredient) annually. Depending upon the drug’s potency and indication, this productionsize may fetch modest revenues of around $50M to $500M, depending upon the cost metrics, enabling profitable market entry. Suchinitial commercialization would allow the Company to turn itself into a stand-alone fully integrated pharmaceutical company, byenabling capital formation for larger scale manufacturing facilities and fueling further growth.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Patents, Trademarks, Proprietary Rights:Intellectual Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The nanomedicine technologies licensedfrom TheraCour serve as the foundation for our intellectual property. NanoViricides holds a worldwide exclusive license to certaintechnology for several drugs with specific targeting mechanisms for the treatment of the following human viral diseases: HumanImmunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Influenzaand Asian Bird Flu Virus. The Company has entered into an Additional License Agreement with TheraCour granting NanoViricides theexclusive licenses for technologies developed by TheraCour for the additional virus types: Dengue viruses, Japanese Encephalitisvirus, West Nile Virus, Viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes, and Ebola/Marburg viruses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On September 1, 2005, the Companyentered into a Material License Agreement, (the “License Agreement”) with TheraCour. Initially, TheraCour granted theCompany an exclusive license for technologies developed by TheraCour for six virus types: HIV, HCV, Herpes Simplex Virus (HSV-1and HSV-2), Rabies, Asian (bird) flu and Influenza. In consideration for obtaining this exclusive license, we agreed: (1) thatTheraCour can charge its costs (direct and indirect) plus no more than 30% of certain costs as a development fee and such developmentfees shall be due and payable in periodic installments as billed; (2) to pay $25,000 per month for usage of lab supplies andchemicals from existing stock held by TheraCour; (3) to pay the greater of $2,000 or actual costs, for other general and administrativeexpenses incurred by TheraCour on our behalf; (4) to make royalty payments of 15% (calculated as a percentage of net salesof the licensed drugs) to TheraCour; (5) that TheraCour shall retain the exclusive right to develop and manufacture the LicensedProducts, exclusively for NanoViricides, and unless such license is terminated, will not develop or synthesize the Licensed Productsfor its own sake or for others; and (6) to pay an advance payment equal to twice the amount of the previous months invoiceto be applied as a prepayment towards expenses. TheraCour may terminate the License upon a material breach by us as specified inthe agreement. However, the Company has the opportunity to cure the breach within 90 days of receipt of notice to terminate theLicense. On February 15, 2010, the Company approved an Additional License Agreement with TheraCour. Pursuant to the exclusiveAdditional License Agreement, in consideration for the issuance of 2,000,000 shares of the Company’s Series A PreferredStock, (the “Series A Preferred”), the Company was granted exclusive license, under the same terms as the originalLicense Agreement, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengueviruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.In 2015 TheraCour stopped billing the Company and the Company stopped paying for the $25,000 per month usage fee for prior existingmaterials, by mutual agreement. There was no amendment to the license contract effected for this purpose.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 1, 2019, the Company enteredinto a Licensing Agreement (the “Agreement”) with TheraCour for an exclusive license for the Company to use, promote,offer for sale, import, export, sell and distribute products for the treatment of VZV derived indications. Process developmentand related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, withno duplication of costs allowed. The Company was not required to make any upfront payments to TheraCour and agreed to the followingmilestone payments to TheraCour; the issuance of 75,000 shares of the Company’s Series A preferred stock upon the grantof an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of PhaseII clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 30; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          30          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2020, the Company entered into aMoU for the field of development of drugs for human coronavirus indications with TheraCour. This MoU granted the Company a limitedlicense to continue drug development while a final license agreement is being perfected. There was no compensation provided toTheraCour under this MoU. The Company has initiated independent valuation of assets to perfect a license agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These licenses are not limited to underlyingpatents, but also include the know-how, trade secrets, and other important knowledge base that is utilized for developing the drugsand making them successful.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, these extremely broad licensesare not limited to some specific chemical structures but comprise all possible structures that we could deploy against the particularvirus, based on the licensed technologies. Further, the licenses are held by NanoViricides for worldwide use. The licenses canrevert only in the case of a default by NanoViricides. The terms of default are such that, effectively, TheraCour would be ableto take the licenses back only in the event that NanoViricides files bankruptcy or otherwise declares insolvency and the inabilityto conduct its business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Patents and other proprietary rights areessential for our operations. If our drugs are protected by a properly designed and enforceable patent, it can be more difficultfor our competitors to use our technology to create competitive products and more difficult for our competitors to obtain a patentthat prevents us from using technology we create. As part of our business strategy, in conjunction with TheraCour, a company controlledby our founder and the holder of the patents underlying our licensed technology, we actively seek patent protection both in theUnited States and internationally and intend to file additional patent applications, when appropriate, to cover improvements inour compounds, products and technology. We also rely on trade secrets, internal know-how, technological innovations and agreementswith third parties to develop, maintain and protect our competitive position. Our ability to be competitive will depend on thesuccess of this strategy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company believes that our drugs bythemselves may be eligible for patent protection. The Company, in conjunction with TheraCour, plans on filing patent applicationsfor protecting these drugs when we have definitive results from in vitro or in vivo studies that enable further drug developmentand IND application filing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has licenses to key patents,patent applications and rights to proprietary and patent-pending technologies related to our compounds, products and technologies(see Table 1), but we cannot be certain that issued patents will be enforceable or provide adequate protection or that pendingpatent applications will result in issued patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Table 1: Intellectual Property, Patents,and Pending Patents Licensed by the Company        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 29%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Patent or Application            </b>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 18%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Date of Issue/            </b>           </font>           <br/>           <b>            Application           </b>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 15%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             US Expiry             <br/>             Date            </b>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 14%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             International            </b>           </font>          </td>          <td style="width: 1%; text-align: center">          </td>          <td style="width: 20%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Owners            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            US6,521,736           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            (Certain specific amphiphilic polymers).           </p>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Issued: Feb 18, 2003           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Feb 18, 2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            N/A           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TheraCour Pharma and Univ. of Massachusetts, Lowell. [Nonexclusive license from TheraCour Pharma].           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PCT/US06/01820            <br/>            (SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS).           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Applied: Jan 19, 2006 PCT U.S. Issuance: May 8, 2012.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            October 2028 (estimated)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Applications are in various prosecution stages. Fifty-two of these have been issued or validated           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TheraCour Pharma, Inc. [Exclusive License].           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 29%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PCT/US2007/001607            <br/>            SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 18%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Applied: Jan 22, 2007           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 15%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ca. 2029(estimated)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 14%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Applications are in various prosecution stages. Nine of these have been issued or validated           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 20%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TheraCour Pharma, Inc. [Exclusive License].           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 31; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          31          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have previously announced certain importantissuances of patents on the TheraCour® technology underlying our Nanoviricides® drugs. A fundamental patent on the polymericmicelles composition, structure and uses was issued in the USA with substantially broad claims. This validates the novelty of ourapproach as well as our leadership position in the nanomedicines based on polymeric micelle technologies. This patent applicationhas so far been issued, granted, and/or validated, with substantially similar broad claims as 52 different patents in differentcountries and multi-country intellectual property organizations. A fundamental patent on which the nanoviricides® technologyis based (US Patent No. 8,173,764) for “Solubilization and Targeted Delivery of Drugs with Self-Assembling AmphiphilicPolymers” was issued on May 8, 2012. The patent term is expected to last through October 1, 2028, including anticipatedextensions in compensation for time spent in clinical trials. This US Patent has been allowed with a very broad range of claimsto a large number of families of chemical structure compositions, pharmaceutical compositions, methods of making the same, anduses of the same. The disclosed structures enable self-assembling, biomimetic nanomedicines. NanoViricides, Inc. holds exclusive,perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases. The other nationaland regional counterparts of the international Patent Cooperation Treaty (“PCT”) application number PCT/US06/01820,which was filed in 2006, have issued as a Singapore National Patent Publication, a South African patent, and also as an ARIPO regionalpatent, an OAPI regional patent (covering Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Republic of Congo, Coted’Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal, and Togo). It has also issuedas a granted patent in New Zealand, China, Mexico, Japan, Australia, Canada, several countries in Europe, Hong Kong, Indonesia, Israel,Korea, Malaysia, Philippines, Pakistan, and Vietnam among others. Estimated expiry dates range nominally from 2026 to 2027, priorto accounting for various extensions available in different regions and countries. Additional issuances are continuing in Europe,and in several other countries around the world.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Another fundamental patent applicationon the antivirals developed using the polymeric micelles has so far been issued, granted, and/or validated, with substantiallybroad claims as well, as 9 different patents. The counterparts of the international PCT application PCT/US2007/001607 have issuedas a granted patent in ARIPO, Australia, China, Japan, Mexico, New Zealand, OAPI, South Africa, and Korea to date. Additional issuancesare expected in Europe, USA, and in several other countries around the world. This patent application teaches antivirals basedon the TheraCour polymeric micelle technologies, their broad structures and compositions of matter, pharmaceutical compositions,methods of making the same, and their uses. The nominal expiry dates are expected to range from 2027 to 2029. Further patent prosecutionin several other regions and countries is continuing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        A total of at least, 61 patents have beenissued globally, on the basis of the two international PCT patent families that cover the fundamental aspects of the platform technologywe license from TheraCour. Additional patent grants are expected to continue as the applications progress through prosecution processes.All of the resulting patents have substantially broad claims.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These patents have nominal expiry datesin 2026 to 2029. The dates can be further extended in several countries and regions for the additional allowances due to the regulatoryburden of drug development processes, or other local considerations, such as licensing to a local majority held company. Many countriesallow up to five years extension for regulatory delays.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 32; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          32          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        No patent applications have been filedfor the actual drug candidates that we intend to develop as drugs as of now. We intend to file the patent application for HerpeCidebefore entering human clinical trials. The estimated expiry date for the HerpeCide patents, if and when issued, would be no earlierthan 2039-2040.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Of the patents and technologieslicensed, the Company believes that it will not be using the intellectual property, compositions of matter, or other aspectsdescribed and secured under the US Patent No. US 6,521,736. The Company believes that this patent describes an inferiortechnology compared to the technology in the later patent filings of Dr. Diwan. This patent, the Company believes,discloses prototype materials that served to establish the proof of principles developed by Dr. Anil Diwan, theCompany’s President and co-founder, whether such materials were possible to create and whether such materials wouldindeed be capable of encapsulation of pharmaceutically relevant compounds. The Company believes that the new and novelcompositions disclosed in the new patent applications, No. PCT/US06/01820, and No. PCT/US2007/001607, andadditional proprietary intellectual property provide the necessary features that enable the development of nanoviricides. TheCompany believes that no other published literature materials or existing patents are capable of providing all of thenecessary features for this development, to the best of our knowledge. However, the Company has no knowledge of the extensiveactive internal developments at a number of companies in the targeted therapeutics area.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        TheraCour may obtain patents for the compoundsmany years before we obtain marketing approval for them. Because patents have a limited life, which may begin to run prior to thecommercial sale of the related product, the commercial value of the patent may be limited. However, we may be able to apply forpatent term extensions, based on delays experienced in marketing products due to regulatory requirements. There is no assurancewe would be able to obtain such extensions. The Company controls the research and work TheraCour performs on its behalf and nocosts may be incurred without the prior authorization or approval of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Patents relating to pharmaceutical,biopharmaceutical and biotechnology products, compounds and processes such as those that cover our existing compounds,products and processes and those that we will likely file in the future, do not always provide complete or adequateprotection. Future litigation or reexamination proceedings regarding the enforcement or validity of our licensor,TheraCour’s existing patents or any future patents, could invalidate TheraCour’s patents or substantially reducetheir protection. In addition, the pending patent applications and patent applications filed by TheraCour, may not result inthe issuance of any patents or may result in patents that do not provide adequate protection. As a result, we may not be ableto prevent third parties from developing the same compounds and products that we have developed or are developing. Inaddition, certain countries do not permit enforcement of these patents, and manufacturers are able to sell generic versionsof our products in those countries. We also rely on unpatented trade secrets and improvements, unpatented internal know-howand technological innovation. In particular, a great deal of our material manufacturing expertise, which is a key componentof our core material technology, is not covered by patents but is instead protected as a trade secret. We protect theserights mainly through confidentiality agreements with our corporate partners, employees, consultants and vendors. Theseagreements provide that all confidential information developed or made known to an individual during the course of theirrelationship with us will be kept confidential and will not be used or disclosed to third parties except in specifiedcircumstances. In the case of employees, the agreements provide that all inventions made by the individual while employed byus will be our exclusive property. We cannot be certain that these parties will comply with these confidentiality agreements,that we have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independentlydiscovered by our competitors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Trademarks        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company currently has no registeredtrademarks.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Glossary of Terms        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Nano         </u>        </font>        - When used as a prefix for something other than a unit of measure, as in “nanoscience,” nano means relatingto nanotechnology, or on a scale of nanometers (one billionth of a meter or greater).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Viricide         </u>        </font>        - An agent that reliably deactivates or destroys a virus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 33; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          33          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Nanoviricide         </u>        </font>        ® – An agent that is made by attaching ligands against a certain virus or family of viruses to a nanomicellebased on the Company’s patent-pending and proprietary technologies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Ligand         </u>        </font>        - A short peptide or chemical molecule fragment that has been designed to specifically recognize one particular typeof virus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Micelle         </u>        </font>        - an aggregate of molecules in a solution, such as those formed by detergents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Nanomicelle         </u>        </font>        - A term coined to describe the micelles formed from the backbone polymer of a nanoviricide sans attached ligands.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Pendantpolymeric micelles         </u>        </font>        - A polymeric micelle forms from a polymer whose chemical constitution is such that even a singlechain of the polymer forms a micelle. A pendant polymer is a polymer that has certain units in its backbone that extend short chainsbranched away from the backbone. Pendant Polymeric Micelles therefore are polymeric micelle materials that are a class of pendantpolymers, and naturally form exceptionally well-defined, self-assembling, globular micelles with a core-shell architecture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          Mutations         </u>        </font>        - The ability (of a virus) to change its genetic structure to avoid the body’s natural defenses. Mutant virusesare created from a parent virus strain through a process of natural selection under pressure as it replicates in a host.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          P-Value         </u>        </font>        - In statistical hypothesis testing, the p-value is the probability of obtaining a result at least as extreme as thatobtained, assuming that the null hypothesis is true; wherein the truth of the null hypothesis states that the finding was the resultof chance alone. The fact that p-values are based on this assumption is crucial to their correct interpretation. The smaller thep-value, the greater is the probability that the observed study results and the comparison control are distinct, and thereforethat the study results are not a result of chance alone.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        More technically, the p-value of an observedvalue observed of some random variable T used as a test statistic is the probability that, given that the null hypothesis is true,T will assume a value as or more unfavorable to the null hypothesis as the observed value observed. “More unfavorable tothe null hypothesis” can in some cases mean greater than, in some cases less than and in some cases further away from a specifiedcenter value.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          InvestigationalNew Drug Application (Investigational New Drug (“IND”)         </u>        </font>        - The process of licensure of a new drug in the USgoes through several steps. A simplified explanation of these steps is as follows. Initially a Company may file a pre-IND applicationto seek meetings with the FDA for guidance on work needed for filing an IND application. The Company obtains data on the safetyand effectiveness of the drug substance in various laboratory studies including cell cultures and animal models. The Company alsoobtains data on chemical manufacturing of the drug substance. These and certain additional data are used to create an IND thatthe Company files with the FDA. After the FDA approves an IND application, the Company may conduct human clinical studies. A PhaseI human clinical trial is designed typically to evaluate safety of the drug and maximum permissible dosage level. A Phase II humanclinical trial that follows is designed to evaluate effectiveness of the drug against the disease in a small cohort of patients.A Phase III human clinical trial thereafter is designed to evaluate effectiveness and safety in larger groups of patients, oftenat multiple sites. The Company may then submit an NDA (New Drug Application) with the data collected in the clinical trials. TheFDA may approve the NDA. Once the NDA is approved, the Company can sell the drug in the USA. European countries have similar processesunder the European Medicines Agency (EMA). Other countries have similar processes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <u>          SAR:         </u>        </font>        Structure-Activity-Relationship study. When an initial lead drug compound is found that has activity, further studieson drug compounds obtained by suitably modifying it are performed with the goal of improving efficacy, safety, or both. Such studiesare called SAR studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         The Company’s Drug Pipeline        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Over the first several years of our operations,we continued to work on different viruses every year, creating a broad pipeline of drug candidates. This provided a validationfor our novel technologies. In addition, we were pursuing non-dilutive drug development and partnering opportunities such as governmentgrants and contracts as well as partnering with other non-governmental agencies, or medium and large pharmaceutical companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 34; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          34          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We had realized that the current pharmaceuticalindustry contract manufacturing operations (CMOs) do not have the expertise in our kinds of nanomedicines. We therefore acquiredthe cGMP-capable nanomedicines drug development and manufacturing facility from Inno-Haven LLC in 2014 at cost. Dr. Anil Diwan,our co-founder, had established Inno-Haven LLC to acquire and develop lab facilities appropriate for his work. On December 31,2014, the Company entered into and consummated an Agreement for the Purchase and Sale of this cGMP-compliant pilot manufacturingand lab facility and property located in Shelton, Connecticut. The purchase price of the facility was comprised solely of the repaymentof the direct costs of the seller, Inno-Haven, LLC incurred in acquiring and renovating the property and the facility plusInno- Haven’s closing costs in connection with the sale.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We were able to drive our drug developmentprograms towards regulatory approval processes only after this modern facility for nanomedicines synthesis, characterization, scale-up,and cGMP-like production became available. The facility became substantially operational at the end of December 2015. Sincethen, we have engaged in activities necessary for filing an IND (Investigational New Drug application) with the US FDA or anotherinternational regulatory agency to begin Phase I human clinical trials of our first drug candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We chose our HerpeCide drug program, andin particular, skin cream for topical treatment of pathologies caused by herpes simplex viruses as our lead program based on regulatoryrequirements, resource requirements, commercial opportunity, ROI maximization opportunities, and other considerations. We had developedcertain broad-spectrum ligands based on molecular modeling for binding to herpes simplex virus and potentially interfere with thisvirus’ binding to its human cell entry receptor, namely HVEM (“herpes virus entry mediator”). The nanoviricidesdesigned using these ligands have shown broad-spectrum activity in cell cultures against multiple HSV strains and both HSV-1 andHSV-2. Our early drug candidates have also shown substantial effectiveness in an animal model of HSV-1 skin disease (for HSV-1 “cold sores” treatment). Additionally, we found that the same drug candidates also demonstrated effectiveness againstVZV, the cause of shingles in adults and chickenpox in children.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This has led to our new strategy for drugdevelopment with the goal of entering our first drug candidate into human clinical trials at the earliest possible timeframe. Table2 below summarizes our drug development programs, specific disease indications we plan on developing against, and the priorityfor each drug in the development pipeline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: #CDD4E9; border-collapse: collapse">        <tbody>         <tr style="background-color: #BDC0BF">          <td colspan="7" style="border: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Table 2. NanoViricides Drug Products in Development            </b>           </font>          </td>         </tr>         <tr style="background-color: #BFBFBF">          <td colspan="2" style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Program            </b>           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Drug            </b>           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Virus            </b>           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Indication            </b>           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Development             <br/>             Stage            </b>           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Priority            </b>           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="width: 5%; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            I           </font>          </td>          <td style="width: 14%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Human Coronavirus Program           </font>          </td>          <td style="width: 5%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>          <td style="width: 16%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            human coronaviruses including SARS-CoV-2           </font>          </td>          <td style="width: 35%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            COVID-19, Seasonal coronavirus afflictions           </font>          </td>          <td style="width: 18%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            IND-enabling           </font>          </td>          <td style="width: 7%; border-bottom: #5E5E5E 1pt solid; padding: 4pt; border-right: #5E5E5E 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td rowspan="8" style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            II           </font>          </td>          <td rowspan="7" style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HerpeCide™ Dermal Topical and Eye Drops           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1a           </font>          </td>          <td rowspan="3" style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Varicella-Zoster Virus  (VZV)           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Shingles           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            IND-Writing           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1b           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            PHN           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Advanced Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            C           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1c           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chickenpox           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Advanced Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            C           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2a           </font>          </td>          <td rowspan="2" style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HSV-1           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Herpes “Cold Sores”           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Advanced Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            B           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2b           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Recurrent Herpes Labialis (RHL)           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Advanced Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            C           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HSV-2           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Genital Herpes           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            B           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HSV-1, HSV-2           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ocular Herpes Keratitis (HK)           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            C           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HerpeCide™ IntraOcular Injection           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            VZV, HSV-2, HSV-1           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            viral Acute Retinal Necrosis (vARN)           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            C           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 35; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          35          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: #CDD4E9; border-collapse: collapse">        <tbody>         <tr style="background-color: #EEEEEE">          <td rowspan="2" style="width: 5%; border: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            III           </font>          </td>          <td rowspan="2" style="width: 14%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            FluCide™ Broad-Spectrum Anti-Influenza nanoviricide           </font>          </td>          <td style="width: 5%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6           </font>          </td>          <td style="width: 16%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All Influenza A           </font>          </td>          <td style="width: 35%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Injectable FluCide™ for hospitalized patients           </font>          </td>          <td style="width: 18%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <p style="margin-top: 0; margin-bottom: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Advanced Preclinical            </font>           </p>           <p style="margin-top: 0; margin-bottom: 0">            <font style="font: 10pt Times New Roman, Times, Serif">            </font>           </p>           <p style="margin-top: 0; margin-bottom: 0">            <font style="font: 10pt Times New Roman, Times, Serif">            </font>            Pre-IND Meeting held with US FDA           </p>          </td>          <td style="width: 7%; border-top: #5E5E5E 1pt solid; border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            D           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All Influenza A           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Oral Flucide™ for outpatients           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            Advanced Preclinical           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            Pre-IND Meeting held with US FDA           </p>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            D           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            IV           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Nanoviricide Eye Drops           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Adenoviruses, HSV-1           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Eye Drops for Viral Diseases of the External Eye           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            E           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            V           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            DengueCide™           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dengue viruses, all types           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Broad-Spectrum nanoviricide against all types of Dengue viruses           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            VI           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HIVCide ™           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HIV/AIDS           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Escape-resistant Anti-HIV nanoviricide           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preclinical           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            D           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            VII           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other Nanoviricides Drug Projects           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ebola/Marburg, Rabies, MERS, Others           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Broad-Spectrum nanoviricide drugs against different viruses and indications           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            R&amp;D           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F           </font>          </td>         </tr>         <tr style="background-color: #EEEEEE">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            VIII           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HerpeCide™ Program Expansion Drug Projects           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Possible            <br/>           </font>           EBV, HCMV, HHV-6A, HHV-6B, HHV7, KSHV          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Broad-Spectrum nanoviricide drugs against different herpes viruses for different indications           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            R&amp;D           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F           </font>          </td>         </tr>         <tr style="background-color: white">          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; border-left: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            IX           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Long Term Projects           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Various           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Technologies for Cures for Persistent Viral Diseases           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            R&amp;D           </font>          </td>          <td style="border-right: #5E5E5E 1pt solid; border-bottom: #5E5E5E 1pt solid; padding: 4pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company currently is focused on thecoronavirus drug program, and has multiple development candidates, with at least one of them moving towards human clinical studies.In addition, the Company is developing drug candidates for more than eight different indications in various stages of developmentin the HerpeCide program alone. Of these, the skin cream for the topical dermal treatment of shingles rash (VZV) has advanced intoIND-enabling GLP Safety/Toxicology studies, having completed candidate optimization through rapidly performed human skin organculture assays in Professor Jennifer Moffat's lab at the SUNY Syracuse Upstate Medical Center. We believe that the Skin Cream forthe dermal topical treatment of HSV-1 cold sores and the skin cream for the dermal topical treatment of HSV-2 genital ulcers areexpected to rapidly mature towards human clinical trials in short succession after the clinical VZV drug candidate, namely NV-HHV-101.We have expanded the HerpeCide program to include additional indications for which we are developing drugs that are the same asor simple modifications of the existing drug candidates in the HerpeCide program, generally with a different formulation due toa different delivery pathway. This enables us to maximally leverage current R&amp;D while expanding our drug pipeline and potentialmarket and making a greater impact on patient lives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Given the large development costs associatedwith FluCide, HIVCide and other drug programs, we believe that these drug candidates will follow later because of the significantdevelopment work that needs to be performed in pre-clinical studies against a number of different influenza virus strains and subtypes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 36; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          36          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management’s beliefs are based onresults of pre-clinical cell culture studies,        <i>         ex vivo        </i>        tissue-based studies (e.g. human skin patch or a culture model), and        <i>         in vivo        </i>        animal studies using small animals.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The overall market size addressed by ourprograms can be estimated at $20 billion to $40 billion, according to research reports prepared by Jain PharmaBiotech and NanotechPlus, LLC. Of this, the market size for a highly effective shingles treatment has been estimated by Nanotech Plus in excess ofone billion dollars, after taking into account the recent introduction of the new Shingrix® vaccine (GSK). The overall marketsize for the HerpeCide program is estimated at over $5 billion based on published market reports from Jain PharmaBiotech in 2014.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Drug Development Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company intends to perform the regulatoryfilings and own all the regulatory licenses for the drugs it is currently developing. The Company will develop these drugs in partvia subcontracts to TheraCour, the exclusive source for these nanomaterials. With sourcingof materials from TheraCour, the Company prefers to manufacture these drugs in our own facility. However, the Company may manufacturethese drugs under subcontract arrangements with external manufacturers that carry the appropriate regulatory licenses and haveappropriate capabilities. The Company intends to distribute these drugs via subcontracts with distributor companies or in partnershiparrangements. The Company plans to market these drugs either on its own or in conjunction with marketing partners. The Companyalso plans to actively pursue co-development, as well as other licensing agreements with other pharmaceutical companies. Such agreementsmay entail up-front payments, milestone payments, royalties, and/or cost sharing, profit sharing and many other instruments thatmay bring early revenues to the Company. Such licensing and/or co-development agreements may shape the manufacturing and developmentoptions that the Company may pursue.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Manufacturing        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Manufacturing of Research Materials        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Nanomaterials that form the basis of ournanoviricide drugs are produced for research by TheraCour at our facilities in Shelton, Connecticut, under our licensing agreementswith TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Manufacturing of Drugs        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company intends to manufacture InjectableCoronavirus drug candidates and drugs, Dermal Topical anti-VZV anti-HSV-1, anti-HSV-2 candidates and drugs, as well as anti-HSVEye Drops/Gels, Injectable and Oral FluCide, HIVCide, DengueCide, RabiCide and other drugs for pre-clinical animal studiesand human clinical studies, in facilities owned by the Company, through human clinical trials of each of the clinical drug candidates.Our cGMP-capable manufacturing facility in Shelton, CT has sufficient capacity for supply of the pre-clinical and clinical batchesneeded for all of our drug candidates as and when they are anticipated to be needed. The Company may go to a cGMP third party providerfor the final fill-and-finish of the clinical drug products if necessary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With recent successes in production scale-up,the Company believes that it now has sufficient capacity at the Shelton cGMP-capable manufacturing facility to enable market-entryof our first drugs upon approval, potentially enabling the Company to build itself into a fully integrated pharmaceutical company("FIPCO"), which could provide substantial shareholder value. We note as a risk factor that there is no guarantee thatthe Company can take its drug candidates successfully through clinical trials, and if it does, that it can obtain marketing approval,and if it does, that it can market the drugs successfully. For our future commercial products, we will need to develop additionalmanufacturing capabilities and establish additional third-party suppliers to manufacture sufficient quantities of our product candidatesto undertake clinical trials and to manufacture sufficient quantities of any products that are approved for commercial sale. Ifwe are unable to develop manufacturing capabilities internally or contract for large scale manufacturing with third parties onacceptable terms for our future antiviral products, our ability to conduct large-scale clinical trials and meet customer demandfor commercial products would be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 37; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          37          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the technology we use tomanufacture our products and compounds is proprietary. For our products, we may have to disclose all necessary aspects of thistechnology to contract manufacturers to enable them to manufacture the products and compounds for us. We plan to have discussionswith manufacturers under non-disclosure and non-compete agreements that are intended to restrict them from using or revealing thistechnology, but we cannot be certain that these manufacturers will comply with these restrictions. In addition, these manufacturerscould develop their own technology related to the work they perform for us that we may need to manufacture our products or compounds.We could be required to enter into an agreement with that manufacturer if we wanted to use that technology ourselves or allow anothermanufacturer to use that technology. The manufacturer could refuse to allow us to use their technology or could demand terms touse their technology that are not acceptable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that we are in compliance withall material environmental regulations related to the manufacture of our products.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Competition        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our products in development target a numberof diseases and conditions that include several different kinds of viral infections. There are many commercially available productsfor many of these diseases and a large number of companies and institutions are spending considerable amounts of money and otherresources to develop additional products to treat these diseases. Most of these companies have substantially greater financialand other resources, larger research and development staffs, and extensive marketing and manufacturing organizations. When andif we are able to successfully develop products, they would compete with existing products based primarily on:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            efficacy;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            safety;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            tolerability;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            acceptance by doctors;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            patient compliance;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            patent protection;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ease of use;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            price;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            insurance and other reimbursement coverage;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            distribution;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            marketing; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            adaptability to various modes of dosing.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There are several drugs in the market thateffectively control HSV cold sores and genital herpes lesions in most patients. These include the nucleoside analogues idoxuridine,vidarabine, acyclovir, famciclovir, ganciclovir, and derivatives. However, their efficacy is limited or toxicities are high. Brincidofovir,based on the toxic drug cidofovir, is in development by Chimerix, but certain clinical trials involving brincidofovir have failedto meet the desired end points. Foscarnet is also used for VZV and ARN, but its toxicity is high. FV-100 was in clinical developmentagainst VZV, but these clinical developments appear to have been abandoned. In addition, pritelivir, antibodies, and some otherdrugs are in advanced stages of development against HSV-1 or HSV-2. A gamma globulin was recently approved.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The prevalence of herpes simplex virustype 1 (HSV-1) and HSV-2 is 47.8% and 11.9%, respectively, for individuals aged 14 to 49 years, and increases with age, in theUSA, according to CDC. HSV-2 causes a more severe disease that also has significant social costs to the patient. In spite of theexisting drugs, both HSV-1 and HSV-2 cause lifelong infection that continues to reactivate at different rates in different patients.Thus, in spite of several existing drugs that are already generic, the market size for a highly effective drug is estimated tobe in tens of billions of dollars for each of HSV-1 and HSV-2 treatments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There are currently no approved drugs forthe treatment of diseases caused by VZV, namely, shingles, PHN, and chickenpox. Valcyclovir or other acyclovir-class drugs areoften prescribed orally but have little effect on shingles. Cidofovir is used in extreme cases of shingles, but it is highly toxic,limiting benefit of the drug, limiting drug dosage and causing significant side effects. Several pain relievers are being developedto treat shingles pain and also the PHN pain. Thus, a safe and effective treatment against VZV is an unmet medical need.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 38; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          38          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company isaware of no approved drugs for the treatment of viral diseases of the external eye.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The current approved drugs for influenzainclude the neuraminidase inhibitors Tamiflu, Relenza, and Peramivir, anti-influenza drugs that are sold by Roche, Glaxo SmithKline(GSK), and BioCryst partners, respectively. In addition, M2 channel inhibitors, generic drugs include amantadine and rimantadine,both oral tablets that only inhibit the replication of the influenza A virus. There is significant viral resistance to the approvedM2 channel inhibitors especially in the US. Several companies are developing anti-influenza drugs at present. Small chemical classesinclude neuraminidase inhibitors, M2-channel inhibitors, and RDRP inhibitors, among others. There are also monoclonal, polyclonal,and mixed antibodies, as well as enzymes as drugs in development. Xofluza, developed by Shionogi Pharma (Japan) is approved inJapan and recently in the USA, licensed by Roche/Genentech. It is an influenza endonuclease inhibitor. It appears to be substantiallymore effective than existing drugs in reducing viral load and viral shedding, but did not have any effect on the length of theinfluenza disease course.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There are a growing number of anti-HIVdrugs being sold or in advanced stages of clinical development. Companies with HCV and HIV products include Gilead, Bristol-MyersSquibb Company (BMS), Roche, Boehringer Ingelheim, Merck &amp; Co., Inc. (Merck), in addition to several other pharmaceuticaland biotechnology firms.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Currently there are two accepted methodsof rabies prophylaxis: rabies vaccines and rabies immune globulin, manufactured by many foreign and multinational manufacturersincluding Aventis Pasteur and Chiron (acquired by Novartis). These accepted methods would be the standard against which our newanti-rabies drug in development will be judged.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In order to compete successfully, we mustdevelop proprietary positions in patented drugs for therapeutic markets. Our products, even if successfully tested and developed,may not be adopted by physicians over other products and may not offer economically feasible alternatives to other therapies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Government Regulation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our operations and activities are subjectto extensive regulation by numerous government authorities in the United States and other countries. In the United States, drugsare subject to rigorous regulation by the United States Food and Drug Administration (“FDA”). The Federal Food, Drugand Cosmetic Act and other federal and state statutes and regulations govern the testing, manufacture, safety, effectiveness, labeling,storage, record keeping, approval, advertising and promotion of our products. As a result of these regulations, product developmentand the product approval process is very expensive and time consuming.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Regulation by governmental authoritiesin the United States and other countries is a significant factor in our research and development and will be a significant factorin the manufacture and marketing of our proposed products. The nature and extent to which such regulation applies to us will varydepending on the nature of any products we may develop. Governmental authorities, including the FDA and comparable regulatory authoritiesin other countries, regulate the design, development, testing, manufacturing, safety, efficacy, labeling, storage, record-keeping,advertising, promotion and marketing of pharmaceutical products, including drugs and biologics, under the Federal Food, Drug, andCosmetic Act, or FFDCA, and its implementing regulations, and, for biologics, under the Public Health Service Act, or PHSA, andits implementing regulations. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions,including product seizures, import restrictions, injunctive actions and criminal prosecutions of both companies and individuals.In addition, administrative remedies can involve requests to recall violative products; the refusal of the government to enterinto supply contracts; or the refusal to approve pending product approval applications until manufacturing or other alleged deficienciesare brought into compliance. The FDA also has the authority to cause the withdrawal of approval of a marketed product or to imposelabeling restrictions. The process of obtaining approvals and the subsequent compliance with appropriate statutes and regulationsrequire the expenditure of substantial time and money, and there can be no guarantee that approvals will be granted.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 39; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          39          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         FDA Approval Process        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA must “license” a drugbefore it can be sold in the United States. Other countries have similar regulatory processes, and most are being harmonized underthe ICH guidelines. As of the date of this filing, the FDA has approved other nano-particulate drugs including Emend® by Merckand Rapamune® by Wyeth, as well as others. The general process for FDA approval is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Preclinical Testing        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The process required by the FDA beforea drug or biological product may be marketed in the United States generally involves the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 2%">          </td>          <td style="width: 2%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="width: 96%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Completion of preclinical testing of new pharmaceutical or biological products, generally conducted in the laboratory and in animal studies in accordance with GLP standard, and applicable requirements for the humane use of laboratory animals or other applicable regulations to evaluate the potential efficacy and safety of the product candidate;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 2%">          </td>          <td style="width: 2%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify; width: 96%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Submission of the results of these studies to the FDA as part of an Investigational New Drug application, which must become effective before clinical testing in humans can begin;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Manufacturing of investigational medicine under cGMP standard;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Performance of adequate and well-controlled human clinical trials according to GCPs and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the product candidate for its intended use;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Submission to the FDA of a new drug application, or NDA, for any new chemical entity drug we seek to market that includes substantive evidence of safety, purity, and potency, or safety and effectiveness from results of nonclinical testing and clinical trials;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product is produced, packaged and distributed, to assess compliance with cGMPs, to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the NDA; and           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            •           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            FDA review and approval of the NDA.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Clinical Trials        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If the FDA accepts the investigationalnew drug application, we study the drug in human clinical trials to determine if the drug is safe and effective. These clinicaltrials involve a time-consuming and costly three-phase process that often overlap, can take many years to compile and are veryexpensive. These three phases, which are themselves subject to considerable regulation, are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1. The drug is given to a small number of healthy human subjects or patients to test for safety, dose tolerance, pharmacokinetics, metabolism, distribution and excretion.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 2. The drug is given to a limited patient population to determine the effect of the drug in treating the disease, the best dose of the drug, and the possible side effects and safety risks of the drug.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 3. If a compound appears to be effective and safe in Phase 2 clinical trials, Phase 3 clinical trials are commenced to confirm those results. Phase 3 clinical trials are long-term, involve a significantly larger population, are conducted at numerous sites in different geographic regions and are carefully designed to provide reliable and conclusive data regarding the safety and benefits of a drug. It is not uncommon for a drug that appears promising in Phase 2 clinical trials to fail in the more rigorous and reliable Phase 3 clinical trials.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 40; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          40          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        If we believe that the data from the Phase3 clinical trials show an adequate level of safety and effectiveness, we will file a new drug application (NDA) with the FDA seekingapproval to sell the drug for a particular use. The FDA will review the NDA and often will hold a public hearing where an independentadvisory committee of expert advisors asks additional questions regarding the drug. This committee makes a recommendation to theFDA that is not binding on the FDA but is generally followed. If the FDA agrees that the compound has met the required level ofsafety and effectiveness for a particular use, it will allow us to sell the drug in the United States for that use. It is not unusual,however, for the FDA to reject an application because it believes that the drug is not safe enough or effective enough or becauseit does not believe that the data submitted is reliable or conclusive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At any point in this process, thedevelopment of a drug could be stopped for a number of reasons including safety concerns and lack of treatment benefit. Wecannot be certain that any clinical trials that we are currently conducting or any that we conduct in the future, will becompleted successfully or within any specified time period. We may choose, or the FDA may require us, to delay or suspend ourclinical trials at any time if it appears that the patients are being exposed to an unacceptable health risk or if the drugcandidate does not appear to have sufficient treatment benefit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA may also require us to completeadditional testing, provide additional data or information, improve our manufacturing processes, procedures or facilities or mayrequire extensive post-marketing testing and surveillance to monitor the safety or benefits of our product candidates if it determinesthat our new drug application does not contain adequate evidence of the safety and benefits of the drug. In addition, even if theFDA approves a drug, it could limit the uses of the drug. The FDA can withdraw approvals if it does not believe that we are complyingwith regulatory standards or if problems are uncovered or occur after approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         United States Review and Approval Process        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        After the completion of clinical trialsof a product candidate, FDA approval of a NDA must be obtained before commercial marketing of the product. The NDA must includeresults of product development, laboratory and animal studies, human trials, information on the manufacture and composition ofthe product, proposed labeling and other relevant information as well as a significant user fee. The FDA may grant deferrals forsubmission of data, or full or partial waivers. The testing and approval processes require substantial time and effort and therecan be no assurance that the FDA will accept the NDA for filing and, even if filed, that any approval will be granted on a timelybasis, if at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA may refuse to file any NDA thatit deems incomplete or not properly reviewable at the time of submission and may request additional information. Once the submissionis accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe, potent,and/or effective for its intended use, and has an acceptable purity profile, and whether the product is safe and effective forits intended use, and in each case, whether the product is being manufactured in accordance with cGMP or GTP, if applicable. Duringthe product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessaryto assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS.The FDA will not approve a NDA without a REMS, if required.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Notwithstanding the submission of relevantdata and information, the FDA may ultimately decide that the NDA does not satisfy its regulatory criteria for approval and denyapproval via a letter detailing such deficiencies. Data obtained from clinical trials are not always conclusive and the FDA mayinterpret data differently than we interpret the same data. If the FDA denies an application, the applicant may either resubmitthe NDA, addressing all of the deficiencies identified by the FDA, or withdraw the application.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Expedited FDA Review Programs         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA has four expedited program designations-Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review - to facilitate and expedite development and reviewof new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 41; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          41          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a4 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Fast Track program that is intendedto expedite or facilitate the process for reviewing new drug products that treat a serious condition and fill an unmet medicalneed. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied.In Fast Track, the FDA may consider for “rolling review” of sections of the IND on a rolling basis before the completeapplication is submitted.        <font style="color: #333333; background-color: white">         Once a drug receives Fast Track designation, earlyand frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process.The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval andaccess by patients.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         TheFDA may also accelerate the approval of a designated drug through the Breakthrough Therapy designation by        </font>        <font style="color: #333333; background-color: white">         expeditingthe development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicatesthat the drug may demonstrate substantial improvement over available therapy        </font>        on one or more clinically significant endpoints.If the FDA designates a drug as a breakthrough therapy, the drug is eligible for all Fast Track designation features, i        <font style="color: #333333">         ntensiveguidance on an efficient drug development program, potentially beginning at Phase 1 and organizational commitment involving seniormanagers        </font>        <font style="background-color: white">         regarding the development of the drug to ensure that the development programand the design of the clinical trials is as efficient as practicable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Accelerated Approval designation allowsthe FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict aproduct’s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trialsto verify the clinical benefit.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Priority Review designation means thatthe FDA’s goal is to take action on the IND within six months, compared to ten months under standard review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Fast Track designation, Priority Review,Accelerated Approval and Breakthrough Therapy designations do not change the standards for approval but may expedite the developmentor approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         Orphan Drug Designation        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="background-color: white">         TheOrphan Drug Act provides granting special status to drugs or biological products for rare diseases and conditions affecting fewerthan 200,000 persons. The first developer to receive FDA marketing approval for an orphan drug is entitled to a seven-year exclusivemarketing period in the United States for that product where the FDA will not approve another version of the same product. However,a drug that the FDA considers to be clinically superior to, or different from, another approved orphan drug, even though for thesame indication, may also obtain approval in the United States during the seven-year exclusive marketing period. In addition, ifthe holder of the orphan drug designation cannot assure the availability of sufficient quantities of their orphan drugs to meetthe needs of patients, the FDA could also grant approval to another product.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         United States Post-Approval Requirements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Any products for which we receive FDA approvalsare subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverseexperiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distributionrequirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumeradvertising, restrictions on promoting products for uses or in patient populations that are not described in the product’sapproved uses, known as off-label use, limitations on industry-sponsored scientific and educational activities and requirementsfor promotional activities involving the internet.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition, quality control and manufacturingprocedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability ofthe product. We rely, and expect to continue to rely, on third parties for the production of some, or all, clinical and commercialquantities of our products in accordance with cGMP and GTP regulations, as applicable. Manufacturers and other entities involvedin the manufacture and distribution of approved products are required to register their establishments with the FDA and certainstate agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP,GTP and other laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 42; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          42          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The FDA also may require post-marketingtesting, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknownproblems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adversepublicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communicationswith doctors, and civil or criminal penalties, among others. Also, new government requirements, including those resulting fromnew legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval ofour product candidates under development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Foreign Regulatory Review and Approval        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Whether or not FDA approval has beenobtained, approval of a product by comparable regulatory authorities in other countries will be necessary prior tocommencement of marketing the product in such countries. The regulatory authorities in each country may impose their ownrequirements and may refuse to grant an approval, or may require additional data before granting it, even though the relevantproduct has been approved by the FDA or another authority. As with the FDA, the regulatory authorities in the European Union,China and other developed countries have lengthy approval processes for pharmaceutical products. The process for gainingapproval in particular countries varies, but generally follows a similar sequence to that described for FDA approval.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the European Union, there is a centralizedapproval procedure that authorizes marketing of a product in all countries in the European Union (which includes most major countriesin Europe). If this procedure is not used, under a decentralized system, an approval in one country of the European Union can beused to obtain approval in another country of the European Union under a simplified application process at present. After approvalunder the centralized procedure, pricing and reimbursement approvals are also required in most countries. These procedures areundergoing revision and modification at present. We have never received approval for a product in the European Union to date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Other Health Care Laws        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the event any of proposed products areever approved for marketing, we may also be subject to healthcare regulation and enforcement by the federal government and thestates and foreign governments where we may market our product candidates, if approved. These laws include, without limitation,state and federal anti-kickback, fraud and abuse, false claims, physician sunshine and privacy and security laws and regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In addition to obtaining FDA approval foreach drug, we obtain FDA approval of the manufacturing facilities for any drug we sell, including those of companies who manufactureour drugs for us as well as our own and these facilities are subject to periodic inspections by the FDA. The FDA must also approveforeign establishments that manufacture products to be sold in the United States and these facilities are subject to periodic regulatoryinspection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are also subject to other federal, stateand local regulations regarding workplace safety and protection of the environment. We use hazardous materials, chemicals, virusesand various radioactive compounds in our research and development activities and cannot eliminate the risk of accidental contaminationor injury from these materials. Any misuse or accidents involving these materials could lead to significant litigation, fines andpenalties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         A Note on US FDA Priority Review Vouchers        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Food and Drug Administration AmendmentsAct of September 2007 authorizes the FDA to award a priority review voucher to any company that the FDA has determined iseligible for priority approval process for a treatment for a neglected tropical disease. The priority review voucher can be tradedto another company in a manner similar to carbon (emissions) credit vouchers. The recipient company can save as much as six monthson their drug review process, and it is anticipated that they would be willing to trade in vouchers with cash benefits to the companydeveloping drugs against neglected tropical diseases. The regulation became effective as of September 30, 2008.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 43; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          43          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Economists at Duke University, who proposedthe voucher concept in 2006, have calculated that reduction of the FDA approval time from 18 to six months could be worth morethan $300 million to a company with a top-selling drug with a net present value close to $3 billion. At this level, the voucherwould be expected to offset the substantial investment and risk required for discovery and development of a new treatment for aneglected tropical disease. (David B. Ridley, Henry G. Grabowski and Jeffrey L. Moe, “Developing Drugs For Developing Countries”,Health Affairs, 25, no. 2 (2006): 313-324; doi: 10.1377/hlthaff.25.2.313; © 2006 by Project Hope. and (        <u>         http://blogs.cgdev.org/globalhealth/2007/10/fda_priority_review.php        </u>        ). Some of the PRVs have been “sold” for as much as $250M or so recently.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        While there is no indication whether NanoViricides, Inc.can obtain priority review vouchers for its drugs against neglected tropical diseases, the high efficacies of our drug candidateslead us to believe that this may be possible. FDA awards priority review status on the basis of several criteria. NanoViricides, Inc.is currently working on several neglected tropical diseases, including Dengue fever viruses, rabies, Ebola/Marburg viruses, amongothers. Of these, Dengue viruses are explicitly included in the list under this Public Law, and the remaining viruses are eligiblefor similar treatment according to the language in the Public Law, at the discretion of the Secretary of Health (Food and DrugAdministration Amendments Act of 2007, P.L. 110–85, Sept. 27, 2007,        <u>         http://www.fda.gov/oc/initiatives/fdaaa/PL110-85.pdf        </u>        ). The Zika virus was added to this list recently.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Time Schedules, Milestones and DevelopmentCosts        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In the ensuing fiscal year, we hope tomeet several important milestones towards establishing human proof-of-concept for the nanoviricides platform:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            Complete IND-enabling studies for a coronavirus        clinical drug candidate.           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">           </p>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           File an IND for coronavirus SARS-CoV-2 treatment for Phase I and Phase II human clinical trials.          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td>           Potentially achieve an emergency use authorization for our SARS-CoV-2 clinical drug candidate.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        If the COVID-19 pandemic recedes and allows us to reengage humanclinical trials for the shingles treatment program, we intend to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Finalize human clinical trials designs for Phase I and Phase II trials for NV-HHV-101 for topical treatment of shingles rash.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Engage a contract Clinical Research Organization for conducting the human clinical trials for shingles.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Submit an IND-application to the US FDA, or an appropriate international regulatory agency for shingles.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Initiate and conduct Phase I human clinical trials, to determine safety and tolerability of NV-HHV-101 in human subjects.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If possible, initiate Phase II human clinical trials to determine effectiveness of NV-HHV-101 in controlling shingles rash and to study the effectiveness of NV-HHV-101 regarding shingles pain.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        All of these studies are dependent on externalcollaborators providing available time slots for us. Thus, there can be delays in achieving the milestones that are beyond theCompany's control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management believes it has sufficient financingto pursue at least one of its drug candidates through initial human clinical trials based on recent financings. There is no assurancethat the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund complete drugdevelopment through approval. The Company cannot provide assurance that its plans will not change or that changed circumstanceswill not result in the depletion of its capital resources more rapidly than it currently anticipates. We have estimated approximately$500,000 for initiation of Phase I clinical trials. The total cost of Phase I and Phase IIa trials could be significantly more.We may need to raise additional funds to support continued program development through Phase II and Phase III studies at leastand revenue realization.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        In addition to the coronavirus and shingles program milestoneslisted above, we plan to continue to advance the HSV-1 and HSV-2 skin cream drug candidates towards IND-enabling studies. AdditionalHerpeCide drug indications (See Table 2) will be advanced as opportunities become available, depending upon available resources(fiscal and manpower). We plan on continuing the work in the FluCide program albeit at a slow rate, with a view towards obtaininga drug development partnership or other external sources of funding for this program. We plan on continuing internal developmentof the HIVCide program at a slow rate. Other programs are currently heavily deprioritized and will be further developed if appropriateopportunities present themselves.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 44; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          44          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Drug Development Status        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has limited experience withpharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by ourassociates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed isnot known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additionalwork may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget.Such changes may also have an adverse impact on our projected timeline of drug development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The work-plan we have developed forthe next twelve months is expected to enable us to file an investigational new drug application (IND) for the coronavirusdrug program soon. Given our dependence on external collaborators for the studies and study reports, we cannot provide timeestimates. Our work-plan is extremely dependent on external factors, collaborations, and unanticipated delays can occur. Weare experiencing extreme staffing constraints as well as facility and resources constraints. We note as a risk factor thatthese resource constraints may cause further delays in our estimated timelines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have taken on the most important riskin nanomedicines, that of enabling cGMP manufacture, with consistent product from batch to batch, "head on" so to speak.Having established critical quality parameters in our manufacturing processes ahead of cGMP scale-up, we believe that we have minimizedthe risk related to manufacturing capabilities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the scale up and optimization ofour production level operations, we continue to work on a number of different polymer backbones (“nanomicelles”) andseveral antiviral ligands in order to make sure that different formulation and pharmacokinetic-pharmacodynamic (PK-PD) needs canbe met during the PK-PD programs for our various drug candidates. While this loads up our initial activities, it is expected tominimize the risk for further drug development towards IND or regulatory filings by making available backup drug candidates withdifferent PK-PD profiles.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This work-plan is expected to reduce certainrisks of drug development. We believe that this coming year’s work-plan will lead us to obtain certain information aboutthe safety and efficacy of our anti-coronavirus drug candidates in animal models in IND-enabling GLP Safety/Toxicology studies.We believe these data will enable us to file an Investigational New Drug (“IND”) application under the expedited FDAregulatory processes. We believe that in the coming fiscal year we will be able to perform Phase I/IIa human clinical trials andobtain valuable information on the safety and tolerability of our anti-coronavirus clinical drug candidate in humans, towards thegoal of obtaining emergency use approval. If our studies are not successful, we will have to develop additional drug candidatesand perform further studies, or further advance our other programs, for example VZV, HSV-1 or HSV-2 drug candidates, into humanclinical trials. If our studies are successful, we would be more confident in further developing our Coronavirus, HerpeCide aswell as other program drug candidates and may be in a position to re-engage our highly valuable drug programs including HIVCideand FluCide.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Managementintends to use equity-based and debt financing, as required, to fund the Company’s operations and to raise additional capitalfor conducting human clinical trials as we advance our pipeline towards IND stage. Management also intends to pursue non-dilutingfunding sources such as government grants and contracts as well as licensing agreements with other pharmaceutical companies. Therecan be no assurance that the Company will be able to obtain the additional financial resources necessary to fund its anticipatedobligations over the next year.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        TheCompany is considered to be a development stage company and will continue in the development stage until generating revenues fromthe sales of its products or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Our Collaborations and Service ContractAgreements        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our development model is to employ collaborationsand service contract relationships with renowned academic labs, government labs, as well as service contracts with external serviceproviders in order to minimize our capital requirements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 45; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          45          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        All of our agreements provide for the evaluationof Nanoviricides® substances created and provided by the Company to the Laboratory (or Collaborator). In general, the Laboratoryis compensated for certain material and personnel costs for these evaluations. The evaluations involve in vitro and in vivo scientificstudies at the Laboratory using their established protocols. In some cases, the Company provides scientific input regarding certainmodifications to their protocols as may be needed. The Laboratory returns the results and data to the Company. The Laboratory isallowed to publish the results after allowing time for the Company to protect intellectual property (IP) as needed. The Companysends nanoviricides as well as positive control (i.e. known therapeutics) and negative control (i.e. known not to work) compoundsas needed in a fully formulated, ready to use form, to the Laboratory. All IP related to the nanoviricide materials, their formulationsand reformulations, and their usage, rests with the Company. Any IP developed by the Laboratory regarding their own know-how, suchas laboratory tests and protocols, their modifications, etc. rests with the Laboratory. Joint inventions are treated as perapplicable US Laws.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company tries to choose thescientific laboratories with the most appropriate facilities and know-how relating to a particular field for the evaluationof an antiviral agent developed by the Company. The Company also tries to work with more than one laboratory for theevaluation of an antiviral agent developed by the Company. The Company also tries to work with more than one laboratory for agiven group of viruses whenever possible. We seek to improve confidence by obtaining independent datasets for corroborationof the efficacy and safety of the nanoviricides we develop. In addition, the Company tries to minimize dependence on aparticular Laboratory for the development of any specific drug candidate in our product pipeline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To date, the Company has engaged in GLPand non-GLP Efficacy and Safety evaluations in both in vitro (cell culture models) and in vivo (animal models) of our differentnanoviricides® research materials and drug candidates at different laboratories.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our current relationships are summarizedbelow:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For Coronavirus Infections:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           1.          </td>          <td style="text-align: justify">           AR Biosystems, Odessa, FL. (for Non-GLP Safety and Animal Efficacy Studies).          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           2.          </td>          <td style="text-align: justify">           Calvert Labs, Scott Township, PA. (for GLP Safety Toxicology Studies).          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For Herpes Virus Infections, Shingles,and for Viral Diseases of the Eye (Adenoviruses, Herpesviruses - Epidemic Kerato-conjunctivitis (EKC), Herpes Keratitis, viralAcute Retinal Necrosis (vARN)):       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Moffat Lab at SUNY Upstate Medical Center, Syracuse, NY.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The CORL at the University of Wisconsin, Madison, WI           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For Influenza Viruses:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Webster Lab at St Jude Children’s Hospital, TN           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For IND-enabling non-GLP and cGLP Safety/ToxicologyStudies:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            AR Biosystems, Inc., Odessa, FL (non-GLP studies)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Bio-Analytical Services, Inc., MI, (“BASi”) – IND-Enabling non-GLP and GLP “Tox Package” studies           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For Regulatory Pathway and Business Development:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We have retained independent consultants with extensive knowledgeof FDA requirements and FDA processes, to help us with the Chemistry, Manufacture and Controls, Non-clinical Studies, Human ClinicalStudies Design, as well as eCTD submission of an IND.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 46; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          46          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Consulting Agreement with Bio-Ensemble,LLC, NJ (BEL)        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2017, we signed a consultingagreement with BEL and its Principal, Dr. Carolyn Myers. The scope is evaluation of the business opportunity for VZV virusfield of drug development, and structuring new license agreements with TheraCour keeping in mind the express intent of the Companyof sublicensing its drug candidates to other Mid Pharma and Big Pharma partners. Dr. Myers is a pharma industry veteran withover 25 years of experience in business development. Her experience spans from leading roles in small to big pharma in businessdevelopment, obtaining partnering opportunities and performing deals from startups and small pharma side, to evaluating hundredsof technology and licensing proposals and performing partnering, collaboration, and outright purchase deals from the big pharmaside.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Regulatory Consulting and Advisory Agreementwith Biologics Consulting Group, VA (BCG).        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In July 2011 we signed an agreementwith Biologics Consulting Group to help us with our regulatory strategy and filings. Several of the members of the BCG facultyhad experience working as part of the US FDA. BCG helps us with the US FDA regulatory pathway strategies, applications processes,and with the development of applications as well as drug development program strategies, as needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Safety/Toxicology Studies Agreementwith Bio-Analytical Services, Inc. (BASi), MI        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2014, we signed an agreementwith BASi. BASi has performed our IND-enabling Safety/Toxicology studies for NV-HHV-101, our skin cream for shingles rash treatment.BASi will also perform the safety toxicology studies for the anti-herpes nanoviricide drug candidates in our HerpeCide program. Wehave signed a Master Services Agreement with Bio-Analytical Services, Inc., MI, (“BASi”) to perform cGLP and GLP-likesafety and toxicological studies that are necessary for filing an IND for each of our drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         AR Biosystems, Inc., Odessa, FL        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We do not have a Master Services Agreementwith AR Bio. From time to time, we discuss certain non-GLP studies, and if suitable, engage this CRO as needed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         VZV (HHV-3) Nanoviricides Efficacy EvaluationAgreement with the Moffat Lab at the SUNY Upstate Medical Center, Syracuse, NY.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In October 2016, we entered into anagreement with SUNY Upstate Medical University for the testing of its nanoviricides® drug candidates against varicella zostervirus, i.e. the shingles virus. The research will be performed in the laboratory of Dr. Jennifer Moffat and will include        <i>         invitro        </i>        ,        <i>         ex vivo        </i>        and possibly        <i>         in vivo        </i>        studies. Dr. Moffat has extensive experience in varicella zoster virus(VZV) infection and antiviral agent discovery. The goal of these studies is to help select a clinical drug development candidatefor toxicology and safety evaluation intended for clinical trials for the treatment of shingles in humans.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        VZV is restricted to human tissue and onlyinfects and replicates in human tissue. The        <i>         in vitro        </i>        studies will evaluate the effectiveness of the Company’s nanoviricidesantiviral agents against VZV infection of certain human cells in culture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The        <i>         ex vivo        </i>        studies will evaluatethe efficacy of the Company’s nanoviricides to inhibit VZV in human skin organ cultures. Dr. Moffat has developed thehuman skin organ culture VZV infection model for the evaluation of therapeutics. This model is a good representative model of naturalVZV infection in humans as well as an important model for evaluating antiviral activity, because it demonstrates behavior similarto the skin lesions caused by VZV in human patients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Dr. Moffat is an internationally recognizedexpert on varicella zoster virus, and her research has focused on the pathogenesis and treatment of infection by this virus. TheNational Institutes of Health has recognized this VZV model via a contract with Dr. Moffat’s lab for evaluating antiviralcompounds against VZV. Dr. Moffat is the director of two research core facilities at SUNY Upstate: the Center for HumanizedMouse Models and        <i>         In vivo        </i>        Imaging.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has established a direct relationshipwith the Moffat lab, without NIH as an intermediary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 47; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          47          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 10, 2017, the Company announcedthe results of successful initial testing of our anti-herpes drug candidates in the        <i>         ex        </i>        vivo human skin patch organ culture(“SOC”) model performed by Dr. Moffat.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The anti-shingles nanoviricides® drugcandidates achieved dramatic reduction in infection of human skin by the varicella-zoster virus (VZV), the shingles virus in thisstudy. These findings corroborate the previously reported findings of inhibition of VZV infection of human cells in culture. Theantiviral effect of certain nanoviricide drug candidates was substantially greater than the effect of the standard positive controlof cidofovir added into media. Even more remarkably, the effect of these nanoviricides drug candidates was equivalent to a topicalformulation of 1% cidofovir applied directly onto the skin patch. A topical skin cream containing 2% cidofovir is clinically usedin very severe cases of shingles. However, the cytotoxicity of cidofovir is known to cause ulceration of the skin to which it isapplied, followed by natural wound healing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have continued our work with the MoffatLab, initially for optimization of the drug candidates and chemistries, and recently, driving towards clinical drug candidate selection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With these results that corroborate findingsin cell culture studies in both our lab and Dr. Moffat’s Lab, we believe that the anti-shingles topical drug candidateis worthy of advancing into further IND-enabling pre-clinical development i.e. safety/toxicology studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the VZV drug candidateprogram is now our most advanced program to advance into Safety/Toxicology studies that are needed for an IND filing and humanclinical trials. However, at present, we do not have a license from TheraCour to develop and commercialize drugs against VZV Licensenegotiations are now in progress.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         HSV-1 and HSV-2 Nanoviricides EfficacyEvaluation Agreement with the Collaborative Ophthalmic Research Laboratories (CORL) at the University of Wisconsin, Madison, WI.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In January 2016, we signed an agreementwith CORL. Under this agreement, CORL will perform evaluation of efficacy of our nanoviricides drug candidates in cell cultureassays as well as in small animal studies towards the goal of filing an IND application for ocular Herpes Keratitis, and possiblyfor Recurrent Herpes Labialis (RHL, “cold sores”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This agreement has been extended to includedrug and research material efficacy evaluation studies in animal models of viral Acute Retinal Necrosis (vARN), and in animal modelsof HSV-2 genital ulcer. The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplexvirus infections and in evaluating anti-viral agents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Research and Development Agreement withProfessor Ken Rosenthal’s laboratory at the Northeastern Ohio Medical University (NEOMED, formerly called NEOUCOM)        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 13, 2010, the Company announcedthat it had signed a research and development agreement with Professor Ken Rosenthal’s laboratory at the Northeastern OhioMedical University (NEOMED). Pursuant to the terms of this Agreement, Professor Rosenthal and NEOMED will evaluate the effectivenessof nanoviricides drug candidates against Herpes Simplex Viruses, HSV-1 and HSV-2, in both cell culture and animal models. The focusof this evaluation will be the development of drug candidates against herpes skin infections (oral and genital herpes). Dr. KenRosenthal is a professor of microbiology, immunology and biochemistry at NEOMED. He is a leading researcher in the field of herpesviruses. His laboratory has developed an improved mouse model of skin-infection with HSV to follow the disease progression. Thismodel has been shown to provide highly uniform and reproducible results. A uniform disease pattern including onset of lesions andfurther progression to zosteriform lesions is observed in all animals in this model. This uniformity makes it an ideal model forcomparative testing of various drug candidates, which, the Company believes, can be expected to lead to a broad-spectrum anti-HSVantiviral treatment capable of attacking both HSV-1 and HSV-2.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 48; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          48          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On August 16, 2010, the Company reportedthat its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies in Dr. RosenthalLab at NEOMED.  Several of the anti-Herpes nanoviricides® demonstrated a dose-dependent maximal inhibition of Herpesvirus infectivity in a cell culture model. Almost complete inhibition of the virus production was observed at clinically usableconcentrations. These studies employed the H129 strain of herpes simplex virus type 1 (HSV-1).  H129 is an encephaliticstrain that closely resembles a clinical isolate; it is known to be more virulent than classic HSV-1 laboratory strains. The H129strain will be used in subsequent animal testing of nanoviricides. Since then the Company was optimizing formulations for use inthe dermal HSV-1 H129c infection animal model in the Rosenthal lab. The Company also continued to further optimize the anti-herpesnanoviricides. Our herpes program was run at a lower priority than other programs until recently. In April 2015, after only4 cycles of SAR (Structure-Activity-Relationship based improvements), our anti-herpes nanoviricides demonstrated strong effectivenessin the lethal HSV-1 H129c dermal infection model in the Rosenthal Lab at NEOMED. Treatment with certain nanoviricides caused significantimprovements in the clinical observations and led to &gt;85% survival of the infected animals, wherein 100% of the untreated animalsdied within 10 days. In August 2015, the Company reported that these results were reproduced in dermal animal model at Transpharm,with 100% of the nanoviricides treated animals surviving.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Professor Rosenthal retired inDecember 2014, continued his laboratory and our R&amp;D through April 2015, and has closed the lab thereafter. Heis now Professor at Roseman University of Health Sciences College of Medicine, NV. He continues as Professor Emeritus atNortheast Ohio Medical University (NEOMED). However, his laboratory is no longer active.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The HSV-1 topical treatment drug candidatesin the HerpeCide program have thus advanced to the lead identification stage. This program is now assigned second priority, followingthe top priority of the VZV program, primarily because the regulatory development of anti-VZV drug candidate was projected to occurmuch more rapidly than that of the anti-HSV-1 drug candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Anti-Influenza Drug Development Agreementwith the Webster Lab at St Jude Children’s Hospital, Memphis, TN        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In May 2016, we signed an agreementwith the Webster Lab at St. Jude Children’s Hospital. Under this Agreement, the Webster Lab will evaluate nanoviricide drugcandidates in cell culture studies against a large number of Influenza viruses to optimize the efficacy and broad-spectrum fora clinical development candidate. Variations on the previously selected ligand in NV-INF-1 and NV-INF-2 will be performed if necessary.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The testing of these candidates for anti-influenzaactivity will be performed in the laboratory of Dr. Elena Govorkova in collaboration with Dr. Robert G. Webster and willinclude both        <i>         in vitro        </i>        and        <i>         in vivo        </i>        studies. They have extensive experience in influenza virus infections with a largenumber of different influenza strains, and in anti-viral agents discovery. The overall objective of these studies will be to helpselect clinical drug development candidates for the treatment of influenza virus in humans, using both the injectable and oraladministration routes. Injectable administration is preferable for hospitalized patients that are extremely sick, while oral administrationis preferred for outpatients.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The most optimal candidate will then beevaluated against a wide variety of Influenza viruses in small animal efficacy studies with a goal of obtaining data for an INDsubmission for Injectable FluCide drug candidate for severely ill hospitalized patients, and also for Oral FluCide drug candidatefor outpatients with Influenza.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Influenza program has been relegatedto lower priority levels due to (a) our belief that the topical drug candidates in the HerpeCide program would reach the clinicfaster and would also have much more rapid clinical development pathway than FluCide, (b) the rapid expansion in breadth ofthe HerpeCide program pipeline that has occurred due to efficacy of closely related drug candidates against different viruses inthe Herpes family and against different indications, and (c) extreme resource constraints in terms of both available skilledmanpower and available financing for driving our programs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 49; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          49          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Nevertheless, we believe that FluCide hasstrong market potential, and therefore we are keeping this program active albeit with limited resource allocation, which has sloweddown the program significantly.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Master Services Agreement, dated August 31,2009, by and between Southern Research Institute (“Southern”) and NanoViricides, Inc.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The term of this agreement was three yearsfrom its execution. The Company agrees to supply necessary quantities of its products in order for Southern to complete specificstudies as to the efficacy and safety of the Company’s compounds. The Company shall pay charges associated with each taskorder and provide payment in the amount and as indicated therein. Under this agreement, Southern will estimate the work load andinvoices for additional task orders, subject to the Company’s agreement on costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s anti-HIV drug testingin cell cultures is performed at the Southern Research Institute in Frederick, MD.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          RelatedParties         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         TheraCour Pharma, Inc.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to an Exclusive License Agreementwe entered into with TheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virustypes: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus, Herpes Simplex Virus (HSV-1 andHSV-2), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. The Company has entered into an Additional License Agreementwith TheraCour granting the Company the exclusive licenses for technologies developed by TheraCour for the additional virus typesfor Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Viruses causing viral Conjunctivitis (a disease of the eye) andOcular Herpes, and Ebola/Marburg viruses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 1, 2019, the Company enteredinto an Agreement with TheraCour for an exclusive, worldwide license to use, promote, offer for sale, import, export, sell anddistribute products for the treatment of Varicella Zoster Virus (VZV) derived indications. The Company was not required to makeany upfront payments to TheraCour and agreed to milestone payments to TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        In June 2020, the Company and TheraCour signed a MoU forthe field of human coronavirus drug indications. This MoU grants the Company a limited license for the development of drugs forthe treatment of human coronavirus indications. There was no compensation paid to TheraCour for this Coronavirus MoU. The Companyhas initiated an independent valuation for this field. A definitive agreement is expected to be negotiated between the partiesthereafter. TheraCour has not denied any licenses sought by the Company in the past.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In consideration for obtaining these exclusivelicenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of a specified portionof certain direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed;(2) the greater of $2,000 or actual costs monthly, whichever is higher, for other general and administrative expenses incurredby TheraCour on our behalf; (3) make royalty payments (calculated as a percentage of net sales of the licensed drugs) of 15%to TheraCour; (4) TheraCour retains the exclusive right to develop and manufacture the licensed drugs. TheraCour will manufacturethe licensed drugs exclusively for NanoViricides, and unless such license is terminated, will not manufacture such product forits own sake or for others; and (5) TheraCour may request and NanoViricides, Inc. will pay an advance payment (refundable)equal to twice the amount of the previous month’s invoice to be applied as a prepayment towards expenses. TheraCour may terminatethe license upon a material breach by us as specified in the agreement. However, we may avoid such termination if within 90 daysof receipt of such termination notice we cure the breach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Development costs and other costs chargedby TheraCour for the years ended June 30, 2020, 2019 and 2018 were $2,158,034, $3,119,863, and $3,176,977, respectively. AtJune 30, 2020, $561,580 was due to TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        No royalties are due TheraCour from theCompany’s inception through June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        On December 17, 2019, the Company entered into a Deferred ExpenseExchange Agreement with TheraCour, whereby the Company and TheraCour agreed to the exchange of 100,000 shares of Series A preferredstock with a fair value of $392,669 for $250,000 previously deferred development fees owed to TheraCour, and recognized a losson the exchange of $142,669. Upon entry into the agreement additional deferrals ceased. The remaining deferred payments will becomedue upon IND filing. At June 30, 2020, $200,000 of the deferred payments remain due.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 50; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          50          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        TheraCour is affiliated with the Companythrough Dr. Anil Diwan, President, who is a director of the corporation, and owns approximately 90 % of the capital stockof TheraCour, which itself owns approximately 5.2% of the common stock of the Company at June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        TheraCour owns 470,959 shares of the Company’soutstanding common stock and 200,000 shares of the Company’s Series A preferred stock at June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Employees       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of October 12, 2020, theCompany had approximately seventeen employees, including those at TheraCour. In addition, most of the business activities ofthe Company including accounting and legal work and business development are provided by subcontractors and consultants.Further, the Company has subcontracted nanomaterials research and development (“R&amp;D”) to TheraCour under thelicense agreement with TheraCour. TheraCour currently has a staff of approximately ten, most of who are scientists with PhDor advanced degrees and experience. The Company has subcontracted its animal studies to various contract researchorganizations, government institutes, academic labs, and private institutions. In the future, the Company anticipates havingadditional service providers. We believe that we have good relations with our employees and subcontractors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Reports to Security Holders        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of November 2006, upon filing ofits Form 10-SB and listing on the FINRA OTC Bulletin Board, the Company became subject to the reporting obligations of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”). These obligations include filing an annual reportunder cover of Form 10-K, with audited financial statements, unaudited quarterly reports on Form 10-Q and the requisiteproxy statements with regard to annual shareholder meetings. The public may read and copy any materials the Company files withthe Securities and Exchange Commission (the “Commission”) at the Commission’s Public Reference Room at 100 FStreet, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling theCommission at 1-800-SEC-0030. The Commission maintains an Internet site (        <i>         www.sec.gov        </i>        ) that contains reports, proxy and informationstatements and other information regarding issuers that file electronically with the Commission. Information about the Companyis also available on its Web site at        <u>         www.nanoviricides.com        </u>        . Information included on the Web site is not part of this Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Further, the Company’s common stockhas been listed on the NYSE MKT (a US national exchange) since September 25, 2013. The NYSE-American Exchange requires additionalcorporate governance, financial and reporting requirements. NYSE MKT has changed its name to “NYSE American” in July 2017.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is fully compliant with therequirements of the NYSE-American regarding requirements for independent board members and board committee compositions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Website        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our website address is        <u>         www.nanoviricides.com        </u>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We intend to make available through ourwebsite, all of our filings with the Commission and all amendments to these reports as soon as reasonably practicable after filing,by providing a hyperlink to the EDGAR website containing our reports.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Our Contact Information        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our principal executive offices are currentlylocated at 1 Controls Drive, Shelton, Connecticut 06484 and our telephone number is (203) 937-6137 (voice mail). We can be contactedby email at        <u>         info@nanoviricides.com        </u>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Description of Property        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s principalexecutive offices are located at 1 Controls Drive, Shelton, CT, and include approximately 18,000 square feet of office,laboratory, and cGMP-capable drug manufacturing space. These facilities are fully owned by the Company. The property issubject to a mortgage note in the amount of approximately $1.1 million provided by its founder, Dr. Diwan in November 2019, which will mature on March15, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 51; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          51          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We subcontract the laboratory researchand development work to TheraCour, under the License Agreement with TheraCour. Management believes that the spaceis sufficient for the Company to monitor the developmental progress at its subcontractors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Legal Proceedings        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From time to time, we are a party to legalproceedings arising in the ordinary course of business. We are not currently a party to any other legal proceedings that we believecould have a material adverse effect on financial condition or results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_001">          </a>          ITEM 1A. RISK FACTORS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our business, financial condition, operatingresults and prospects are subject to the following risks. Additional risks and uncertainties not presently foreseeable to us mayalso impair our business operations. If any of the following risks or the risks described elsewhere in this report actually occurs,our business, financial condition or operating results could be materially adversely affected. In such case, the trading priceof our common stock could decline, and our stockholders may lose all or part of their investment in the shares of our common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This Form 10-K containsforward-looking statements that involve risks and uncertainties. These statements can be identified by the use offorward-looking terminology such as “believes,” “expects,” “intends,” “plans,” “may,” “will,” “should,” “predict” or “anticipation” or the negative thereof or other variations thereon or comparable terminology. Actual resultscould differ materially from those discussed in the forward-looking statements as a result of certain factors, includingthose set forth below and elsewhere in this Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Risk Related to the COVID-19 Pandemic        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The recent COVID-19 pandemic may adversely affect ourbusiness, and ability to file timely and accurate financial information.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">        While the complete impact on our business from the recent outbreak of the COVID-19 coronavirus is unknown at this time and difficult topredict, various aspects of our business are being adversely affected by it and may continue to be adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">        COVID-19 has been declared a pandemic by the World Health Organization, has been declared a National Emergency by the United States Governmentand has resulted in several states being designated disaster zones. COVID-19 coronavirus caused significant volatility in global markets,including the market price of our securities. The spread of COVID-19 coronavirus has caused public health officials to recommend precautionsto mitigate the spread of the virus, especially as to travel and congregating in large numbers. In addition, certain states and municipalitieshave enacted, and additional cities are considering, quarantining and "shelter-in-place" regulations which severely limit the ability ofpeople to move and travel, and require non-essential businesses and organizations to close.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">        Thus far, these restrictions have adversely affected our resultsof operations and financial condition. A significant portion of our business, financial and governance operations are contractedwith certain independent contractors and third-parties currently subject to “lock-down” orders or “shelter inplace” recommendations related to the national health crisis created by the COVID-19 pandemic, including key people responsiblefor assisting us in the preparation of our financial statements. As a result of the travel and work restrictions stemming fromthe COVID-19 pandemic, we were unable to fully review and certify the financial statements that were needed for us to file ourQuarterly Report on Form 10-Q for the quarter ended March 31, 2020 by May 15, 2020, the prescribed deadline, because our operationsand business experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic as more fully describedbelow. Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 was filed on June 22, 2020 and the Company filedForm NT 10-K  on September 28, 2020 to obtain a 15 day extension to file its Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">        We have been working diligently on development of therapeutics for the treatment of COVID-19, in addition to our current primary businessactivity of development of therapeutics against Shingles. Although our employees and their immediate families did not have any known incidencesof COVID-19 infection, several of our key employees have been on self-isolation from time to time, due to potential unintended exposureto likely COVID-19 cases. While such personnel continue to work remotely on matters such as documentation and paper research, our primarywork of is focused in the laboratory and such personnel are then unavailable to conduct such work. These absences have created a numberof shortages of essential personnel needed to perform various operations for our company including the preparation of our financial statementsand management report. Additionally, our accounting staff has been unavailable from time to time due to self-isolation and other localtravel and shelter-in-place restrictions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          The filing of an Investigational Drug Application forour first drug candidate, namely NV-HHV-101, may be delayed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0">        The IND application contains several sections that require information from different parties. In particular, completion of the informationregarding the drug substance and drug product, as well as characterization and detection of manufacturing intermediates may be delayeddue to specific personnel having been unavailable, or becoming unavailable in the near future, due to COVID-19 social distancing and self-isolationguidelines or illness. In addition, the development of clinical protocol section is experiencing delays due to the impact of COVID-19pandemic on the design and conduct of clinical trials. While we are fortunate that we do not have any on-going clinical trials, we willneed to take into account the effect of COV1D-19 pandemic related issues in terms of the design and conduct of a clinical trial for shingles.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Specific to Our Business        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our company is a development stagecompany that has no products approved for commercial sale, never generated any revenues and may never achieve revenues or profitability.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our company is a developmentstage company that has no products approved for commercial sale, never generated any revenues and may never achieve revenues orprofitability. Currently, we have no products approved for commercial sale and, to date, we have not generated any revenues. Ourability to generate revenue depends heavily on:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            successful development of our first product candidate in our pipeline;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the successful commercialization of our product candidates; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            market acceptance of our products.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        All of our existingproduct candidates are in early stages of development. It will be several years, if ever, until we have a commercial drug productavailable for resale. If we do not successfully develop and commercialize these products, we will not achieve revenues or profitabilityin the foreseeable future, if at all. If we are unable to generate revenues or achieve profitability, we may be unable to continueour operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 52; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          52          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are a developmentstage company with a limited operating history, making it difficult for you to evaluate our business and your investment. We arein the development stage and our operations and the development of our proposed products are subject to all of the risks inherentin the establishment of a new business enterprise, including but not limited to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the absence of an operating history;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the lack of commercialized products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            insufficient capital;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            expected substantial and continual losses for the foreseeable future;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            limited experience in dealing with regulatory issues; the lack of manufacturing experience and limited marketing experience;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an expected reliance on third parties for the development and commercialization of our proposed products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; font-size: 10pt">          </td>          <td style="width: 48px; font-size: 10pt">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="font-size: 10pt; text-align: justify">           <font style="font-size: 10pt">            a competitive environment characterized by numerous, well-established and well capitalized competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 10pt">            reliance on key personnel;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Because we are subject to these risks,you may have a difficult time evaluating our business and your investment in our company.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our ability to becomeprofitable depends primarily on the following factors:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to develop drugs, obtain approval for such drugs, and if approved, to successfully commercialize our nanoviricide drug(s);           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our R&amp;D efforts, including the timing and cost of clinical trials; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to enter into favorable alliances with third parties who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing and distribution.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Even if we successfully develop andmarket our drug candidates, we may not generate sufficient or sustainable revenue to achieve or sustain profitability.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have incurred significantoperating losses and may not ever be profitable. As of June 30 2020, we had a cash and cash equivalent balance of $13,708,594.Also, we have incurred significant operating losses since its inception, resulting in an accumulated deficit of $105,563,124 atJune 30, 2020. Such losses are expected to continue for the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We will need to raise substantialadditional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptableterms.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        While we believe wewill be able to raise sufficient cash in the capital markets, to be able to take at least one of our drug candidates into initialhuman clinical trials, we currently do not have sufficient resources to complete the development, clinical trials, and commercializationof any of our proposed products.  Management is actively exploring additional required funding through debt or equity financingpursuant to its plan. There is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptableto the Company to fund continuing operations. Management believes that as a result of the management plan, the Company’sexisting resources and access to the capital markets will permit the Company to fund planned operations and expenditures. However,the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletionof its capital resources more rapidly than it currently anticipates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 53; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          53          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In the event that wecannot obtain acceptable financing, or that we are unable to secure additional financing on acceptable terms, we would be unableto complete development of our various drug candidates. This would necessitate implementing staff reductions and operational adjustmentsthat would include reductions in the following business areas:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            research and development programs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            preclinical studies and clinical trials; material characterization studies, regulatory processes;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a search for third party marketing partners to market our products for us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The amount of capital we may need willdepend on many factors, including the:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            progress, timing and scope of our research and development programs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            progress, timing and scope of our preclinical studies and clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            time and cost necessary to obtain regulatory approvals;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            time and cost necessary to establish our own marketing capabilities or to seek marketing partners;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            time and cost necessary to respond to technological and market developments;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes made or new developments in our existing collaborative, licensing and other commercial relationships; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            new collaborative, licensing and other commercial relationships that we may establish.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our fixed expenses,such as real estate taxes and facility and equipment maintenance, rent, and other contractual commitments, may increase in thefuture, as we may:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enter into leases for new facilities and capital equipment;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enter into additional licenses and collaborative agreements; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            incur additional expenses associated with being a public company.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have limited experience in drugdevelopment, have not yet conducted any clinical trials and may not be able to successfully develop any drugs.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Until the formationof NanoViricide, Inc. (the Company’s predecessor prior to the reverse merger in 2005) our management and key personnelhad no experience in pharmaceutical drug development and, consequently, may not be able to successfully develop any drugs. To date,we have engaged only in pre-clinical activities and have not yet conducted any clinical trials. Our ability to achieve revenuesand profitability in our business will depend, among other things, on our ability to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            develop products internally or obtain rights to them from others on favorable terms;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            complete laboratory testing and human studies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <!-- Field: Page; Sequence: 54; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          54          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtain and maintain necessary intellectual property rights to our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            successfully complete regulatory review to obtain requisite governmental agency approvals;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enter into arrangements with third parties to manufacture our products on our behalf; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enter into arrangements with third parties to provide sales and marketing functions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Development of pharmaceutical productsis a time-consuming process, subject to a number of factors, many of which are outside of our control. Consequently, we can provideno assurance of the successful and timely development of new drugs.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our drugcandidates are in their developmental stage. Further development and extensive testing will be required to determine theirtechnical feasibility and commercial viability. Our success will depend on our ability to achieve scientific andtechnological advances and to translate such advances into reliable, commercially competitive drugs on a timely basis. Drugsthat we may develop are not likely to be commercially available for a few years. The proposed development schedules for ourdrug candidates may be affected by a variety of factors, including technological difficulties, proprietary technology ofothers, and changes in government regulation, many of which will not be within our control. Any delay in the development,introduction or marketing of our drug candidates could result either in such drugs being marketed at a time when their costand performance characteristics would not be competitive in the marketplace or in the shortening of their commercial lives.In light of the long-term nature of our projects, the unproven technology involved and the other factors described elsewherein “Risk Factors”, we may not be able to complete successfully the development or marketing of any drugs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may fail to successfullydevelop and commercialize our drug candidates if they:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are found to be unsafe or ineffective or fail to meet the appropriate endpoints in clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            do not receive necessary approval from the FDA or foreign regulatory agencies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            fail to conform to a changing standard of care for the diseases they seek to treat; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            are less effective or more expensive than current or alternative treatment methods.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Drug development failurecan occur at any stage of clinical trials and as a result of many factors and there can be no assurance that we or our collaboratorswill reach our anticipated clinical targets. Even if we or our collaborators complete our clinical trials, we do not know whatthe long-term effects of exposure to our drug candidates will be. Furthermore, our drug candidates may be used in combination withother treatments and there can be no assurance that such use will not lead to unique safety issues. Failure to complete clinicaltrials or to prove that our drug candidates are safe and effective would have a material adverse effect on our ability to generaterevenue and could require us to reduce the scope of or discontinue our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We must comply with significant andcomplex government regulations, compliance with which may delay or prevent the commercialization of our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The R&amp;D, manufactureand marketing of drug candidates are subject to regulation, primarily by the FDA in the United States and by comparable authoritiesin other countries. These national agencies and other federal, state, local and foreign entities regulate, among other things,R&amp;D activities (including testing in primates and in humans) and the testing, manufacturing, handling, labeling, storage, recordkeeping, approval, advertising and promotion of the products that we are developing. Noncompliance with applicable requirementscan result in various adverse consequences, including approval delays or refusals to approve drug licenses or other applications,suspension or termination of clinical investigations, revocation of approvals previously granted, fines, criminal prosecution,recalls or seizures of products, injunctions against shipping drugs and total or partial suspension of production and/or refusalto allow a company to enter into governmental supply contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 55; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          55          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The process of obtainingFDA approval has historically been costly and time consuming. Current FDA requirements for a new human drug or biological productto be marketed in the United States include: (1) the successful conclusion of pre-clinical laboratory and animal tests, ifappropriate, to gain preliminary information on the product’s safety; (2) filing with the FDA of an IND applicationto conduct human clinical trials for drugs or biologics; (3) the successful completion of adequate and well-controlled humanclinical investigations to establish the safety and efficacy of the product for its recommended use; and (4) filing by a companyand acceptance and approval by the FDA of a New Drug Application, or NDA, for a drug product or a biological license application,or BLA, for a biological product to allow commercial distribution of the drug or biologic. A delay in one or more of the proceduralsteps outlined above could be harmful to us in terms of getting our drug candidates through clinical testing and to market.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The FDA reviews theresults of the clinical trials and may order the temporary or permanent discontinuation of clinical trials at any time if it believesthe drug candidate exposes clinical subjects to an unacceptable health risk. Investigational drugs used in clinical studies mustbe produced in compliance with current good manufacturing practice, or GMP, rules pursuant to FDA regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Sales outside the UnitedStates of products that we develop will also be subject to regulatory requirements governing human clinical trials and marketingfor drugs and biological products and devices. The requirements vary widely from country to country, but typically the registrationand approval process takes several years and requires significant resources. In most cases, even if the FDA has not approved aproduct for sale in the United States, the product may be exported to any country if it complies with the laws of that countryand has valid marketing authorization by the appropriate authority. There are specific FDA regulations that govern this process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We also are subjectto the following risks and obligations, related to the approval of our products:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The FDA or foreign regulators may interpret data from pre-clinical testing and clinical trials in different ways than we interpret them.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If regulatory approval of a product is granted, the approval may be limited to specific indications or limited with respect to its distribution.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In addition, many foreign countries control pricing and coverage under their respective national social security systems.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The FDA or foreign regulators may not approve our manufacturing processes or manufacturing facilities.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The FDA or foreign regulators may change their approval policies or adopt new regulations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Even if regulatory approval for any product is obtained, the marketing license will be subject to continual review, and newly discovered or developed safety or effectiveness data may result in suspension or revocation of the marketing license.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If regulatory approval of the product candidate is granted, the marketing of that product would be subject to adverse event reporting requirements and a general prohibition against promoting products for unapproved or “off-label” uses.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            In some foreign countries, we may be subject to official release requirements that require each batch of the product we produce to be officially released by regulatory authorities prior to its distribution by us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.5in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We will be subject to continual regulatory review and periodic inspection and approval of manufacturing modifications, including compliance with current GMP regulations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 56; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          56          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We can provide no assurance thatour drug candidates will obtain regulatory approval or that the results of clinical studies will be favorable.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company reportssummary of its studies as the data become available to the Company, after analyzing and verifying same, in its press releases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        All of our productsin development are still in the pre-clinical stage, and not submitted to any regulatory agencies in any formal drug licensing orapproval processes. We have previously held a pre-IND meeting with the US FDA regarding our anti-influenza drug candidates, inMarch 2012. However, since then, we have re-evaluated our priorities. We have now prioritized our HerpeCide™ programdrug candidates as our highest priority candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Such strategic changesare necessitated due to the limited resources available to us for drug development. We perform such strategic changes in orderto maximize our chances of entering into human clinical trials in the regulatory process in the earliest time frame possible, andwithin the funding available to the Company, guided by input from a number of sources. Such changes are designed to acceleratesome programs and would lead to delays in some other programs that receive lower priority, due to our limited resources. We maynot be able to accurately assess the effect of such changes on our business plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The testing,marketing and manufacturing of any product for use in the United States will require approval from the FDA. We cannot predictwith any certainty the amount of time necessary to obtain such FDA approval and whether any such approval will ultimately begranted. Preclinical and clinical trials may reveal that one or more products are ineffective or unsafe, in which eventfurther development of such products could be seriously delayed or terminated. Moreover, obtaining approval for certainproducts may require testing on human subjects of substances whose effects on humans are not fully understood or documented.Delays in obtaining FDA or any other necessary regulatory approvals of any proposed drug and failure to receive suchapprovals would have an adverse effect on the drug’s potential commercial success and on our business, prospects,financial condition and results of operations. In addition, it is possible that a proposed drug may be found to beineffective or unsafe due to conditions or facts that arise after development has been completed and regulatory approvalshave been obtained. In this event, we may be required to withdraw such proposed drug from the market. To the extent that oursuccess will depend on any regulatory approvals from government authorities outside of the United States that perform rolessimilar to that of the FDA, uncertainties similar to those stated above will also exist.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212121">        <b>         <i>          Preclinical and clinicalstudies of our product candidates may not be successful. If we are unable to generate successful results from preclinical and clinicalstudies of our product candidates, or experience significant delays in doing so, our business may be materially harmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white; color: #212121">        Wehave no products on the market and all of our product candidates are in preclinical development. In particular, none of our productcandidates have ever been tested in a human subject. Our ability to achieve and sustain profitability depends on obtaining regulatoryapprovals for and, if approved, successfully commercializing our product candidates, either alone or with third parties. Beforeobtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaboratormust conduct extensive preclinical tests and clinical trials to demonstrate the safety, purity and potency of our product candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white; color: #212121">        Thesuccess of our product candidates will depend on several factors, including the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            successfully designing preclinical studies which may be predictive of clinical outcomes;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            successful results from preclinical and clinical studies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            receipt of marketing approvals from applicable regulatory authorities;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            obtaining and maintaining patent and trade secret protection for future product candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            establishing and maintaining manufacturing relationships with third parties or establishing our own manufacturing capability; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <!-- Field: Page; Sequence: 57; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          57          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 0.25in; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            successfully commercializing our products, if and when approved, whether alone or in collaboration with others.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white; color: #212121">        Ifwe do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inabilityto successfully complete the development or commercialization of our product candidates, which would materially harm our business.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">         <b>          <i>           Becausethe results of          </i>         </b>        </font>        <b>         <i>          <font style="color: #252525">           preclinical          </font>          <font style="color: #212121">           testingare not necessarily predictive of future results, our products may not have favorable results in our planned clinical trials.          </font>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212121">         Evenif we have positive results from our        </font>        <font style="color: #252525">         preclinical        </font>        <font style="color: #212121">         testingof our products, this may not necessarily be predictive of the results from our planned clinical trials in humans. Many companiesin the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positiveresults in        </font>        <font style="color: #252525">         preclinical        </font>        <font style="color: #212121">         development, and we cannotbe certain that we will not face similar setbacks. Moreover,        </font>        <font style="color: #252525">         preclinical        </font>        <font style="color: #212121">         andclinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidatesperformed satisfactorily in        </font>        <font style="color: #252525">         preclinical        </font>        <font style="color: #212121">         studiesand clinical trials nonetheless failed to obtain FDA approval. If we fail to produce positive results in our clinical trials, thedevelopment timeline and regulatory approval and commercialization prospects for our products, and, correspondingly, our businessand financial prospects, would be materially adversely affected.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          Even if we obtain regulatory approvals, our marketed drugcandidates will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and foreign regulations, wecould lose our approvals to market these drugs and our business would be seriously harmed.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Following any initialregulatory approval of any drugs we may develop, we will also be subject to continuing regulatory review, including the reviewof adverse experiences and clinical results that are reported after our drug candidates are made commercially available. This wouldinclude results from any post-marketing tests or vigilance required as a condition of approval. The manufacturer and manufacturingfacilities we use to make any of our drug candidates will also be subject to periodic review and inspection by the FDA. The discoveryof any previously unknown problems with the drug, manufacturer or facility may result in restrictions on the drug or manufactureror facility, including withdrawal of the drug from the market. If we are required to withdraw all or more of our drugs from themarket, we may be unable to continue revenue-generating operations. Reliance on third-party manufacturers entails risks to whichwe would not be subject if we manufactured drugs ourselves, including reliance on the third-party manufacturer for regulatory compliance.Our drug promotion and advertising is also subject to regulatory requirements and continuing FDA review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Development of our drug candidatesrequires a significant investment in R&amp;D. Our R&amp;D expenses in turn, are subject to variation based on a number of factors,many of which are outside of our control. A sudden or significant increase in our R&amp;D expenses could materially and adverselyimpact our results of operations.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">        Our R&amp;D cost estimates and budgets are based on discussions with industry professionals and service providers. These may not takeinto account all of the activities involved for the development. Additionally, regulatory requirements may change from time to time andmay dictate additional activities that lead to increased expenditures beyond budgeted. For example, U.S. FDA is now requiring that INDapplications be submitted in eCTD format.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        Because we expect to expend substantial resources on R&amp;D, our success depends in large part on the results as well as the costs ofour R&amp;D. A failure in our R&amp;D efforts or substantial increase in our R&amp;D expenses would adversely affect our results of operations.R&amp;D expenditures are uncertain and subject to much fluctuation. Factors affecting our R&amp;D expenses include, but are not limitedto:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="width: 24px; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; width: 24px; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-size: 10pt">            the number and outcome of clinical studies we are planning to conduct; for example, our R&amp;D expenses may increase based on the number of late-stage clinical studies that we may be required to conduct;           </font>          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-size: 10pt">            the number, extent, and outcome of pre-clinical studies we are planning to conduct; for example, our R&amp;D expenses may increase based on the number and extent of IND-enabling pre-clinical studies including CMC Studies, Tox Package Studies, and Quality Programs that we may be required to conduct;           </font>          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-size: 10pt">            the number of drugs entering into pre-clinical development from research; for example, there is no guarantee that internal research efforts will succeed in generating sufficient data for us to make a positive development decision;           </font>          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; text-align: justify">          </td>         </tr>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-size: 10pt">            licensing activities, including the timing and amount of related development funding or milestone payments; for example, we may enter into agreements requiring us to pay a significant up-front fee for the purchase of in-process R&amp;D that we may record as R&amp;D expense; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <!-- Field: Page; Sequence: 58; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          58          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify; width: 24px">          </td>          <td style="vertical-align: top; padding-right: 1.8pt; padding-left: 1.8pt; text-align: justify; width: 24px">           <font style="font: 10pt Symbol">            ·           </font>          </td>          <td style="vertical-align: top; text-align: justify">           <font style="font-size: 10pt">            maintenance            <font style="font-family: Times New Roman, Times, Serif">             of our relationship with ourlicensing partner TheraCour and our rights and obligations under the license agreements, including any conflict, dispute or disagreementarising from our failure to satisfy payment obligations under such agreement, our ability to develop and commercialize the affectedproduct candidate may be adversely affected. Any loss of our rights under our license agreements could delay or completely terminateour product development efforts for the affected product candidate; for example, since 2018 we had agreed to defer a monthly developmentfee owed to TheraCour.            </font>            On December 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour,whereby the Company and TheraCour agreed to the exchange of 100,000 shares of Series A preferred stock with a fair value of $392,669for $250,000 previously deferred development fees owed to TheraCour, and recognized a loss on the exchange of $142,669. Upon entryinto the agreement additional deferrals ceased. The remaining deferred payments will become due upon IND filing. At June 30, 2020$200,000 of the deferred payments remain due.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">        <b>         <i>          We will be unable to proceedwith our business plan without obtaining additional financing to support its budgeted Research and Development and other costs.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We believe we have sufficient funds on handto take one drug candidate into the IND application stage.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        However,we believe we will require approximately an additional $3 million to pursue the FDA approval process including an initial IND filing.There can be no assurance that we will be able to raise sufficient funds or that such funds will be raised on terms that will befavorable to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have estimateda total cash expenditure budget of approximately $11.6 million for the next 12 months, of which approximately $9.6 million is expectedto be spent on research and development for our drug candidates, including the IND filing, human clinical trials of one of ourlead drug candidates, namely Skin Cream for Topical Treatment of Shingles, and approximately, $3 million is expected to be spenton research and development for our COVID-19 drug candidate, and $2 million is budgeted for general and administrative expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are aware of numerousproducts under development or manufactured by competitors that are used for the prevention or treatment of certain diseases wehave targeted for drug development. Various companies are developing biopharmaceutical products that potentially directly competewith our drug candidates even though their approach to such treatment is different.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We hope that our drugcandidates under development and in clinical trials will address major markets within the anti-viral sector. Our competition willbe determined in part by the potential indications for which drugs are developed and ultimately approved by regulatory authorities.Additionally, the timing of the market introduction of some of our potential drugs or of competitors' products may be an importantcompetitive factor. Accordingly, the relative speed with which we can develop drugs, complete pre-clinical testing, clinical trials,approval processes and supply commercial quantities to market are important competitive factors. We expect that competition amongdrugs approved for sale will be based on various factors, including product efficacy, safety, reliability, availability, priceand patent protection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0; text-align: justify; text-indent: 0.5in">        <b>         <i>          Thesuccessful development of biopharmaceuticals is highly uncertain. A variety of factors including, pre-clinical study results orregulatory approvals, could cause us to abandon development of our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Successful developmentof biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Productsthat appear promising in the early phases of development may fail to reach the market for several reasons including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">        <font style="font-family: Symbol">         ·        </font>        <font style="font-family: Times New Roman, Times, Serif">        </font>        pre-clinical study results that may show the product to be less effective than desired (e.g., the study failed to meet itsprimary objectives) or to have harmful or problematic side effects;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">        <font style="font-family: Symbol">         ·        </font>        <font style="font-family: Times New Roman, Times, Serif">        </font>        failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delaysmay be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements fordata analysis or an IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinicaldata or unexpected safety or manufacturing issues;       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">        <font style="font-family: Symbol">         ·        </font>        <font style="font-family: Times New Roman, Times, Serif">        </font>        manufacturing costs, pricing or reimbursement issues, or other factors that make the product not economical; and       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">        <font style="font-family: Symbol">         ·        </font>        <font style="font-family: Times New Roman, Times, Serif">        </font>        the proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">        Success in pre-clinical and early clinical studies does notensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretationsthat may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submitan application for marketing approval for a final decision by a regulatory authority varies significantly from one product to thenext, and may be difficult to predict.       </p>       <p style="margin: 0">        <font style="font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 59; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          59          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have limited experience in conductingor supervising clinical trials and must outsource all clinical trials.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have limited experiencein conducting or supervising clinical trials that must be performed to obtain data to submit in concert with applications for approvalby the Food and Drug Administration (“FDA”). The regulatory process to obtain approval for drugs for commercial saleinvolves numerous steps. Drugs are subjected to clinical trials that allow development of case studies to examine safety, efficacy,and other issues to ensure that sale of drugs meets the requirements set forth by various governmental agencies, including theFDA. In the event that our protocols do not meet standards set forth by the FDA, or that our data is not sufficient to allow suchtrials to validate our drugs in the face of such examination, we might not be able to meet the requirements that allow our drugsto be approved for sale.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Because we have limitedexperience in conducting or supervising clinical trials, we plan to outsource our clinical trials to third parties. We have nocontrol over their compliance with procedures and protocols used to complete clinical trials in accordance with standards requiredby the agencies that approve drugs for sale. If these subcontractors fail to meet these standards, the validation of our drugswould be adversely affected, causing a delay in our ability to meet revenue-generating operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We are subject to risks inherentin conducting clinical trials. The risk of non-compliance with FDA-approved good clinical practices by clinical investigators,clinical sites, or data management services could delay or prevent us from developing or ever commercializing our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Agreements with clinicalinvestigators and medical institutions for clinical testing and with other third parties for data management services place substantialresponsibilities on these parties, which could result in delays in, or termination of, our clinical trials if these parties failto perform as expected. For example, if any of our clinical trial sites fail to comply with FDA-approved good clinical practices,we may be unable to use the data gathered at those sites. If these clinical investigators, medical institutions or other thirdparties do not carry out their contractual duties or obligations or fail to meet expected deadlines, or if the quality or accuracyof the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons,our clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approval for or successfullycommercialize our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 60; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          60          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We or regulators maysuspend or terminate our clinical trials for a number of reasons. We may voluntarily suspend or terminate our clinical trials ifat any time we believe that they present an unacceptable risk to the patients enrolled in our clinical trials. In addition, regulatoryagencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinicaltrials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safetyrisk to the patients enrolled in our clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our clinical trialoperations will be subject to regulatory inspections at any time. If regulatory inspectors conclude that we or our clinical trialsites are not in compliance with applicable regulatory requirements for conducting clinical trials, we may receive reports of observationsor warning letters detailing deficiencies, and we will be required to implement corrective actions. If regulatory agencies deemour responses to be inadequate, or are dissatisfied with the corrective actions that we or our clinical trial sites have implemented,our clinical trials may be temporarily or permanently discontinued, we may be fined, we or our investigators may be precluded fromconducting any ongoing or any future clinical trials, the government may refuse to approve our marketing applications or allowus to manufacture or market our drug candidates or we may be criminally prosecuted. If we are unable to complete clinical trialsand have our products approved due to our failure to comply with regulatory requirements, we will be unable to commence revenue-generatingoperations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Efforts of government and third-partypayers to contain or reduce the costs of health care may adversely affect our revenues even if we were to develop an FDA approveddrug.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our ability toearn sufficient returns on our drug candidates may depend in part on the extent to which government health administrationauthorities, private health coverage insurers and other organizations will provide reimbursement for the costs of such drugsand related treatments. Significant uncertainty exists as to the reimbursement status of newly approved health care drugs,and we do not know whether adequate third-party coverage will be available for our drug candidates. If our current andproposed drugs are not considered cost-effective, reimbursement to the consumers may not be available or sufficient to allowus to sell drugs on a competitive basis. The failure of the government and third-party payers to provide adequate coverageand reimbursement rates for our drug candidates could adversely affect the market acceptance of our drug candidates, ourcompetitive position and our financial performance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we were to successfullydevelop approvable drugs, before we can begin selling these drugs, we must obtain regulatory approval of our manufacturing facilityand process or the manufacturing facility and process of the third party or parties with whom we may outsource our manufacturingactivities. In addition, the manufacture of our products must comply with the FDA’s current Good Manufacturing Practicesregulations, commonly known as GMP regulations. The GMP regulations govern quality control and documentation policies and procedures.Our manufacturing facilities, if any in the future and the manufacturing facilities of our third party manufacturers will be continuallysubject to inspection by the FDA and other state, local and foreign regulatory authorities, before and after product approval.We cannot guarantee that we, or any potential third party manufacturer of our products, will be able to comply with the GMP regulationsor other applicable manufacturing regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of the date of thisfiling, we have approximately seventeen employees including the employees at TheraCour, and several consultants and independentcontractors. The only consultant/contractor that we consider critical to the Company is TheraCour. Our relationship with TheraCouris discussed below. All other consultant/contractors would be more readily replaceable. We have significantly expanded our operationsand staff materially and our new employees include a number of key managerial, technical, financial, R&amp;D and operations personnel.The expansion of our business will continue to place a significant strain on our limited managerial, operational and financialresources. We may need to hire additional personnel, in key managerial, technical, financial, R&amp;D and operations areas. Wehave no experience in integrating multiple employees when hired. Therefore, there is a substantial risk that we will not be ableto integrate new employees into our operations which would have a material adverse effect on our business, prospects, financialcondition and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Confidentiality agreementswith employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. Disclosureof our trade secrets or proprietary information could compromise any competitive advantage that we have.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 61; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          61          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a5 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We depend upon confidentialityagreements with our officers, employees, consultants, and subcontractors to maintain the proprietary nature of the technology.These measures may not afford us sufficient or complete protection and may not afford an adequate remedy in the event of an unauthorizeddisclosure of confidential information. In addition, others may independently develop technology similar to ours, otherwise avoidingthe confidentiality agreements, or produce patents that would materially and adversely affect our business, prospects, financialcondition, and results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We will rely upon licensed patentsto protect our technology. We may be unable to obtain or protect such intellectual property rights, and we may be liable for infringingupon the intellectual property rights of others.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our ability to competeeffectively will depend on our ability to maintain the proprietary nature of our technologies and the proprietary technology ofothers with which we have entered into licensing agreements. We have exclusive licenses from TheraCour to novel technologies, proprietarytechnologies, and knowhow, some of which has been filed in patent applications, and we expect to file patents of our own in thecoming years. There can be no assurance that any of these patent applications will ultimately result in the issuance of a patentwith respect to the technology owned by us or licensed to us. The patent position of pharmaceutical or biotechnology companies,including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the United StatesPatent and Trademark Office use to grant patents are not always applied predictably or uniformly and can change. There is alsono uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnologypatents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that willbe allowed in any patents issued to us or to others. Further, we rely on a combination of trade secrets, know-how, technology andnondisclosure, and other contractual agreements and technical measures to protect our rights in the technology. If any trade secret,know-how or other technology not protected by a patent were to be disclosed to or independently developed by a competitor, ourbusiness and financial condition could be materially adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We do not believe thatany of the drug candidates we are currently developing infringe upon the rights of any third parties nor are they infringed uponby third parties; however, there can be no assurance that our technology will not be found in the future to infringe upon the rightsof others or be infringed upon by others. In such a case, others may assert infringement claims against us, and should we be foundto infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages,potentially including treble damages, if we are found to have willfully infringed on such parties’ patent rights. In additionto any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property, enterinto royalty agreements, or redesign our drug candidates so as not to utilize this intellectual property, each of which may proveto be uneconomical or otherwise impossible. Conversely, we may not always be able to successfully pursue our claims against othersthat infringe upon our technology and the technology exclusively licensed from the TheraCour Pharma. Thus, the proprietary natureof our technology or technology licensed by us may not provide adequate protection against competitors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Moreover, the costto us of any litigation or other proceeding relating to technology we license and other intellectual property rights, even if resolvedin our favor, could be substantial, and the litigation would divert our management’s efforts. Uncertainties resulting fromthe initiation and continuation of any litigation could limit our ability to continue our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Other companies or organizationsmay assert patent rights that prevent us from developing and commercializing our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are in a relativelynew scientific field that has generated many different patent applications from organizations and individuals seeking to obtainimportant patents in the field. Because the field is so new, very few of these patent applications have been fully processed bygovernment patent offices around the world, and there is a great deal of uncertainty about which patents will issue, when, to whom,and with what claims. It is possible that there will be significant litigation and other proceedings, such as interference proceedingsin various patent offices, relating to patent rights in the field. Others may attempt to invalidate TheraCour’s patents orother intellectual property rights. Even if our rights are not directly challenged, disputes among third parties could lead tothe weakening or invalidation of those intellectual property rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 62; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          62          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Thus, it is possiblethat one or more organizations will hold patent rights to which we will need a license. Any license required under any patent maynot be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be non-exclusive and,therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and areunable to design around a patent, we may be unable to effectively market some of our technology and drug candidates, which couldlimit our ability to generate revenues or achieve profitability and possibly prevent us from generating revenue sufficient to sustainour operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We are dependent upon TheraCour forthe rights to develop the products we intend to sell and our license agreements with TheraCour require that TheraCour is the soledeveloper and supplier of our licensed products.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our ability to develop,manufacture and sell the products the Company plans to develop is derived from our Licensing Agreements with TheraCour. The Agreements may be terminated by TheraCour as a result of: the insolvency or bankruptcy proceedingsby or against the Company, a general assignment by the Company to its creditors, the dissolution of the Company, cessation by theCompany of business operations for ninety (90) days or more or the commencement by the Company or an affiliate to challenge orinvalidate the issued patents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company does nothold the rights to any other patents nor does the Company conduct its own research and development to develop other products tomanufacture and sell. In addition, TheraCour is the sole developer of our licensed products and we are required to pay TheraCourfess for indirect and direct costs incurred by TheraCour for its licensed products. Therefore, we are dependent upon TheraCourfor all of our product development needs. If the Company’s Agreement with TheraCour is terminated, it is unlikely we willbe able to commence revenue-generating operations or that the Company could continue operating at all.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The expiration or loss of patent protectionmay adversely affect our future revenues and operating earnings.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We rely on patent,trademark, trade secret and other intellectual property protection in the discovery, research and of our product candidates. Inparticular, patent protection is important in the development and eventual commercialization of our products and product candidates.Patents covering our products and product candidates normally provide market exclusivity, which is important in order for our productsand product candidates to become profitable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Certain of the patents,that comprise the intellectual property that we license, expire between 2020 and 2028. While we believe the patent holders mayseek additional patent coverage that may protect the technology underlying these patents, there can be no assurances that suchadditional patent protection will be granted, or if granted, that these patents will not be infringed upon or otherwise held enforceable.Even if we are successful in obtaining a patent, patents have a limited lifespan and we currently do not have any products forsale. In the United States, the natural expiration of a utility patent typically is generally 20 years after it is filed.Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protectionfor our products and product candidates, we may be open to competition from generic versions of such methods and devices.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We lack suitable facilities for clinicaltesting; reliance on third parties.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company does nothave facilities that could be used to conduct clinical testing. We expect to contract with third parties to conduct all clinicaltesting required to obtain approvals for any drugs that we might develop. We currently outsource all testing to a number of thirdparties in various collaborations and service contracts. Any of our collaborators or service providers may discontinue the servicecontract or collaboration. If this were to occur, then we would be required to modify our priorities and goals, obtain other collaboratorsor service providers to replace the ones we lose, or we may even be forced to abandon certain drug development programs. In addition,any failures by third parties to adequately perform their responsibilities may delay the submission of our proposed products forregulatory approval, impair our ability to deliver our products on a timely basis, increase our costs, or otherwise impair ourcompetitive position.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 63; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          63          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have limited manufacturing experience.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has nevermanufactured products in the highly regulated environment of pharmaceutical manufacturing. There are numerous regulations and requirementsthat must be maintained to obtain licensure and the permits required to commence manufacturing, as well as additional requirementsto continue manufacturing pharmaceutical products. We now own facilities that could be used to manufacture clinical quantitiesof any products that might be developed by the Company. We believe that this cGMP-capable facility may allow us to produce limitedquantities of a drug after approval for initial market entry, and that such an effort may make commercial sense if the treatmentcourse requirements and afflicted patient populations are limited, and if the remuneration for the treatment course is appropriate.However, we do not own, nor lease facilities suitable for cGMP manufacture of any of our drug candidates in large commercial quantities,nor do we have the resources at this time to acquire or lease suitable facilities. At present, we have not retained any contractmanufacturing organizations (CMO) for commercial manufacture or for clinical product manufacture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          We may be unable to attract, retain, and motivate skilledpersonnel which will delay our product development programs and our research and development efforts.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our success dependson our continued ability to attract, retain, and motivate highly qualified scientific personnel who must undergo extensive trainingto assist in our research programs. Competition for skilled and qualified personnel and academic and other research collaborationsis intense. If we lose the services of personnel with the necessary skills, or if there are extensive delays in training such personnel,it could significantly impede the achievement of our research and development objectives. We are currently experiencing extremestaffing constraints as well as financing constraints that have already caused substantial delays and may continue to cause furtherdelays in our estimated timelines, unless we are successful at raising additional funds and at attracting and retaining highlyskilled employees with specific skill-sets. There can be no assurance that we will be able to raise sufficient funding or thateven if we are able to raise funding on terms favorable to the Company, that we will be able to hire and retain such qualifiedemployees, The inability to hire and retain these employees will significantly delay our objectives including filing an IND withthe FDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We have no sales and marketing personnel.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are an early stagedevelopment company with limited resources. We do not currently have any products available for sale, so have not secured salesand marketing staff at this early stage of operations. We cannot generate sales without a sales or marketing staff and we cannotguarantee we will be successful in developing one. Even if we were to successfully develop approvable drugs, we will not be ableto sell these drugs if we or our third-party manufacturers fail to comply with manufacturing regulations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Since we cannot predict whether orwhen we will obtain regulatory approval to commercialize our product candidates, we cannot predict the timing of any future revenuefrom these product candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">        Wecannot commercialize any of our product candidates to generate revenue until the appropriate regulatory authorities have reviewedand approved the marketing applications for the product candidates. We cannot ensure that the regulatory agencies will completetheir review processes in a timely manner or that we will obtain regulatory approval for any product candidate that we or our collaboratorsdevelop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and noveltyof the product and requires the expenditure of substantial resources. Regulatory approval processes outside the United States includeall of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based upon additionalgovernment regulation from future legislation or administrative action or changes in FDA policy during the period of product development,clinical trials and FDA regulatory review.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 64; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          64          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We license our core technology fromTheraCour and we are dependent upon them as they have exclusive development rights. If we lose the right to utilize any of theproprietary information that is the subject of this license agreement, we may incur substantial delays and costs in developmentof our drug candidates         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company has enteredinto Material License Agreements with TheraCour. TheraCour has exclusive rights to develop exclusively for us, the materials that comprise the core drugs of ourplanned business. TheraCour is a development stage company with limited financial resources and needs the Company’s progresspayments to further the development of the nanoviricides. The Company controls the research and work TheraCour performs on itsbehalf and no costs may be incurred without the prior authorization or approval of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We depend on TheraCourand other third parties to perform manufacturing activities effectively and on a timely basis. If these third parties fail to performas required, this could impair our ability to deliver our products on a timely basis or cause delays in our clinical trials andapplications for regulatory approval, and these events could harm our competitive position and adversely affect our ability tocommence revenue-generating operations. The manufacturing process for pharmaceutical products is highly regulated, and regulatorsmay shut down manufacturing facilities that they believe do not comply with regulations. We, and our manufacturers are subjectto the FDA’s current Good Manufacturing Practices, which are extensive regulations governing manufacturing processes, stabilitytesting, record keeping and quality standards and similar regulations are in effect in other countries. In addition, our manufacturingoperations are subject to routine inspections by regulatory agencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our collaborative relationships withthird parties could cause us to expend significant resources and incur substantial business risk with no assurance of financialreturn.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We anticipatesubstantial reliance upon strategic collaborations for marketing and the commercialization of our drug candidates and we mayrely even more on strategic collaborations for R&amp;D of our other drug candidates. Our business depends on our ability tosell drugs to both government agencies and to the general pharmaceutical market. Offering our drug candidates for non-medicalapplications to government agencies does not require us to develop new sales, marketing or distribution capabilities beyondthose already existing in the company. Selling antiviral drugs, however, does require such development. We plan to sellantiviral drugs through strategic partnerships with pharmaceutical companies. If we are unable to establish or manage suchstrategic collaborations on terms favorable to us in the future, our revenue and drug development may be limited. To date, wehave not entered into any strategic collaboration with third parties capable of providing these services. In addition, wehave not yet marketed or sold any of our drug candidates or entered into successful collaborations for these services inorder to ultimately commercialize our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        If we determine toenter into R&amp;D collaborations during the early phases of drug development, our success will in part depend on the performanceof our research collaborators. We will not directly control the amount or timing of resources devoted by our research collaboratorsto activities related to our drug candidates. Our research collaborators may not commit sufficient resources to our programs. Ifany research collaborator fails to commit sufficient resources, our preclinical or clinical development programs related to suchcollaboration could be delayed or terminated. Also, our collaborators may pursue existing or other development-stage products oralternative technologies in preference to those being developed in collaboration with us. Finally, if we fail to make requiredmilestone or royalty payments to our collaborators or to observe other obligations in our agreements with them, our collaboratorsmay have the right to terminate those agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Manufacturers producingour drug candidates must follow current GMP regulations enforced by the FDA and foreign equivalents. If a manufacturer of our drugcandidates does not conform to the current GMP regulations and cannot be brought up to such a standard, we will be required tofind alternative manufacturers that do conform. This may be a long and difficult process and may delay our ability to receive FDAor foreign regulatory approval of our drug candidates and cause us to fall behind on our business objectives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Establishing strategiccollaborations is difficult and time-consuming. Our discussion with potential collaborators may not lead to the establishment ofcollaborations on favorable terms, if at all. Potential collaborators may reject collaborations based upon their assessment ofour financial, regulatory or intellectual property position. Even if we successfully establish new collaborations, these relationshipsmay never result in the successful development or commercialization of our drug candidates or the generation of sales revenue.To the extent that we enter into collaborative arrangements, our drug revenues are likely to be lower than if we directly marketedand sold any drugs that we may develop.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 65; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          65          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Management of our relationshipswith our collaborators will require:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            significant time and effort from our management team;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            coordination of our marketing and R&amp;D programs with the marketing and R&amp;D priorities of our collaborators; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            effective allocation of our resources to multiple projects.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We employ the use of certain chemicaland biological agents and compounds that may be deemed hazardous and we are therefore subject to various environmental laws andregulations. Compliance with these laws and regulations may result in significant costs, which could materially reduce our abilityto become profitable.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We use hazardous materials,including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment.As appropriate, we safely store these materials and wastes resulting from their use at our laboratory facility pending their ultimateuse or disposal. We contract with a third party to properly dispose of these materials and wastes. We are subject to a varietyof federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal ofthese materials and wastes. We may incur significant costs complying with environmental laws and regulations adopted in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We cannot eliminatethe risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardousmaterials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incursignificant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. Wemay incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Thesecurrent or future laws and regulations may impair our research, development or production efforts. Our failure to comply with theselaws and regulations also may result in substantial fines, penalties or other sanctions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we use biological and hazardousmaterials in a manner that causes injury, we may be liable for damages.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our R&amp;D and manufacturingactivities will involve the use of biological and hazardous materials. Although we believe our safety procedures for handling anddisposing of these materials comply with federal, state and local laws and regulations, we cannot entirely eliminate the risk ofaccidental injury or contamination from the use, storage, handling or disposal of these materials. We carry $7,000,000 casualtyand general liability insurance policies. Accordingly, in the event of contamination or injury, we could be held liable for damagesor penalized with fines in an amount exceeding our resources and insurance coverage, and our clinical trials or regulatory approvalscould be suspended.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We depend upon our senior managementand their loss or unavailability could put us at a competitive disadvantage.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We currently dependupon the efforts and abilities of our management team. The loss or unavailability of the services of any of these individuals forany significant period of time could have a material adverse effect on our business, prospects, financial condition and resultsof operations. We have not obtained, do not own, nor are we the beneficiary of key-person life insurance for all of our key personnel.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company believesthat Dr. Anil Diwan, is critical to the success of the Company. The Company is a limited beneficiary of a certain amount of keyman insurance for Anil Diwan that the Company maintains. However, there can be no assurances that the amount of the key man insurancecoverage would be sufficient to provide replacement of this key officer for continuing the Company’s operations in a timelymanner, should such an event arise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company also maintainsa limited amount of Directors and Officers Liability insurance coverage to protect all of its directors and executive officerstaken together. There can be no assurance that this D&amp;O coverage will be sufficient to cover the costs of the events that maylead to its invocation, in which case, there could be a substantial impact on the Company’s ability to continue operations,should such an unforeseen event occur.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 66; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          66          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          There are conflicts of interest amongour officers, directors and stockholders.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Certain of our executiveofficers and directors and their affiliates are engaged in other activities and have interests in other entities on their own behalfor on behalf of other persons. Neither we, nor our stockholders will have any rights in these ventures or their income or profits.Specifically, Dr. Anil Diwan owns approximately 90% of the capital stock of TheraCour, which as of June 30, 2020, owned 5.2%of our common stock, and 200,000 shares of the Company’s Series A preferred stock, and provides the nanomaterials tothe Company with which it intends to develop its products and is the holder of the intellectual property rights the Company usesto conduct its operations. While the Company is not aware of any conflict that has arisen or any transaction that has not beenconducted on an arm’s length basis to date, Dr. Diwan may have conflicting fiduciary duties between the Company andTheraCour, for which he must recuse himself from certain decision-making processes of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, a formerindependent director, Dr. Milton Boniuk has dispositive power over 523,145 shares of common stock, and 16,850 shares of Series Apreferred stock as of June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company does notallow a conflicted shareholder, director, or executive officer to vote on matters wherein a conflict may be perceived. The conflictedperson or entity is not allowed to nominate an alternate person to vote for them either. Other than this safeguard, the Companycurrently does not have any policy in place, should such a conflict arise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In particular:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our executive officers or directors or their affiliates may have an economic interest in, or other business relationship with, partner companies that invest in us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our executive officers or directors or their affiliates have interests in entities that provide products or services to us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In any of these cases:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our executive officers or directors may have a conflict between our current interests and their personal financial and other interests in another business venture.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our executive officers or directors may have conflicting fiduciary duties to us and the other entity.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The terms of transactions with the other entity may not be subject to arm’s length negotiations and therefore may be on terms less favorable to us than those that could be procured through arm’s length negotiations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We anticipate entering into contractswith various U.S. government agencies. In contracting with government agencies, we will be subject to various federal contractrequirements. Future sales to U.S. government agencies will depend, in part, on our ability to meet these requirements, certainof which we may not be able to satisfy.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We may enter into contractswith various U.S. government agencies which have special contracting requirements that give the government agency various rightsor impose on the other party various obligations that can make the contracts less favorable to the non- government party. Consequently,if a large portion of our revenue is attributable to these contracts, our business may be adversely affected should the governmentalparties exercise any of these additional rights or impose any of these additional obligations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        U.S. government contractstypically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion,which subjects us to additional risks. These risks include the ability of the U.S. government to unilaterally:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            suspend or prevent us for a set period of time from receiving new contracts or extending existing contracts based on violations or suspected violations of laws or regulations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            terminate our existing contracts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <!-- Field: Page; Sequence: 67; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          67          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reduce the scope and value of our existing contracts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            audit and object to our contract-related costs and fees, including allocated indirect costs;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            control and potentially prohibit the export of our drug candidates; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            change certain terms and conditions in our contracts.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The U.S. governmentmay terminate any of its contracts with us either for its convenience or if we default by failing to perform in accordance withthe contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurredor committed, and settlement expenses and profit on the work completed prior to termination. Termination for default provisionsdo not permit these recoveries and make us liable for excess costs incurred by the U.S. government in procuring undelivered itemsfrom another source.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As a U.S.government contractor, we may become subject to periodic audits and reviews. Based on the results of these audits, the U.S.government may adjust our contract-related costs and fees, including allocated indirect costs. As part of any such audit orreview, the U.S. government may review the adequacy of, and our compliance with, our internal control systems and policies,including those relating to our purchasing, property, compensation and/or management information systems. In addition, if anaudit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties andadministrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines andsuspension or prohibition from doing business with the U.S. government. We could also suffer serious harm to our reputationif allegations of impropriety were made against us. In addition, under U.S. government purchasing regulations, some of ourcosts, including most financing costs, amortization of intangible assets, portions of our R&amp;D costs and some marketingexpenses, may not be reimbursable or allowed under our contracts. Further, as a U.S. government contractor, we may becomesubject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legalactions and liabilities to which purely private sector companies are not.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may fail to obtain contracts tosupply the U.S. government, and we may be unable to commercialize our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The U.S. governmenthas undertaken commitments to help secure improved countermeasures against bio-terrorism. The process of obtaining government contractsis lengthy and uncertain, and we would compete for each contract. Moreover, the award of one government contract would not necessarilysecure the award of future contracts covering the same drug. If the U.S. government makes significant future contract awards forthe supply of its emergency stockpile to our competitors, our business will be harmed and it is unlikely that we will be able toultimately commercialize our competitive drug candidate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        In addition, the determinationof when and whether a drug is ready for large scale purchase and potential use will be made by the government through consultationwith a number of government agencies, including the FDA, the NIH, the CDC and the Department of Homeland Security. Congress hasapproved measures to accelerate the development of bio-defense drugs through NIH funding, the review process by the FDA and thefinal government procurement contracting authority. While this may help speed the approval of our drug candidates, it may alsoencourage competitors to develop their own drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We cannot predict with certainty the size of the market, if anyfor all of the antiviral drugs that the governments may want to stockpile. Consequently, we cannot predict whether sales, if any,to governments will be sufficient to fund our business plan and commence revenue-generating operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 68; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          68          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="margin: 0pt 0">        <b>         <i>          If the U.S. government fails to continue funding bio-defense drug candidate development effortsor fails to purchase sufficient quantities of any future bio-defense drug candidate, we may be unable to generate sufficient revenuesto continue operations.         </i>        </b>       </p>       <p style="margin: 0pt 0">        <b>         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        While we have not yetreceived U.S. government funding, we hope to receive funding from the U.S. government for the development of our bio-defense drugcandidates. Changes in government budgets and agendas, however, may result in future funding being decreased and de-prioritized,and government contracts typically contain provisions that permit cancellation in the event that funds are unavailable to the governmentagency. Furthermore, we cannot be certain of the timing of any future funding, and substantial delays or cancellations of fundingcould result from protests or challenges from third parties. If the U.S. government fails to continue to adequately fund R&amp;Dprograms, we may be unable to generate sufficient revenues to continue operations. Similarly, if we develop a drug candidate thatis approved by the FDA, but the U.S. government does not place sufficient orders for this drug, our future business may be harmed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to the Biotechnology/BiopharmaceuticalIndustry        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The biotechnology and biopharmaceuticalindustries are characterized by rapid technological developments and a high degree of competition. We may be unable to competewith enterprises equipped with more substantial resources than us.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The biotechnology andbiopharmaceutical industries are characterized by rapid technological developments and a high degree of competition based primarilyon scientific and technological factors. These factors include the availability of patent and other protection for technology andproducts, the ability to commercialize technological developments and the ability to obtain government approval for testing, manufacturingand marketing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our shingles drugcandidate would compete with Valtrex®, an approved drug (valacyclovir), and other acyclovir-related nucleoside analogs,and new drugs in the pipeline. FV-100, a VZV-specific nucleoside analog was in Phase III clinical trials that wereterminated. Development of ASP2151, a helicase/primase inhibitor, was terminated due to adverse events in healthy persons inclinical trials. We are not aware of any further drugs in clinical trials for the treatment of shingles. Painkillers such aslidocaine formulations and oxycodone formulations were in clinical trials for symptomatic relief of PHN.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our HSV-1 and HSV-2skin cream drug candidates would compete with branded and unbranded available skin creams, such as Abreva™, as well as withbranded and unbranded oral drug candidates against herpes, such as those based on acyclovir, valacyclovir, gancyclovir, among others.It is not known until after human clinical trials whether our drug candidates provide patient benefits beyond those of these drugs.Other drugs against herpes that are in the pipeline, if approved prior to our drug approval, would also be competition. Severaldrugs are in clinical trials for HSV-1 and/or HSV-2 treatment. These include brincidofovir, cyclopropavir, valamocyclovir, pritelivir,letermovir, as well as antibodies. Their patient benefit profiles are not known at present.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our anti-influenzadrug in development, Flucide, would compete with neuraminidase inhibitors Tamiflu and Relenza, anti-influenza drugs that are soldby Roche and Glaxo SmithKline (GSK), respectively. Generic competitors include amantadine and rimantadine, both oral. BioCrystPharmaceuticals, Inc. has achieved US FDA approval for IV Infusions formulations of peramivir, an influenza neuraminidaseinhibitor, for the treatment of uncomplicated influenza. Peramivir is approved in Japan and had obtained emergency use authorizationin the US. Its effectiveness during multiple clinical trials was found to be severely limited. Recently, a new drug, Xofluza (Baloxavirmarboxil), developed by Shionogi, Inc., has been approved in Japan, and licensed in the US and the rest of the world by Genetech/Rocheand is in fast track Phase 3 clinical trials under the US FDA. It is an influenza viral endonuclease PA inhibitor. Other drugsin this class are in clinical trials. So are drugs targeting the m7G cap-snatching activity (PB2) of influenza virus such as VX787,and antibodies. Several H5N1 bird flu, and influenza novelH1N1/2009 vaccines are also in development worldwide. Several companiesare developing anti-influenza drugs and vaccines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We compete with specializedbiopharmaceutical firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companiesthat are applying biotechnology to their operations, many of which have greater market presence and resources than we do. Manybiopharmaceutical companies have focused their development efforts in the human therapeutics area, including cancer. Many majorpharmaceutical companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with otherbiopharmaceutical companies. These companies, as well as academic institutions, government agencies and private research organizations,also compete with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to competesuccessfully with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availabilityof capital to us.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 69; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          69          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are aware of numerousproducts under development or manufactured by competitors that are used for the prevention or treatment of certain diseases wehave targeted for drug development. Various companies are developing biopharmaceutical products that potentially directly competewith our drug candidates even though their approach to such treatment is different.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We hope that our drugcandidates under development and in clinical trials will address major markets within the anti-viral sector. Our competition willbe determined in part by the potential indications for which drugs are developed and ultimately approved by regulatory authorities.Additionally, the timing of the market introduction of some of our potential drugs or of competitors’ products may be animportant competitive factor. Accordingly, the relative speed with which we can develop drugs, complete pre-clinical testing, clinicaltrials, approval processes and supply commercial quantities to market are important competitive factors. We expect that competitionamong drugs approved for sale will be based on various factors, including product efficacy, safety, reliability, availability,price and patent protection.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The successful development of biopharmaceuticalsis highly uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandondevelopment of our drug candidates.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Successful developmentof biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Productsthat appear promising in the early phases of development may fail to reach the market for several reasons including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            pre-clinical study results that may show the product to be less effective than desired (e.g., the study failed to meet its primary objectives) or to have harmful or problematic side effects;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis or a IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinical data or unexpected safety or manufacturing issues;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            manufacturing costs, pricing or reimbursement issues, or other factors that make the product not economical; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Success in pre-clinical and early clinicalstudies does not ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varyinginterpretations that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studiesand to submit an application for marketing approval for a final decision by a regulatory authority varies significantly from oneproduct to the next, and may be difficult to predict.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 70; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          70          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Risks Related to the Securities Marketsand Investments in Our Common Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <i>          General securities market uncertainties resulting fromthe COVID-19 pandemic.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Since the outset ofthe pandemic the US and worldwide national securities markets have undergone unprecedented stress due to the uncertainties of thepandemic and the resulting reactions and outcomes of government, business and the general population. These uncertainties haveresulted in declines in all market sectors, increases in volumes due to flight to safety and governmental actions to support themarkets. As a result, until the pandemic has stabilized, the markets may not be available to us for purposes of raising requiredcapital. Should we not be able to obtain financing when required, in the amounts necessary to execute on our plans in full, oron terms which are economically feasible we may be unable to sustain the necessary capital to pursue our strategic plan and mayhave to reduce the planned future growth and scope of our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          If we do not meet the continued listingstandards of the NYSE American our common stock could be delisted from trading, which could limit investors’ ability to maketransactions in our common stock and subject us to additional trading restrictions.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of September 25,2013, our common stock became listed on the NYSE MKT (now known as “NYSE American”), a national securities exchange,which imposes continued listing requirements with respect to listed shares. If, however, we fail to satisfy the continued listingstandards, such as, for example, the requirement that our shares not trade “for a substantial period of time at a low priceper share,” fail to meet stockholders equity requirements, or that we not dispose of our principal operating assets or discontinuea substantial portion of our operations, among other requirements, the NYSE American may issue anon-compliance letter or initiatedelisting proceedings. If our securities are delisted from trading on the NYSE American and we are not able to list our securitieson another exchange or to have them quoted on NASDAQ, our securities could be quoted on the OTC Bulletin Board or on the “pinksheets.” As a result, we could face significant adverse consequences including:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a limited availability of market quotations for our securities;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a determination that our common stock is a “penny stock” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a limited amount of news and analyst coverage for us; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a decreased ability to issue additional securities (including pursuant to short-form registration statements on Form S-3 or obtain additional financing in the future).           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our Company is subject to the periodicreporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which will requireus to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs will reduce ormight eliminate our profitability.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Our Company is requiredto file periodic reports with the Commission pursuant to the Exchange Act and the rules and regulations promulgated thereunder.To comply with these requirements, our independent registered auditors will have to review our quarterly financial statements andaudit our annual financial statements. Moreover, our legal counsel will have to review and assist in the preparation of such reports.The costs charged by these professionals for such services cannot be accurately predicted at this time, because factors such asthe number and type of transactions that we engage in and the complexity of our reports cannot be determined at this time and willhave a major effect on the amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs willobviously be an expense to our operations and thus have a negative effect on our ability to meet our overhead requirements andearn a profit. We may be exposed to potential risks resulting from new requirements under Section 404 of the Sarbanes-OxleyAct of 2002. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed,investors could lose confidence in our reported financial information, the trading price of our common stock, if a market everdevelops, could drop significantly, or we could become subject to Commission enforcement proceedings.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our Common Stock may be considereda “penny stock” and may be difficult to sell.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Commission hasadopted regulations which generally define “penny stock” to be an equity security that has a market price of less than$5.00 per share or an exercise price of less than $5.00 per share, subject to specific exemptions. Historically, the price of ourCommon Stock has fluctuated greatly. If, the market price of the Common Stock is less than $5.00 per share and the Common Stockdoes not fall within any exemption, it therefore may be designated as a “penny stock” according to Commission rules.The “penny stock” rules impose additional sales practice requirements on broker-dealers who sell securities topersons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annualincome exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer mustmake a special suitability determination for the purchase of securities and have received the purchaser’s written consentto the transaction before the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the broker-dealermust deliver, before the transaction, a disclosure schedule prescribed by the Commission relating to the penny stock market. Thebroker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and currentquotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited marketin penny stocks. These additional burdens imposed on broker-dealers may restrict the ability or decrease the willingness of broker-dealersto sell our common shares, and may result in decreased liquidity for our common shares and increased transaction costs for salesand purchases of our common shares as compared to other securities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 71; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          71          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Our stock price may be volatile andyour investment in our common stock could suffer a decline in value.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The price of our CommonStock, as quoted on the NYSE American, may fluctuate significantly in response to a number of factors, many of which are beyondour control. These factors include but are not limited to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            progress of our products through the regulatory process           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            results of preclinical studies and clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements of technological innovations or new products by us or our competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            government regulatory action affecting our products or our competitors’ products in both the United States and foreign countries;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            developments or disputes concerning patent or proprietary rights;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general market conditions for emerging growth and pharmaceutical companies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            economic conditions in the United States or abroad;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            actual or anticipated fluctuations in our operating results;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            broad market fluctuations; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">          </td>          <td style="width: 48px">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in financial estimates by securities analysts.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          There is a risk of market fraud.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Shareholders shouldbe aware that, according to SEC Release No. 34-29093, the market for penny stocks has suffered in recent years from patternsof fraud and abuse. Such patterns include (1) control of the market for the security by one or a few broker-dealers that areoften related to the promoter or issuer; (2) manipulation of prices through prearranged matching of purchases and sales andfalse and misleading press releases; (3) boiler room practices involving high-pressure sales tactics and unrealistic priceprojections by inexperienced sales persons; (4) excessive and undisclosed bid-ask differential and markups by selling broker-dealers;and (5) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated toa desired level, along with the resulting inevitable collapse of those prices and with consequent investor losses. We are awareof the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictatethe behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practicallimitations to prevent the described patterns from being established with respect to our securities. The occurrence of these patternsor practices could increase the volatility of our share price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of September 25,2013, our common stock was listed on the NYSE American national exchange. However, shareholders should be aware that the occurrenceof the above-mentioned patterns and practices cannot be entirely precluded and that the occurrence of these patterns or practicescould increase the volatility of our share price.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          A registration of a significant amountof our outstanding restricted stock may have a negative effect on the trading price of our stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        At September 30,2020, shareholders of the Company held 1,415,419 shares of restricted stock, or approximately 13.3% of the outstanding Common Stock.If we were to file a registration statement including all of these shares, and the registration is allowed by the SEC, these shareswould be freely tradable upon the effectiveness of the planned registration statement. If investors holding a significant numberof freely tradable shares decide to sell them in a short period of time following the effectiveness of a registration statement,such sales could contribute to significant downward pressure on the price of our stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 72; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          72          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We do not intend to pay any cashdividends in the foreseeable future and, therefore, any return on your investment in our capital stock must come from increasesin the fair market value and trading price of the capital stock.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We have not paid anycash dividends on our Common Stock and do not intend to pay cash dividends on our Common Stock in the foreseeable future. We intendto retain future earnings, if any, for reinvestment in the development and expansion of our business. Any credit agreements, whichwe may enter into with institutional lenders, may restrict our ability to pay dividends. Whether we pay cash dividends in the futurewill be at the discretion of our board of directors and will be dependent upon our financial condition, results of operations,capital requirements and any other factors that the board of directors decides is relevant. Therefore, any return on your investmentin our capital stock must come from increases in the fair market value and trading price of the capital stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          We may issue additional equity sharesto fund the Company’s operational requirements, which would dilute share ownership.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company’scontinued viability depends on its ability to raise capital. Changes in economic, regulatory or competitive conditions may leadto cost increases. Management may also determine that it is in the best interest of the Company to develop new services or products.In any such case additional financing is required for the Company to meet its operational requirements. There can be no assurancesthat the Company will be able to obtain such financing on terms acceptable to the Company and at times required by the Company,if at all. In such event, the Company may be required to materially alter its business plan or curtail all or a part of its operationalplans as detailed further in Management’s Discussion and Analysis in this prospectus. The sale or the proposed sale of substantialamounts of our common stock in the public markets may adversely affect the market price of our common stock and our stock pricemay decline substantially. In the event that the Company is unable to raise or borrow additional funds, the Company may be requiredto curtail significantly its operational plans as further detailed in Requirements for Additional Capital in the Management’sDiscussion and Analysis of this prospectus.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The Company is authorizedto issue up to 150,000,000 shares of common stock without additional approval by shareholders. As of September 30, 2020, wehad 10,658,756 shares of common stock outstanding, 22,218 warrants convertible to 22,218 shares of common stock, 5,000 stock optionsconvertible to 5,000 shares of common stock and 368,602 shares of Series A preferred stock convertible into 1,290,107 sharesof common stock only in the event of a change in control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Large amounts of our common stockwill be eligible for resale under Rule 144.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        As of September 30,2020, 1,415,419 of 10,658,756 issued and outstanding shares of the Company’s common stock were restricted securities as definedunder Rule 144 of the Securities Act of 1933, as amended (the “Act”) and under certain circumstances may be resoldwithout registration pursuant to Rule 144. In addition the 368,602 shares of Series A Preferred Stock are restrictedand convertible into 1,290,107 shares of common stock only in the event of a Change of Control of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        Approximately 825,746shares of our restricted shares of common stock are held by non-affiliates who may avail themselves of the public information requirementsand sell their shares in accordance with Rule 144. As a result, some or all of these shares may be sold in accordance withRule 144 potentially causing the price of the Company’s shares to decline.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In general, under Rule 144, a person(or persons whose shares are aggregated) who has satisfied a six month holding period may, under certain circumstances, sell withinany three-month period a number of securities which does not exceed the greater of 1% of the then outstanding shares of commonstock or the average weekly trading volume of the class during the four calendar weeks prior to such sale. Rule 144 also permits,under certain circumstances, the sale of securities, without any limitation, by a person who is not an Affiliate, as such termis defined in Rule 144(a)(1), of the Company and who has satisfied a one-year holding period. Any substantial sale of theCompany’s common stock pursuant to Rule 144 may have an adverse effect on the market price of the Company’s shares.This filing will satisfy certain public information requirements necessary for such shares to be sold under Rule 144.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 73; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          73          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The requirements of complying withthe Sarbanes-Oxley act may strain our resources and distract management.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We are subject to thereporting requirements of the Exchange Act, and the Sarbanes-Oxley Act of 2002. The costs associated with these requirements mayplace a strain on our systems and resources. The Exchange Act requires that we file annual, quarterly and current reports withrespect to our business and financial condition. The Sarbanes-Oxley Act requires that we maintain effective disclosure controlsand procedures and internal controls over financial reporting. Historically, we have maintained a small accounting staff, but inorder to maintain and improve the effectiveness of our disclosure controls and procedures and internal control over financial reporting,significant additional resources and management oversight will be required. This includes, among other things, activities necessaryfor supporting our independent public auditors. This effort may divert management’s attention from other business concerns,which could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition,we may need to hire additional accounting and financial persons with appropriate public company experience and technical accountingknowledge, and we cannot assure you that we will be able to do so in a timely fashion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Sales of additional equity securitiesmay adversely affect the market price of our common stock and your rights in the Company may be reduced.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        We expect to continueto incur drug development and selling, general and administrative costs, and in order to satisfy our funding requirements, we mayneed to sell additional equity securities. Our stockholders may experience substantial dilution and a reduction in the price thatthey are able to obtain upon sale of their shares. Also, any new securities issued may have greater rights, preferences or privilegesthan our existing common stock that may adversely affect the market price of our common stock and our stock price may decline substantially.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_002">          </a>          ITEM 1B: UNRESOLVED STAFF COMMENTS.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_003">          </a>          ITEM 2: PROPERTIES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Description of Property        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s principal executiveoffices are located at 1 Controls Drive, Shelton, CT, and include approximately 18,000 square feet of office, laboratory, and cGMP-capabledrug manufacturing space. These facilities are fully owned by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The property is subject to a mortgage notein the amount of $1.1 million in favor of the Company’s founder Dr. Anil Diwan. The mortgage note was made in December 2019and will mature on March 15, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We subcontract the laboratory researchand development work to TheraCour under the License Agreement with TheraCour. Management believes that the space is sufficientfor the Company to monitor the developmental progress at its subcontractors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_004">          </a>          ITEM 3: LEGAL PROCEEDINGS.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From time to time, we are a party to legalproceedings arising in the ordinary course of business. We are not currently a party to any other legal proceedings that we believecould have a material adverse effect on financial condition or results of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_005">          </a>          ITEM 4: MINE SAFETY DISCLOSURES.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 74; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          74          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <u>          <a name="c_007">          </a>          PART II         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_008">          </a>          ITEM 5: MARKET FOR REGISTRANT’SCOMMON EQUITY RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our Common Stock commenced trading on theNYSE MKT on September 25, 2013 under the symbol “NNVC”. The Company’s Common Stock, after the Company becamea publicly traded company in May 2005, was initially traded on the Pink Sheets under the symbol NNVC and from June 29,2007, through September 24, 2013, the Company’s Common Stock has been quoted on the Over The Counter Bulletin Board.The table below sets forth the high and low prices for the Company’s Common Stock for the quarters included within the pasttwo fiscal years. Quotations reflect inter-dealer prices, without retail markup, markdown commission, and may not represent actualtransactions. No assurance can be given that an active market will exist for the Company’s common stock and the Company doesnot expect to declare dividends in the foreseeable future since the Company intends to utilize its earnings, if any, to financeits future growth, including possible acquisitions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">           Quarter ended          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Low price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           High price          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td colspan="2" style="font-size: 10pt; text-align: center">          </td>          <td style="font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif">           June 30, 2020          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5.09          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           11.56          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.56          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           16.76          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           December 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1.52          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3.26          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           September 30, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2.05          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           June 30, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.40          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           6.20          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           March 31, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           13.60          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           December 31, 2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           4.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           September 30, 2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           10.00          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Number of Shareholders.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, a total of 9,083,414shares of the Company’s common stock are outstanding and held by 156 shareholders of record. This number of shareholdersdoes not reflect the persons or entities that hold their stock in nominee or street name through various brokerage firms. Of thisamount, approximately 7,667,995 shares are unrestricted, of which, approximately 0 shares are held by affiliates, approximately826,000 shares are restricted securities held by non-affiliates, and the remaining approximate 589,400, shares are restricted securitiesheld by affiliates. These shares may only be sold in accordance with Rule 144. As of June 30, 2020, there were 22,218warrants and 5,000 options to purchase the Company’s common stock outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Dividends.        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has not paid any cash dividendssince its inception. The Company currently intends to retain any earnings for use in its business, and therefore does not anticipatepaying dividends in the foreseeable future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Long-Term Incentive Plans Awards inLast Fiscal Year        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The NanoViricides, Inc. ExecutiveEquity Incentive Plan (the “2018 Plan”) was adopted to assist the Company in attracting, motivating, retaining andrewarding high-quality executives and other employees, officers, directors, consultants and other persons who provide servicesto us, by enabling such persons to acquire or increase a proprietary interest in the Company. The 2018 Plan provides for the issuanceof stock options, stock appreciation rights, or SARs, restricted stock, restricted stock units, reload options, and otherstock-based awards        <i>         .        </i>        Performance awards may be based on the achievement of certain business or personal criteria orgoals, as determined by the Committee. The total number of shares of our common stock that may be subject to the granting of awardsunder our 2018 Plan is equal to 250,000 shares and 100,000 shares of our Series A preferred stock. To date, no shares of commonstock or Series A preferred stock have been issued under the 2018 Plan.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 75; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          75          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ending June 30, 2018 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Scientific Advisory Board was granted fully vested warrants to purchase 2,287 shares of common stock at exercise prices between$12.80- $31.20 per share expiring in the fiscal year ending June 30, 2022.  These warrants were valued at $16,770and recorded as consulting expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,Eugene Seymour was granted five year warrants (the “Warrants”) to purchase 12,500 shares of the Company’s commonstock, par value $0.001 per share (the “Common Stock”) at an exercise price of $40.00 per share, vesting in three,equal installments over three years with the last installment vesting on May 1, 2021. The fair value of these warrants werevalued at $53,500 and recorded as employee compensation expense for severance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company’s Board of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which arefully vested with a restrictive legend for employee compensation. The Company recorded an expense of $136,106, which is the fairvalue at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company recognized a noncash compensation expense of $267,144 related to Series A preferred shares issued on July 21,2015 in accordance with Dr. Anil Diwan’s employment agreement that vest over the three years ended June 30, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company recognized a noncash compensation expense of $121,008 related to Series A preferred stock issued on July 21,2015 in accordance with Dr. Eugene Seymour’s employment agreement that vested over three years. On January 27,2018, Dr. Eugene Seymour resigned as Chief Executive Officer and as a Director of the Company. See Note 10 to the FinancialStatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company’s Board of Directors authorized the issuance of 7,500 shares of its Series A Convertible preferred stock,which are fully vested with a restrictive legend to the Holder of the company’s Series C Convertible Debenture in considerationfor its waiver of all early redemption payments provided for in the Debenture. The Company recorded an expense of $314,343, whichis the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company’s Board of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation forseverance. The Company recognized a noncash compensation expense of $65,716.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company’s Board of Directors authorized the issuance of 12,188 fully vested shares of its common stock with a restrictivelegend for consulting services. The Company recorded an expense of $156,190, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018,the Company’s Board of Directors authorized the issuance of 2,489 fully vested shares of its common stock with a restrictivelegend for Director services. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018 theHolders of the Company’s Series C Debentures elected to receive 275,000 shares of the Company’s restricted commonstock in redemption for its $5,000,000 Series C Debenture, quarterly interest payments of $375,000 and deferred interest of$125,000. For the year ended June 30, 2018, the Company’s Board of Directors authorized the issuance of 275,000 sharesof the Company’s restricted common stock for the redemption of the debenture payable to the Holder and quarterly and deferredinterest payments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ended June 30, 2019 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 11, 2018 the Board of Directorsapproved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the termsof the employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 of the Company’s Series Apreferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30,2020 and June 30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expense related to theissuance of the Series A preferred stock of $189,040 for the year ended June 30, 2019. The balance of $371,650 will berecognized as the shares vest and service is rendered.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 76; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          76          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 19, 2018, the Company enteredinto an Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1,2018. Dr. Taraporewala was granted options to purchase up to 15,000 shares of the Company’s common stock, par value$0.001 per share at an exercise price equal to 20% above the closing bid price of $8.20 of the Common Stock on September 1,2018 (“Effective Date”). The options were to vest in three, equal, annual installments commencing on the effectivedate. The grant date fair value of the options was $35,761 of which $11,920 was recognized and recorded as compensation expensefor the year ended June 30, 2019. On January 24, 2019, Dr. Taraporewala resigned as the Chief Executive Officerof NanoViricides, Inc. for personal reasons. All unvested options were forfeited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019,the Scientific Advisory Board was granted fully vested warrants to purchase 2,287 shares of common stock at exercise prices between$6.00- $9.40 per share expiring in the fiscal year ending June 30, 2023.  These warrants were valued at $5,475 andrecorded as consulting expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On February 27, 2019, the Companyentered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), for a registereddirect offering of 347,223 shares of common stock at the purchase price of $7.20 per share for an aggregate of $2,500,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The offer and sale of the shares in theregistered direct offering was registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuantto the Company’s shelf registration statement on Form S-3, as amended (File No. 333-216345), which became effectiveon April 25, 2017. Pursuant to Rule 424(b) under the Securities Act, the Company has filed a prospectus supplementin connection with such offering.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In a concurrent private placement, thePurchasers received warrants (the “Warrants”) to purchase up to 347,223 shares of common stock. The Warrants have anexercise price of $12.20 per share, shall be exercisable on the six month anniversary of issuance and will expire five (5) yearsthereafter. The Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus,by cashless exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The exercise price of the Warrants issubject to adjustment in the case of customary events such as stock dividends or other distributions on shares of commonstock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stockcombinations, reclassifications or similar events affecting our common stock, and also, subject to limitations, upon anydistribution of assets, including cash, stock or other property to our stockholders. The exercise of the Warrants is subjectto certain beneficial ownership and other limitations set forth in the Warrants. The Company will receive proceeds from theconcurrent private placement transaction solely to the extent the Warrants are exercised for cash.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019,the Company’s Board of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which arefully vested with a restrictive legend for employee compensation. The Company recorded an expense of $48,828, which was the fairvalue at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019,the Company’s Board of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation.The Company recognized a noncash compensation expense of $28,572 which was the fair value on the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019,the Company’s Board of Directors authorized the issuance of 28,210 fully vested shares of its common stock with a restrictivelegend for consulting services. The Company recorded an expense of $208,960, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019,the Company’s Board of Directors authorized the issuance of 7,325 fully vested shares of its common stock with a restrictivelegend for director services. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 77; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          77          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ended June 30, 2020 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 11, 2018 the Board of Directorsapproved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the termsof the employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 of the Company’s Series Apreferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30,2020 and June 30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expense related to theissuance of the Series A preferred stock of $189,040 for the year ended June 30, 2020. The balance of $182,610 will berecognized as the remaining 8,750 shares vest and service is rendered for the year ended June 30, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020,the Scientific Advisory Board was granted fully vested warrants to purchase 2,286 shares of common stock at exercise prices between$2.63- $12.16 per share expiring in the fiscal year ending June 30, 2024.  These warrants were valued at $7,373and recorded as consulting expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 21, 2020, the Company enteredinto an Underwriting Agreement with Aegis Capital Corp. Pursuant to the terms and conditions of the Underwriting Agreement, weagreed to issue and sell 2,500,000 shares of our common stock, par value $0.001 per share, at a price to the public of $3.00 pershare. Pursuant to the Underwriting Agreement, we also granted the underwriter an option to purchase up to an additional 375,000shares of our common stock within 45 days after the date of the Underwriting Agreement to cover over-allotments, if any. The FinalProspectus for the offering was filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(1) ofthe Securities Act of 1933, as amended, on January 23, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The offering was consummated on January 25,2020. The Company sold the Underwritten Shares and the underwriter exercised its option to purchase an additional 375,000 sharesof common stock at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commissionand agreed upon customary fees and expenses, and deducting the Company's legal and accounting expenses related to the Offeringwas $7,457,575.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 24, 2020, the Companyentered into a Binding Term Sheet which was incorporated on January 27, 2020 in a Settlement Agreement and MutualRelease (the “Settlement Agreement”) with the investor parties (collectively, the “Investors”) tothat certain Securities Purchase Agreement dated as of February 27, 2019 (the "Securities Purchase Agreement")to settle an action commenced by the Investors to, among other things, enjoin the Company’s previously disclosedunderwritten public offering (the “Action”)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 27, 2020, the Company enteredinto an Exchange Agreement with each of the Investors pursuant to the Settlement Agreement. Pursuant to the terms and conditionsof the Exchange Agreement, the Investors agreed to terminate certain restrictive covenants in the Securities Purchase Agreement,including a bar on all offerings of securities below the exercise price of the Warrants to purchase common stock issued February 19,2019 (the “Old Warrants”), and the Company agreed to exchange 347,222 of the Investors’ Old Warrants for an aggregateof (i) 677,224 shares of common stock and (ii) new warrants, to purchase 347,222 shares of common stock at an exerciseprice of $3.00 per share and expire on August 24, 2024  (the “New Warrants”). The common stock issued hada fair value of $5,722,543 using the closing price of $8.45 on January 24, 2020 resulting in an increase to common stock of$677 and additional paid in capital of $5,721,866 and the New Warrants had a fair market value of $2,066,425 which was recordedas a derivative liability. The aggregate fair value of the common stock and New Warrants issued as part of the Exchange Agreementwas $7,788,968. The Old Warrants were remeasured to a fair value of $8,403,468 on January 24, 2020 immediately prior to theexchange. As a result of the Exchange Agreement, a gain on warrant settlement was recognized in the amount of $614,494 calculatedas the difference between the fair value of the Old Warrants immediately prior to the exchange and the aggregate fair value ofthe common stock and New Warrants issued in the exchange. On March 16, 2020 the shareholders of NanoViricides authorized anincrease in the number of authorized common stock to 150,000,000 shares and the New Warrants were issued and exercisable. Thesewarrants contained a full-ratchet anti-dilution feature but also contained other adjustment features which required that the warrantsbe classified as a derivative liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 78; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          78          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The 347,222 New Warrants were exercisedon March 23, 2020 and March 25, 2020 pursuant to a cashless exercise provision resulting in the issuance of 180,087 sharesof common stock. The fair value of the warrants were reset to fair value as of March 23, 2020 and March 25, 2020, and,upon exercise of the warrants, the derivative liability was reclassified to equity of $1,153,881.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        On May 21,2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for an offering of 1,400,000shares (the “Shares”) of the Company’s common stock, par value $0.001 per share at the purchase price of $7.30per share. The Shares were issued pursuant to a prospectus supplement dated May 21, 2020 which was filed with the Securitiesand Exchange Commission on May 22, 2020 in connection with a takedown from the Company’s shelf registration statementon Form S-3, as amended (File No. 333-237370), which became effective on April 2, 2020 and the base prospectus datedApril 2, 2020 contained in that registration statement. The Offering closed on May 22, 2020. The net proceeds to theCompany from the offering are approximately $9.3 million after placement agent fees and other estimated offering expenses payableby the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 10,000 fully vested shares of its Series A preferred stock for a loan originationfee to a related party with a fair value of $39,301, which is the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 100,000 fully vested shares of its Series A preferred stock with a fair value of$392,669 in exchange for $250,000 of previously deferred development fees to a related party and recognized a loss on the exchangeof $142,669.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020,the Company’s Board of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which arefully vested with a restrictive legend for employee compensation. The Company recorded an expense of $41,857, which was the fairvalue at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020,the Company’s Board of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation.The Company recognized a noncash compensation expense of $29,251, which was the fair value on the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020,the Company’s Board of Directors authorized the issuance of 78,958 fully vested shares of its common stock with a restrictivelegend for consulting services. The Company recorded an expense of $254,250, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020,the Company’s Board of Directors authorized the issuance of 10,728 fully vested shares of its common stock with a restrictivelegend for Director services. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 25,667 fully vested shares of its common stock with a restrictive legend to satisfyopen accounts payable of $77,000 for consulting services. The number of shares issued to settle the accounts payable was calculatedusing the market price of the common stock on the settlement date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the settlement with a vendor to redeem and cancel 17,200 shares of its common stock with a restrictivelegend, which were initially issued in payment of accounts payable of $25,000. The shares were canceled and reported as reductionsof common stock issued in exchange for accounts payable reported in the Statement of Changes in Stockholders’ Equity as adecrease of $25,000. The redemption and cancellation had no effect on the results of operations for the year ended June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 79; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          79          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_009">          </a>          ITEM 6: SELECTED FINANCIAL DATA         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The selected financial data presented beloware for each fiscal year in the five-year period ended June 30, 2020. This data is derived from, and qualified by referenceto, our audited financial statements and notes thereto appearing elsewhere in this Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Statements of Operations Data:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="18" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year Ended June 30,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2018            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2017            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2016            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Operating expenses:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 45%; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Research and development           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,695,524           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,921,720           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,913,720           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6,565,966           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,028,970           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            General and administrative           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,300,935           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,737,962           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,411,449           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,034,758           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,830,531           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total operating expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,996,459           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,659,682           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,325,169           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,600,724           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,859,501           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss from operations           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,996,459           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,659,682           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9,325,169           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (9,600,724           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,859,501           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other income (expense):           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest income           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17,079           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55,497           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            100,429           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            60,955           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62,638           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest expense           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (93,670           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gain on warrant settlement           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            614,494           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss on issuance of Series A Preferred stock for accounts payable-related party           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (142,669           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest expense on convertible debentures           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (185,274           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (780,767           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,042,470           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss on extinguishment of debt           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,348,247           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (332,524           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Discount on convertible debentures           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (359,214           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,347,748           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,427,218           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Change in fair value of derivatives           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5,845,313           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            179,745           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,554,020           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,696,318           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            541,922           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other (expense)income, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (5,450,079           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            235,242           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            761,714           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (703,766           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,865,128           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss before income tax provision           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13,446,538           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,424,440           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,563,455           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10,304,490           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10,724,629           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Income tax provision           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net loss           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13,446,538           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,424,440           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,563,455           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10,304,490           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (10,724,629           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NET LOSS PER COMMON SHARE-           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -  Basic &amp; diluted           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2.39           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2.35           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2.64           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3.40           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3.79           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Weighted average common shares outstanding           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -  Basic &amp; diluted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,616,728           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,590,070           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,246,043           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,005,143           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,827,692           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 80; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          80          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Balance Sheets Data:        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="18" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           As of June 30,          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2020          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2019          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2018          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2017          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           2016          </td>          <td style="padding-bottom: 1pt; font: bold 9pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td colspan="2" style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td colspan="2" style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td colspan="2" style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td colspan="2" style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td colspan="2" style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 45%; font: 9pt Times New Roman, Times, Serif; text-align: left">           Cash and cash equivalents          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 9pt Times New Roman, Times, Serif; text-align: right">           13,708,594          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 9pt Times New Roman, Times, Serif; text-align: right">           2,555,207          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 9pt Times New Roman, Times, Serif; text-align: right">           7,081,771          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 9pt Times New Roman, Times, Serif; text-align: right">           15,099,461          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 8%; font: 9pt Times New Roman, Times, Serif; text-align: right">           24,162,185          </td>          <td style="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           Working capital          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           11,829,280          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (22,732          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           6,440,080          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           10,624,109          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           17,637,629          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           Total assets          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           23,914,339          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           13,448,513          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           18,546,212          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           27,002,814          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           36,633,418          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt">          </td>          <td style="font-size: 9pt; text-align: left">          </td>          <td style="font-size: 9pt; text-align: right">          </td>          <td style="font-size: 9pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           Long-term liabilities          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           2,015,354          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           6,841,190          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           Accumulated deficit          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (105,563,124          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (92,116,586          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (83,692,146          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (75,128,691          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           (64,824,201          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">           Stockholders’ equity          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           21,757,962          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           10,600,360          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           17,664,264          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           20,321,942          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: right">           23,048,214          </td>          <td style="font: 9pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_010">          </a>          ITEM 7: MANAGEMENT’S DISCUSSIONAND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following discussion should be readin conjunction with the information contained in the financial statements of the Company and the notes thereto appearing elsewhereherein and in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2020. Readersshould carefully review the risk factors disclosed in this Form 10-K and other documents filed by the Company with the SEC.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As used in this report, the terms “Company”, “we”, “our”, “us” and “NNVC” refer to NanoViricides, Inc., a Nevada corporation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        PRELIMINARY NOTE REGARDING FORWARD-LOOKINGSTATEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        This Annual Report contains forward-lookingstatements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentionsor strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “NNVC believes,” “management believes”and similar language. The forward-looking statements are based on the current expectations of NNVC and are subject to certain risks,uncertainties and assumptions, including those set forth in the discussion under “Management’s Discussion and Analysisof Financial Condition and Results of Operations” in this report. Actual results may differ materially from results anticipatedin these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assumeno obligation to update them.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Investors are also advised to refer tothe information in our previous filings with the Securities and Exchange Commission (SEC), especially on Forms 10-K, 10-Q and 8-K,in which we discuss in more detail various important factors that could cause actual results to differ from expected or historicresults. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factorsto be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Management’s Plan of Operation        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s drug development businessmodel was formed in May 2005 with a license to the patents and intellectual property held by TheraCour that enabled creationof drugs engineered specifically to combat viral diseases in humans. This exclusive license from TheraCour serves as a foundationfor our intellectual property. The Company was granted a worldwide exclusive license to this technology for several drugs withspecific targeting mechanisms for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS),Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian BirdFlu Virus. The Company entered into an Additional License Agreement with TheraCour granting the Company the exclusive licensesfor technologies developed by TheraCour for the additional virus types: Dengue viruses, Japanese Encephalitis virus, West NileVirus, Viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes, and Ebola/Marburg viruses. The Company completeda license agreement for the field of VZV indications in November 2019 from TheraCour. The Company and TheraCour have signeda Memorandum of Understanding for the field of human coronavirus drug indications in June 2020. This MoU grants the Companya limited license for the development of drugs for the treatment of human coronavirus indications. There was no compensation paidto TheraCour for this Coronavirus MoU. The Company has initiated an independent valuation for this field. A definitive agreementis expected to be negotiated between the parties thereafter. TheraCour has not denied any licenses sought by the Company in thepast.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 81; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          81          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company discloses the risk that whilewe are working with the assumption that we will be able to come to mutually agreeable terms for an additional license for the humancoronavirus indications area with TheraCour. However, there can be no assurance that the Company will be able to enter into anagreement with TheraCour for such license or that the agreement will be on terms that are favorable to the Company. The Companymay want to add further virus types to its drug pipeline as the Company progresses further. The Company would then need to negotiatewith TheraCour appropriate license agreements to include those of such additional viruses that the Company determines it wantsto follow for further development. We are seeking to add to our existing portfolio of products through our internal discovery pre-clinicaldevelopment programs and through an in-licensing strategy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The licenses granted by TheraCour are forentire set of pathologies that the licensed virus is a causative agent for. The licenses are not for single drug/indication pairs,which is the customary mode of licensing in the Pharmaceutical industry. Thus these are very broad licenses and enable NanoViricidesto pursue a number of indications as well as develop drug candidates with different characteristics as is best suited for the indications,without having to license the resulting drugs for each indication separately, as with normal pharmaceutical industry licensing.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company plans to develop severaldrugs through the preclinical studies and clinical trial phases with the goal of eventually obtaining approval from theUnited States Food and Drug Administration (“FDA”) and International regulatory agencies for these drugs. TheCompany plans, when appropriate, to seek regulatory approvals in several international markets, including developed marketssuch as Europe, Japan, Canada, Australia, and Emerging Regions such as Southeast Asia, India, China, Central and SouthAmerica, as well as the African subcontinent. The seeking of these regulatory approvals would only come when and if one ormore of our drugs have significantly advanced through the US FDA and international regulatory process. If and as theseadvances occur, the Company may attempt to partner with more established pharmaceutical companies to advance the variousdrugs through the approval process.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company intends to perform the regulatoryfilings and own all the regulatory licenses for the drugs it is currently developing. The Company will develop these drugs in partvia subcontracts to TheraCour, the exclusive source for these nanomaterials. The Company may manufacture these drugs itself, orunder subcontract arrangements with external manufacturers that carry the appropriate regulatory licenses and have appropriatecapabilities. The Company intends to distribute these drugs via subcontracts with distributor companies or in partnership arrangements.The Company plans to market these drugs either on its own or in conjunction with marketing partners. The Company also plans toactively pursue co-development, as well as other licensing agreements with other pharmaceutical companies. Such agreements mayentail up-front payments, milestone payments, royalties, and/or cost sharing, profit sharing and many other instruments that maybring early revenues to the Company. Such licensing and/or co-development agreements may shape the manufacturing and developmentoptions that the Company may pursue. The Company has received significant interest from certain pharmaceutical companies for potentiallicensing or co-development of some of our drug candidates. However, none of these distributor or co-development agreements isin place at the current time.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There can be no assurance that the Companywill be able to develop effective nanoviricides, or if developed, that we will have sufficient resources to be able to successfullymanufacture and market these products to commence revenue-generating operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There can be no assurance that other developmentsin the field would not impact our business plan adversely. For example, successful creation and availability of an effective vaccinemay reduce the potential market size for a particular viral disease, or an effective drug may be developed by competitors thatbecomes difficult to compete against with our limited resources. Our goal, which we can give no assurancethat we will achieve, is for NanoViricides, Inc. to become the premier company developing highly safe and effective drugsthat employ an integrated multiplicity of actions as enabled by our nanomedicine approach for anti-viral therapy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 82; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          82          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To date, we have engaged in organizationalactivities; developing and sourcing compounds and preparing nano-materials; and experimentation involving preclinical studies usingcell cultures and animal models of efficacy and safety. We have generated funding through the issuances of debt and the sales ofsecurities under our shelf registration and the private placement of common stock (        <i>         See,        </i>        Item 5). The Company does notcurrently have any long-term debt. We have not generated any revenues and we do not expect to generate revenues in the near future.We may not be successful in developing our drugs and start selling our products when planned, or we may not become profitable inthe future. We have incurred net losses in each fiscal period since inception of our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Current Financial Status        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides technology is now maturingrapidly toward clinical drug trials, with the new facility, expanded staff, and the financial strength that we have attained sinceuplisting to NYSE-MKT (now NYSE American) in September 2013.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, the end of thereporting period, we have $13,708,594 in cash and cash equivalents, prepaid expenses of $277,063 and $9,544,431 of property andequipment, net of accumulated depreciation. Our liabilities are $2,156,377 including a short term mortgage loan of $1,081,987 payableto Dr. Diwan, accounts payable of $380,727 payable to third parties and accounts payable to TheraCour of $561,580 of which$300,000 of such accounts payable is deferred until the filing of an IND. Stockholders’ equity was $21,757,962 at June 30,2020. In comparison, as of June 30, 2019, we had $2,555,207 in cash and cash equivalents, prepaid expenses of $270,214 andproperty and equipment was $10,227,247, net of accumulated depreciation. Our liabilities were $2,848,153 with $1,645,606 attributableto derivative liabilities of warrants, accounts payable of $309,893 payable to third parties, and accounts payable to TheraCourof $823,783 of which $200,000 is deferred until an IND filing. Stockholders’ equity was $10,600,360 at June 30, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During the year ended June 30, 2020, wespent approximately $6.7 million in cash toward operating activities and approximately $8,600 in capital investment. In contrast,we spent approximately $6.8 million in cash toward operating activities and approximately $74,000 in capital investment in theyear ended June 30, 2019. We anticipate capital costs of approximately $200,000 in the next twelve months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, we have a cashand cash equivalent balance of $13,708,594 that is expected to be sufficient to fund our currently budgeted operations for morethan one year from the filing of the Company’s Form 10K. Additionally, o        <font style="background-color: white">         nJuly 8, 2020,  subsequent to the date of the reporting period, the Company entered into an underwriting agreement (the “UnderwritingAgreement”) with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. (“Kingswood”). The offeringwas consummated on July 10, 2020, whereby the Company sold 1,369,863 shares of Common Stock and a fully exercised Underwriters’over-allotment option of 205,479 additional shares the public offering price of $7.30 per share. No warrants were issued in thisOffering. The net proceeds to the Company from the offering was approximately $10.53 million after deducting underwriting discountsand commissions and other estimated offering expenses payable by the Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 31, 2020, the Company entered intoan At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and Kingswood CapitalMarkets, a division of Benchmark Investments, Inc. (each a “Sales Agent” and collectively, the “Sales Agents”),pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of Common Stock (the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATM Offering”). Salespursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannotprovide any assurances that it will issue any Shares pursuant to the Sales Agreement. Actual sales will depend on a variety offactors to be determined by the Company from time to time, including (among others) market conditions, the trading price of theCompany’s Common Stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company.The Company is not obligated to make any sales of Common Stock under the Sales Agreement and the Company cannot provide any assurancesthat it will issue any shares pursuant to the Sales Agreement. The Company will pay a commission rate of up to 3.5% of the grosssales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursementsof its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales Agents an amount not to exceed $2,500per quarter during the term of the Sales Agreement for legal fees to be incurred by the Sales Agents. The Company has also agreedpursuant to the Sales Agreement to provide each Sales Agent with customary indemnification and contribution rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company hasincurred significant operating losses since its inception resulting in an accumulated deficit of $105,563,124 at June 30,2020. For the year ended June 30, 2020, the Company had a net loss of $13,446,538. Such losses are expected to continue forthe foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations.The Company believes that it has several important milestones that it will be achieving in the ensuing year. Management believesthat as it achieves these milestones, the Company’s ability to raise additional funds in the public markets would be enhanced.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management believes that the Company’sexisting resources will be sufficient to fund the Company’s planned operations and expenditures through October 2021. However,the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletionof its capital resources more rapidly than it currently anticipates. The accompanying audited financial statements do not includeany adjustments that may result from the outcome of such unidentified uncertainties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 83; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          83          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Results of Operations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is a biopharmaceutical companyand does not have any revenue for the years ended June 30, 2020, 2019 and 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Comparison of the Year End June 30,2020 to the Year Ended June 30, 2019         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Revenues          </i>         </b>        </font>        - The Company is a non-revenue producing entity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OperatingExpenses          </i>         </b>        </font>        - Research and development expenses for the year ended June 30, 2020 decreased $1,226,196 to $4,695,524from $5,921,720 for the year ended June 30, 2019. This year-to-year decrease is generally attributable to a decrease in labsupplies and chemicals, and a decrease in employee compensation expenses and by a decrease in lab fees for pre IND studies. Generaland administrative expenses increased $562,973 to $3,300,935 for the year ended June 30, 2020 from $2,737,962 for the yearended June 30, 2019. The increase in general and administrative expenses is generally attributable to an increase in legaland professional expenses offset by a decrease in salary and stock compensation paid to retired executive officers and to employeesother than research scientists and a decrease in consultants costs unrelated to research and development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           InterestIncome          </i>         </b>        </font>        - Interest income was $17,079 and $55,497 for the years ended June 30, 2020 and 2019, respectively.Interest income decreased due to lower cash and cash equivalents for the majority of the year ended June 30, 2020 as well as lowerinterest rates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           InterestExpense-          </i>         </b>        </font>        The Company has incurred interest expense of $93,670 and $0 for the years ended June 30, 2020 andJune 30, 2019, respectively. The increase is as a result of interest paid on the mortgage note, amortization of the mortgageloan origination fee, and interest paid on a short term loan payable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Losson issuance of Series A preferred stock for accounts payable – related party –          </i>         </b>        </font>        Loss of $142,669for the year ended June 30, 2020 represents the difference on the exchange of 100,000 shares of Series A preferred stock with afair value of $392,669 for $250,000 of previously deferred development fees owed to Theracour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Gainon Warrant Settlement-          </i>         </b>        </font>        For the year ended June 30, 2020, the gain on warrant settlement resulted from an ExchangeAgreement with certain Investors pursuant to a Settlement Agreement with the same investors. The Investors exchanged 347,222 oldwarrants for 647,224 shares of common stock and 347,222 new warrants. The aggregate fair value of the common stock and New Warrantsissued as part of the Exchange Agreement was $7,788,968. The Old Warrants were remeasured to a fair value of $8,403,462 on January 24,2020 immediately prior to the exchange. As a result of the Exchange Agreement, a gain on warrant settlement was recognized in theamount of $614,494 calculated as the difference between the fair value of the Old Warrants immediately prior to the exchange andthe aggregate fair value of the common stock and New Warrants issued in the exchange.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Changein fair value of derivative          </i>         </b>        </font>        - Change in fair value of derivative for the year ended June 30, 2020 decreased$6,025,058 to ($5,845,313) from $179,745 for the year ended June 30, 2019. For the year ended June 30, 2020, the changein fair value of derivatives resulted from an Exchange Agreement with certain Investors pursuant to a Settlement Agreement withthe same investors. For the year ended June 30, 2019, the change in the fair value of derivative liabilities was calculatedprimarily on the change in fair value of 5.5 year warrants issued on February 27, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           IncomeTaxes          </i>         </b>        </font>        <b>         -        </b>        There is no provision for income taxes due to ongoing operating losses. As of June 30, 2020,we had estimated cumulative tax benefits and development tax credits and other deferred tax credits resulting in a deferred taxasset of $35,089,911. This amount has been offset by a full valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 84; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          84          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           NetLoss          </i>         </b>        </font>        - For the year ended June 30, 2020, the Company had a net loss of $13,446,538, or a basic and fully dilutedloss per share of $2.39 compared to a net loss of $8,424,440, or a basic and fully diluted loss per share of $2.35 for the yearended June 30, 2019. The increase in the Company’s net loss for the year ended June 30, 2020 from the year endedJune 30, 2019 of $5,022,098 is generally attributable to the change in fair value of derivatives, and an increase in generaland administrative expenses, offset by a decrease in research and development costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Comparison of the Year End June 30,2019 to the Year Ended June 30, 2018         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Revenues          </i>         </b>        </font>        - The Company is a non-revenue producing entity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OperatingExpenses          </i>         </b>        </font>        - Research and development expenses for the year ended June 30, 2019 increased $8,000 to $5,921,720from $5,913,720 for the year ended June 30, 2018. This year-to-year increase is generally attributable to an increase in labsupplies and chemicals, and a decrease in employee compensation expenses offset by increases in lab fees for pre IND studies. Generaland administrative expenses decreased $673,487 to $2,737,962 for the year ended June 30, 2019 from $3,411,449 for the yearended June 30, 2018. The decrease in general and administrative expenses is generally attributable to a decrease in salaryand stock compensation paid to retired executive officers and to employees other than research scientists, a decrease in consultantscosts unrelated to research and development offset by an increase in legal, and professional expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OtherIncome (Expenses)          </i>         </b>        </font>        - Interest income was $55,497 and $100,429 for the years ended June 30, 2019, and 2018, respectively.Interest income included interest on cash or cash equivalent deposits in interest-bearing account. Interest income decreased dueto a decrease in deposits. The Company has incurred interest expense of $0 and $185,274 for the years ended June 30, 2019and June 30, 2018, respectively. The decrease was due to the redemption of the Series B Debentures at maturity, and theSeries C Debentures pursuant to a redemption agreement. The Company amortized the discount on its Series B and Series CDebenture, which were calculated at issuance. The Company recognized an amortization of bond discount expense of $0 and $359,214for the years ended June 30, 2019 and 2018, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Changein fair value of derivative          </i>         </b>        </font>        - Change in fair value of derivative for the year ended June 30, 2019 decreased$2,374,275 to $179,745 from $2,554,020 for the year ended June 30, 2018. The decrease was due to the reduction of the fairvalue of derivative liability in the fiscal year ending June 30, 2018 of the obligation to issue shares related to the redemptionof the Company’s Series C Convertible Debenture of $819,994, a change of the fair value of the derivative liabilityof the Series C Convertible Debenture, and a change of the fair value in the derivative liabilities of the Company’swarrants expiring September 12, 2018 and January 14, 2019. For the year ended June 30, 2019, the change in the fairvalue of derivative liabilities was calculated primarily on the change in fair value of 5.5 year warrants issued on February 27,2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           IncomeTaxes          </i>         </b>        </font>        <b>         -        </b>        There is no provision for income taxes due to ongoing operating losses. As of June 30, 2019,we had estimated cumulative tax benefits and development tax credits and other deferred tax credits resulting in a deferred taxasset of approximately $34,157,707. This amount has been offset by a full valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           NetLoss          </i>         </b>        </font>        - For the year ended June 30, 2019, the Company had a net loss of $8,424,440, or a basic and fully dilutedloss per share of $2.35 compared to a net loss of $8,563,455, or a basic and fully diluted loss per share of $2.64 for the yearended June 30, 2018. The decrease in the Company’s net loss for the year ended June 30, 2019 from the year endedJune 30, 2018 of $139,015 is generally attributable to the decrease in general and administrative expenses, decreases in interestexpenses, and discount on convertible debentures, offset by the net of a Loss on extinguishment of debt and change in fair valueof derivatives for the year ended June 30, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Liquidity and Capital Reserves         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company had cash and cash equivalentsof $13,708,594 and $2,555,207 as of June 30, 2020 and 2019, respectively. On the same dates, current liabilities outstandingtotaled $2,156,377 and $2,848,153, respectively. As of June 30, 2020, the total current liabilities included a mortgage note payable-relatedparty of $1,081,987 and loan payable of $62,843. As of June 30, 2020 and 2019, the derivative liability associated with itsoutstanding warrants was reported as a current liability of $0 and $1,645,606, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 85; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          85          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since inception, the Company has expendedsubstantial resources on research and development. Consequently, we have sustained substantial losses. The Company has an accumulateddeficit of $105,563,124 and $92,116,586 at June 30, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company anticipatesseveral important milestones that it will be achieving in the ensuing year. Management believes that as it achieves these milestones,the Company’s ability to raise additional funds in the public markets would be enhanced.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management believes that the Company’sexisting resources will be sufficient to fund the Company’s planned operations and expenditures through October, 2021. However,the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletionof its capital resources more rapidly than it currently anticipates. The accompanying audited financial statements do not includeany adjustments that may result from the outcome of such unidentified uncertainties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, we have a cashand cash equivalent balance of $13,708,594 that is expected to be sufficient to fund our currently budgeted operations for morethan one year from the filing of the Company’s Form 10K. Additionally,        <font style="background-color: white">         onJuly 8, 2020, subsequent to the date of the reporting period, the Company entered into an underwriting agreement (the “UnderwritingAgreement”) with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. (“Kingswood”). The offeringwas consummated on July 10, 2020, whereby the Company sold 1,369,863 shares of Common Stock and a fully exercised Underwriters’over-allotment option of 205,479 additional shares the public offering price of $7.30 per share. No warrants were issued in thisOffering. The net proceeds to the Company from the offering was approximately $10.53 million after deducting underwriting discountsand commissions and other estimated offering expenses payable by the Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Research and Development Costs        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company does not maintain separateaccounting line items for each project in development. The Company maintains aggregate expense records for all research and developmentconducted. Because at this time all of the Company’s projects share a common core material, the Company allocates expensesacross all projects at each period-end for purposes of providing accounting basis for each project. Project costs are allocatedbased upon labor hours performed for each project.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has signed several cooperativeresearch and development agreements with different agencies and institutions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company expects to enter into additionalcooperative agreements with other governmental and non-governmental, academic, or commercial, agencies, institutions, and companies.There can be no assurance that a final agreement may be achieved and that the Company will execute any of these agreements. However,should any of these agreements materialize, the Company will implement a system to track these costs by project and account forthese projects as customer-sponsored activities and show these project costs separately.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following Table 4 summarizes the primarycomponents of our research and development expenses as allocated, during the periods presented in this Annual Report on Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 86; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          86          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Table 4: R&amp;D Cost Allocations        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; text-align: center">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year Ended             <br/>             June 30, 2020            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year Ended             <br/>             June 30, 2019            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year Ended             <br/>             June 30, 2018            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 61%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HerpeCide™    Program. Herpes Simplex virus infections (HSV-1, HSV-2) and VZV Indications: Cold Sores, Genital Ulcers, Shingles and    ARN           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,131,724           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,601,720           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,723,720           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Covid -19           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,563,800           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All Influenzas: FluCide™           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            HIV-Cide™           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            EKC-Cide™, other Eye Viral Infections           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dengue           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other (Ebola, and other projects)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Unallocated stock compensation           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150,000           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,000           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 9pt; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Total           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,695,524           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,921,720           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,913,720           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Anticipated Budgets and Expenditures in the Near Future        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has ended the year on a reasonablefinancial footing by controlling costs and expenditures. We project that ourcurrent available financing is sufficient for accomplishing the goal of filing one IND or equivalent regulatory applications. Wewill need additional financing to execute on our business plan and to complete human clinical trials of our drug candidates intodrug approval. Our Coronavirus drug candidate is entering IND-enabling studies, and is expected to rapidly move into human clinicalstudies in response to the COVID-19 pandemic. Our Shingles Skin Cream, is in IND-writing and Clinical Trials Design stage, andwe intend to file an IND for this drug once the COVID-19 situation abates. At present, we are working on the scale up of manufacturingof these drug candidates in a manner that will be compliant with US FDA cGMP and corresponding ICH guidelines. We intend to requesta pre-IND meeting with the USFDA for the Coronavirus drug candidate at an appropriate time, as we develop the dataset for thisdiscussion. A pre-IND meeting will help us determine the level of detail needed in the cGLP Safety/Toxicology study required forthe IND application, and also to refine our human clinical trials design. We anticipate that these drug candidates will move forwardinto IND or equivalent regulatory filings, and ensuing human clinical trials. As these drug candidates are advancing into the clinic,we believe that our additional drug candidates, including two or more drug candidates in the HerpeCide program will also move forwardinto IND-enabling studies. We intend to further re-engage our FluCide and HIVCide drug development programs once we have establishedour platform technology with the Coronavirus and HerpeCide program drug candidates. We are thus poised for strong growth with anumber of drug candidates in a number of disease indications.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Financings        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management engaged in efforts to raisefinancing in September 2019. On September 24, 2019, the Company effected a reverse stock split of its outstanding shares of commonstock and shares of preferred stock at a ratio of one for twenty (the “Reverse Stock Split”). The Reverse Stock split,which was approved by the Company’s Board of Directors under authority granted under the laws of the State of Nevada, wasconsummated pursuant to a Certificate of Amendment filed with the Secretary of State of Nevada on September 23, 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 16, 2019, the Company enteredinto an Open End Mortgage Note (the “Note”) with Dr. Anil Diwan, the Company’s founder, Chairman and President,to loan the Company up to $2,000,000 in two traches of $1,000,000 (the “Loan”). The Note bears interest at a rate of12% per annum and is secured by a mortgage granted against the Company’s headquarters. Dr. Anil Diwan received 10,000 sharesof the Company’s Series A preferred stock as a loan origination fee. As of June 30, 2020, the Company has drawn down $1.1million on this loan. On April 30, 2020, the Company and Dr. Diwan have mutually agreed to extend the maturity date of the note,at the Company’s option, to May 15, 2021, with the rest of the terms remaining the same.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 17, 2019, the Company enteredinto a Deferred Expense Exchange Agreement with TheraCour, whereby the Company and TheraCour agreed to exchange 100,000 sharesof Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred development fees owed to TheraCour.The Company recognized a loss on the exchange of $142,669. Dr. Diwan is principal shareholder of TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These two transactions together provided a much needed cashinfusion of up to $2.3 million to the Company at a critical time. There were no agents or brokers in these transactions and nocommissions or agency fees were paid other than legal and regulatory fees. Dr. Diwan, being a party with interest, recusedhimself from, and was not present at, the discussions and negotiations of the independent members of Company’s Board of Directorson both of these transactions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 24, 2020, the Company announcedin a press release that it had completed an underwritten public offering (the “Offering”) with gross proceeds of $8,625,000before deducting underwriting discounts and other estimated offering expenses. The Offering included 2,500,000 shares of the Company’scommon stock, and 375,000 additional shares from the exercise of the underwriter’s option to purchase to cover over-allotmentsat the public offering price of $3.00 per share. No warrants were issued in this Offering. The net proceeds to the Company Afterdeducting offering costs was $7,457,575.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 26, 2020, the Company announced in a press releasethat it had raised $10,220,000 in gross proceeds from the sale of 1,400,000, shares of common stock, at a price of $7.30 per share,in a previously announced registered direct offering (the “May Offering”). No warrants were issued in this May Offering.The net proceeds to the Company were approximately  $9,219,400 after deducting placement agent fees and other costs. The MayOffering closed on May 22, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        With these financings and continued controlof expenditures, the Company ended the current fiscal year with approximately $13.7 million in cash and cash equivalents,and $9.5 million in property and equipment, net of accumulated depreciation. As of June 30, 2020, the Company had a mortgage notepayable-related party of approximately $1.1 million and a loan payable of approximately $60,000 that will mature on December 15,2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 87; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          87          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On July 8, 2020, subsequent to the date of the reporting period,the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Kingswood Capital Markets, aDivision of Benchmark Investments, Inc. (“Kingswood”). The offering was consummated on July 10, 2020, whereby the Companysold 1,369,863 shares of Common Stock and a fully exercised Underwriters’ over-allotment option of 205,479 additional sharesthe public offering price of $7.30 per share. No warrants were issued in this Offering. The net proceeds to the Company from theoffering was approximately $10.53 million after deducting underwriting discounts and commissions and other estimated offering expensespayable by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company thus believes that it is ina strong financial position now and can undertake the COVID-19 clinical program, and also, when opportune, reengage the NV-HHV-101clinical program. The Company also believes that additional non-dilutive financing will be available under the COVID-19 programupon advancing it further toward or into human clinical trials. The Company also believes that due to the pandemic, it will bepossible to rapidly take our anti-coronavirus drug into human clinical trials under the COVID-19 regulatory pathways of the USFDA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Requirement for Additional Capital        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, we had a cashand cash equivalent balance of $13,708,594 that is expected to be sufficient to fund our currently budgeted operations for morethan one year from the filing of the Company’s Form 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On July 8, 2020, subsequent to the date of the reporting period,the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Kingswood Capital Markets, aDivision of Benchmark Investments, Inc. (“Kingswood”). The offering was consummated on July 10, 2020, whereby the Companysold 1,369,863 shares of Common Stock and a fully exercised Underwriters’ over-allotment option of 205,479 additional sharesthe public offering price of $7.30 per share. No warrants were issued in this Offering. The net proceeds to the Company from theoffering was approximately $10.53 million after deducting underwriting discounts and commissions and other estimated offering expensespayable by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 31, 2020, the Company entered intoan At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and Kingswood CapitalMarkets, a division of Benchmark Investments, Inc. (each a “Sales Agent” and collectively, the “Sales Agents”),pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of Common Stock (the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATM Offering”). Salespursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannotprovide any assurances that it will issue any Shares pursuant to the Sales Agreement. Actual sales will depend on a variety offactors to be determined by the Company from time to time, including (among others) market conditions, the trading price of theCompany’s Common Stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company.The Company is not obligated to make any sales of Common Stock under the Sales Agreement and the Company cannot provide any assurancesthat it will issue any shares pursuant to the Sales Agreement. The Company will pay a commission rate of up to 3.5% of the grosssales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursementsof its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales Agents an amount not to exceed $2,500per quarter during the term of the Sales Agreement for legal fees to be incurred by the Sales Agents. The Company has also agreedpursuant to the Sales Agreement to provide each Sales Agent with customary indemnification and contribution rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company believes that our cash andcash equivalent balance and the proceeds from the aforesaid Securities Purchase Agreement will provide sufficient funds for usto continue our operations beyond October, 2021 and to be able to advance at least one of its drug candidates into human clinicaltrial stage with the available cash. The Company estimates that it will need additional funding to continue further developmentof its drug candidates through later stages of human clinical trials if it does not form a collaborative licensing or partnershipagreement with a party that would provide such funding  such as Big Pharma.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Based on our current rate ofexpenditures and anticipated changes, we have estimated a total cash expenditure budget of approximately $16 million fromOctober 2020 through October  2021, of which approximately $12.0 million is expected to go towards research anddevelopment for our drug candidates, including IND-enabling studies and anticipated human critical trial of our antiviraltreatment for COVID, and approximately $4.0 million is budgeted for general and administrative expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        These anticipated expenses for the ensuing one year period commencingabout October 16, 2021 can be summarized as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            1.           </font>          </td>          <td style="text-align: justify">           Planned Research and Development Costs of $5,000,000: Planned costs for in vivo and in vitro studies for the Coronavirus programindications, the VZV (Shingles) drug development program, and other indications in HerpeCide program, indications in FluCide program,Eye Nanoviricide, DengueCide, and HIVCide, and Other programs (see Table 2). This includes staffing costs of approximately $2,500,000,for the scientific staff and consulting firms to assist with FDA compliance, material characterization, pharmaco-kinetic, pharmaco-dynamicand toxicology studies, and other items related to FDA compliance, as required for development of necessary data for filing anInvestigational New Drug with the United States Food and Drug Administration.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.25in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            2.           </font>          </td>          <td style="text-align: justify">           Clinical Trial Manufactured Batch of Drug Product approximately $2,000,000 for Phase 1 and 2a for the first Coronavirus (COVID-19)program drug candidate.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.25in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            3.           </font>          </td>          <td style="text-align: justify">           Anticipated Clinical Trial Costs for the COVID-19 drug candidate of approximately $5,000,000 for Phase 1 and 2a. We anticipatethat these clinical trials will be designed with the goal of an emergency use approval during the current pandemic provided itcontinues to persist. We may need to modify the program to seek full-fledged approval for our broad-spectrum coronavirus drug candidateif the pandemic is resolved by the time we are completing Phase 2a human clinical trials of this drug candidate.          </td>         </tr>        </tbody>       </table>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.25in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            4.           </font>          </td>          <td style="text-align: justify">           Corporate overhead of $3,000,000: This amount includes budgeted office salaries, legal, accounting, investor relations, publicrelations, business development, and other costs expected to be incurred by being a public reporting company.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 0.25in">          </td>          <td style="text-align: justify; width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            5.           </font>          </td>          <td style="text-align: justify">           Capital costs of $1,000,000: This is the estimated cost for additional equipment and laboratory improvements.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        Thereafter, we estimate that beyond the current budgetaryone-year period ending October 15, 2021, over the following two years for human clinical development of the Skin Creamfor Topical Treatment of Shingles, for further clinical studies towards full-fledged approval of our Coronavirus drugcandidate as may be necessary, and for developing additional drug indications based on the Shingles skin cream candidate,NV-HHV-101, in the HerpeCide program, we  may need approximately an additional $24 million, or approximately $16 million more than our current cash reserves. The additional funds will be needed to pay additional, subcontract costsrelated to the expansion and further development of our drug pipeline, for human clinical trials, and for additional capitaland operational expenditures       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These anticipated additional expenses forthe two-year period commencing October 16, 2021 can be summarized as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            1.           </font>          </td>          <td style="text-align: justify">           Planned Research and Development Costs of $10,000,000: Planned costs for additional indicationsin HerpeCide program, indications in FluCide program, Eye Nanoviricide, DengueCide, and HIVCide, and Other programs (see Table2). This includes staffing costs of approximately $5,000,000, for the scientific staff and consulting firms to assist with FDAcompliance, material characterization, pharmaco-kinetic, pharmaco-dynamic and toxicology studies, and other items related to FDAcompliance, as required for development of necessary data for filing an Investigational New Drug with the United States Food andDrug Administration.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            2.           </font>          </td>          <td style="text-align: justify">           Clinical Trial Manufactured Batch of Drug Product approximately $2,000,000 for Phase 1 and 2a forthe VZV Shingles program drug candidate.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            3.           </font>          </td>          <td style="text-align: justify">           Clinical Trials Costs budgeted at $5,000,000 for the Skin Cream for Shingles.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            4.           </font>          </td>          <td style="text-align: justify">           Corporate overhead of $5,000,000.          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            5.           </font>          </td>          <td style="text-align: justify">           Capital costs for laboratory and pilot manufacturing equipment of $2,000,000.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            6.           </font>          </td>          <td style="text-align: justify">           As our programs mature and as we are able to move additional drug candidates into human clinicaltrials we will continue to require additional funding for such activities. As a rule of thumb, we estimate that, for each drugcandidate that goes into clinical trials, if Phase I and Phase II are successful, we anticipate approximately $10 million for PhaseIII human clinical trials for that drug candidate to enable us to file a New Drug Application (NDA) with the US FDA for obtainingmarketing approval. These estimates are based on rough quotes from potential investigators, and assumptions relative to additionalcosts. These estimates assume that our drug candidates are highly effective and therefore would require relatively few patientsin each arm of the each trial in order to establish statistically significant results.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that as we become a clinicalstage company, and as our programs mature towards FDA approval, the Company’s market capitalization should improve substantially,based on market capitalizations of comparable public companies in clinical stages. If so, we believe that we will be able to raisethe additional necessary funds through public financings as needed. We believe that our coronavirus program is maturing rapidlytowards human clinical trials, and if we are successful in achieving an emergency use approval for a coronavirus drug candidate,we may be able to generate substantial revenues during the current pandemic using our existing cGMP-capable manufacturing capacityitself.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 88; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          88          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe we have sufficient funding fortaking both a Coronavirus drug candidate and our NV-HHV-101 skin cream for the treatment of Shingles rash into initial human clinicaltrials. We will need to raise additional funds to take additional Topical HerpeCide drug candidate indications into an IND applicationstage. There is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Companyto fund these programs. Management believes that as a result of the management plan, the Company’s existing resourcesand access to the capital markets will permit the Company to fund planned operations and expenditures. However, the Company cannotprovide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capitalresources more rapidly than it currently anticipates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has limited experience withpharmaceutical drug development. Thus, our budget estimates are not based on experience, but rather based on advice given by ourassociates and consultants. As such these budget estimates may not be accurate. In addition, the actual work to be performed isnot known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additionalwork may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget.Such changes may also have an adverse impact on our projected timeline of drug development.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the coming year’sworkplan will lead us to obtain certain information about the safety and efficacy of some of the drugs under development in animalmodels and very likely, our coronavirus drug candidate in human clinical trials. If our studies are not successful, we will haveto develop additional drug candidates and perform further studies. If our studies are successful, then we expect to be able toundertake further studies in animal models to obtain necessary data regarding the pharmaco-kinetic and pharmaco-dynamic profilesand further human clinical studies, expanding into Phase 2b, and Phase 3 human clinical trials of our drug candidates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 89; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          89          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our strategy is to minimize capital expenditure.We therefore rely on third party collaborations for the testing of our drug candidates. We continue to engage with our previouscollaborators.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our animal efficacy studies as well assafety/toxicology studies are performed by third parties. We opt into drug developments against specific disease indications forwhich we have appropriate partners that can perform the necessary cell culture and animal efficacy studies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company reports summaries of its studiesas the data becomes available to the Company, after analyzing and verifying same, in its press releases. The studies of biologicaltesting of materials provide information that is relatively easy to understand and therefore readily reported. In addition, wecontinue to engage in substantial work that is needed for the optimization of synthesis routes and for the chemical characterizationof the nanoviricide drug candidates. We also continue to work on improving the drug candidates and the virus binding ligands wherenecessary. We continue to work on creating the information needed for the development of controlled chemical synthesis proceduresthat is vital for developing c-GMP manufacturing processes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We cannot accurately project the timelineof when we would be able to take a drug candidate into clinical studies, nor can we predict when we may be able to achieve ourfirst drug approval, if any. As such we do not provide any guidance on expected timelines. The Company has no experience in havingtaken a single drug through the US FDA or any international drug approval process as of now. As such, we may not be able to estimatethe time or cost of these studies accurately. However, we try to do our best by using expert consultants and preparing reasonableestimates based on quotations from various contract research organizations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our timelines depend upon several assumptions,many of which are outside the control of the Company, and thus are subject to delays.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management intends to use capital and debtfinancing, as required, to fund the Company’s operations. There can be no assurance that the Company will be able to obtainthe additional capital resources necessary to fund its anticipated obligations for the next twelve months.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is considered to be a developmentstage company and will continue in the development stage until it generates revenues from the sales of its products or services.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Off Balance Sheet Arrangements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have not entered into any off-balancesheet arrangements during the year ended June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          CRITICAL ACCOUNTING POLICIES AND ESTIMATES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Accounting                                         for Stock Based Compensation         </i>        </b>        – The Company follows the provisions of        <i>         ASC                                         718 – Stock Compensation        </i>        , which requires the measurement of compensation expense                                         for all shared-based payment awards made to employees, non-employee directors, and non-employees                                         including employee stock options. Shared-based compensation expense is based on the grant                                         date fair value estimated in accordance with the provisions of ASC 718 and is generally                                         recognized as an expense over the requisite service period, net of forfeitures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 90; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          90          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         RECENT ACCOUNTING PRONOUNCEMENTS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Recently Issued Accounting Pronouncements         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting,”which simplifies the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 appliesto all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’sown operations by issuing share-based payment awards. The Company’s adoption of this ASU as of July 1, 2019 had no impacton the financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In July 2017, the FASB issued AccountingStandards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity(Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II.Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and CertainMandatorily Redeemable Non-controlling Interests with a Scope Exception (“ASU 2017-11”) ASU 2017-11 revises the guidancefor instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity,which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivativeaccounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down roundfeatures are no longer classified as liabilities. The Company has adopted ASU 2017-11 retrospectively as of January 1, 2019. Theadoption of this ASU did not have any impact on its financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_011">          </a>          ITEM 7A. QUANTITATIVE AND QUALITATIVEDISCLOSURES ABOUT MARKET RISK         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is not exposed to market riskrelated to interest rates on foreign currencies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_012">          </a>          ITEM 8. FINANCIAL STATEMENTS ANDSUPPLEMENTARY DATA         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The information required by Item 8 appearsafter the signature page to this report.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_013">          </a>          ITEM 9. CHANGES IN AND DISAGREEMENTSWITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="text-transform: uppercase">         <b>          <u>           <a name="c_014">           </a>           Item9A. Controls and Procedures.          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         <u>          Evaluation of Disclosure Controls and Procedures         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Disclosure controls and procedures (asdefined in Rules 13a-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended (the “ExchangeAct”) are controls and other procedures that are designed to ensure that information required to be disclosed by us in thereports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specifiedin the rules and forms of the Securities and Exchange Commission (the “SEC”). Disclosure controls and proceduresinclude, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reportsthat we file under the Exchange Act is accumulated and communicated to our management including our chief executive officer andour chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluatingthe disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed andoperated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitation ofcontrols systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-makingcan be faulty and that breakdowns can occur because of a simple error or mistakes. Additionally, controls can be circumvented bythe individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls andprocedures can only provide reasonable, not absolute, assurance that the above objectives have been met.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 91; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          91          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, an evaluationwas carried out under the supervision and with the participation of our management, of the effectiveness of our disclosure controlsand procedures (as defined in Rule 13a-15(e) and Rule 15d-15(f) under the Securities Exchange Act of 1934).Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosurecontrols and procedures are not effective as of June 30, 2020 because of a material weakness in our internal control over financialreporting described below.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Management’s Report on Internal Control Over FinancialReporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management is responsible for establishingand maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) underthe Exchange Act. Under the supervision and with the participation of management, including our Chief Executive Officer and ChiefFinancial Officer, we conducted an evaluation of the effectiveness, as of June 30, 2020, of our internal control over financialreporting based on the framework in 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizationsof the Treadway Commission. Based on our evaluation under this framework, our management concluded that our internal control overfinancial reporting was not effective as of June 30, 2020 due to the material weakness described below :       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management did not maintain effective procedurespertaining to the review of the 10-K. The material weakness resulted from the lack of timely and effective review of the Company’speriod-end closing process and adequate personnel and resources. Specifically, the Company has established procedures for thoroughreview by management,  on a timely basis, of Form 10-K and other filings. Management’s responsibility isto oversee that the Company is capable of developing accurate and timely financial information. The Company must continue to reinforceadditional procedures ensuring that Form 10-K as well as other required filings are done on a timely and accurate basis.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Changes in Internal Control over FinancialReporting        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following changes in our internal controlover financial reporting during the quarter ended June 30, 2020 have materially affected, or are reasonably likely to materiallyaffect, our internal control over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management previously reported a materialweakness in our internal control over financial reporting in our 2019 Form 10-K, filed on August 23, 2019, related tothe review of all financial transactions including engagement of outside specialists to evaluate our financial transactions andto assist the preparation of the Company’s tax provisions and Company’s personnel in preparing the Company’sincome tax provision footnote.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We remediated the material weaknesses by,among other things, implementing a process of enhanced review of all financial transactions including engagement of outside specialiststo evaluate our financial transactions as they arise. The actions that we are taking are subject to ongoing senior managementreview and Audit Committee oversight.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company engaged outside tax counselto assist in the preparation of the Company’s tax provisions and Company’s personnel in preparing the Company’sincome tax provision footnote.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        We believe that the previously reported material weakness relatedto the third party valuation reports and income taxes has been remediated as of June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Remediation Plan        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has established a financialreporting controls committee comprised of members of senior management and a member of the Audit Committee of the Board of Directors.The committee will provide oversight to the Company’s efforts for ensuring appropriate internal control over financial reportingincluding, but not limited to, remediation of the aforesaid material weakness and identifying and testing for potential internalcontrol weakness in the financial reporting process to assure reliability and accuracy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management believes the foregoing effortswill effectively remediate the material weakness identified above. As we continue to evaluate and work to improve our internalcontrol over financial reporting, management may execute additional measures to address potential control deficiencies or modifythe remediation plan described above and will continue to review and make necessary changes to the overall design of our internalcontrols       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Other than was described above, there were no material changesin our system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934)during the quarter ended June 30, 2020 that has materially affected, or is reasonably likely to materially affect, our internalcontrol over financial reporting.       </p>       <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          I          <font style="text-transform: uppercase">           <a name="c_015">           </a>           TEM9B. Other Information          </font>         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 92; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          92          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_016">          </a>          ITEM 10. DIRECTORS, EXECUTIVE OFFICERS,PROMOTERS AND CORPORATE GOVERNANCE         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table sets forth the namesand ages of our current directors and executive officers, their principal offices and positions and the date each such person becamea director or executive officer. Each executive officer holds the office until he/she resigns, is removed by the Board or his/hersuccessor is appointed by the Board upon appropriate due diligence. Directors are elected biannually by our stockholders at theannual meeting. Each director holds his/her office until the successor is elected and qualified or his/her earlier resignationor removal.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following persons are the directorsand executive officers of our company:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="width: 30%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="width: 2%">          </td>          <td style="width: 10%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="width: 2%">          </td>          <td style="width: 56%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Title            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Anil Diwan, PhD.           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President; Chairman of the Board, CEO           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stanley Glick, CPA           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            84           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director, Independent           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Makarand “Mak” Jawadekar           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            69           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director, Independent           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Theodore Edward (“Todd”) Rokita           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director, Independent           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Meeta Vyas           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62           </font>          </td>          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s directors are electedbiannually and serve until their term expires, and may be re-elected for an additional term at the annual meeting of shareholders.The executive officers that become members of the Board of Directors are elected via biennial election and serve as director throughthe term, and may be re-elected for an additional term at the annual meeting of shareholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          AnilDiwan, PhD,         </b>        </font>        age 62, has been President and the Chairman of the Board of Directors of the Company sinceconsummation of the merger on June 1, 2005. Dr. Diwan simultaneously therewith and since its formation, has alsoserved as the Chief Executive Officer and Director of AllExcel, Inc. (from 1995 to the present) and TheraCourPharma, Inc. (from 2004 to the present) and is the original inventor of the technologies licensed to NanoViricides Inc.,as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched anddeveloped TheraCour nanomaterials. Dr. Diwan was the first to propose the development of novel pendant polymers for drugdelivery that led to an explosion of research in pharmacological applications of polymeric micelles. Dr. Diwan has wonover 12 NIH SBIR grants. Dr. Diwan holds several issued patents, and three PCT international patent applications invarious stages of prosecution in a number of countries, and also has several additional patentable discoveries.Dr. Diwan has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination ofall IIT’s. He holds a Ph.D. in Biochemical Engineering from Rice University (1986) and B.S. in Chemical Engineeringfrom Indian Institute of Technology (IIT) Bombay (1980). We concluded Dr. Diwan’s experience plus his status ascreator of the Company’s technologies render him uniquely qualified to serve in these capacities.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          StanleyGlick, CPA,         </b>        </font>        age 84, was appointed as an independent Director and as chair of the Audit Committee of the Companyon June 22, 2013. Mr. Glick has over forty years of experience in his long career of providing auditing, accounting,tax, and management advisory services, to clients in various industries. Mr. Glick has been a member of several Boards ofDirectors for not-for-profit organizations in the Westport, CT area. In particular, he has served as a Director and member of AuditCommittee of “A Better Chance” of Westport, CT, from 2000 to 2005. From 1977 until present, Mr. Glick has managedan independent practice as a Certified Public Accountant in Connecticut and New York States. Prior to forming his own CPA firm,Mr. Glick was employed by local and regional CPA firms where he performed and supervised audits and financial reporting. Mr. Glickis a member of the American Institute of Certified Public Accountants, The Connecticut Society of Certified Public Accountants,and the New York State Society of Certified Public Accountants. He holds a Bachelor of Business Administration degree in Accountingfrom Baruch College of Business (now Baruch College of the City University of New York). Mr. Glick is married and lives inTrumbull, CT. We concluded that Mr. Glick’s broad business, accounting and auditing experience meets the criteria ofan independent director and an “Audit Committee Financial “expert”. Mr. Glick’s appointment as an independentdirector and audit committee chairman, significantly improves the Company’s financial oversight and management.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 93; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          93          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           Makarand “Mak” Jawadekar, 69,          </i>         </b>        </font>        was appointed as an Independent Member of the Board of Directors, and willserve as a member of the Company’s Audit, Compensation and Nominating Committees. Dr. Jawadekar has over 35 yearsof experience in the pharma industry spanning both business and research activities. Dr. Jawadekar has extensiveexperience in joint ventures, alliance management, contracting, outsourcing, benchmarking, performance metrics,pharmaceutical research and development, drug delivery technologies, formulations, clinical supply manufacturing andpackaging, clinical trial materials, pharmaceutics, and pharmaceutical sciences. He also has deep knowledge and globalexperience working across the United States, Europe, India, and other parts of Asia, including Japan and China. He hashelped create several pharma R&amp;D partnerships, joint ventures, and collaborations during his career. Dr. Jawadekarserves as a strategic advisor to pharmaceutical and biotechnology companies through his independent consultancy, founded in2010, after retiring from Pfizer, Inc., as Director, Portfolio Management &amp; Analytics, and as Vice President,Asia Colleague Resource Group, in Pfizer Global R&amp;D division. From 1982 to 2010, Dr. Jawadekar held roles ofincreasing responsibility in technical, management, and business development positions at Pfizer, in the areas of DrugDelivery Technology Assessment, Strategic External Alliance Management, Strategic CMC, Pharma R&amp;D, ClinicalManufacturing, Manufacturing Technology Transfer and Scale-up, beginning as a research scientist in formulations development.Dr. Jawadekar serves on the boards of two public companies, namely: Preveceutical Medical Inc. (CSE: PREV), andCardax, Inc. (OTC: CDXI), as an independent board member. He also serves on the Strategic and Scientific Advisory Boardsof several companies, including Actinium Pharma (NYSE-Amer.: ATNM), Saama Technologies, Inc., and DiantPharma, Inc., as well as Tonino Lamborghini SpA, Italy. He also serves as a member of the Board of Directors atAbilities Inc., a New York based, non-profit organization. Mak holds a Ph.D. in Pharmaceutics from the University ofMinnesota, and was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India. TheCompany believes Dr. Jawadekar’s long history as a pharmaceutical and biotech professional, particularly inalliance development and management, in business strategy, and in pharmaceutical sciences and CMC in drug delivery, renderhim well qualified to serve as an independent member of the Board of Directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          <i>           TheodoreEdward (“Todd”) Rokita, 50, Director.          </i>         </b>        </font>        Mr. Rokita was appointed as an Independent Memberof the Board of Directors, and will serve as a member of the Company’s Audit, Compensation and Nominating Committees.Mr. Rokita currently serves as co-owner and General Counsel and Vice President of External Affairs, Apex BenefitsGroup, Inc. where he serves as a member of the executive team and the corporate board. He is responsible for legalstrategies, including litigation, acquisitions and other matters, primarily involving ERISA and employment laws, and isresponsible for the regulatory compliance of Apex’s clients. In his role, he serves as the public face of the companyand is responsible for external messaging, events, and other outreach functions. Mr. Rokita was elected to the UnitedStates Congress as a Representative from the State of Indiana, serving four terms from 2011 to 2019. As a member of the USCongress, he served as the Chairman, House Subcommittee on Early Childhood, Elementary, and Secondary Education, as the ViceChairman, House Committee on the Budget, as a Member, House Committee on Education and the Workforce (Health, Employment,Labor and Pensions subcommittee), as a Member, House Committee on Transportation and Infrastructure, (aviation, railroad, andpipeline subcommittees), as a Member, Committee on House Administration (2011-2014), as a Member, Steering Committee(2011-2012) (elected by peers to make their committee assignments), and also as a Director, Republican Study Committee (2014-2019) (group affecting policy direction and tactics). Prior thereto Mr. Rokita served as the Secretary ofState, Indiana, from 2003 to 2011) and as Chief Operating Officer and General Counsel, Office of Indiana Secretary ofState from 2000-2002. Mr. Rokita serves or has served as a Member of the Board of Directors on a number of commercialand charitable institutions, among them: Aircraft Owners and Pilots Association Foundation, (2014-Present); AchieveInternational, Indianapolis, IN (helping troubled teens), (2012-2018); Saint Vincent Hospital Foundation,(2011-2013); Indiana Council for Economic Education, (2004-2010). Mr. Rokita also serves or has served as an AdvisoryBoard Member for several institutions, among them: Merchandise Warehouse, Inc. Indianapolis, IN, (2019-Present);WishBone Medical, Inc., Warsaw, IN, (2019-Present); and Acel 360, Inc., Reston, VA Advisory Board member(2019-Present). Mr. Rokita has also served as a Member, Board of Trustees of Saint Joseph’s College,Rensselaer, IN, (2007-2017). In addition to his public service, Mr. Rokita is involved as a Volunteer for theVeterans Airlift Command and Angel Flight, Volunteer (2011- Present), actively flying missions for Veterans Airlift Commandand other similar non-profits dedicated to providing free air transportation to children and post-9/11 combat woundedveterans and their families for medical and other compassionate purposes. Mr. Rokita holds a Bachelor of Arts degreefrom Wabash College in Crawfordsville, Indiana, where he was an Eli Lilly Fellow and a Juris Doctor from IUPUI's IndianaUniversity Robert H. McKinney School of Law. The Company believes Mr. Rokita’s long history as an executive and asa board member of a number of institutions and his long record of public service, uniquely qualifies him to serve as a memberof the Company’s Board of Directors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 94; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          94          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Split-Segment; Name: a8 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         <b>          MeetaVyas, SB, MBA         </b>        </font>        , age 62, is known as a strong leader with board level experience and successful achievements as a SeniorExecutive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to largesize companies. Ms. Vyas has over twenty-five years of experience in performance and process improvement of both publiclylisted companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meetaholds the distinction of being the first Indian woman to be named CEO of a publicly listed U.S. corporation, Signature Brands, Inc.,best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairmanof the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resultingin Signature’s return to profitability and growth. Later, as the CEO of the World-Wide Fund for Nature - India (WWF-India)and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raisedunrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a varietyof performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementationplan for the highly successful information technology outsourcing program at General Electric (“GE”). Also at GE, Ms. Vyasran GE Appliances’ Range Products business unit having revenues exceeding $1 billion where her team doubled operating incomein less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companiesin chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations,and logistics operations. Ms. Vyas is married to Anil Diwan, the Company’s President and Chairman and principal shareholderof TheraCour Pharma, Inc. Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business,and a SB in Chemical Engineering from the Massachusetts Institute of Technology. We concluded that Ms. Vyas’ experienceand training render her qualified to serve as the Company’s Chief Financial Officer.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        AUDIT COMMITTEE       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2013, Stanley Glick, CPA waselected, as an independent member, to the Company’s Board of Directors and the Chair of the Company’s Audit Committee.Due to his education and extensive experience as a Certified Public Accountant, Mr. Glick meets the criteria of an independentdirector and an “Audit Committee Financial Expert” as provided in Release 33-8173 and 34-47235. In addition, on February 7,2020 Makarand “Mak” Jawadekar and on May 15, 2020 Theodore Edward (“Todd”) Rokita were appointed asindependent directors and members of the Audit Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        CODE OF ETHICS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have adopted a code of ethicsmeeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of ethics is reasonablydesigned to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandabledisclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provideaccountability for adherence to the provisions of the code of ethic. Our code of ethics is filed as an exhibit to thisForm 10-K.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 95; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          95          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_017">          </a>          ITEM 11. EXECUTIVE COMPENSATION         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table reflects all formsof compensation for the years ended June 30, 2020, 2019 and 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name and            </b>           </font>           <font style="font-size: 10pt">            <br/>            <b>             Principal            </b>            <br/>            <b>             Position            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Salary            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Bonus            </b>           </font>           <font style="font-size: 10pt">            <br/>            <b>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock            </b>           </font>           <font style="font-size: 10pt">            <br/>            <b>             Award(s)            </b>            <br/>            <b>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option            </b>           </font>           <font style="font-size: 10pt">            <br/>            <b>             Awards(#)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             All Other            </b>           </font>           <font style="font-size: 10pt">            <br/>            <b>             Compensation            </b>            <br/>            <b>             ($)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Total ($)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Anil Diwan           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            400,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            189,038           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            589,038           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CEO, President, Director           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            400,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            189,038           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            589,038           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            397,917           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            75,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            267,143           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            740,060           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Meeta Vyas           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129,600           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            20,869           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150,469           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CFO           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129,600           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            24,488           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            154,088           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129,600           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            75,381           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            204,980           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Irach Taraporewala           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ex-CEO           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            144,783           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            72,000           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,920           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,000           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            228,703           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: #CCEEFF">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="vertical-align: bottom; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Eugene Seymour,           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Ex-CEO, Ex-Director           </font>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2018           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            631,250           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            118,750           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            121,008           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            63,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            934,508           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table sets forth for eachnamed executive officer certain information concerning the outstanding equity awards as of June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name and             <br/>             Principal             <br/>             Position            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number of             <br/>             Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options             <br/>             Exercisable            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number             <br/>             of Securities             <br/>             Underlying             <br/>             Unexercised             <br/>             Options             <br/>             Unexercisable            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Exercise             <br/>             Price ($)            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option             <br/>             Expiration             <br/>             Date            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number             <br/>             of             <br/>             Shares             <br/>             or Units             <br/>             of Stock             <br/>             that             <br/>             Have             <br/>             Not             <br/>             Vested            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Market             <br/>             Value of             <br/>             Shares             <br/>             or Units             <br/>             of Stock             <br/>             that             <br/>             Have             <br/>             Not             <br/>             Vested            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Equity             <br/>             Incentive             <br/>             Plan             <br/>             Awards:             <br/>             Number of             <br/>             Unearned             <br/>             Shares,             <br/>             Units or             <br/>             Other             <br/>             Rights that             <br/>             Have Not             <br/>             Vested            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Equity             <br/>             Incentive             <br/>             Plan             <br/>             Awards:             <br/>             Market or             <br/>             Payout             <br/>             Value of             <br/>             Unearned             <br/>             Shares,             <br/>             Units or             <br/>             Other             <br/>             Rights that             <br/>             Have Not             <br/>             Vested            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Anil Diwan,            <br/>            President and Director           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 12%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Eugene Seymour, MD           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,332           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            40.00           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            05/01/2023           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,168           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 8%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Irach Taraporewala           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            09/01/2021           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mukund Kulkarni           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stanley Glick           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Meeta Vyas           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            —           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">       </p>       <!-- Field: Page; Sequence: 96; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          96          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        COMPENSATION OBJECTIVES       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We believe that the compensation programsfor the Company’s executive officers should reflect the Company’s performance and the value created for the Company’sstockholders. In addition, the compensation programs should support the short-term and long-term strategic goals and values ofthe Company, and should reward individual contributions to the Company’s success. Our compensation plans are consequentlydesigned to link individual rewards with Company’s performance by applying objective, quantitative factors including theCompany’s own business performance and general economic factors. We also rely upon subjective, qualitative factors such astechnical expertise, leadership and management skills, when structuring executive compensation in a manner consistent with ourcompensation philosophy.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        ELEMENTS OF COMPENSATION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        BASE SALARY. All full time executives arepaid a base salary. Base salaries for our executives are established based on the scope of their responsibilities, professionalqualifications, academic background, and the other elements of the executive’s compensation, including stock-based compensation.However, at this time current total annual compensation is not in line with comparable companies, because our philosophy was topay modest salaries with minimum bonuses to conserve capital resources for future company growth. Our intent is to set executives’base salaries near the median of the range of salaries for executives in similar positions with similar responsibilities at comparablecompanies, in line with our compensation philosophy. Base salaries are reviewed annually, and may be increased to align salarieswith market levels after taking into account the subjective evaluation described previously.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        EQUITY INCENTIVE COMPENSATION. We believethat long-term performance is achieved through an ownership culture participated in by our executive officers through the use ofstock-based awards. Currently, we do not maintain any incentive compensation plans based on pre-defined performance criteria. TheBoard of Directors has the general authority, however, to award equity incentive compensation, i.e. stock options, to our executiveofficers in such amounts and on such terms as the committee determines in its sole discretion. The Board of Directors does nothave a determined formula for determining the number of options available to be granted. The Board of Directors will review eachexecutive’s individual performance and his or her contribution to our strategic goals periodically. With the exception ofstock options automatically granted in accordance with the terms of the employment agreement with our executive officers, our Boardof Directors grants equity incentive compensation at times when we do not have material non-public information to avoid timingissues and the appearance that such awards are made based on any such information. As additional compensation for the year endedJune 30, 2018, under the Company’s employment agreements, the Company issued 10,383 shares of the Company’s Series APreferred Stock and 3,572 of the Company’s restricted Common Stock. The convertible preferred series A shares are subjectto restriction on sale. The valuation applied to the shares was based upon an appraisal derived from the application of statisticalcalculations and based upon assumptions at the time of the appraisal that may not be realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        DETERMINATION OF COMPENSATION       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s executive compensationprogram for the named executive officers (NEOs) is administered by the Board of Directors. The Board of Directors makes independentdecisions about all aspects of NEO compensation, and takes into account compensation data and benchmarks for comparable positionsand companies in different applicable geographical areas. The Compensation Committee of the Board assists the Board in achievingthese objectives.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 97; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          97          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         BENEFICIAL OWNERSHIP OF COMPANY COMMONSTOCK BY DIRECTORS, OFFICERS AND PRINCIPAL STOCKHOLDERS        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_018">          </a>          ITEM 12. SECURITY OWNERSHIP OF CERTAINBENEFICIAL OWNERS, MANAGEMENT, AND RELATED STOCKHOLDERS MATTERS.         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        The following tablesets forth, as of June 30, 2020, certain information regarding the beneficial ownership of the Company’s Common Stockand Series A Convertible Preferred Stock outstanding by (i) each person known to us to own or control 5% or more of ourCommon Stock, (ii) each of our directors, (iii) each of our “Named Executive Officers” (as defined in Item402(a)(3) of Regulation S-K) and (iv) our current Named Executive Officers and directors as a group. Unless otherwiseindicated, each person named in the table below has sole voting and investment power with respect to the shares beneficially owned.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Common Stock            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="6" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Series A Convertible             <br/>             Preferred Stock(1)            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; text-align: center">          </td>          <td style="white-space: nowrap">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name and Address of Beneficial Owner            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Amount and             <br/>             Nature of             <br/>             Beneficial             <br/>             Owner             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Percent of             <br/>             Class             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Amount and             <br/>             Nature of             <br/>             Beneficial             <br/>             Owner             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Percent of             <br/>             Class             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Percent of             <br/>             Voting             <br/>             Power             <sup>              (3)             </sup>            </b>           </font>          </td>          <td style="white-space: nowrap">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 35%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TheraCour Pharma, Inc.            <sup>             (4)            </sup>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            470,959           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.2           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            200,000           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            54.3           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            18.3           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Anil Diwan            <sup>             (4)(5)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            100,269           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.1           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            86,074           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23.4           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7.1           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stanley Glick           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,868           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Meeta Vyas            <sup>             (6)            </sup>           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,352           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,936           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.0           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.0           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Makarand Jawadekar           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Theodore Rokita           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,750           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            All Directors and Executive Officers as a Group (6 persons)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            595,698           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6.5           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            297,010           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            80.6           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            26.4           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other 5% Holders           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Milton Boniuk            <sup>             (7)            </sup>            <br/>            1111 Herman Drive, Unit 29E            <br/>            Houston, TX 77004           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            523,145           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.8           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            16,850           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.6           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.4           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        (1)            TheSeries A Convertible Preferred Shares (the “Series A”) vote at the rate of nine shares of Common Stock pereach share of Series A and is convertible into three and one half shares of Common Stock upon a change in control of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        (2)            Foreach shareholder, the calculation of percentage of beneficial ownership is based upon 9,083,414 shares of Common Stock and 368,602shares of Series A Preferred Stock outstanding, and shares of Common Stock subject to options, warrants and/or conversionrights held by the shareholder that are currently exercisable or exercisable within 60 days, which are deemed to be outstandingand to be beneficially owned by the shareholder holding such options, warrants, or conversion rights. The percentage ownershipof any shareholder is determined by assuming that the shareholder has exercised all options, warrants and conversion rights toobtain additional securities and that no other shareholder has exercised such rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 98; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          98          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        (3)            Amountstated reflects the number of votes held on all matters submitted to a vote of our stockholders.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        (4)            AnilDiwan, the Company’s President and Chairman, also serves as the CEO and Director of TheraCour Pharma Inc. and owns approximately90% of the outstanding capital stock of TheraCour. Anil Diwan has both investment and dispositive power over the NanoViricidesshares held by TheraCour Pharma, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        (5)            Doesnot include 1,170,959 shares of common stock owned by TheraCour Pharma, Inc. after including the Series A preferred stockon an as converted basis which votes at the rate of 3 and one-half shares of common stock for each Share of Series A preferredstock (the “Series A preferred stock”), over which Dr. Diwan holds voting and dispositive power on an asconverted basis. Does not include 86,074 shares of Series A Preferred Stock. Does not include the beneficial ownership ofthe securities held by Meeta Vyas, the wife of Anil Diwan, over which Dr. Diwan disclaims beneficial ownership and votingand dispositive control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        (6)            Includes1,072 shares held by Connect Capital LLC, over which Ms. Vyas holds voting and dispositive power. Does not include 10,936shares of Series A Preferred Stock. Does not include the beneficial ownership of the securities held by Anil Diwan, the husbandof Ms. Vyas, or TheraCour over which Ms. Vyas disclaims beneficial ownership and voting and dispositive control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        (7)            MiltonBoniuk resigned as an Independent Member of the Board of Directors on July 10, 2018. Includes 8,315 shares of Common Stockowned by the reporting person, 32,858 shares of Common Stock owned by the reporting person and his wife Laurie Boniuk, and 343,132shares of Common Stock owned by Milton Boniuk IRA. Includes 138,840 shares of Common Stock held by Boniuk Interests Ltd. Does notinclude 16,850 shares of Series A Preferred Stock held by Milton Boniuk IRA, which are not readily convertible. Dr. Boniukholds voting and dispositive power over Boniuk Interests Ltd. Does not include any shares held by the Boniuk Charitable Foundationsince on February 3, 2017, Dr. Boniuk filed a Form 4 which indicated that Dr. Boniuk no longer holds votingand dispositive power over the shares of Common Stock owned by the Boniuk Charitable Foundation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        (8)            Heldby Milton Boniuk IRA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        EMPLOYMENT AGREEMENTS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company and Dr. Diwan, Presidentand Chairman of the Board of Directors, entered into an employment agreement effective July 1, 2015 for a term of three years.Dr. Diwan’s compensation is $350,000 for the first year of employment, $375,000 for the second year and $400,000 forthe final year. Additionally, Dr. Diwan was awarded a grant of 225,000 shares of the Company’s Series A PreferredStock. 75,000 shares vested on June 30, 2016, 2017 and 2018. The employment agreement also provided incentive bonuses of $75,000per year payable on or before July 31, 2016, 2017 and 2018. Incentive bonuses for 2016 and 2017 have been paid according tothe terms of the contract. The Company and Dr. Diwan agreed that the 2018 bonus would be earned and paid upon a filing ofan IND. The Company and Dr. Diwan entered into an extension of employment agreement effective July 1, 2018 for a term of threeyears. Dr. Diwan’s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 26,250shares of the Company’s Series A preferred stock. 8,750 shares vest equally on June 30, 2019, 2020 and 2021. Any unvestedshares are subject to forfeiture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company and Dr. Seymour, the Company’sChief Executive Officer and Director, entered into an employment agreement effective July 1, 2015, for a term of three years.Dr. Seymour’s compensation would be $350,000 for the first year of employment, $375,000 for the second year and $400,000for the final year. Additionally, Dr. Seymour was awarded a grant of 225,000 shares of the Company’s Series A preferredstock. 75,000 shares vested on June 30, 2016, 75,000 shares vested on June 30, 2017 and 75,000 shares were scheduledto vest on June 30, 2018. The employment agreement also provided incentive bonuses of $75,000 per year payable on or beforeJuly 31, 2016, 2017 and 2018. The incentive bonuses for 2016 and 2017 have been paid according to the terms of the contract.A prorated bonus of $43,750 was paid in 2018 due to the departure of Dr. Seymour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 99; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          99          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 27, 2018, Dr. EugeneSeymour resigned as the Chief Executive Officer and as a Director of the Company. On April 30, 2018, the Company and Dr. Seymourfinalized a Severance Agreement. The separation agreement calls for continued payment of his salary through December 2018,the vesting of 50,000 of the 75,000 Series A Preferred shares that were originally scheduled to vest on June 30, 2018and issuance of warrants to purchase 250,000 shares of the Company’s common stock. The remainder of his unvested shares wasforfeited. The warrants were valued at $53,500 and vest in three equal installments over three years with the last installmentvesting on May 1, 2021. The Company reversed the compensation recorded from July 1, 2017 through January 31, 2018related to the 75,000 shares that will no longer vest under the terms of the employment agreement and then calculated the fairvalue of the 50,000 shares as a result of the modification of the award as of January 27, 2018. The Company then recognizednoncash compensation expense related to the issuance of the Series A Preferred Shares pursuant to the Settlement Agreementof $121,008 for the fiscal year ended June 30, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 3, 2010, the Company enteredinto an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.  Theemployment agreement provides for a term of four years with a base salary of $150,000.  In addition, the Company issued1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and issued anadditional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date of the agreement.The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards the achievementof several patents by the Company. The Compensation Committee of the Board of Directors has extended the current provisions ofthe employment agreement pending its review of current industry compensation arrangements and employment agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 3, 2010, the Company entered intoan employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.  The employment agreement providedfor a term of four years with a base salary of $150,000.  In addition, the Company issued 1,786 shares of common stockupon entering into the agreement, and will issue an additional 1,786 shares of common stock on each anniversary date of the agreement.The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending itsreview of current industry compensation arrangements and employment agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 30, 2013, the Company enteredinto an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer.  The employment agreement providedfor a term of three years with a base salary of $9,000 per month and 129 shares of Series A preferred stock, also on a monthlybasis. On January 1, 2015, her compensation was increased to $10,800 per month. The Compensation Committee of the Board ofDirectors has extended the current provisions of the employment agreement pending its review of current industry compensation arrangementsand employment agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        COMPENSATION OF DIRECTORS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At this time, directors, who are officersof the Company, receive no remuneration for their services as directors of the Company. The Company reimburses directors for expensesincurred in their service to the Board of Directors. The Company paid accrued fees to its independent directors of $36,250 to eachDirector, of which $11,250 is to be paid in the Company’s common stock.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        COMPENSATION OF SCIENTIFIC ADVISORY BOARD       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company anticipates holding four ScientificAdvisory Board meetings per annum. As compensation, each member of the Scientific Advisory Board (SAB) will be granted 572 warrantseach quarter to purchase the Company’s common stock at 120% of the Company’s closing stock quote on the day followingthe meeting. Should the Company not call a quarterly meeting, quarterly warrants will be granted on May 15, August 15,November 15, and February 15. The warrants have a four-year expiration date. In addition the Company will reimburse eachSAB member for travel and other out-of-pocket expenses incurred in the course of performing their services. For the year endedJune 30, 2020, 2019 and 2018, the SAB was granted a total of 2,286, 2,287 and 2,287 of stock warrants, respectively. The warrantsare exercisable into common shares at prices from $2.63 to $12.16, $6.00 to $9.40 and $12.80 to $31.20 per share, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 100; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          100          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        EMPLOYEES AND SERVICE PROVIDERS       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has seven full time employees.In addition, most of the business activities of the Company including accounting and legal work and business development are providedby subcontractors and consultants. Further, the Company has subcontracted nanomaterials research and development (“R&amp;D”)to TheraCour under the license agreement with TheraCour. TheraCour currently has a staff of about twenty, most of who are scientistswith PhD or advanced degrees and experience. The Company has subcontracted its animal studies to various contract research organizations,government institutes, academic labs, and private institutions. Some of the Company’s R&amp;D work was performed by agenciesin Vietnam. In the future, the Company anticipates having additional service providers. We believe that we have good relationswith our employees and subcontractors.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_019">          </a>          ITEM 13. CERTAIN RELATIONSHIPS ANDRELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        On May 13, 2013,Meeta Vyas was appointed as the Company’s Chief Financial Officer. During the term of Ms. Vyas’ service, she willbe compensated on the basis of $9,000 per month and 129 shares of Series A Preferred Stock, also on a monthly basis.Ms. Vyas is married to Anil Diwan, the President and Chairman of the Company. On January 1, 2015, her compensation wasincreased to $10,800 per month.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 16, 2019, the Companyentered into an Open End Mortgage Note (the “Note”) with Anil Diwan, the Company’s founder, Chairman and President,to loan the Company up to $2,000,000 in two tranches of $1,000,000 (the “Loan”). The Note bears interest at the rateof 12% per annum and is secured by a mortgage granted against the Company’s headquarters. The unpaid principal balance isdue and payable on May 15, 2021. The lender received 10,000 shares of the Company’s Series A preferred stock asa loan origination fee which is to be amortized over the one-year term of the loan using effective interest method. The fair valueof the 10,000 shares of the Company’s Series A preferred stock when issued on December 16, 2019 was $39,301. TheSeries A preferred stock fair value is based on the greater of the i) the converted value to common at a ratio of 1:3.5; orii) the value of the voting rights since the Holder would lose the voting rights upon conversion. For the assumptions used in calculatingthe fair value of the preferred shares, the conversion of the shares is triggered by a Change of Control. See note 7 for inputsused in calculation of fair value. Amortization expense on the loan origination fee for the year ended June 30, 2020 was $21,288.As of June 30, 2020, the Company has drawn down $1.1 million of this loan and may, at its option, draw down the remainderof the loan. Interest is payable only on the amount drawn down. The lender had escrowed $132,000 of interest payable pursuant tothe Loan. The balance at June 30, 2020 of the prepaid interest escrowed by the lender is $62,773 and is included in prepaidexpenses. For the year ended June 30, 2020, the Company incurred interest expense of $69,227, which reduced the interest escrowbalance included in prepaid expenses.        <font style="background-color: white">         On April 30, 2020, the Company and Dr. Diwanmutually agreed to extend the maturity date of the note at the Company’s option, to May 15, 2021, with the rest of theterms remaining the same.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At June 30, 2020, mortgage note payable – related party consisted of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Mortgage note payable          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,100,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Less: unamortized loan origination fee          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (18,013          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Net mortgage note payable          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,081,987          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 101; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          101          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         TheraCour Pharma, Inc.        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 12, 2005, we entered intoa Material License Agreement, amended as of January 8, 2007 (the “License”) with TheraCour Pharma, Inc.(“TheraCour”), an approximately 5.3% common shareholder. Anil Diwan, our founder, President and Chairman, ownsapproximately 90% of TheraCour’s capital stock. We were granted exclusive licenses in perpetuity for technologiesdeveloped by TheraCour for the virus types: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird FluVirus, Herpes Simplex Virus (HSV-1 and HSV-2), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. OnFebruary 15, 2010, we entered into an Additional License Agreement with TheraCour. Pursuant to the exclusive AdditionalLicense Agreement, in consideration for the issuance of 100,000 shares of our Series A Preferred Stock, (the “Series A Preferred”), we were granted exclusive licenses, in perpetuity, for technologies, developed byTheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, JapaneseEncephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In consideration for obtaining these exclusivelicenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of a specified portionof certain direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed;(2) we will pay the greater $2,000 or actual costs monthly, whichever is higher, for other general and administrative expensesincurred by TheraCour on our behalf; (3) make royalty payments (calculated as a percentage of net sales of the licensed drugs)of 15% (calculated as a percentage of net sales of the licensed drugs) to TheraCour; (4) TheraCour retains the exclusive rightto develop and manufacture the licensed drugs. TheraCour will manufacture the licensed drugs exclusively for us, and unless suchlicense is terminated, will not manufacture such product for its own sake or for others; and (5) TheraCour may request andwe will pay an advance payment (refundable) equal to twice the amount of the previous month’s invoice to be applied as aprepayment towards expenses. TheraCour may terminate the license upon a material breach by us as specified in the agreement. However,we may avoid such termination if within 90 days of receipt of such termination notice we cure the breach.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On October 2, 2018, we entered into an agreement with TheraCourto defer the $25,000 payment until the earlier of April 2, 2019 or the date that we file an IND with the FDA. On May 9,2019, we entered into an agreement with TheraCour that extended the April 2, 2019 date to June 30, 2019 and on September 24,2019 we entered into an agreement with TheraCour that extended such date to the later of December 31, 2019 or the filing onan IND with the FDA. Deferred development fees as of June 30, 2020 was $200,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 1, 2019, the Company enteredinto a License Agreement (the “Agreement”) with TheraCour for an exclusive, worldwide license to use, promote, offerfor sale, import, export, sell and distribute products for the treatment of Varicella Zoster Virus derived indications. The Companywas not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuanceof 75,000 shares of Series A Convertible Preferred Stock upon the grant of an IND Application; $1,500,000 in cash upon completionof Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completionof Phase III clinical trials. In addition, the Company is required to pay to TheraCour fifteen percent (15%) of net sales of licensedproducts, and any income from sublicensed products. Under the Agreement, TheraCour retains the exclusive right to develop and manufacturethe Licensed Products. As in previous licensing agreements with TheraCour, the Company agreed to pay the following amounts to TheraCourto the extent not previously paid under existing licensing agreements: (1) costs (direct and indirect) plus 30%, subject tocertain specified exclusions, as a Development Fee and such development fees shall be due and payable in periodic installmentsas billed and (2) a deposit equal to estimated development costs for two months (refundable), such estimates to be reconciledquarterly. Payments not made within 90 days after due date will be charged an interest at the rate of 1% per month. TheraCour andthe Company have agreed to enter into a manufacture and supply agreement, under which TheraCour would manufacture the licensedproducts exclusively for the Company, and the Company would also have customary backup manufacture rights, as specified in theAgreement. TheraCour may terminate the license upon a material breach by the Company as specified in the agreement. However, theCompany may avoid such termination if the breach is cured within 90 days of receipt of such termination.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnDecember 17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour whereby TheraCour agreedto exchange $250,000 of deferred development fees owed to TheraCour into 100,000 Series A preferred stock with a fair value of$392,669 for $250,000 previously deferred development fees owed to TheraCour, and recognized a loss on the exchange of $142,669.Upon entry into the agreement additional deferrals ceased.        </font>        The remaining deferred payments will become due upon IND filing.At June 30, 2020 $200,000 of the deferred payments remain due.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        TheraCour acquired property and equipmenton behalf of the Company from third party vendors and sold such property and equipment, to the Company, at cost, in the amountsof  $8,638 and $23,666 for the fiscal years ended June 30, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 102; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          102          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Split-Segment; Name: a9 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Accounts payable to TheraCour were $561,580and $823,783 at June 30, 2020 and June 30, 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Development costs charged by and paid toTheraCour were $2,158,034 and $3,119,863 for the years ended June 30, 2020 and, 2019, respectively. No royalties are due orhave been paid from inception through June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020 TheraCour owned470,959 shares of the Company’s outstanding common stock and 200,000 shares of series A preferred stock, which votes at therate of nine shares of common stock per each share of series A preferred stock and is convertible into three and one halfshares of common stock upon a change in control of the Company. Dr. Diwan, also serves as the CEO and Director of TheraCourand owns approximately 90% of the outstanding capital stock of TheraCour.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 8, 2020, the Company executeda Memorandum of Understanding (“MOU”) with TheraCour that provides a limited license to the Company for the entireapplication of human coronavirus infections, while the full license is being perfected. The Company is in the process of appointinga third party consulting firm for independent evaluation of this market space. Dr. Anil Diwan is recused from these discussionsdue to a conflict of interest. The terms of the COVID License Agreement, shall, except as otherwise specified in the MOU, be generallyconsistent with the VZV License Agreement dated October 28, 2019, and shall include consistent milestone payments, royaltiesand sublicense and income derived from grants and contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_020">          </a>          ITEM 14. PRINCIPAL ACCOUNTING FEESAND SERVICES         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Audit Fees        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate fees for each of the lasttwo years for professional services rendered by the independent registered public accounting firm for our audits of our annualfinancial statements and interim reviews of our financial statements included in our fillings with Securities and Exchange Commissionon Form 10-K and 10-Qs or services that are normally provided by the accountant in connection with statutory and regulatoryfilings or engagements for those years were approximately:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 78%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 46%">           <font style="font-size: 10pt">            June 30, 2020           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            270,480           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 40%; text-align: justify">           <font style="font-size: 10pt">            EisnerAmper LLP           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            June 30, 2019           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            190,600           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            EisnerAmper LLP.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Audit Related Fees        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate fees in each of the lasttwo years for the assurance and related services provided by the principal accountant that are not reasonably related to the performanceof the audit or review of the Company’s financial statements and are not reported in paragraph (1) were approximately:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 78%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 46%; font: 10pt Times New Roman, Times, Serif">           June 30, 2020          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           June 30, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate fees in each of the lasttwo years for the professional services rendered by the principal accountant for tax compliance, tax advice and tax planning wereapproximately:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 78%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 46%; font: 10pt Times New Roman, Times, Serif">           June 30, 2020          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           June 30, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         All Other Fees        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The aggregate fees in each of the lasttwo years for the products and services provided by the principal accountant, other than the services reported in paragraph (1) wereapproximately:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 78%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 46%; font: 10pt Times New Roman, Times, Serif">           June 30, 2020          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif">           June 30, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           0          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           EisnerAmper LLP          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 103; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          103          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <u>         Pre-Approval Policies        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Board of Directors, and the Audit Committeeappointed by the Board, currently do not have any pre-approval policies or procedures concerning services performed by EisnerAmperLLP. All the services performed by EisnerAmper LLP as described above were pre-approved by the Audit Committee.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_021">          </a>          ITEM 15. EXHIBITS         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; width: 7%">           <font style="font-size: 10pt">            <b>             Exhibits            </b>           </font>          </td>          <td style="padding-bottom: 1pt; width: 1%; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; width: 47%; text-align: center">           <font style="font-size: 10pt">            <b>             Description            </b>           </font>          </td>          <td style="padding-bottom: 1pt; width: 1%; text-align: center">          </td>          <td style="border-bottom: black 1pt solid; width: 12%; text-align: center">           <font style="font-size: 10pt">            <b>             Filed / furnished    /             <br/>             incorporated by             <br/>             reference from            </b>           </font>          </td>          <td style="padding-bottom: 1pt; width: 1%; text-align: center">          </td>          <td style="width: 13%; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Incorporated by             <br/>             reference from exhibit            </b>           </font>          </td>          <td style="padding-bottom: 1pt; width: 1%; text-align: center">          </td>          <td style="width: 17%; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Date filed            </b>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036109010162/formdefr14c.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036109010162/formdefr14c.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    and Restated Articles of Incorporation            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036109010162/formdefr14c.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Schedule    14C            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036109010162/formdefr14c.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             A            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036109010162/formdefr14c.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             April    23, 2009            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420413049761/v354598_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420413049761/v354598_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Change            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420413049761/v354598_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420413049761/v354598_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420413049761/v354598_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             September    9, 2013            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419045967/tv530096_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.3            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419045967/tv530096_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Change            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419045967/tv530096_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419045967/tv530096_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419045967/tv530096_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             September    26, 2019            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920036792/tm20133451_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.4            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920036792/tm20133451_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate of Amendment            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920036792/tm20133451_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920036792/tm20133451_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920036792/tm20133451_ex3-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             March 20, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036110007767/ex3_1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.4            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036110007767/ex3_1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    and Restated Bylaws            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036110007767/ex3_1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-Q            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036110007767/ex3_1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             3.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036110007767/ex3_1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             February    22, 2010            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Specimen    Common Stock Certificate of the Registrant            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Designation of Series A Convertible Preferred Stock            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-Q            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex4-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             February    22, 2010            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex4-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.3*            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex4-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Amendment to Certificate of Designation of Series A Convertible Preferred Stock            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex4-4.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.4*            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex4-4.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Certificate    of Amendment to Certificate of Designation of Series A Convertible Preferred Stock            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             4.5            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Warrant            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             March    1, 2019            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Scientific Advisory Board Agreement            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.5            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-5.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amended    License Agreement with TheraCour Pharma, Inc.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.6            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.3            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of First Subscription Agreement            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.8            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-6.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-9.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.4            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-9.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Second Subscription Agreement            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-9.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-9.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.9            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-9.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.5            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Amendment    to License Agreement with TheraCour Pharma, Inc.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.11            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_11.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January    17, 2007            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_12.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.6            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_12.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Memorandum    of Understanding with Vietnam’s National Institute of Hygiene and Epidemiology (NIHE) dated December 23, 2005            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_12.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_12.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.12            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114036107001282/ex10_12.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January    17, 2007            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex10-7.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.7*            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex10-7.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Employment    Agreement with M Vyas            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420415001176/v398311_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.8            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420415001176/v398311_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Agreement    of Purchase and Sale between the Registrant and Inno-Haven, LLC            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420415001176/v398311_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420415001176/v398311_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420415001176/v398311_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January    7, 2015            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420417008029/v459353_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.9            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420417008029/v459353_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Conversion    and Settlement Agreement            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420417008029/v459353_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420417008029/v459353_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420417008029/v459353_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             February    13, 2017            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418025443/tv493106_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.10            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418025443/tv493106_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Confidential    Separation Agreement and General Release of Eugene Seymour            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418025443/tv493106_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418025443/tv493106_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418025443/tv493106_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             May    4, 2018            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.11            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Employment    Agreement with Anil Diwan            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             July    23, 2018            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.12            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Employment    Agreement with Irach Taraporewala            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420418039366/tv498940_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             July    23, 2018            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.13            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Securities    Purchase Agreement, dated February 27, 2019, between the Registrant and certain purchasers            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             March    1, 2019            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.14            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Letter    Agreement with Chardan Capital Markets, LLC            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.3            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419011452/tv515117_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             March    1, 2019            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419030343/tv523310_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.15            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419030343/tv523310_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Director    Retainer Agreement, dated as of June 6, 2019, between the Registrant and Mark Day            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419030343/tv523310_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419030343/tv523310_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420419030343/tv523310_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             June    10, 2019            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex10-16.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.16*            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465919068364/tm1922708d1_ex10-16.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    of Series A Conversion Waiver            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007211/tm205945d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.17            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007211/tm205945d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Underwriting with Aegis Capital Corp. dated January 21, 2020            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007211/tm205945d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007211/tm205945d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007211/tm205945d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January 27, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.18            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form of Settlement Agreement and Mutual Release            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January 28, 2020            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 104; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          104          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="vertical-align: top; width: 7%">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.19            </font>           </a>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: top; width: 47%">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form of Exchange Agreement            </font>           </a>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; text-align: center; width: 12%">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; text-align: center; width: 13%">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>           </a>          </td>          <td style="vertical-align: bottom; width: 1%">          </td>          <td style="vertical-align: bottom; text-align: center; width: 17%">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January 28, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.20            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form of Common Stock Purchase Warrant            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.3            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920007313/tm205996d1_ex10-3.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             January 28, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920016291/tm207421d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.21            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920016291/tm207421d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Director Retainer Agreement between NanoViricides, Inc. and    Makarand Jawadekar            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920016291/tm207421d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920016291/tm207421d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920016291/tm207421d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             February 11, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920063847/tm2020222d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.22            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920063847/tm2020222d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Director Retainer Agreement, dated as of May 15, 2020, between    NanoViricides, Inc. and Todd Rokita            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920063847/tm2020222d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920063847/tm2020222d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920063847/tm2020222d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             May 19, 2015            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <font style="font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-1.htm" style="-sec-extract: exhibit">             10.23            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <font style="font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-1.htm" style="-sec-extract: exhibit">             Form of Securities Purchase Agreement dated May 21, 2020 by and between NanoViricides, Inc. and certain purchasers            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-1.htm" style="-sec-extract: exhibit">             Form 8-K            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-1.htm" style="-sec-extract: exhibit">             10.1            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-1.htm" style="-sec-extract: exhibit">             May 22, 2020            </a>           </p>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.24            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Placement Agent Agreement, dated May 21, 2020 by and between    among NanoViricides, Inc. Maxim Group LLC and Kingswood Capital Markets, a division of Benchmark Investments, Inc.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form 8-K            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.2            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920065358/tm2020761d1_ex10-2.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             July 13, 2020            </font>           </a>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920083121/tm2024738d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.25            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="https://www.sec.gov/Archives/edgar/data/1379006/000110465920083121/tm2024738d1_ex10-1.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Underwriting Agreement with Kingswood Capital Markets, a Division    of Benchmark Investments, Inc. dated July 8, 2020.            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">          </td>         </tr>         <tr>          <td style="vertical-align: top">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1379006/000110465920089704/tm2026397d1_ex1-1.htm" style="-sec-extract: exhibit">             10.26            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <a href="http://www.sec.gov/Archives/edgar/data/1379006/000110465920089704/tm2026397d1_ex1-1.htm" style="-sec-extract: exhibit">             At Market Issuance Sales Agreement by and between NanoViricides, Inc., B. Riley Securities, Inc. and Kingswood Capital Markets, a division of Benchmark Investments, Inc., dated July 31, 2020            </a>           </p>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1379006/000110465920089704/tm2026397d1_ex1-1.htm" style="-sec-extract: exhibit">             Form 8-K            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1379006/000110465920089704/tm2026397d1_ex1-1.htm" style="-sec-extract: exhibit">             1.1            </a>           </font>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/1379006/000110465920089704/tm2026397d1_ex1-1.htm" style="-sec-extract: exhibit">             August 3, 2020            </a>           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-10.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             14.1            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: top">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-10.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Code    of Ethics            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-10.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             Form    10-SB            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-10.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             10.10            </font>           </a>          </td>          <td style="vertical-align: bottom">          </td>          <td style="vertical-align: bottom; text-align: center">           <a href="http://www.sec.gov/Archives/edgar/data/1379006/000114420406047712/v057372_ex10-10.htm" style="-sec-extract: exhibit">            <font style="font-size: 10pt">             November    14, 2006            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="text-align: justify; width: 7%">           <a href="tm20247371_ex31-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             31.1            </font>           </a>          </td>          <td style="text-align: justify; width: 1%">          </td>          <td style="text-align: left; width: 47%">           <a href="tm20247371_ex31-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of    Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended            </font>           </a>          </td>          <td style="text-align: left; width: 1%">          </td>          <td style="text-align: left; width: 12%">          </td>          <td style="text-align: left; width: 1%">          </td>          <td style="text-align: left; width: 13%">          </td>          <td style="text-align: left; width: 1%">          </td>          <td style="text-align: left; width: 17%">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <a href="tm20247371_ex31-2.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             31.2            </font>           </a>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <a href="tm20247371_ex31-2.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of    Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended            </font>           </a>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <a href="tm20247371_ex32-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             32.1            </font>           </a>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <a href="tm20247371_ex32-1.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of    Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended,    and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: left">           <a href="tm20247371_ex32-2.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             32.2            </font>           </a>          </td>          <td style="text-align: left">          </td>          <td style="text-align: left">           <a href="tm20247371_ex32-2.htm" style="-sec-extract: exhibit">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certification of    Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended,    and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.            </font>           </a>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.INS           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Instance Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.SCH           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Schema Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.CAL           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Calculation    Linkbase Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.DEF           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Definition    Linkbase Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.LAB           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Label Linkbase    Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.PRE           </font>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Presentation    Linkbase Document.           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        * Previously filed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          <a name="c_022">          </a>          ITEM 16. FORM 10-K SUMMARY         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        None.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 105; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          105          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <b>         <a name="c_023">         </a>         SIGNATURES        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to the requirements of Section 13or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf bythe undersigned, thereunto duly authorized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Dated: October 13, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%">          </td>          <td style="width: 50%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             NANOVIRICIDES, INC.            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/ Anil Diwan, PhD            </i>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name: Anil R. Diwan, PhD.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: President and Executive Chairman of the Board of Directors           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Principal Executive Officer)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/ Meeta Vyas            </i>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name:  Meeta Vyas           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: Chief Financial Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Principal Accounting Officer)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to the requirements of the SecuritiesExchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacitiesand on the dates indicated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; text-align: justify">           October 13, 2020          </td>          <td style="width: 50%; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/ Anil Diwan, PhD            </i>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name: Anil Diwan, PhD           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: President and Executive Chairman of the Board of Directors           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Principal Executive Officer)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; text-align: justify">           October 13, 2020          </td>          <td style="width: 50%; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/ Meeta Vyas            </i>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name: Meeta Vyas           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: Chief Financial Officer           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Principal Accounting Officer)           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           October 13, 2020          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/ Stanley Glick            </i>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name: Stanley Glick           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: Director           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           October 13, 2020          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             /s/            </i>           </font>           <i>            Makarand Jawadekar           </i>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Name: Makarand Jawadekar           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Title: Director           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 106; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <font style="font-size: 10pt">          Page          <!-- Field: Sequence; Type: Arabic; Name: PageNo -->          106          <!-- Field: /Sequence -->          of 106         </font>        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Index to the Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 89%; border-bottom: black 1pt solid; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Contents            </b>           </font>          </td>          <td style="width: 1%; text-align: right">          </td>          <td style="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page(s)            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting Firm            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-2            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Balance Sheets at June 30, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-3            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statements of Operations for the fiscal years ended June 30, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-4            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statement of Changes in Stockholders’ Equity for the period from July 1, 2017 through June 30, 2020            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-5            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Statements of Cash Flows for the fiscal years ended June 30, 2020, 2019 and 2018            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-6            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: white">          <td>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">          </td>         </tr>         <tr style="vertical-align: top; background-color: #CCEEFF">          <td>           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to the Financial Statements            </font>           </a>          </td>          <td style="text-align: right">          </td>          <td style="white-space: nowrap; text-align: center">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             F-7            </font>           </a>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 107; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <a name="a_001">         </a>         REPORT OF INDEPENDENT REGISTERED PUBLICACCOUNTING FIRM        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        To the Board of Directors and Stockholdersof       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Opinion on the Financial Statements         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have audited the accompanying balance sheets of NanoViricides,Inc. (the "Company") as of June 30, 2020 and 2019, and the related statements of operations, changes in stockholders'equity, and cash flows for each of the years in the three-year period ended June 30, 2020, and the related notes (collectivelyreferred to as the "financial statements"). In our opinion, the financial statements present fairly, in all materialrespects, the financial position of the Company as of June 30, 2020 and 2019, and the results of its operations and its cash flowsfor each of the years in the three-year period ended June 30, 2020, in conformity with accounting principles generally acceptedin the United States of America.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          Basis for Opinion         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        These financial statements are the responsibilityof the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicablerules and regulations of the Securities and Exchange Commission and the PCAOB.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We conducted our audits in accordance withthe standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whetherthe financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are requiredto obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on theeffectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our audits included performing proceduresto assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing proceduresthat respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosuresin the financial statements. Our audits also included evaluating the accounting principles used and significant estimates madeby management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide areasonable basis for our opinion.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have served as the Company's auditorsince 2014.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        /s/ EisnerAmper LLP       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 50%; text-align: justify">           <font style="font-size: 10pt">            EISNERAMPER LLP           </font>          </td>          <td style="width: 50%; text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            Iselin, New Jersey           </font>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-size: 10pt">            October 13, 2020           </font>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 108; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_002">        </a>        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Balance Sheets       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30, 2020            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30, 2019            </b>           </font>          </td>          <td style="white-space: nowrap; padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            ASSETS           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            CURRENT ASSETS:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%; padding-left: 9pt">           <font style="font-size: 10pt">            Cash and cash equivalents           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            13,708,594           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            2,555,207           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Prepaid expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            277,063           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            270,214           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Total current assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            13,985,657           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            2,825,421           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            PROPERTY AND EQUIPMENT           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Property and equipment           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            14,100,815           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            14,092,177           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Accumulated depreciation           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (4,556,384           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (3,864,930           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Property and equipment, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            9,544,431           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            10,227,247           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            TRADEMARK AND PATENTS           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Trademark and patents           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            458,954           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            458,954           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Accumulated amortization           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (100,566           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (92,296           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Trademark and patents, net           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            358,388           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            366,658           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            OTHER ASSETS           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Security deposits           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,515           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,515           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Deferred equity financing costs           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            12,190           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Service agreements           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            10,158           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            25,672           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Other assets           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            25,863           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            29,187           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 27pt">           <font style="font-size: 10pt">            Total assets           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            23,914,339           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            13,448,513           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            LIABILITIES AND STOCKHOLDERS' EQUITY           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            CURRENT LIABILITIES:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Mortgage note payable- related party           </font>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,081,987           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Accounts payable           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            380,727           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            309,893           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Accounts payable – related party           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            561,580           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            823,783           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Loan payable           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            62,843           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Derivative liability – warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            1,645,606           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Accrued expenses           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            69,240           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            68,871           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-size: 10pt">            Total current liabilities           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            2,156,377           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            2,848,153           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            COMMITMENTS AND CONTINGENCIES           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            STOCKHOLDERS' EQUITY:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Series A convertible preferred stock, $0.001 par value, 10,000,000 shares designated, 368,602 and 255,714 shares issued and outstanding, at June 30, 2020 and 2019, respectively           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            369           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            256           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Common stock, $0.001 par value; 150,000,000 shares authorized, 9,083,414, and 3,844,921 shares issued and outstanding at June 30, 2020 and 2019, respectively           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            9,083           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            3,845           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 9pt">           <font style="font-size: 10pt">            Additional paid-in capital           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            127,311,634           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            102,712,845           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-size: 10pt">            Accumulated deficit           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (105,563,124           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (92,116,586           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 27pt">           <font style="font-size: 10pt">            Total stockholders' equity           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            21,757,962           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            10,600,360           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 27pt">           <font style="font-size: 10pt">            Total liabilities and stockholders' equity           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            23,914,339           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            13,448,513           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to the financialstatements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 109; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_003">        </a>        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Statements of Operations       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Year Ended June 30,          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2020          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2019          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           2018          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           OPERATING EXPENSES          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Research and development          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           4,695,524          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,921,720          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,913,720          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           General and administrative          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,300,935          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,737,962          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,411,449          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">           Total operating expenses          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           7,996,459          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,659,682          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           9,325,169          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           LOSS FROM OPERATIONS          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (7,996,459          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,659,682          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,325,169          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           OTHER INCOME (EXPENSE):          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Interest income          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           17,079          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           55,497          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           100,429          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Interest expense          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (93,670          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (185,274          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Gain on warrant settlement          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           614,494          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Loss on issuance of Series A preferred stock for accounts payable-related party          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (142,669          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Loss on extinguishment of debt          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,348,247          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">           Discount on convertible debentures          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (359,214          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 9pt">           Change in fair value of derivatives          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,845,313          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           179,745          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,554,020          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">           Other    (expense) income, net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,450,079          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           235,242          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           761,714          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           LOSS BEFORE INCOME TAX PROVISION          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (13,446,538          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,424,440          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,563,455          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           INCOME TAX PROVISION          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           NET LOSS          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (13,446,538          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,424,440          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (8,563,455          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Net loss per common share- basic and diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2.39          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2.35          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           (2.64          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Weighted average common shares – basic and diluted          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,616,728          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,590,070          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           3,246,043          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to the financialstatements        </i>        .       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 110; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: 1 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_004">        </a>        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Statement of Changes in Stockholders' Equity       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        For the period from July 1, 2017 throughJune 30, 2020       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Series    A Preferred             <br/>             Stock:             <br/>             Par $0.001            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Common Stock: Par             <br/>             $0.001            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Additional            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="padding-bottom: 1pt; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Total            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Number    of            </b>           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Number    of            </b>           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Paid-in            </b>           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Accumulated            </b>           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Stockholders'            </b>           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Shares            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Amount            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Shares            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Amount            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Capital            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Deficit            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            <b>             Equity            </b>           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 30%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Balance, July 1, 2017           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            217,443           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            217           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,165,342           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,165           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            95,447,251           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (75,128,691           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="width: 7%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            20,321,942           </font>          </td>          <td style="width: 1%">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for employee    stock compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2,888           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            524,255           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            524,258           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock forfeited in Separation    Agreement           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (1,250           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (1           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            1           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for Series C    debenture           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            7,500           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            8           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            314,335           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            314,343           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for consulting and legal    services rendered           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            12,188           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            12           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            156,178           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            156,190           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Warrants issued to Scientific Advisory Board           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            16,770           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            16,770           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Warrants issued as severance payment           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            53,500           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            53,500           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for employee compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,572           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            65,712           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            65,716           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for Series C debenture           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            275,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            275           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4,729,725           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4,730,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for Directors fees           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2,489           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            44,998           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            45,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Net loss           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (8,563,455           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (8,563,455           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Balance, June 30, 2018           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            226,581           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            227           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,458,591           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,459           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            101,352,724           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (83,692,146           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            17,664,264           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for employee    stock compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            29,133           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            29           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            237,839           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            237,868           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Net proceeds from issuance of common stock in    connection with equity financing           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            347,223           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            347           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            822,394           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            822,741           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Options issued for employee compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            11,920           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            11,920           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for consulting and legal    services rendered           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            28,210           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            28           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            208,932           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            208,960           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Warrants issued to Scientific Advisory Board           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            5,475           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            5,475           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for employee compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,572           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            28,568           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            28,572           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for Directors fees           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            7,325           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            7           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            44,993           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            45,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Net loss           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (8,424,440           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (8,424,440           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Balance, June 30, 2019           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            255,714           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            256           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,844,921           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,845           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            102,712,845           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (92,116,586           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            10,600,360           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for employee    stock compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            2,888           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            230,894           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            230,897           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for accounts    payable-related party           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            100,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            100           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            392,569           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            392,669           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Series A Preferred stock issued for loan origination    fee           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            10,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            10           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            39,291           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            39,301           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Net proceeds from issuance of common stock in    connection with equity financings           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4,275,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4,275           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            16,672,700           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            16,676,975           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for consulting and legal    services rendered           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            78,958           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            79           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            254,171           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            254,250           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for accounts payable           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            8,467           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            8           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            51,992           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            52,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued in exchange for warrants           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            677,224           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            677           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            5,721,866           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            5,722,543           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued upon cashless exercise of    warrants           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            180,087           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            180           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            1,153,701           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            1,153,881           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Warrants issued to Scientific Advisory Board           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            7,373           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            7,373           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for employee compensation           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            3,572           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            29,247           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            29,251           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Common stock issued for Directors fees           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            10,728           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            11           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            44,985           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            45,000           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Rounding - fractional shares           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4,457           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            4           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (4)           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Net loss           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (13,446,538           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (13,446,538           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: right">           <font style="font-size: 8pt">           </font>          </td>          <td>           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            Balance, June 30,    2020           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            368,602           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            369           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            9,083,414           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            9,083           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            127,311,634           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            (105,563,124           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            )           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">            21,757,962           </font>          </td>          <td style="padding-bottom: 2.5pt">           <font style="font-size: 8pt">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to the financialstatements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 111; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_005">        </a>        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Statements of Cash Flows       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year Ended June 30,            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             2018            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CASH FLOWS FROM OPERATING ACTIVITIES:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 61%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net loss           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (13,446,538           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,424,440           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,563,455           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 9pt; text-indent: -9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Adjustments to reconcile net loss to net cash used in operating activities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Preferred shares issued as compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            230,897           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            237,868           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            524,258           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss on issuance of preferred shares for accounts payable-related party           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            142,669           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common shares issued as compensation and for services           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            328,501           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            282,532           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            266,906           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common shares issued for debenture interest           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            60,274           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Options granted as compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,920           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Warrants granted to Scientific Advisory Board           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,373           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,475           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            16,770           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Warrants granted for severance agreement           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53,500           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Depreciation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            691,454           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            687,640           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            671,789           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amortization           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,270           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,271           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,269           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amortization of loan origination fees           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            21,288           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Change in fair value of derivative liabilities           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,845,313           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (179,745           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2,554,020           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gain on warrant settlement           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (614,494           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Amortization of debt discount convertible debentures           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            359,214           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Loss on extinguishment of debt           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,348,247           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Changes in operating assets and liabilities:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Prepaid expenses           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6,849           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (29,957           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (50,091           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Other long term assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,513           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (21,025           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50,767           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accounts payable           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            122,834           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            86,554           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            87,553           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accounts payable - related parties           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (12,203           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            716,315           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (233,227           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accrued expenses           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            369           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (184,178           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            219,045           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Deferred interest payable           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (41,667           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NET CASH USED IN OPERATING ACTIVITIES           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6,665,603           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (6,802,770           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (7,775,868           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CASH FLOWS FROM INVESTING ACTIVITIES:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Purchase of property and equipment           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,638           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (73,794           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (241,822           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CASH FLOWS FROM FINANCING ACTIVITIES:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Proceeds from note payable-related party           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,100,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net proceeds from issuance of common stock and warrants           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            16,676,975           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,350,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Deferred financing costs           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (12,190           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Proceeds from loan payable           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            155,173           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Payment of loan payable           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (92,330           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt; padding-left: 18.7pt; text-indent: -0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NET CASH PROVIDED BY FINANCING ACTIVITIES           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17,827,628           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,350,000           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NET CHANGE IN CASH AND CASH EQUIVALENTS           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11,153,387           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4,526,564           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (8,017,690           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash and cash equivalents at beginning of period           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,555,207           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,081,771           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,099,461           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cash and cash equivalents at end of period           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,708,594           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,555,207           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,081,771           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:           </font>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Interest paid           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            166,667           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 2.5pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Income tax paid           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            NON CASH FINANCING AND INVESTING ACTIVITIES:           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cashless exercise of warrants reclassed from warrant liability to common stock           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,153,881           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Series A preferred stock issued for accounts payable-related party           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            250,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Series A preferred stock issued for loan origination fee           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            39,301           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common stock issued to settle accounts payable           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            52,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common stock issued for debenture payment           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            230,250           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common stock issued for deferred interest           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6,250           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Series A Preferred stock issued for Series C debenture           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15,718           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-left: 18.7pt; text-indent: -9.35pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock warrants classified as a liability issued in connection with registered direct offering           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            76,363           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <i>         See accompanying notes to the financialstatements        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 112; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <a name="a_006">        </a>        NanoViricides, Inc.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        June 30, 2020, 2019 and 2018       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Notes to the Financial Statements       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 1 – Organization and Natureof Business        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        NanoViricides, Inc. (the “Company”)is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercializationof drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharmafield in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of thenanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinicaltrials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety,bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contractorganizations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are a company with several drugs invarious stages of early development. In our lead antiviral program against herpes viruses, i.e. the HerpeCide™ program alone,we have drug candidates against at least five indications at different stages of development. Of these, the Company is advancingthe shingles drug candidate towards human clinical trials. The IND-enabling Safety/Toxicology studies required for doing so havebegun as of the end of December 2018 at the contract research organization (“CRO”) BASi, Indiana. Typically these studiesmay last six to nine months. If successful, the Company intends to file an IND after receiving a formal report on these studiesfrom BASi. In addition, our drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are inadvanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chickenpox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). There are estimatedto be approximately 120,000-150,000 annual chickenpox cases in the USA in the post-vaccination-era, i.e. since childhood vaccinationwith the live attenuated varicella virus Oka strain has become standard. In addition, we have drugs in development against allinfluenzas in our FluCide™ program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As the pandemic COVID-19 caused by theSARS-CoV-2 coronavirus was breaking out, the Company bootstrapped a rapid drug development program to develop drug candidates forthe treatment of SARS-CoV-2 infection. With the advantages of our prior work on coronaviruses, and having a library of chemicalligands, many of them already synthesized in our lab, we were able to advance this program very quickly into cell culture studiesagainst coronaviruses. We reported these studies were successful in a May 12, 2020 press release. We believe that this programis likely to advance rapidly towards human clinical trials due to the global COVID-19 pandemic emergency situation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Our drugs are based on several patents, patentapplications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc.(“TheraCour”), to which we have broad, exclusive licenses. The first license agreement we executed with TheraCouron September 1, 2005 (“Exclusive License Agreement”), gave us an exclusive, worldwide license for the treatmentof the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus(HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed anAdditional License Agreement with TheraCour.  Pursuant to the Additional License Agreement, the Company was grantedexclusive licenses for technologies, developed by TheraCour, for the development of drug candidates for the treatment ofDengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) andOcular Herpes. In addition, on November 1, 2019, the Company entered into a world-wide, exclusive, sub-licensable, license touse, promote, offer for sale, import, export, sell and distribute drugs that treat VZV infections, using TheraCour’sproprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as wellas formulations, the chemistry and chemical characterization, as well as process development and related work will beperformed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication ofcosts allowed. Upon commercialization, NanoViricides will pay 15% of Net Sales to TheraCour, as defined in the agreement. TheCompany was not required to make any upfront payments to TheraCour and agreed to the following milestone payments toTheraCour; the issuance of 75,000 shares of the Company’s Series A Convertible Preferred Stock upon the grant of an INDApplication; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase IIclinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials        <font style="font-size: 10pt">         . TheCompany has requested TheraCour for a license on the field of coronaviruses. A Memorandum of Understanding towards licensingthis field is being negotiated by the Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Reverse Stock Split         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On September 24, 2019, the Company effected a reverse stocksplit of its outstanding shares of common stock and shares of preferred stock at a ratio of one-for-twenty (the “ReverseStock Split”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Reverse Stock Split, which was approved by the Company’sBoard of Directors under authority granted under the laws of the State of Nevada, was consummated pursuant to a Certificate of Amendmentfiled with the Secretary of State of Nevada on September 23, 2019. Unless the context otherwise requires, all references in thesefinancial statements to shares of the Company’s common stock and Series A preferred stock, including prices per share ofits common stock and Series A preferred stock, reflect the Reverse Stock Split. Fractional shares were not issued, and the finalnumber of shares were rounded up to the next whole share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 2 – Liquidity        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s financial statementshave been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realizationof assets and liquidation of liabilities in the normal course of business. As reflected in the financial statements, the Companyhas an accumulated deficit at June 30, 2020 of approximately $105.6 million and a net loss of approximately $13.4 million and netcash used in operating activities of approximately $6.7 million for the fiscal year then ended. In addition, the Company has notgenerated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engagedexclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commencedany product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, asthe Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company willachieve or maintain profitability in the future. As of June 30, 2020, the Company had available cash and cash equivalents of approximately$13.7 million.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 113; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has focused its efforts primarilyon a single lead program to minimize cost outlays, namely, taking the shingles drug candidate against VZV into human clinical trials.Management has engaged in an additional drug development program for COVID-19 with limited additional costs in the current developmentstage, and anticipates that costs of advanced drug development for COVID-19 are likely to be supported by non-dilutive governmentfunding or equity-based funding if needed for future human clinical trials. During the current fiscal year, the Company has beenable to raise funds in the public markets. See Note 9        <b>         .        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        On July 8, 2020,subsequent to the date of the reporting period, the Company entered into an underwriting agreement (the “Underwriting Agreement”)with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. (“Kingswood”). The offering was consummatedon July 10, 2020, whereby the Company sold 1,369,863 shares of Common Stock and a fully exercised Underwriters’ over-allotmentoption of 205,479 additional shares the public offering price of $7.30 per share. No warrants were issued in this Offering. Thenet proceeds to the Company from the offering was approximately $10.53 million after deducting underwriting discounts and commissionsand other estimated offering expenses payable by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        On July 31, 2020,the Company entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc.and Kingswood Capital Markets, a division of Benchmark Investments, Inc. (each a “Sales Agent” and collectively, the “Sales Agents”), pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents,shares of Common Stock (the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATMOffering”). Sales pursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents,and the Company cannot provide any assurances that it will issue any Shares pursuant to the Sales Agreement. Actual sales willdepend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, thetrading price of the Company’s common stock, capital needs and determinations by the Company of the appropriate sources offunding for the Company. The Company is not obligated to make any sales of common stock under the Sales Agreement and the Companycannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The Company will pay a commissionrate of up to 3.5% of the gross sales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses,including the fees and disbursements of its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the SalesAgents an amount not to exceed $2,500 per quarter during the term of the Sales Agreement for legal fees to be incurred by the SalesAgents. The Company has also agreed pursuant to the Sales Agreement to provide each Sales Agent with customary indemnificationand contribution rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company believesthat it has several important milestones that it will be achieving in the ensuing year. Management believes that as it achievesthese milestones, the Company’s ability to raise additional funds in the public markets would be enhanced.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        The Company hasnot experienced a direct financial adverse impact of the effects of the Coronavirus (COVID-19) pandemic.  However the emergenceof widespread health emergencies due to COVID-19 may lead to regional quarantines, shutdowns, shortages, disruptions of supplychains, and economic instability. The impact of COVID-19 on the financial markets and the overall economy are highly uncertainand cannot be predicted at this time. Though the Company has not experienced a direct financial impact, if the financial marketsand/or the overall economy are impacted for an extended period, the Company’s ability to raise funds, in the future, maybe materially adversely affected.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Management believes that the Company’sexisting resources will be sufficient to fund the Company’s planned operations and expenditures through October 2021. However,the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletionof its capital resources more rapidly than it currently anticipates. The Company will need to raise additional capital to fundits long-term operations and research and development plans including human clinical trials for its various drug candidates untilit generates revenue which reaches a level sufficient to provide self-sustaining cash flows. The accompanying financial statementsdo not include any adjustments that may result from the outcome of such unidentified uncertainties.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 3– Summary of Significant Accounting Policies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Basis of Presentation         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s financial statementshave been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and includeall adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Net Loss per Common Share         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Basic net loss per common share is computedby dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss percommon share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstandingshares of common stock during the period to reflect the potential dilution that could occur from common shares issuable throughstock options, warrants, convertible preferred stock, and convertible debentures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table shows the numberof potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as their effectwere anti-dilutive:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Potentially Outstanding           <br/>           Dilutive Common Shares          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           For the Years Ended          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30, 2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30, 2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           June 30, 2018          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 58%; font: 10pt Times New Roman, Times, Serif">           Warrants          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           22,218          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           398,156          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           348,480          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Options          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,000          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,000          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">           Total          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           27,218          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           403,156          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           348,480          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has 368,602, 255,714 and266,570 shares of Series A preferred stock outstanding as of June 30, 2020, 2019 and 2018, respectively. Only in the event ofa “change of control” of the Company, each Series A preferred share is convertible to 3.5 shares of its newcommon stock. A “change of control” is defined as an event in which the Company’s shareholders become 60%or less owners of a new entity as a result of a change of ownership, merger or acquisition of the Company or theCompany’s intellectual property. In the absence of a change of control event, the Series A preferred stock is notconvertible into common stock, and does not carry any dividend rights or any other financial effects. At June 30, 2020, 2019and 2018 the number of potentially dilutive shares of the Company’s common stock into which these Series A preferredshares can be converted into is 1,290,107, 894,999 and 792,993, respectively, and is not included in diluted earnings pershare since the shares are contingently convertible only upon a change of control.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Series B Convertible Debentures wereconverted into common stock on February 8, 2017. The Series C Convertible Debenture was redeemed for common stock effective November13, 2017. The Series C Convertible Debenture was excluded from the loss per share calculation for the year ended June 30, 2018because the impact was anti-dilutive.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Use of Estimates         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The preparation of financial statementsin conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financialstatements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that arebelieved to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balancesheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which areused for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes.Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 114; Options: NewSection; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Fair Value of Financial Instruments         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Fair value is defined as the price thatwould be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants atthe measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or mostadvantageous market in which we would transact and we consider assumptions market participants would use when pricing the assetor liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair valuehierarchy to prioritize inputs used in measuring fair value as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 1: Observable inputs such as quoted prices in active markets;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Long-Lived Assets         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Long-lived assets are reviewed for impairmentwhenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverabilityof assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted net cashflows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measuredby the amount by which the carrying amount of the assets exceeds the fair value of the assets and would be charged to earnings.Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-partyindependent appraisals, as considered necessary. The Company has not recorded an impairment charge for the years ended June 30,2020, 2019 and 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Cash and Cash Equivalents         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company considers all highly liquidinstruments with original maturities of three months or less to be cash equivalents.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Property and Equipment         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Property and equipment is stated at costand depreciated over the estimated useful lives of the assets, using the straight-line method. The Company generally assigns usefullives of thirty years for assets classified as GMP facility, fifteen years for assets classified as furniture and fixtures, tenyears for assets classified as lab equipment, and five years for assets classified as office equipment. Expenditures for majoradditions and betterments are capitalized.  Maintenance and repairs are charged to operations as incurred. Upon saleor retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gainor loss is reflected in the statements of operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Trademarks and Patents         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company amortizes the costs of trademarksand patents on a straight-line basis over their estimated useful lives, the terms of the exclusive licenses and/or agreements,or the terms of legal lives of the patents, whichever is shorter. Upon becoming fully amortized, the related cost and accumulatedamortization are removed from the accounts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Research and Development         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Research and development expensesconsist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and otherexpenses for research and development, personnel, supplies and development materials, costs for consultants and relatedcontract research and facility costs. Expenditures relating to research and development are expensed as incurred.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 115; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Stock-Based Compensation         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company follows the provisions of ASC718 – “Stock Compensation”, which requires the measurement of compensation expense for all shared-based paymentawards made to employees and non-employee directors, including employee stock options. Stock-based compensation expense is basedon the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized as an expense overthe requisite service period, net of forfeitures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The fair value of common stock issued asemployee compensation is the average of the open and close share price on the date the common shares are issued.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Series A preferred shares are not tradedin any market. The assumptions used to determine the fair value of the Series A preferred shares issued as employee compensationare presented in Note 10 to the financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The fair value of each option award isestimated on the date of grant using a Black-Scholes option-pricing valuation model.  The ranges of assumptions for inputsare as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected term of share options and similar instruments: The expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value of the instruments. The Company uses the simplified method to calculate expected term of share options and similar instruments, as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected volatility of the Company’s shares and the method used to estimate it:  Expected volatility is based on the average historical volatility of the Company’s common stock over the expected term of the option.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected annual rate of quarterly dividends: The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0in">          </td>          <td style="width: 0.5in">           <font style="font-family: Symbol; font-size: 10pt">            ·           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk-free rate(s):  The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s policy is to recognizecompensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisiteservice period for the entire award.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         Equity Instruments Issued to Parties other than Employeesfor Acquiring Goods or Services        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2018, the FASB issued ASU No.2018-07,        <i>         Improvements to Nonemployee Shared-Based Payment Accounting        </i>        , (“ASU 2018-07”) which supersedes ASC505-50 and expands the scope of ASC 718 to include all share-based payments arrangements related to the acquisition of goods andservices from both employees and non-employees. The Company adopted ASU 2018-07 as of July 1, 2019. After the adoption of ASU2018-07, the measurement date for non-employee awards is the date of grant. Compensation expense for non-employees is recognizedover the requisite period, which is the vesting period of the respective award.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 116; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: 2 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Income Tax Provision         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company uses the asset and liabilitymethod of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operatingloss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred taxassets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferredtax assets will not be realized.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognizes uncertainty inincome taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken orexpected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to alltax positions, which resulted in no unrecognized taxbenefits as of June 30, 2020 and 2019. TheCompany has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant taxlaw as general and administrative expenses, in the statements of operations. For the years ended June 30, 2020, 2019 and 2018there was no such interest or penalty.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Concentrations of Risk         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Financial instruments that potentiallysubject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintainsdeposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed tosignificant credit risk due to the financial position of the depository institutions in which those deposits are held.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 117; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Recently Issued Accounting Pronouncements         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting,” which simplifies theaccounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-basedpayment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations byissuing share-based payment awards. The Company’s adoption of this ASU as of July 1, 2019 had no impact on the financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In July 2017, the FASB issued AccountingStandards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity(Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II.Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and CertainMandatorily Redeemable Non-controlling Interests with a Scope Exception (“ASU 2017-11”) ASU 2017-11 revises the guidancefor instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity,which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivativeaccounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down roundfeatures are no longer classified as liabilities. The Company has adopted ASU 2017-11 retrospectively as of January 1, 2019. The adoption of this ASU did not haveany impact on its financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 118; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 4 – Related Party Transactions        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Related Parties         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Related parties with whom the Company hadtransactions are:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 30%; border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Related Parties            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 69%; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Relationship            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dr. Anil R. Diwan           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman, President, CEO, significant stockholder and Director           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            TheraCour Pharma, Inc. (“TheraCour”)           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            An entity owned and controlled by Dr. Anil R.Diwan           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Milton Boniuk, MD           </font>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director (retired July 10, 2018) and former    significant stockholder           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 119; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Property and Equipment         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           For the Year Ended          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2018          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           During the reporting period, TheraCour acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment at cost, to the Company          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,638          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           23,666          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           30,321          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Accounts Payable- Related Party         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           As of          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">            Pursuant to an Exclusive License Agreement we entered into withTheraCour, the Company was granted exclusive licenses for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes,Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour cancharge its costs (direct and indirect) plus no more than 30% of certain direct costs as a development fee and such developmentfees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whicheveris higher for other general and administrative expenses incurred by TheraCour on our behalf, (3) to make royalty payments of 15%(calculated as a percentage of net sales of the licensed drugs) to TheraCour and; (4) to pay an advance payment equal totwice the amount of the previous months invoice to be applied as a prepayment towards expenses. On October 2, 2018, the Companyagreed to enter into an agreement with TheraCour for a waiver of two months worth of prepaid balance in advance of anticipatedinvoicing until the filing of an IND and the application of the current advance as a credit against current open invoices. Additionally,TheraCour agreed to defer $25,000 per month of development fees, beginning with July 2018 through December 31, 2019. On December17, 2019, the Company entered into a Deferred Expense Exchange Agreement with TheraCour, whereby the Company and TheraCour agreedto the exchange of 100,000 shares of Series A preferred stock with a fair value of $392,669 for $250,000 previously deferred developmentfees owed to TheraCour, and recognized a loss on the exchange of $142,669. Accounts payable due TheraCour on the reportingdate was           </p>          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           561,580          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           823,783          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Research and Development Costs Paidto Related Party         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           For the Year Ended          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2018          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Development fees    and other costs charged by TheraCour pursuant to the License Agreements between TheraCour and the Company for the    development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at June 30, 2020, 2019 and    2018          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,158,034          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,119,863          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="width: 1%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           3,176,977          </td>          <td style="width: 1%; padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 120; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Mortgage Note Payable - Related Party         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>        </i>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        On December 16, 2019, the Companyentered into an Open End Mortgage Note (the “Note”) with Dr. Anil Diwan, the Company’s founder, Chairman,President and CEO, to loan the Company up to $2,000,000 in two tranches of $1,000,000 (the “Loan”). The Notebears interest at the rate of 12% per annum and is secured by a mortgage granted against the Company’s headquarters.Dr. Anil Diwan received 10,000 shares of the Company’s Series A preferred stock as a loan origination fee which wasrecorded as a debt discount and is to be amortized over the one-year term of the loan using effective interest method. Thefair value of the 10,000 shares of the Company’s Series A preferred stock when issued on December 16, 2019 was $39,301.The Series A preferred stock fair value is based on the greater of the i) the converted value to common at a ratio of 1:3.5;or ii) the value of the voting rights since the holder would lose the voting rights upon conversion. For the assumptions usedin calculating the fair value of the preferred shares, the conversion of the shares is triggered by a change of control. Seenote 7 for inputs used in calculation of fair value. Amortization expense on the loan origination fee for the year ended June30, 2020 was $21,288. As of June 30, 2020, the Company has drawn down $1.1 million of this loan and may, at its option, drawdown the remainder of the loan. Interest is payable only on the amount drawn down. The lender had escrowed $132,000 ofinterest payable pursuant to the Loan. The balance at June 30, 2020 of the prepaid interest escrowed by the lender is $62,773and is included in prepaid expenses. For the year ended June 30, 2020, the Company incurred interest expense of $69,227,which reduced the interest escrow balance included in prepaid expenses.        <font style="background-color: white">         On April30, 2020, the Company and Dr. Diwan mutually agreed to extend the maturity date of the note at the Company’s option, toMay 15, 2021, with the rest of the terms remaining the same.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At June 30, 2020, mortgage note payable – related party consisted of:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Mortgage note payable          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,100,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Less: unamortized loan origination fee          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (18,013          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Net mortgage note payable          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,081,987          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Debenture Interest Payable to a Director         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        Coupon interest expense on the $5,000,000 Series C Debenturepaid to Milton Boniuk IRA for the years ended June 30, 2020, 2019 and 2018 was $0, $0, and $185,274,respectively. The Series C Debenture was redeemed effective November 13, 2017. (See Note 7).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 5 – Property and Equipment        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Property and equipment, stated at cost,less accumulated depreciation consisted of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           GMP Facility          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,020,471          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,020,471          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">           Land          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           260,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           260,000          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">           Office Equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57,781          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           57,781          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">           Furniture and Fixtures          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,607          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,607          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">           Lab Equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,756,956          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           5,748,318          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -9pt; padding-left: 9pt">           Total Property and Equipment          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14,100,815          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           14,092,177          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; text-align: justify; text-indent: -9pt; padding-left: 9pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt; text-align: left">          </td>          <td style="font-size: 10pt; text-align: right">          </td>          <td style="font-size: 10pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">           Less Accumulated Depreciation          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (4,556,384          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (3,864,930          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">           Property and Equipment, Net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           9,544,431          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,227,247          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Depreciation expense for the years endedJune 30, 2020, 2019 and 2018 was $691,454, $687,640 and $671,789, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 121; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 6 – Trademark and Patents        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Trademark and patents, stated at cost,less accumulated amortization consisted of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Trademarks and Patents          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           458,954          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           458,954          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Less Accumulated Amortization          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (100,566          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (92,296          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Trademarks and Patents, Net          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           358,388          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           366,658          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Amortization expense amounted to $8,270,$8,271, and $8,269 for the years ended June 30, 2020, 2019 and 2018, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company amortizes our trademarks andpatents over their expected original useful lives of 17 years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        Amortization expense in future years is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Years ended June 30        </u>        ,       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: justify">           2021          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           8,271          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           2022          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,271          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           2023          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,271          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           2024          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,271          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           2025          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           8,271          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">           Thereafter          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           317,033          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">           Total amortization          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           358,388          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 122; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 7 – Convertible Debentures and Derivatives        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <u>          Debenture - Series C         </u>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 2, 2014 (the “Closing Date”),the Company accepted a subscription in the amount of $5,000,000 for a 10% Coupon Series C Convertible Debenture (the “ SeriesC Debenture”) from the Milton Boniuk IRA, a trust controlled by a member of the Company’s Board of Directors, (the “Holder”). The Series C Debenture was due on June 30, 2018 (the “Maturity Date”) and was convertible, atthe sole option of the Holder, into restricted shares of the Company’s common stock, par value $0.001 per share at the conversionprice of $5.25 per share of common stock. The Series C Debenture bore interest at the coupon rate of ten percent (10%) per annum,computed on an annual basis of a 365 day year, payable in quarterly installments on March 31, June 30, September 30 and December31 of each calendar year until the Maturity Date. In accordance with the debenture agreement, the interest for the initial yearof the debenture for a total of $500,000 was deferred, to be paid over the remainder of the term at $166,667 per year. The Holderat its option may choose to receive such coupon interest payment in shares of common stock calculated using the average of theopen and close prices of the Company’s common stock on the date such interest payment was due.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Series C Debenture was redeemed onNovember 13, 2017. For the year ended June 30, 2018, the Holder elected to receive $60,274 (through November 13, 2017) of its couponinterest payment and $125,000 of deferred interest payment in common stock of the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 123; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 2, 2014, in conjunction with theissuance of the Company’s Series C Debenture, the Company issued 9,350 shares of its Series A preferred stock(the “Series A”) to Dr. Milton Boniuk, pursuant to the terms of the Debenture. Proceeds received in a financing transactionare allocated to the instruments issued prior to evaluating hybrid contracts for bifurcation of embedded derivatives. Since theSeries A preferred stock is classified as equity, the proceeds allocated to the preferred stock are recorded at relativefair value. The fair value of the Series A was $1,645,606 at issuance and the relative fair value was calculated as $1,152,297.The remaining amount of the proceeds was allocated to the  Series C Debenture and a debt discount of $1,152,297 was recordedto offset the amount of the proceeds allocated to the Series A. Then, the embedded derivative was bifurcated at its fair valueof $1,879,428 with the remaining balance allocated to the host instrument (Debenture). The total debt discount was amortized overthe actual term of the  Series C Debenture using the effective interest method.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company recognized amortization ofthis discount as an additional interest charge to “Discount on convertible debentures” in the amount of $359,214, forthe year ended June 30, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Holder of the Series C Debenture andthe Company agreed on November 13, 2017 that the Series C Debenture would be redeemed for the Company’s common stock, asdescribed further below. The Holder waived all early redemption payments provided for in the Series C Debenture in considerationfor 7,500 shares of the Company’s Series A preferred shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 124; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: 4 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s Series CDebenture in the amount of $5,000,000 was due to mature on June 30, 2018. On November 13, 2017, the Company entered into aDebenture Redemption Agreement (the “Agreement”) with the Holder, to redeem (the “Redemption”) its$5,000,000 Series C Debenture for an aggregate of 275,000 shares of the Company’s $0.001 par value common stock(“Purchase Price”) comprising 250,000 shares for the principal of the Series C Debenture and 25,000 shares forunpaid coupon interest from October 1, 2017 through June 30, 2018. The unpaid interest included $60,274 of accrued interestthrough November 13, 2017, $314,726 in coupon interest through June 30, 2018 and $125,000 of unpaid deferred interest. Theprice per share was equal to the closing price of the Company’s common stock on Friday, November 10, 2017 of twentydollars per share. The Holder waived all early redemption penalty payments provided for in the  Series C Debenture forconsideration of 7,500 shares of the Company’s $0.001 par value Series A preferred stock. The Company did not incurplacement agent fees in redemption of the Series C Debenture. The Company recognized a non-cash loss on extinguishment ofdebt of $1,348,247 on the extinguishment of the aforesaid principal attributable to the Series C Debenture into theCompany’s common and preferred stock. The loss on extinguishment arises from, the obligation to issue 7,500 shares ofthe Company’s Series A preferred shares with a fair value of $364,337, as of November 13, 2017, obligation to issue15,737 shares of the Company’s $0.001 par value common stock with a fair value of $314,726 as of November 13, 2017, inconsideration of Series C Debenture coupon interest from the redemption date through June 30, 2018, and unamortizeddiscount of $684,633 as of the redemption date, offset by the derivative liability of ($15,449) as of the redemptiondate.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pursuant to the Agreement for the Company’sSeries C Debenture, the Company issued 275,000 shares of its registered common stock from its shelf registration and 7,500shares of its Series A preferred stock upon receiving consent to issue the shares pursuant to New York Stock Exchange (“NYSE”)regulations. The Company submitted a request for authorization to issue the common stock and Series A preferred shares to the NYSE,which was authorized on March 18, 2018 and the shares were issued on March 21, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On November 13, 2017, the Company recognizeda liability from the obligation to issue the shares in settlement of the redemption of the Company’s Series C Debenture totaling$5,864,337. On March 21, 2018, when the shares were issued, the 7,500 Series A preferred shares had a fair value of $314,343and the common shares had a fair value of $4,730,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The change in the fair value of the obligationto issue registered shares was recorded in the statements of operations as “change in the fair value of derivatives”.For the year ended June 30, 2018, the gain from change in fair value of the obligation to issue registered shares was $819,994.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 21, 2018, when the shares wereissued, the liability for the obligation to issue registered shares of $4,730,000 for the common shares and $314,343 for the SeriesA preferred shares was reclassified to stockholders’ equity.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Series A preferred stock fairvalue as of November 13, 2017 and March 21, 2018 is based on the greater of i) the converted value to common at a ratio of1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion ofthe shares is triggered by a change of control. The valuations of the Series A preferred stock at each date used thefollowing inputs:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The common stock price was in the range $22.80 to $18.40;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            b.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of shares of common stock in the period;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            c.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A 26.63% premium over the common shares for the voting preferences;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            d.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 12.27% to 15.25% of the total;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            e.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The conversion value is based on an assumption for calculation purposes only of a change of control in 4 years from October 31, 2016 and a remaining restricted term of 3.00 to 2.59 years;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.95pt; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            f.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.69% to 30.43% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 58.33% to 52.49% volatility, 1.62% to 2.30% risk free rate) applied to the converted common.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 125; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 8 – Accrued expenses        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Accrued expenses consisted of the following:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2020          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30,           <br/>           2019          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">           Severance payment          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           21,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           57,000          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           Personnel and compensation costs          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           38,240          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           11,871          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">           Consultant          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           10,000          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           69,240          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           68,871          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 9 – Loan Payable        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company financed its Directors andOfficers liability insurance policies through BankDirect. The original loan balance, as of January 1, 2020, is $155,173 payableat the rate of $15,874 per month through October 2020 including interest at an annual interest rate of 5%. At June 30, 2020, theloan balance was $62,843. For the year ended June 30, 2020, the Company incurred interest expense of $2,916.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 10 – Equity Transactions        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ended June 30, 2018 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the ScientificAdvisory Board was granted fully vested warrants to purchase 2,287 shares of common stock at exercise prices between $12.80- $31.20per share expiring in the fiscal year ending June 30, 2022.  These warrants were valued at $16,770 and recorded as consultingexpense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Companyestimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-ScholesOption-Pricing Model with the following weighted-average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 87%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected life (year)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected volatility           </font>          </td>          <td>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53.56% -56.10           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected annual rate of quarterly dividends           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.00           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk-free rate(s)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.67 – 2.84           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, EugeneSeymour was granted five year warrants (the “Warrants”) to purchase 12,500 of the Company’s common stock, parvalue $0.001 per share (the “Common Stock”) at an exercise price of $40.00 per share, vesting in three, equal installmentsover three years with the last installment vesting on May 1, 2021. The fair value of these warrants was $53,500 and recorded asemployee compensation expense for severance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Companyestimated the fair value of the warrants granted to Eugene Seymour on the date of grant using the Black-Scholes Option-PricingModel with the following weighted-average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 87%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected life (year)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected volatility           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            53.56           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected annual rate of quarterly dividends           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.00           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk-free rate(s)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.56           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 126; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Company’sBoard of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which are fully vestedwith a restrictive legend for employee compensation. The Company recorded an expense of $136,106, which is the fair value at dateof issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The fair value of the Series A Preferred Stock was the followingfor the dates indicated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Date            </b>           </font>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Shares            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Value            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 62%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/31/2017           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 16%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 16%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,242           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/31/2017           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,397           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/30/2017           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,588           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10/31/2017           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,011           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/30/2017           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6,313           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12/31/2017           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6,513           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,552           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2/28/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,404           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/03/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,340           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            60,725           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,811           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/30/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5,215           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,639           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/30/2018           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3,696           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,888           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            136,106           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There is currently no market for the sharesof Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Companyas more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferredstock granted to various employees and others on the date of grant. The Series A preferred stock fair value is based on the greaterof i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would lose thevoting rights upon conversion. The conversion of the shares is triggered by a change of control. The valuations of the Series Apreferred stock at each issuance used the following inputs:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The common stock price was in the range $11.60 to $22.80;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            b.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of shares of common stock in the period;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            c.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A 26.63% premium over the common shares for the voting preferences;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            d.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 10.25% to 15.50% of the total;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            e.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The conversion value was based on an assumption for calculation purposes only, for the period ended September 30, 2016 of a change of control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years. For the period from October 1, 2016 to June 30, 2017, the conversion value was based on an assumption for calculation purposes only of a change of control in 4 years and a remaining restricted term of 4 to 3.34 years;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            f.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            21.76% to 38.87% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 53.22% to 85.39% volatility, 0.37% to 2.10% risk free rate) applied to the converted common.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 127; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Companyrecognized a noncash compensation expense of $267,144 related to Series A preferred shares issued on July 21, 2015 in accordancewith Dr. Anil Diwan’s employment agreement that vest over the three years ended June 30, 2018.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Companyrecognized a noncash compensation expense of $121,008 related to Series A preferred shares issued on July 21, 2015 in accordancewith Dr. Eugene Seymour’s employment agreement that vested over three years. On January 27, 2018, Dr. Eugene Seymour resignedas Chief Executive Officer and as a Director of the Company. See Note 12.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Company’sBoard of Directors authorized the issuance of 7,500 shares of its Series A preferred stock, which are fully vestedwith a restrictive legend to the Holder of the Company’s Series C Debenture in consideration for its waiver ofall early redemption payments provided for in the Debenture. See Note 7. The Company recorded an expense of $314,343, which isthe fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Company’sBoard of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation. The Companyrecognized a noncash compensation expense of $65,716.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Company’sBoard of Directors authorized the issuance of 12,188 fully vested shares of its common stock with a restrictive legend for consultingservices. The Company recorded an expense of $156,190, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018, the Company’sBoard of Directors authorized the issuance of 2,489 fully vested shares of its common stock with a restrictive legend for Directorservices. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2018 the Holderof the Company’s Series C Debentures elected to receive 275,000 shares of the Company’s restricted common stock inredemption for its $5,000,000 Series C Debenture, quarterly interest payments of $375,000 and deferred interest of $125,000. Forthe year ended June 30, 2018, the Company’s Board of Directors authorized the issuance of 275,000 shares of the Company’srestricted common stock for the redemption of the debenture payable to the Holder and quarterly and deferred interest payments.(See Note 7)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ended June 30, 2019 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 11, 2018 the Board of Directorsapproved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms ofthe employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 of the Company’s SeriesA preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30, 2019, June 30, 2020 and June30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expense related to the issuance of the SeriesA preferred stock of $189,040 for the year ended June 30, 2019. The balance of $371,650 will be recognized as the shares vest andservice is rendered.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 19, 2018, the Company entered intoan Employment Agreement with Dr. Irach Taraporewala as Chief Executive Officer of the Company beginning on September 1, 2018. Dr.Taraporewala was granted options to purchase up to 15,000 shares of the Company’s common stock, par value $0.001 per shareat an exercise price equal to 20% above the closing bid price of $8.20 of the common stock on September 1, 2018 (“EffectiveDate”). The options shall vest in three, equal, annual installments commencing on the effective date. The grant date fairvalue of the options was $35,761 of which $11,920 was recognized and recorded as compensation expense for the year ended June 30,2019. On January 24, 2019, Dr. Taraporewala resigned as the Chief Executive Officer of NanoViricides, Inc. (the “Company”)for personal reasons and all unvested options were forfeited. (See Note 14).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company estimated the fair value ofthe options granted to Dr. Taraporewala on the date of the grant using a lattice model that values the options based upon a stockprice modeled such that it follows a geometric Brownian motion with constant drift and volatility.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the ScientificAdvisory Board was granted fully vested warrants to purchase 2,287 shares of common stock at exercise prices between $6.00- $9.40per share expiring in the fiscal year ending June 30, 2023.  These warrants were valued at $5,475 and recorded as consultingexpense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the Companyestimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-ScholesOption-Pricing Model with the following weighted-average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 86%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected life (year)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected volatility           </font>          </td>          <td>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47.46-55.12           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected annual rate of quarterly dividends           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.00           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk-free rate(s)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.14-2.93           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 128; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On February 27, 2019, the Company enteredinto a Securities Purchase Agreement (the “Agreement”) with certain institutional investors (the “Purchasers”),for a registered direct offering (the “Offering”) of 347,223 shares of common stock (“Shares”) at the purchaseprice of $7.20 (“Purchase Price”) per share for an aggregate of $2,500,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The offer and sale of the Shares in theregistered direct offering was registered under the Securities Act of 1933, as amended (the “Securities Act”), pursuantto the Company’s shelf registration statement on Form S-3, as amended (File No. 333-216345), which became effective on April25, 2017. Pursuant to Rule 424(b) under the Securities Act, the Company has filed a prospectus supplement in connection with suchoffering.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In a concurrent private placement, thePurchasers received warrants (the “Warrants”) to purchase up to 347,223 shares of common stock. The Warrants have anexercise price of $12.20 per share, shall be exercisable on the six-month anniversary of issuance and will expire five (5) yearsthereafter. The Warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus,by cashless exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company accounted for the proceedsof the Offering at February 27, 2019 as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 84%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gross proceeds           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 13%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,500,000           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Less: Offering costs           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            150,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net proceeds           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,350,000           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Portion allocated to derivative liability - warrants           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,527,259           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net proceeds from issuance of common stock           </font>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            822,741           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The exercise price of the Warrants is subjectto adjustment in the case of customary events such as stock dividends or other distributions on shares of common stock or any otherequity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications orsimilar events affecting our common stock, and also, subject to limitations, upon any distribution of assets, including cash, stockor other property to our stockholders. The exercise of the Warrants is subject to certain beneficial ownership and other limitationsset forth in the Warrants. The Company will receive proceeds from the concurrent private placement transaction solely to the extentthe Warrants are exercised for cash.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In connection with the Offering and theconcurrent private placement, the Company engaged Chardan Capital Markets, LLC (the “Placement Agent”) to act as itsexclusive placement agent. The Company agreed to pay the Placement Agent a cash placement fee equal to 5% of the aggregate purchaseprice for the common stock sold in the offering, plus $25,000 in legal fees. The net proceeds from the offering were $2,350,000.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company determined the fair value ofthe Warrants at February 27, 2019 to be $1,527,259. The Company used a lattice model to calculate the fair value of the derivativewarrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potentialoutcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. Underapplicable accounting guidance contained in ASU 2017-11, adopted by the Company on January 1, 2019, stock warrants are to be accountedfor as equity if the warrants contain full-ratchet anti-dilution provisions. The warrants described above contained a full-ratchetanti-dilution feature but also contained other adjustment features which required that the warrants be classified as a derivativeliability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Warrants were valued as of February27, 2019 (the issuance date) and June 30, 2019 with the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The 5.5-year warrants were issued on February 27, 2019 with an exercise price of $12.20 (subject to adjustments-full ratchet reset).           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with the Company’s projected volatility.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -17.95pt">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrants as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times the projected exercise/reset price or 2 times the stock price.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrant at maturity if the stock price was above the project reset prices.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The risk free rate at February 27, 2019 and June 30, 2019 was 2.48% and 1.95% respectively.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The fundamental transaction projected with 0% probability increasing 1% per quarter to maximum of 10% and settlement based on the Black Scholes value.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock price at February 27, 2019 was $9.60           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Stock price at June 30, 2019 was $4.80           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 129; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The next capital raise is projected to occur during 2020 (annually 12 months from issuance) at prices approximating 100% market triggering a reset event and exercise price adjustment.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 38px">          </td>          <td style="width: 19px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation period. The projected annual volatility for the valuation date is:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             1 Year            </b>           </font>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2/27/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            75           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 82%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/30/2019           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 15%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            76.1           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The primary factors driving the economicvalue of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over theremaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assignedto each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option valuewas then probability weighted and discounted to the present. (See Note 11).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the Company’sBoard of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which are fully vested with a restrictivelegend for employee compensation. The Company recorded an expense of $48,828, which is the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The fair value of all Series A preferred stock issued duringthe year ended June 30, 2019 was the following for the dates indicated:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Date            </b>           </font>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Shares            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Value            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 58%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/11/2018           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 18%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            26,250           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 18%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            560,690           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,795           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,374           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9/30/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,598           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,233           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11/30/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,883           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12/31/2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,245           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1/31/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,203           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2/28/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,949           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/01/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,340           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            24,340           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3/31/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2,336           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4/30/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,636           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5/31/2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,540           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6/30/2019           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            129           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,696           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: center">          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            29,138           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            609,518           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There is currently no market for the sharesof Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Companyas more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferredstock granted to various employees and others on the date of grant. The Series A preferred stock fair value is based on the greaterof i) the converted value to common stock at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would losethe voting rights upon conversion. The conversion of the shares is triggered by a change of control. The valuations of the SeriesA preferred stock at each issuance used the following inputs:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The common stock price was in the range $4.00 to $11.60;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            b.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of shares of common stock in the period;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            c.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A 26.63% premium over the common shares for the voting preferences;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            d.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 19.28% to 19.52% of the total;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            e.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The conversion value was based on an assumption for calculation purposes only, of a change of control in 4 years from October 31, 2016 and a remaining restricted term of 2.34 to 1.34 years.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            f.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.25% to 33.16% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 79.20% to 90.60% volatility, 2.50% to 2.35% risk free rate) applied to the converted common.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 130; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the Company’sBoard of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation. The Companyrecognized a noncash compensation expense of $28,572, which was the fair value on the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the Company’sBoard of Directors authorized the issuance of 28,210 fully vested shares of its common stock with a restrictive legend for consultingservices. The Company recorded an expense of $208,960, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2019, the Company’sBoard of Directors authorized the issuance of 7,325 fully vested shares of its common stock with a restrictive legend for directorservices. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <i>         <u>          Fiscal Year Ended June 30, 2020 Transactions         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 11, 2018 the Board ofDirectors approved an extension of the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant tothe terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 26,250 of theCompany’s Series A preferred stock to Dr. Anil Diwan. The shares shall be vested in one-third increments on June 30,2019, June 30, 2020 and June 30, 2021 and are subject to forfeiture. The Company recognized non-cash compensation expenserelated to the issuance of the Series A preferred stock of $189,040 for the year ended June 30, 2020. The balance of $182,610will be recognized as the remaining 8,750 shares vest and service is rendered for the year ended June 30, 2021.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the ScientificAdvisory Board was granted fully vested warrants to purchase 2,286 shares of common stock at exercise prices between $2.63- $12.16per share expiring in the fiscal year ending June 30, 2024.  These warrants were valued at $7,373 and recorded as consultingexpense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Companyestimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-ScholesOption-Pricing Model with the following weighted-average assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 86%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected life (year)           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected volatility           </font>          </td>          <td>          </td>          <td>          </td>          <td style="white-space: nowrap; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47.99-90.32           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expected annual rate of quarterly dividends           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.00           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Risk-free rate(s)           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            0.25-1.63           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            %           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 131; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 21, 2020, the Company enteredinto an Underwriting Agreement with Aegis Capital Corp. Pursuant to the terms and conditions of the Underwriting Agreement, weagreed to issue and sell 2,500,000 shares of our common stock, par value $0.001 per share, at a price to the public of $3.00 pershare. Pursuant to the Underwriting Agreement, we also granted the underwriter an option to purchase up to an additional 375,000shares of our common stock within 45 days after the date of the Underwriting Agreement to cover over-allotments, if any. The FinalProspectus for the offering was filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(1) of the SecuritiesAct of 1933, as amended, on January 23, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 1.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The offering was consummated on January25, 2020. The Company sold the Underwritten Shares and the underwriter exercised its option to purchase an additional 375,000 sharesof common stock at the public offering price of $3.00 per share. The net proceeds to the Company after underwriter's commissionand agreed upon customary fees and expenses, and deducting the Company's legal and accounting expenses related to the Offeringwas $7,457,575.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company accounted for the proceedsof the Offering at January 25, 2020 as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 86%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gross proceeds           </font>          </td>          <td style="width: 2%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,625,000           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Less: offering costs           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1,167,425           </font>          </td>          <td style="text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Net proceeds from issuance of common stock           </font>          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7,457,575           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 24, 2020, the Company enteredinto a Binding Term Sheet which was incorporated on January 27, 2020 in a Settlement Agreement and Mutual Release (the “SettlementAgreement”) with the investor parties (collectively, the “Investors”) to that certain Securities Purchase Agreementdated as of February 27, 2019 (the "Securities Purchase Agreement") to settle an action commenced by the Investors to,among other things, enjoin the Company’s previously disclosed underwritten public offering (the “Action”)       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On January 27, 2020, the Companyentered into an Exchange Agreement with each of the Investors pursuant to the Settlement Agreement. Pursuant to the terms andconditions of the Exchange Agreement, the Investors agreed to terminate certain restrictive covenants in the SecuritiesPurchase Agreement, including a bar on all offerings of securities below the exercise price of the Warrants to purchasecommon stock issued February 19, 2019 (the “Old Warrants”), and the Company agreed to exchange 347,222 of theInvestors’ Old Warrants for an aggregate of (i) 677,224 shares of common stock and (ii) new warrants, to purchase347,222 shares of common stock at an exercise price of $3.00 per share and expire on August 24, 2024  (the “NewWarrants”). The common stock issued had a fair value of $5,722,543 using the closing price of $8.45 on January 24, 2020resulting in an increase to common stock of $677 and additional paid in capital of $5,721,866 and the New Warrants had a fairmarket value of $2,066,425 which was recorded as a derivative liability. The aggregate fair value of the common stock and NewWarrants issued as part of the Exchange Agreement was $7,788,968. The Old Warrants were remeasured to a fair value of$8,403,462 on January 24, 2020 immediately prior to the exchange. As a result of the Exchange Agreement, a gain on warrantsettlement was recognized in the amount of $614,494 calculated as the difference between the fair value of the Old Warrantsimmediately prior to the exchange and the aggregate fair value of the common stock and New Warrants issued in the exchange.On March 16, 2020 the shareholders of NanoViricides authorized an increase in the number of authorized common stock to150,000,000 shares and the New Warrants were issued and exercisable. These warrants contained a full-ratchet anti-dilutionfeature but also contained other adjustment features which required that the warrants be classified as a derivativeliability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The 347,222 New Warrants were exercisedon March 23, 2020 and March 25, 2020 pursuant to a cashless exercise provision resulting in the issuance of 180,087 shares of commonstock. The fair value of the warrants were reset to fair value as of March 23, 2020 and March 25, 2020, and, upon exercise of thewarrants, the derivative liability was reclassified to equity of $1,153,881.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        OnMay 21, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for anoffering of 1,400,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share atthe purchase price of $7.30 per share. The Shares were issued pursuant to a prospectus supplement dated May 21, 2020which was filed with the Securities and Exchange Commission on May 22, 2020 in connection with a takedown from theCompany’s shelf registration statement on Form S-3, as amended (File No. 333-237370), which became effectiveon April 2, 2020 and the base prospectus dated April 2, 2020 contained in that registration statement. The Offeringclosed on May 22, 2020. The net proceeds to the Company from the offering are approximately $9.2 million after placementagent fees and other estimated offering expenses payable by the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company accounted for the proceedsof the Offering at May 22, 2020 as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 86%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gross proceeds           </font>          </td>          <td style="width: 2%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10,220,000           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Less: offering costs           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid">          </td>          <td style="border-bottom: Black 1pt solid; text-align: right">           (           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1,000,600           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left; vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-left: 0.125in">           Net proceeds from issuance of common stock          </td>          <td>          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9,219,400           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 10,000 fully vested shares of its Series A preferred stock for a loan originationfee to a related party with a fair value of $39,301, which is the fair value at date of issuance. See Note 4.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 100,000 fully vested shares of its Series A preferred stock with a fair value of$392,669 in exchange for $250,000 of previously deferred development fees to a related party and recognized a loss on the exchangeof $142,669. See Note 4.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 2,888 shares of its Series A preferred stock, which are fully vested with a restrictivelegend for employee compensation. The Company recorded an expense of $41,857, which is the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There is currently no market for the sharesof Series A preferred stock and they can only be converted into shares of common stock upon a change of control of the Companyas more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A preferredstock granted to various employees and others on the date of grant. The Series A preferred stock fair value is based on the greaterof i) the converted value to common stock at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would losethe voting rights upon conversion. The conversion of the shares is triggered by a change of control. The valuations of the SeriesA preferred stock at each issuance, except for the period April 1, 2020 through June 30, 2020 used the following inputs:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 132; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <!-- Field: Split-Segment; Name: 5 -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The common stock price was in the range $2.03 to $10.82;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            b.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of shares of common stock in the period;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            c.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            A 26.63% premium over the common shares for the voting preferences;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            d.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 14.9% to 18.3% of the total;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            e.           </font>          </td>          <td style="text-align: justify">           Prior to January 1, 2020, the conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from October 31, 2016 and a remaining restricted term of 1.08 to .92 years. From January 1, 2020 the conversion value is based on the assumption for calculation purposes only, of a Change of Control in five years from 12/31/2019 for the issuances and a remaining restricted term of 5.00 to 4.84 years;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            f.           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            29.30% to 48.66% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 80.41% to 82.23% volatility, 1.69% to 1.73% risk free rate) applied to the converted common.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        For the period April 1, 2020 throughJune 30, 2020, the Series A preferred stock fair value is based on the converted value to common stock at a ratio of 1:3.5 multipliedby the monthly average of the daily open and close price of the common stock.        <font style="font-size: 10pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 3,572 fully vested shares of its common stock for employee compensation. The Companyrecognized a noncash compensation expense of $29,251, which was the fair value on the date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 78,958 fully vested shares of its common stock with a restrictive legend for consultingservices. The Company recorded an expense of $254,250, which was the fair value at the dates of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, the Company’sBoard of Directors authorized the issuance of 10,728 fully vested shares of its common stock with a restrictive legend for directorservices. The Company recorded an expense of $45,000, which was the fair value at date of issuance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, theCompany’s Board of Directors authorized the issuance of 25,667 fully vested shares of its common stock with arestrictive legend to satisfy open accounts payable of $77,000 for consulting services. The number of shares issued to settlethe accounts payable was calculated using the market price of the common stock on the settlement date.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended June 30, 2020, theCompany’s Board of Directors authorized the settlement with a vendor to redeem and cancel 17,200 shares of its commonstock with a restrictive legend, which were initially issued in payment of accounts payable of $25,000. The shares werecanceled and reported as reductions of common stock issued in exchange for accounts payable reported in the Statement ofChanges in Stockholders’ Equity as a decrease of $25,000. The redemption and cancellation had no effect on the results ofoperations for the year ended June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 11 – Stock Options and Warrants        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">        <u>         Stock Options        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The following table presents the activity of stock options forthe years ended June 30, 2020 and 2019:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Stock Options            </b>           </font>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Number of             <br/>             Shares            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Exercise             <br/>             Price             <br/>             per share ($)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Remaining             <br/>             Contractual             <br/>             Term (years)            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="white-space: nowrap; border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             Aggregate             <br/>             Intrinsic             <br/>             Value ($)            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Outstanding at June 30, 2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            15,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            .50           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Forfeited           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            .50           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Canceled           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid; padding-bottom: 1pt; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Outstanding at June 30, 2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            5,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            10.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            2.16           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="width: 48%">           <font style="font-size: 10pt">            Granted           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Forfeited           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Canceled           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Outstanding and exercisable at June 30, 2020           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            5,000           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            10.00           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            1.16           </font>          </td>          <td>          </td>          <td>          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Of the above options, 5,000 became vestedand exercisable on September 1, 2018. The options expire on August 31, 2021. On January 24, 2019, Dr. Taraporewala resigned asthe Chief Operating Officer of the Company and the 10,000 remaining unvested options were forfeited.  See Note 14.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company estimated the fair value ofthe options granted to Dr. Taraporewala on the date of the grant using a lattice model that values the options based upon a stockprice modeled such that is follows a geometric Brownian motion with constant drift and volatility.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 133; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the years ended June 30, 2020 and 2019,the Company recognized compensation expense of $0 and $11,920 related to vested options granted to Dr. Taraporewala. As of June30, 2020, there was no unrecognized compensation cost.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Stock Warrants        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stock Warrants            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Number of             <br/>             Shares            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Exercise             <br/>             Price             <br/>             per share ($)            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Weighted             <br/>             Average             <br/>             Remaining             <br/>             Contractual             <br/>             Term (years)            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Aggregate             <br/>             Intrinsic             <br/>             Value ($)            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 48%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Outstanding and exercisable at June 30, 2017           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            333,693           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            98.60           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.36           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14,787           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            37.40           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expired           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Canceled           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Outstanding and exercisable at June 30, 2018           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            348,480           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            96.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            .53           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            349,509           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12.20           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expired           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            299,837           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.60           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Canceled           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Outstanding and exercisable at June 30, 2019           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            398,156           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            18.20           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.69           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Granted           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            349,508           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Exercised           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            347,222           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Expired           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            378,224           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            17.00           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Canceled           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Outstanding and exercisable at June 30, 2020           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22,218           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            30.82           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.28           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,533           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Of the above warrants; 2,858 expire infiscal year ending June 30, 2021; 2,286 expire in fiscal year ending June 30, 2022; 14,788 expire in fiscal year ending June 30,2023; and 2,286 expire in fiscal year ending June 30, 2024.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 12 – Fair Value Measurement        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Fair value measurements         <i>         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At June 30, 2020 and 2019, the fair valueof derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferredand common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life,risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures.        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 134; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At June 30, 2020 and 2019, the estimatedfair values of the liabilities measured on a recurring basis are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td colspan="9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            <b>             Fair Value Measurements at            </b>           </font>          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td colspan="9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font: 10pt Times New Roman, Times, Serif">            <b>             June 30, 2020:            </b>           </font>          </td>          <td style="padding-bottom: 1pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center; font-size: 10pt; padding-bottom: 1pt">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Level 1)            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Level 2)            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">          </td>          <td style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">          </td>          <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (Level 3)            </b>           </font>          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Derivative liability – Warrants          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Total derivatives          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">           Fair Value Measurements at          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           June 30, 2019:          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           (Level 1)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           (Level 2)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           (Level 3)          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Derivative liability – Warrants          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,645,606          </td>          <td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">           Total derivatives          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           1,645,606          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In a concurrent private placement on February27, 2019, the purchasers received warrants (the “Old Warrants”) to purchase up to 347,222 shares of common stock. TheOld Warrants had an exercise price of $12.20 per share, shall be exercisable on the six month anniversary of issuance and wereto expire five (5) years thereafter. The Old Warrants are exercisable for cash or, solely in the absence of an effective registrationstatement or prospectus, by cashless exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company accounts for stock purchasewarrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Underapplicable accounting guidance contained in ASU 2017-11, adopted by the Company on January 1, 2019, stock warrants are to be accountedfor as equity if the warrants contain full-ratchet anti-dilution provisions. The Old Warrants issued on February 27, 2019, containeda full-ratchet anti-dilution feature but also contained other adjustment features which required that the Old Warrants be classifiedas a derivative liability.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company used a lattice model to calculatethe fair value of the derivative warrants based on a probability weighted discounted cash flow model.  This model is basedon future projections of the various potential outcomes. The features that were analyzed and incorporated into the model includedthe exercise and full reset provisions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Old Warrants were valued as of June30, 2019 with the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The 5 year warrants issued on February 27, 2019 (expire February 27, 2024) included with an exercise price of $12.20 (subject to adjustments – full ratchet reset and fundamental transactions).           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with the Company projected volatility.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            The holder would exercise thewarrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times the projectedreset exercise price or 2 times the stock price.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The holder would exercise the warrant at maturity if the stock price was above the project reset prices.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            The next capital raise is projectedto occur during 2020 (annually 12 months from issuance) at prices approximating 100% of market triggering a reset event and exerciseprice adjustment.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            The fundamental transaction projectedwith 0% probability increasing 1% per quarter to a maximum of 10% and settlement based on the Black Scholes value.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            The stock price would fluctuatewith an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuationperiod.           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 135; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <table align="CENTER" cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">           1 Year          </td>          <td style="font-size: 10pt; padding-bottom: 1pt">          </td>          <td colspan="2" style="font-size: 10pt">          </td>          <td style="padding-bottom: 1pt; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 87%; font: 10pt Times New Roman, Times, Serif">           6/30/19          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           76.1          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company remeasured the fair value of the derivative OldWarrants at January 24, 2020 to $8,403,468 with the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Valuation based on 347,222 warrants with an exercise price of $12.20           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lattice model based on market stock price of $8.45           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrant at maturity if the stock price was above the projected exercise price.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            An imminent reset event to $3.00 was projected based on the Company’s offering.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future capital raises are projected to occur starting 1/31/21, and annually thereafter, at prices approximating 100% of market, which may trigger a reset event adjusting the exercise and the number of warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The fundamental transaction was projected to occur 10% of the time, tested on an annual basis, with settlement equal to the Black Scholes value.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatility of the Company for the valuation date. The projected annual volatility for the valuation date was 106.5%.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 56.4pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The fair value of the New Warrants was$2,066,425 upon issuance at January 24, 2020 using the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Valuation based on 347,222 warrants with an exercise price of $3.00           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lattice model simulation based on market stock price of $8.45           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrant at maturity if the stock price was above the projected exercise price.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future capital raises are projected to occur starting 1/31/21, and annually thereafter, at prices approximating 100% of market, which may trigger a reset event adjusting the exercise and the number of warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20pt 0pt 60.95pt; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The fundamental transaction was projected to occur 10% of the time, tested on an annual basis, with settlement equal to the Black Scholes value.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.35pt 0pt 60.95pt; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatility of the Company for the valuation date. The projected annual volatility for the valuation date was 106.5%.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 56.4pt">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The 347,222 New Warrants were exercisedon March 23, 2020 and March 25, 2020 pursuant to a cashless exercise provision resulting in the issuance of 180,087 shares of commonstock. The Company remeasured the fair value of the new warrants just prior to their exercise.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company remeasured the fair value of the derivative NewWarrants exercised at March 23, 2020 to $941,701 with the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Valuation based on 266,614 warrants exercised with an exercise price of $3.00           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lattice model based on market stock price of $6.11           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrant at maturity if the stock price was above the projected exercise price.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 136; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future capital raises are projected to occur starting 4/30/21, and annually thereafter, at prices approximating 100% of market, which may trigger a reset event adjusting the exercise and the number of warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The fundamental transaction was projected to occur 10% of the time, tested on an annual basis, with settlement equal to the Black Scholes value.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatility of the Company for the valuation date. The projected annual volatility for the valuation date was 122.6%.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        The Company remeasured the fair value of the derivative NewWarrants at March 25, 2020 to $212,180 with the following assumptions:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Valuation based on 80,608 warrants exercised with an exercise price of $3.00           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Lattice model based on market stock price of $4.80           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Holder would exercise the warrant at maturity if the stock price was above the projected exercise price.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Future capital raises are projected to occur starting 4/30/21, and annually thereafter, at prices approximating 100% of market, which may trigger a reset event adjusting the exercise and the number of warrants.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The fundamental transaction was projected to occur 10% of the time, tested on an annual basis, with settlement equal to the Black Scholes value.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.15in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The stock price would fluctuate with an annual volatility. The projected volatility curve was based on historical volatility of the Company for the valuation date. The projected annual volatility for the valuation date was 123.0%.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following table presents the activityfor liabilities measured at estimated fair value using unobservable inputs for the years ended June 30, 2018, 2019 and 2020:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Fair Value Measurement       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Using Significant       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        Unobservable Inputs       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-size: 10pt">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Obligation           <br/>           to issue           <br/>           shares          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Derivative           <br/>           liability –           <br/>           Series C          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>          <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">           Derivative           <br/>           liability –           <br/>           warrant          </td>          <td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 61%; font: 10pt Times New Roman, Times, Serif">           Balance at July 1, 2017          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           32,213          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">           2,015,354          </td>          <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Additions during the year          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,864,337          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Change in fair value          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (819,994          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (16,764          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (1,717,262          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Transfer in and/or out of Level 3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (5,044,343          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (15,449          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Balance at July 1, 2018          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           298,092          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Additions during the year          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,527,259          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Change in fair value          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           (179,745          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Transfer in and/or out of Level 3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif">           Balance at July 1, 2019          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           1,645,606          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Additions during the year          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           2,066,425          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left">           Change in fair value          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">           5,845,313          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">           Transfer in and/or out of Level 3          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">           (9,557,344          </td>          <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">           Balance at June 30, 2020          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>          <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">           $          </td>          <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">           -          </td>          <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">        <b>        </b>       </p>       <!-- Field: Page; Sequence: 137; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 13 – Income Tax Provision        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company has no current tax expensedue to its losses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The income tax expense for the years endedJune 30, 2020, 2019, and 2018 differed from the amounts computed by applying the U.S. federal income tax rate of 21%, 21% and 28.1%respectively as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             For the Year Ended            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30,             <br/>             2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30,             <br/>             2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30,             <br/>             2018            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 61%">           <font style="font-size: 10pt">            Federal Statutory Rate           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -21.00           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            %           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -21.00           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            %           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            -28.10           </font>          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Research and Development Credit           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            0.13           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -9.21           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            0.40           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            State Tax Rate           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -5.93           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -7.49           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -3.79           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Stock Based Compensation           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            0.14           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Change in Statutory Federal Rate           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            80.30           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            62.36           </font>          </td>          <td>           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Valuation Allowance           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            26.79           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            %           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -42.74           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            %           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            -30.87           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            %           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            Effective Tax Rate           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 138; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The significant components of the Company’sdeferred tax assets and liabilities at June 30, 2020 and 2019 are as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30, 2020            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">           <font style="font-size: 10pt">            <b>             June 30, 2019            </b>           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="width: 74%">           <font style="font-size: 10pt">            Net operating loss           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            24,301,203           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="width: 10%; text-align: right">           <font style="font-size: 10pt">            22,191,536           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>           <font style="font-size: 10pt">            Research and development credit           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6,998,172           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            6,980,633           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Other           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            3,790,537           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            4,985,538           </font>          </td>          <td style="padding-bottom: 1pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td>           <font style="font-size: 10pt">            Total gross deferred tax assets           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            35,089,911           </font>          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">           <font style="font-size: 10pt">            34,157,707           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            Less: valuation allowance           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (35,089,911           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>          <td style="padding-bottom: 1pt">          </td>          <td style="border-bottom: black 1pt solid">          </td>          <td style="border-bottom: black 1pt solid; text-align: right">           <font style="font-size: 10pt">            (34,157,707           </font>          </td>          <td style="padding-bottom: 1pt">           <font style="font-size: 10pt">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="padding-bottom: 2.5pt">           <font style="font-size: 10pt">            Net deferred tax asset           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="padding-bottom: 2.5pt">          </td>          <td style="border-bottom: black 2.25pt double">           <font style="font-size: 10pt">            $           </font>          </td>          <td style="border-bottom: black 2.25pt double; text-align: right">           <font style="font-size: 10pt">            -           </font>          </td>          <td style="padding-bottom: 2.5pt">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        At June 30, 2020 and 2019, the Companyhas recorded a full valuation allowance against its net deferred tax assets of $35,089,911 and $34,157,707, respectively, sincein the judgment of management, these assets are not more than likely than not to be realized. The increase in the valuation allowanceduring the year ended June 30, 2020 was $(932,204).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of June 30, 2020, the Company has approximately$85.5 million of gross net operating loss carryforwards available to reduce future taxable income, if any for federal and statetax purposes. The aggregate federal net operating losses generated for the years ended June 30, 2019 and 2020 of approximately$15.4 million can be carried forward indefinitely. However, the deduction for net operating losses incurred in tax years beginningafter January 1, 2018 is limited to 80% of annual taxable income. Net operating losses generated in years ended June 30, 2018 andprior have a 20-year carryforward and will begin expiring in 2025. As of June 30, 2020 and 2019, research and development creditcarryforwards for federal and state purposes are $6,542,050 and $6,584,541, respectively. The state net operating loss and creditcarryforwards begin to expire in 2025.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 27, 2020, the Coronavirus Aid,Relief, and Economic Security (CARES) Act was signed into law. The Act contains several new or changed income tax provisions, includingbut not limited to the following: increased limitation threshold for determining deductible interest expense; class life changesto qualified improvements (in general, from 39 years to 15 years), and the ability to carry back net operating losses incurredfrom tax years 2018 through 2020 up to the five preceding tax years. The Company has evaluated the new tax provisions of the CARESAct and determined the impact to be either immaterial or not applicable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Due to the change in ownership provisionsof the Internal Revenue Code, the availability of the Company’s net operating loss carry-forwards could be subject to annuallimitations against taxable income in future periods, which could substantially limit the eventual utilization of such carryforwards.The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and thereforeno determination has been made whether the net operating loss carryforward is subject to any Internal Revenue Code Section 382limitation. To the extent there is a limitation, there could be a reduction in the deferred tax asset with an offsetting reductionin the valuation allowance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 14 – Commitments and Contingencies        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <u>         Legal Proceedings        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        There are no pending legal proceedingsagainst the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, noaction, suit or proceeding has been threatened against the Company.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 139; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          Employment Agreements         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company and Dr. Diwan, President andChairman of the Board of Directors, entered into an extension of employment agreement effective July 1, 2018 for a term of threeyears. Dr. Diwan’s will be paid an annual base salary of $400,000. Additionally, Dr. Diwan was awarded a grant of 26,250shares of the Company’s Series A Preferred Stock. 8,750 shares vest equally on June 30, 2019, 2020 and 2021. Any unvestedshares are subject to forfeiture.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company and Dr. Irach Taraporewala,the Company’s Chief Executive Officer, entered into an employment agreement effective September 1, 2018, for a term of threeyears. Dr. Taraporewala would be paid an annual base salary of $360,000. Additionally, Dr. Taraporewala was awarded a grant of15,000 options to purchase shares of the Company’s common stock. 5,000 options vested on September 1, 2018 and the remainderof the options would vest over the two-year vesting period and are subject to forfeiture. On January 24, 2019, Dr. Taraporewalaresigned as the Chief Executive Officer of the Company for personal reasons. Also on that date, the Company and Dr. Taraporewalaagreed that Dr. Taraporewala would become a consultant for the Company for a period of two years.  In connection with hisresignation and new consulting services, the Company and Dr. Taraporewala entered into a Confidential Separation and ConsultingAgreement and General Release (the “Agreement”) pursuant to which the Company will pay Dr. Taraporewala monthly consulting paymentsof $3,000 from February 1, 2019, the effective date of the Agreement, through January 31, 2021.  The Agreement includes ageneral release of claims against the Company, obligations of confidentiality, non-disclosure, non-disparagement and other customaryprovisions found in similar agreements. The remaining 10,000 options not vested upon resignation have been forfeited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 3, 2010, the Company enteredinto an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development.  Theemployment agreement provides for a term of four years with a base salary of $150,000.  In addition, the Companyissued 1,340 shares of Series A preferred stock and 1,786 shares of common stock upon entering into the agreement, and willissue an additional 1,340 shares of Series A preferred stock and 1,786 shares of common stock on each anniversary date ofthe agreement. The shares of Series A preferred stock were issued in recognition of Dr. Tatake’s work towards theachievement of several patents by the Company. The Compensation Committee of the Board of Directors has extended the currentprovisions of the employment agreement pending its review of current industry compensation arrangements and employmentagreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 3, 2010, the Company entered intoan employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer.  The employment agreement providedfor a term of four years with a base salary of $150,000.  In addition, the Company issued 1,786 shares of common stockupon entering into the agreement, and will issue an additional 1,786 shares of common stock on each anniversary date of the agreement.The Compensation Committee of the Board of Directors has extended the current provisions of the employment agreement pending itsreview of current industry compensation arrangements and employment agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On May 30, 2013, the Company entered into an employment agreementwith Meeta Vyas, wife of our President and Chairman of the Board, to serve as its Chief Financial Officer.  The employmentagreement provided for a term of three years with a base salary of $9,000 per month and 129 shares of Series A preferred stock,also on a monthly basis. On January 1, 2015, her cash compensation was increased to $10,800 per month. The agreement is renewableon an annual basis. The Compensation Committee of the Board of Directors has extended the current provisions of the employmentagreement pending its review of current industry compensation arrangements and employment agreements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <i>         <u>          License Agreements         </u>        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company is dependent upon its licenseagreements with TheraCour (See Notes 1 and 4). If the Company lost the right to utilize any of the proprietary information thatis the subject of the TheraCour license agreement on which it depends, the Company will incur substantial delays and costs indevelopment of its drug candidates. On November 1, 2019, the Company entered into a Licensing Agreement (the “Agreement”)with TheraCour for an exclusive license for the Company to use, promote, offer for sale, import, export, sell and distribute productsfor the treatment of VZV derived indications. Process development and related work will be performed by TheraCour under the samecompensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricideswill pay 15% of Net Sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront paymentsto TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company’sSeries A preferred stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials;$2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On June 8, 2020, the Company executed aMemorandum of Understanding (“MOU”) with TheraCour that provides a limited license to the Company for the entire applicationof human coronavirus infections, while the full license is being perfected. The Company is in the process of appointing a thirdparty consulting firm for independent evaluation of this market space. Dr. Anil Diwan is recused from these discussions due toa conflict of interest. The terms of the COVID License Agreement, shall, except as otherwise specified in the MOU, be generallyconsistent with the VZV License Agreement dated November 1, 2019, and shall include consistent milestone payments, royalties andsublicense and income derived from grants and contracts.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 140; Value: 8 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 15 - Subsequent Events        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; background-color: white">         OnJuly 8, 2020, subsequent to the date of the reporting period, the Company entered into an underwriting agreement (the “UnderwritingAgreement”) with Kingswood Capital Markets, a Division of Benchmark Investments, Inc. (“Kingswood”). The offeringwas consummated on July 10, 2020, whereby the Company sold 1,369,863 shares of common stock and a fully exercised Underwriters’over-allotment option of 205,479 additional shares the public offering price of $7.30 per share. No warrants were issued in thisOffering. The net proceeds to the Company from the offering was approximately $10.53 million after deducting underwriting discountsand commissions and other estimated offering expenses payable by the Company.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 31, 2020, the Company entered intoan At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. and Kingswood CapitalMarkets, a division of Benchmark Investments, Inc. (each a “Sales Agent” and collectively, the “Sales Agents”),pursuant to which the Company may offer and sell, from time to time, through or to the Sales Agents, shares of common stock (the “Placement Shares”), having an aggregate offering price of up to $50 million (the “ATM Offering”). Salespursuant to the Sales Agreement will be made only upon instructions by the Company to the Sales Agents, and the Company cannotprovide any assurances that it will issue any Shares pursuant to the Sales Agreement. Actual sales will depend on a variety offactors to be determined by the Company from time to time, including (among others) market conditions, the trading price of theCompany’s common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company.The Company is not obligated to make any sales of common stock under the Sales Agreement and the Company cannot provide any assurancesthat it will issue any shares pursuant to the Sales Agreement. The Company will pay a commission rate of up to 3.5% of the grosssales price per share sold and agreed to reimburse the Sales Agents for certain specified expenses, including the fees and disbursementsof its legal counsel in an amount not to exceed $50,000 and have agreed to reimburse the Sales Agents an amount not to exceed $2,500per quarter during the term of the Sales Agreement for legal fees to be incurred by the Sales Agents. The Company has also agreedpursuant to the Sales Agreement to provide each Sales Agent with customary indemnification and contribution rights.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 141; Options: Last -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">        <p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>      </text>     </description>    </filename>   </sequence>  </type> </document></body>